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Abstract
Members of the gamma subgroup of the herpesvirus family are
characterised by their ability to establish lifelong latent infection in lymphocytes,
and their association with lymphoproliferative disease and a range of malignant
tumours. Members include the Epstein-Barr virus (EBV) and Kaposi's sarcoma-
associated herpesvirus (KSHV), which are linked with clinically important human
diseases, as well as alcelaphine herpesvirus 1 (A1HV-1) and ovine herpesvirus 2
(OvHV-2), which are of veterinary importance. Due to the severe limitations on
the study of gammaherpesviruses presented by their species specificity and
restricted growth in vitro, infection of laboratory mice with the naturally
occurring virus murine gammaherpesvirus 68 (MHV-68) has become an excellent
model system for the study of gammaherpesvirus pathogenesis.
This project involved the characterisation of murine herpesvirus 76
(MHV-76), another of the murine herpesviruses isolated at the same time as
MHV-68. Molecular analysis revealed that MHV-76 is a deletion mutant of
MHV-68, that lacks four genes unique to MHV-68 (Ml, M2, M3 and M4) and
eight viral tRNA-like genes that are all present at the left end of the MHV-68
genome. Biological characterisation of MHV-76, including the generation and
study of rescue viruses which restored the deleted sequence into MHV-76,
showed that loss of these genes leads to enhanced clearance of virus from the
lungs due to a vigorous inflammatory response. There was also a significant
reduction in splenomegaly and the amount of latent virus detectable in the spleen.
These results show that the genes present at the left end of the unique region of
the MHV-68 genome play a critical role in the viral immune evasion strategy.
Detailed studies on one of these unique MHV-68 genes, M2, show that it
is a 30kDa protein that has localised homology with the Gab2 and semaphorin
protein families. Expression ofM2 in mammalian cells reveals that it co-localises
to the plasma membrane, as well as being present in diffuse areas of the nucleus
and cytoplasm. Generation of a recombinant virus with a disruption in the M2
ORE showed that the M2 gene plays a critical role in the establishment of latency
and the regulation of the numbers of latently infected cells in the spleen. The M2
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gene is not involved in the genesis of splenomegaly. These studies uncover some
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The Herpesviridae family currently contains over 120 known viruses
(Minson et al., 2000), with new members being discovered every year, and they
are found in humans, animals and invertebrates (Arzul et al., 2001). They are
ubiquitous in their host populations, with over 90% of the human population
infected with the Epstein Barr virus (EBV) and over 95% carrying latent
varicella-zoster virus (VZV). Their most important biological characteristic is the
ability to establish latent infections, which allows herpesviruses to persist for the
lifetime of the host. In most instances, this latent virus remains undisturbed in co¬
existence with the host organism. However, if this balance is disrupted by a
variety of external stimuli, for example immunosupression, the latent virus can
reactivate leading to the generation of a vast spectrum of diseases. This has made
the herpesvirus family the subject ofmuch scientific research.
1.1.1. Characteristics of herpesviruses
Members of the Herpesviridae family are distinguished by the architecture
of the virus particle (Figure 1.1.1). The virion consists of a core containing a large
double-stranded DNA genome enclosed in an icosadeltahedral capsid,
approximately 100-110nm in diameter, comprised of 162 capsomeres. An
amorphous tegument, predominantly composed of viral proteins present in
variable amounts surrounds the nucleocapsid. Surrounding the tegument is the
viral envelope, derived from the host cell and containing numerous viral
glycoprotein spikes which project from the surface. These structures make up the
virus particle, which is 120-300nm in diameter, depending on the amount of
tegument present.
All herpesviruses share four major biological properties (Roizman, 1996):
1. They contain open reading frames (ORFs) that specify for enzymes
involved in nucleic acid synthesis (e.g. DNA polymerase) and nucleotide
metabolism (e.g. thymidine kinase).
2. Viral DNA synthesis and capsid assembly occur in the nucleus.
2
CHAPTER ONE INTRODUCTION
Figure 1.1.1 Electron micrograph of HSV-1 virion. The nuclcocapsid (N) is
approximately lOOnm in diameter, and is surrounded by the tegument (T). The
outer envelope (E) containing glycoprotein spikes (G) has been permeabilised
during the staining process, and therefore appears larger than normal. Photograph
taken by Linda Stannard and reproduced from the Big Picture Book of Viruses,
available at http://www.virology.net/Big Virology/BVPNAherpes.html
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3. Lytic replication (the production of infectious viral particles) leads to the
irreversible destruction of the infected cell.
4. All herpesviruses can remain latent in their natural host. During latent
infection, the viral genome forms a closed circular molecule, and
expression of a limited subset of viral genes occurs. During latency, no
infectious viral particles are produced. However, the latent viral genome
can reactivate under certain conditions, leading to lytic viral replication
and the production of infectious viral particles.
Despite these similarities in virion structure and general biological
properties, there is a massive diversity in pathogenesis and disease associations of
the different herpesviruses. This has led to various attempts to divide the
herpesvirus family into different subfamilies.
1.1.2. Classification of herpesviruses
Initial attempts to classify herpesviruses into three subfamilies (alpha, beta
and gamma) were made on the basis of biological properties (Roizman et al.,
1981). Table 1.1 details the main biological properties that were used including
host range, duration of reproductive cycle, cytopathology and sites of latency.
However there are substantial areas of overlap between the three families, in
particular the variable in vitro growth characteristics of gammaherpesviruses, that
led to the difficulty in the classification of some viruses such as Marek's disease
virus that replicates rapidly in vitro yet causes lymphoid tumours in chickens.
Another characteristic used to classify herpesviruses was the structure of
the genome, and in particular the arrangement of reiterated sequences. The
location of repeat sequences positioned at either the end of the viral genome
(terminal repeats) or within the genome (internal repeats) means that
herpesviruses can be divided into six groups, designated A to F (Figure 1.1.2.1;







Prototype virus HSV-1 HCMV EBV
Host range Variable In vivo — narrow
In vitro - usually
fibroblasts
In vivo - usually
narrow





















Table 1.1 Sub-division of herpesviruses according to their biological

























Figure 1.1.2.1 Schematic diagram of the sequence arrangements in the six classes of viral
genomes (A-F) in the herpesvirus family, with examples of viruses in each class given in red
on the right side. The unique region of the genome is represented by a black horizontal line.
Group A viruses (such as channel catfish herpesvirus, CCHV; equine herpesvirus-2, EHV-2)
contain a sequence that is directly repeated at both termini (left and right terminal repeats,
LTR and RTR). Group B viruses (such as herpesvirus saimiri, HVS; murine
gammaherpesvirus-68, MHV-68; Kaposi's sarcoma associated herpesvirus, KSHV) contain
numerous copies of a directly repeated sequence at each termini (TR, terminal repeats). Group
C viruses (such as Epstein-Barr virus, EBV) contain terminal repeat sequences like Group B
viruses, but also contain unrelated internal repeat sequences (IR) greater than lOObp which
divide the unique region into several well delineated stretches. In Group D viruses (such as
varicella zoster virus, VZV) the sequence at one terminus (TR) is repeated in an inverted
orientation internally (IR). This divides up the unique region of the genome into a short
component (Us) and a long component (U,), and these components can invert relative to each
other leading to the formation of two isomers of viral DNA. In Group E viruses (such as
herpes simplex virus, HSV), sequences from both termini are repeated in an inverted
orientation (b and b', c and c'), and juxtaposed internally, with a further repeat sequence (a) at
the end of each termini. This means that the unique region of the genome is also divided into
Us and U, components, which can invert relative to each other leading to the formation of four
isomers of viral DNA. Group F viruses (such as tree shrew herpesvirus, TSHV) do not contain
terminal repeat sequences. Adapted from Roizman et al„ 1992.
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The development of DNA sequencing has led to the determination of the
nucleotide sequence of a number of herpesviruses, and this enabled the
Herpesvirus Study Group to state "nucleotide sequence data are necessarily the
basis of the taxonomy of the family Herpesviridae" (Roizman et al., 1992).
Sequence analysis of viral genomes means that herpesviruses can be classified
according to DNA sequence homology, conservation of genes and gene clusters,
and the arrangement of these gene clusters relative to each other. This is assisted
by the fact that herpesvirus genomes are compact, with open reading frames that
tend to be closely spaced or even overlap. Genes can be transcribed from both
strands, and use alternative initiation, polyadenylation or splice sites to give a
multitude of different proteins with different functions, such as the six EBNA
proteins of EBV. Fortunately, the classification of herpesviruses according to
nucleotide sequence of the genome closely matches that based on biological
criteria (Roizman et al., 1992), with the notable exceptions of Marek's disease
vims, which was reclassified as an alphaherpesvirus on the basis of its genome
sequence (Buckmaster et al., 1988; Lee et al., 2000), and human herpesvirus 6,
which was reclassified as a betaherpesvirus (Gompels et al., 1995).
The division of the herpesvirus family with examples of members causing
disease in humans and animals is illustrated in Figure 1.1.2.2.
1.1.3. Reproductive cycle of herpesviruses
Infection of a cell by herpesviruses can lead to two completely different
outcomes. Lytic or productive replication is the replication of the virus with the
release of virus progeny and consequent death of the cell. In contrast, latent
infection leads to the maintenance of the viral genome as a circular episome and
expression of a restricted number of viral genes. The circular episome is amplified
to give multiple copies per cell (Sugden et al., 1979), and these viral episomes are
partitioned into the two daughter cells at mitosis. No virus progeny is generated
during latent infection, although the virus can reactivate leading to production of
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Figure 1.1.2.2 The herpesvirus family. The family Herpesviridae is shown
in red, with the subfamilies in green and the genera in blue. Examples of
each of the genera are shown on the right. Classification is according to the
International Committee on Taxonomy of Viruses, available at




The vast majority of our knowledge of herpesvirus lytic replication has
been amassed from the study of HSV-1 (reviewed by Roizman & Sears, 1996).
The virus attaches to the cell surface via interactions of the viral glycoproteins
with cell surface molecules. In the case of HSV-1, there are multiple attachment
pathways including cell surface heparin sulphate and viral gB and gC, and it is
thought that these multiple pathways are due to the different cell types that HSV-1
naturally infects (epithelial cells and neurons). In contrast, EBV infection of B
lymphocytes is mediated by binding of the viral envelope protein gp350/220 to
the cell surface complement receptor CD21 (Fingeroth et al., 1984; Nemerow et
al., 1985; Carel et al., 1990), a factor that is thought to result in the restricted host
range of EBV in vitro. However, recent studies using viruses deleted in
gp350/220 (Janz et al., 2000) and demonstration of EBV infection in cells lacking
surface CD21 (Yoshiyama et al., 1997) suggests that there may be other
mechanisms independent of gp350 that lead to EBV infection, particularly in
epithelial cells (Maruo et al., 2001). The attachment process initiates fusion of the
viral envelope and cell plasma membrane, a process mediated by the viral
glycoproteins gD, gB and gH/gL in HSV-1. Penetration of EBV into the cell is
slightly different; the EBV virus particle is internalised into cytoplasmic vesicles,
and the viral envelope then fuses with the vesicle membrane (Nemerow &
Cooper, 1984). It is also thought that different viral glycoproteins are involved in
EBV penetration into the cell as, unlike HSV-1, EBV gB is not localised to the
virus envelope or cell surface (Gong et al., 1987; Gong & Kieff, 1990). The
glycoprotein complex gH(gp85) / gL(gp25) / gp42 has also been implicated in the
penetration of EBV into cells (Wang et al., 1998; Haddad & Hutt-Fletcher, 1989;
Oda et al., 2000). After membrane fusion, the virus is uncoated and the
nucleocapsids are transported to the cell nucleus where the viral DNA is released
and circularises.
Tegument proteins are also liberated during this stage, and serve important
functions during HSV-1 infection. The virion host shut-off (VHS) protein causes
non-specific degradation of mRNA and closes down host macromolecular
synthesis in the cytoplasm (Kwong et al., 1988). Another tegument protein called
9
CHAPTER ONE INTRODUCTION
VP 16 (or aTIF) trans-activates the transcription of the immediate-early (or a)
viral genes by host cell RNA polymerase II. HSV-1 contains five immediate-early
genes (ICPO, ICP4, ICP22, ICP27 and ICP47) that are transcribed, translated in
the cytoplasm and imported into the nucleus where they activate transcription of
the early (or (3) viral genes. ICP4 also serves to down-regulate transcription of the
immediate-early genes (autoregulation). The early genes are translated in the
cytoplasm, and the early proteins are involved in viral DNA replication, and
include the major DNA binding protein (ICP8), thymidine kinase and DNA
polymerase. Viral DNA replication is then initiated, starting from the viral origins
of replication, and proceeds by the rolling circle mechanism to produce long
concatemeric DNA molecules (Jacob & Roizman, 1977; Jacob et ai, 1979). The
late (or y) genes are then transcribed and translated, and these primarily consist of
viral structural proteins and proteins needed for virus assembly and egress. The
late proteins also function to down-regulate transcription of the immediate-early
and early viral genes.
Viral glycoproteins are synthesised and glycosylated in the rough
endoplasmic reticulum (ER), and then transported to the Golgi apparatus for
further modification and processing. Mature glycoproteins are then transported to
the plasma membrane of the cell. Capsids are assembled in the nucleus, and
newly replicated viral DNA is cleaved into one genome lengths and packaged into
these preformed capsids (Deiss et al., 1986). These DNA-containing capsids bud
from the inner nuclear membrane into the lumen of the ER, and therefore acquire
an envelope. Two hypotheses then describe the mechanisms whereby the
enveloped viral particles in the ER lumen progress to the cell surface in HSV-1
infected cells. In the luminal model, the enveloped virus in the ER is transported
via exocytic vesicular transport to the Golgi for modification and processing of
the precursor viral glycoproteins, and then to the plasma membrane. The envelope
in the mature virions therefore originates from the inner nuclear membrane. In the
de-envelopment model, the virions in the ER lumen lose this initial membrane by
fusion at the outer nuclear membrane-ER, and the capsids acquire the mature viral
envelope by re-envelopment at the Golgi or post-Golgi compartment. In this
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model, the envelope in the mature virions therefore originates from the Golgi.
Recent studies showing that retention of the viral glycoproteins gH and gD in the
ER prevents their incorporation into the viral envelope of secreted virions
(Browne et al., 1996; Whiteley et al., 1999; Skepper et al., 2001) and differential
ultracentrifugation which showed that enveloped virions are present in the Golgi
apparatus and not lysosomes or other cellular compartments (Harley et al., 2001)
support the hypothesis that the final virion envelope is acquired in the Golgi and
thus the de-envelopment model. Ultrastructural studies suggest that this also
occurs in other alphaherpesviruses (Granzow et al., 2001) and also EBV (Gong &
Kieff, 1990). Tegument proteins are added during transport to the Golgi
apparatus, and the enveloped virus is then transported to the plasma membrane for
release by exocytosis.
1.1.3.2. Latent infection
Latent herpesvirus infection is characterised by the lifelong persistence of
the viral genome in a circular episomal form, with restricted gene expression and
the absence of infectious virus particles (see 1.1.1). The mechanisms that
herpesviruses utilise to establish and maintain latency vary greatly between the
three sub-families, and the majority of our knowledge of latent infection has
emerged from the study of EBV latency in vitro. EBV attaches and enters B
lymphocytes as previously described (see 1.1.3.1). The viral genome enters the
nucleus and immediately circularises to form an episome, and a restricted number
of viral genes are then transcribed. The Wp promoter initiates the transcription of
messages encoding the six nuclear proteins (EBNA1-6) as a long polycistronic
transcript that is spliced to give the individual mRNAs. After the early stages of
latent infection (4-6 days post-infection), initiation of transcription of the EBNA
proteins is switched in many cells to the nearby Cp promoter (Woisetschlaeger et
al., 1990), via an EBNA2-dependant enhancer (Woisetschlaeger et al., 1991).
Transactivation of the promoter of the three latent membrane proteins (LMP1, 2A
and 2B) by EBNA2 leads to upregulation of LMP transcription (Abbot et al.,
1990). Two small non-polyadenylated RNAs (EBER1 and 2) are also transcribed,
as are a number of complex transcripts arising from the BamR\ A fragment (the
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BARTs). The significance of the BARTs is unclear, as no translated protein has
yet been identified. The expression of all the EBV latency-associated transcripts is
seen during the latency III gene expression programme, but even more highly
restricted latent gene expression patterns have been demonstrated (see 1.2.1.2).
The EBNA1 protein binds to the latent viral origin of replication (orz'P),
resulting in the maintenance of the viral episome in latently infected cells (Yates
et al., 1985). EBNA1 also associates with metaphase chromosomes, ensuring that
viral episomes are equally distributed into the two daughter cells at mitosis
(Harris et al., 1985). The viral episome is replicated early in S phase by cellular
DNA polymerase, and latently infected cells contain multiple copies of the viral
episome (Sugden et al., 1979). As well as the transactivation of the latent viral
genes LMP1, 2A and 2B, EBNA2 transactivates a number of cellular genes and
plays an important role in the immortalisation of B lymphocytes (Cohen et al.,
1989). The LMP1 protein is also a viral oncogene essential for B lymphocyte
immortalisation (Kaye et al., 1993), and upregulates cellular activation and
adhesion molecules such as ICAM-1 as well as vimentin and bcl-2. EBNA3 and 6
are also required for the immortalisation of B lymphocytes (Tomkinson et al.,
1993). These functions of the EBV latent proteins ensure that the infected cell
enters into the cell cycle, and continuous cell proliferation occurs. The role of the
EBERs is less well understood. They are dispensable for cellular transformation
and replication in vitro (Swaminathan et al., 1991), and it was thought that they
might play a role in RNA splicing or viral mechanisms to counter the interferon
response (Sharp et al., 1993) but this has not been fully demonstrated
(Swaminathan et al., 1992). Recent studies using the Burkitt's lymphoma cell line
Akata showed that the EBERs play a role in cellular transformation and
oncogenesis (Komano et al., 1999; Ruf et al., 2000; Takada & Nanbo, 2001).
Members of the Rhadinovirus genus of the gammaherpesviruses do not contain
homologues of the EBV latent genes, but they do contain latent genes with similar
functions. The LANA-1 protein (ORF73) of KSHV is hypothesised to tether the
viral genome to the host cell chromosomes during mitosis in a similar fashion to
EBNA1 (Ballestas et al., 1999).
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By comparison, the molecular basis of alpha and betaherpesvirus latency
is poorly understood. During latent infection of neurons by HSV-1 the normal
lytic cycle transcription cascade is blocked, and transcription is restricted to the
production of a single mRNA called the latency-associated transcript (LAT). The
LAT mRNA is spliced and a number of small ORFs (ORF-O and ORF-P) have
been detected (Lagunoff & Roizman, 1994), but their translation into protein or
possible function is unclear (Lock et al., 2001). Changes in the normal physiology
of the neuron lead to alterations in the permissiveness of the neuron to HSV-1
lytic replication, and the virus can therefore reactivate from latency. VZV
establishes latency in trigeminal and dorsal root ganglia, and at least five ORFs
(4, 21, 29, 62, 63) are transcribed during latent infection (Cohrs et al., 1996;
Kennedy et al., 1999). These ORFs encode a number of immediate-early proteins
involved in the transactivation of viral genes during productive infection, but their
detection in the cytoplasm of latently infected cells raises the possibility that VZV
maintains latency by restricting these regulatory proteins away from the nucleus
(Lungu et al., 1998).
Initial studies on betaherpesvirus latency were complicated by the
dilemma of differentiating true latency (which indicates that recurrence would
require the reactivation of lytic gene transcription) from low-level persistent
productive replication (which signifies that recurrence would require the
expansion of existing gene transcription programmes). Extremely sensitive
techniques for the detection of infectious virus (sensitive to 1 PFU per organ) and
molecular techniques such as PCR and RT-PCR demonstrated the presence of
latent murine CMV in multiple organs including the lung, spleen and kidney
(Yuhasz et al., 1994; Pollock & Virgin, 1995; Kurz et al., 1997). The presence of
latent human CMV in macrophages and granulocyte-macrophage progenitor cells
was demonstrated by the presence of circular viral DNA using Gardella gel
analysis (Bolovan-Fritts et al., 1999), and the mapping of latency-associated
transcripts originating from both strands of the UL122/UL123 (iel/iel) region of
the viral genome (Kondo et al., 1996; Hahn et al., 1998). However, the function
of ORFs encoded by these transcripts remains unclear as some of these genes are
non-essential for latent CMV infection (White et al., 2000). Similar transcripts
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from the ie\Uel region have been described during murine CMV latency (Kurz et
al., 1999; Grzimek et al., 2001). Reactivation from latency is typically observed
in the immunocompromised host, possibly via immune activation of the
productive viral replication cycle (Soderberg-Naucler & Nelson, 1999).
The switch from latent infection to lytic replication in EBV is mediated by
the immediate-early genes BZLF1 (Z transactivator or Zta) and BRLF-1 (R
transactivator or Rta). The Zta promoter is activated by cellular factors (usually
via chemical induction for in vitro studies) and transactivates the Zta and Rta
genes, as well as the early genes. This then leads to the orderly cascade of early
and late genes similar to that observed during HSV-1 lytic replication (see
1.1.3.1). Repression of the promoters of these transactivators by cellular factors
prevents reactivation from latency. The other gammaherpesviruses also contain
homologues of Rta (ORF50), another EBV transactivator Mta (ORF57) and Zta
(ORF K8 in KSHV; Lin et al., 1999). However, in contrast to EBV, it appears that
the Rta performs the major role in the reactivation of HVS, KSHV and MHV-68
from latency (Sun et al., 1998; Wu et al., 2000; Goodwin et al., 2001).
1.2. Gammaherpesviruses
The gammaherpesvirus sub-family contains a number of important human
and animal pathogens and they have been intensively studied due to their
association with transformation and oncogenesis. Their genomes contain genes
that are shared between all known mammalian herpesviruses (e.g. thymidine
kinase) as well as genes unique to the gammaherpesvirus family. Sequence
analysis of the viral genomes reveals the wide diversity of the
gammaherpesviruses (McGeoch, 2001).
1.2.1. The Epstein Barr Virus
EBV is the prototypic lymphocryptovirus (yi), and persistently infects over
90% of the adult human population. EBV, like the other gammaherpesviruses, has
a restricted host range (see table 1.1) with humans as its natural host. The virus
establishes a latent infection of circulating B lymphocytes and this latent infection
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does not usually cause disease. However, in certain situations EBV is associated
with lymphoproliferative disease and oncogenesis. EBV can infect and
immortalise B lymphocytes in vitro, resulting in the generation of lymphoblastoid
cell lines (LCLs), which are used to study EBV latent infection in detail (see
1.1.3.2). A small percentage of cells (approximately 5%) within the LCL
population will also undergo lytic replication.
1.2.1.1. EBV-associated diseases
Asymptomatic primary infection with EBV in developing countries usually
occurs in early childhood, and is contracted from persistently infected humans
who shed EBV via the saliva. However, in developed countries with high
standards of living, primary infection is delayed and occurs in adolescence. This
delayed primary infection causes the condition infectious mononucleosis (IM),
which varies in severity from a mild fever to a prolonged debilitating illness. The
virus enters the body via the oropharynx, and the exact route by which EBV
enters the body has been the subject of much debate. EBV can replicate in
squamous epithelial cells in vitro (Sixbey et al., 1983) and in vivo (Niedobitek et
al., 1991b), and is also associated with a range of human epithelial tumours (Imai
et al., 2001). Thus one hypothesis proposes that EBV initially replicates in the
surface epithelial cells before infecting B lymphocytes. However, studies showing
that patients with X-linked agammaglobulinaemia who lack mature B cells are not
infected with EBV (Faulkner et al., 1999) and sections of tonsils removed from
patients with IM demonstrating infection of B cells only (Anagnostopoulos et al.,
1995) suggests that EBV enters the body via infection of intraepithelial resting B
lymphocytes (Thorley-Lawson & Babcock, 1999; Faulkner et al., 2000). The
primary infection induces humoral and cell mediated immune responses,
especially a CTL response to viral antigens, which serves to limit the infection.
Immunodeficiency syndromes can dramatically alter the course of IM; the genetic
defect X-linked lymphoproliferative syndrome is due to a mutated gene encoding
the signalling lymphocytic activation molecule-associated protein (SAP; Howie et
al., 2000). Upon primary EBV infection, a fatal IM-like syndrome occurs
characterised by B lymphocyte proliferation and dysgammaglobulinaemia.
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Iatrogenic immunosupression following organ transplantation also results in
lymphoproliferative disease during primary EBV infection (Hopwood &
Crawford, 2000).
Following primary infection, EBV persists for life with approximately 1 in
106 circulating B lymphocytes carrying latent EBV. Bone marrow and lymphoid
tissue are thought to be the other major reservoirs of EBV in vivo and, as
previously mentioned, infectious virus is continuously or intermittently shed in
the saliva. However, in certain individuals who become immunocompromised, the
equilibrium between viral latency and immune control becomes unbalanced, and
this leads to a variety of malignant conditions. The first lymphoid tumour to be
associated with EBV was Burkitt's lymphoma (BL), a B lymphocyte tumour of
the jaw and occasionally other sites. BL occurs in three recognised forms:
endemic BL in equatorial Africa, sporadic (or non-African) BL that occurs at low
incidence worldwide, and AIDS-associated BL. The EBV genome is present in
96% of endemic BL tumours (Magrath, 1990), but the association with sporadic
BL is not as marked. EBV is considered to be one of the three principal co-factors
in the causation of endemic BL, along with malaria (or HIV infection in the case
ofAIDS-associated BL) and the constitutive expression of the c-myc oncogene. It
is postulated that EBV viral replication, in conjunction with malaria or HIV,
results in polyclonal B-lymphocyte activation. The B lymphocyte proliferation
leads to chromosomal translocations, t(8:14, 8:2 or 8:22), that result in the
juxtaposition of the c-myc oncogene on chromosome 8 and the immunoglobulin
heavy (chromosome 14) or light chains (chromosome 2 or 22). This leads to the
constitutive expression of c-myc, which drives the B lymphocyte into proliferation
and inhibits differentiation leading to BL (Klein & Klein, 1985). Recent studies
using the Akata BL cell line have demonstrated that EBV plays a direct role in the
maintenance of the tumour by upregulation of bcl-2 expression and
downregulation of c-myc protein levels, thus circumventing cellular apoptotic
pathways (Ruf et al., 1999; Takada, 2001). This role of EBV in the maintenance
of BL is mediated in part by expression of the EBERs (Komano et al., 1999; Ruf
et al., 2000; Takada & Nanbo, 2001).
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Nasopharyngeal carcinoma (NPC) is a squamous epithelial tumour of the
post-nasal space. It is highly prevalent in southern China, where it is the most
common cancer affecting men and the second commonest in women. The
commonest form ofNPC, termed undifferentiated NPC, is always EBV associated
as demonstrated by the presence of EBV DNA in the malignant cells (Niedobitek
et al., 1991a) as are a proportion of the differentiated NPC cases (Raab-Traub et
al., 1987). Like BL, it is thought that EBV is one component of a complex
process resulting in the development of NPC with other co-factors including
genetic predisposition (Lu et al., 1990) and environmental factors such as
traditional Chinese herbal remedies and salt fish dishes containing carcinogens
(Armstrong et al., 1998).
Post-transplant lymphoproliferative disease (PTLD, also called B-
lymphoproliferative disease) is observed in transplant patients undergoing
immunosuppressive drug therapy or as an AIDS-related condition, and can occur
during primary or latent EBV infection (Haque et al., 1996). Over 90% of the
lymphomas are EBV positive as demonstrated by the presence of viral DNA or
antigens (Thomas et al., 1990). It is proposed that the lymphoproliferative disease
is driven by either the expression of viral oncogenes (such as EBNA2 and LMP1)
or the high levels of cytokines produced by infiltrating CD4+ T lymphocytes in
the lymphomas (Hopwood & Crawford, 2000). Oral hairy leukoplakia (OEIL) is a
benign lesion caused by lytic EBV replication in the superficial layers of the
tongue epithelium (Greenspan et al., 1985; Niedobitek et al., 1991b). It is almost
exclusively observed during HIV infection. Another condition that has been
associated with EBV is Hodgkin's lymphoma (HL). EBV is associated with
approximately 50% of cases of HL, due to the presence of EBV DNA in the
lymphoma cells (Weiss et al., 1987; Brocksmith et al., 1991). It is thought that the
latent EBV genes LMP1 and LMP2A are central to the pathogenesis of EBV-
related HL by providing the growth and survival signals necessary for the
initiation of oncogenesis (Kuppers & Rajewsky, 1998; Thorley-Lawson &
Babcock, 1999). EBV has also been associated with a number of other diseases,
including various T cell lymphomas (Ott et al., 1992) and gastric carcinomas
17
CHAPTER ONE INTRODUCTION
(Tokunaga et al., 1993) but the contribution of EBV to their causation remains
unclear.
1.2.1.2. Molecular biology ofEBV
The EBV genome was the first herpesvirus to be fully sequenced (Baer et
al., 1984), although the B95-8 strain sequenced was subsequently found to
contain a 12kb deletion and this region of EBV DNA was sequenced later from
the Raji strain (Parker et al., 1990). It is 172kb in length, and contains a unique
region flanked by reiterated 0.5kb terminal repeat sequences that covalently link
to form the viral episome during latency. The unique region is divided by four
reiterated 3kb internal repeat sequences. There are two subtypes of EBV, EBV-1
and 2, which share extensive homology but differ mainly in the regions of the
viral genome encoding the EBNA2-6 proteins and the EBERs (Sample et al.,
1990). The two subtypes differ in their geographical distribution and their ability
to immortalise B lymphocytes in vitro (Rickinson et al., 1987), but these
differences are not thought to reflect different disease associations.
During the latent infection of B lymphocytes in vitro, EBV expresses a
highly restricted subset of viral genes that contribute to the maintenance of the
viral genome in infected cells and B lymphocyte immortalisation (see 1.1.3.2).
Several different patterns of gene expression have been observed in vitro and in
vivo, and have been classified into three groups. Latency III is observed during
latent infection of in vitro transformed LCL cells, and is characterised by the
expression of all the major latent gene transcripts; namely EBNA1-6, LMP1, 2A
and 2B, EBER1 and 2 and the BARTs. This latency program utilises the Wp and
Cp promoters (see 1.1.3.2), and is also observed during infectious mononucleosis
and PTLD in vivo. It is thought that Latency III gene expression is utilised by the
virus to ensure growth transformation of the host cells and therefore amplify the
number of latently infected cells to ensure viral persistence. In contrast, Latency I
involves the silencing of the Cp/Wp promoter, and expression of only EBNA1
from the downstream Qp promoter. The only other detectable gene transcripts are
the EBERs and the BARTs, and this highly restricted form of latency is seen in
BL cells. Latency II also exhibits restricted expression of EBV latent genes, with
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expression of EBNA1 (from the Qp promoter), LMP1, 2A and 2B, the EBERs
and BARTs. Latency II gene expression is observed in NPC and HL cells in vivo.
The significance of these different latency programmes is still the subject ofmuch
debate, but one hypothesis is that EBV is taking advantage of normal B cell
biology and maturation pathways to establish lifelong persistence in the memory
B cell. The viral gene expression programmes mimic the B cell activation and
differentiation signals to enable EBV infected cells to survive and mature into
memory B cells (Thorley-Lawson & Babcock, 1999). Another hypothesis is that
EBV severely restricts latent gene expression to only express EBNA1 during the
maintenance of latency to avoid detection by the immune system, as the internal
repeat region in EBNA1 interferes with antigen processing and thus prevents CTL
recognition of infected cells (Levitskaya et al., 1995).
EBV is the most intensively studied of the gammaherpesviruses, and as
more knowledge is amassed concerning its biology, the complexity of the
mechanisms that EBV uses to ensure persistence and cause malignant tumours
becomes apparent. However, relatively little is known about the initial events
during primary infection as is demonstrated by the continuing debate concerning
the role of squamous epithelium during primary EBV infection.
1.2.2. Kaposi's sarcoma associated herpesvirus
KSHV (also called human herpesvirus 8 or HHV8) is the most recently
discovered human herpesvirus. A viral aetiology had long been suspected for
Kaposi's sarcoma (Beral et al., 1990), and the presence of unique herpesvirus
DNA in over 90% ofKaposi's sarcoma lesions was confirmed by the technique of
representational difference analysis (Chang et al., 1994). Subsequent cloning and
sequence analysis of the KSHV genome demonstrated that it was a
gammaherpesvirus of the genus Rhadinovirus (Moore et al., 1996; Russo et al.,
1996).
1.2.2.1. KSHV-associated diseases
Kaposi's sarcoma (KS) occurs in four distinct epidemiological forms.
Classic KS is predominantly seen in elderly men in the Mediterranean, and
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consists of benign indolent tumours of the extremities. Endemic KS is more
aggressive, and occurs in equatorial Africa. The two most recent forms of KS
recognised are AIDS-KS, a very aggressive disseminated disease with a high
mortality rate, and post-transplant (or iatrogenic) KS. The involvement of an
infectious agent in the pathogenesis of AIDS-KS was postulated before the
isolation of KSHV due to the fact that KS is 300 times more common in AIDS
patients than other immunosupressed patient groups, and 10 times more common
in HIV-positive homosexual men than patients who contracted HIV through non¬
sexual routes (Beral et al., 1990). KSHV is linked to the aetiopathogenesis of KS
by the detection of KSHV sequences and gene expression in all forms of KS and
KS lesions (Schalling et al., 1995; Dupin et al., 1999), the detection of KSHV
sequences in the blood of HIV-positive individuals that predicts those who will
subsequently develop KS (Whitby et al., 1995) and serological studies.
KSHV is also associated with primary effusion lymphoma (PEL, also
called body-cavity based lymphoma), a B cell lymphoma observed in AIDS
patients (Cesarman et al., 1995). Cell lines latently infected with KSHV have
been established from cases of PEL, and some are also co-infected with EBV.
Studies of these cell lines have greatly assisted the study of KSHV. KSHV is also
associated with multicentric Castleman's disease (MCD), a lymphoproliferative
disease frequently associated with HIV infection (Soulier et al., 1995). Therefore,
like EBV, immunosupression of the host plays a critical role in the pathogenesis
of KSHV-associated diseases. The prevalence of KSHV in the general population
is the subject of much current debate, but it is currently thought that unlike most
other human herpesviruses, KSHV is not ubiquitous in the general population.
KSHV seroprevalence in the general population is less than 5%, with a higher
prevalence in Mediterranean and African countries and homosexual men (up to
50%) reflecting the higher incidence of KS in these groups (reviewed by Schulz,
2000; Boshoff & Weiss, 2001). Transmission is thought to be by sexual contact,
with childhood transmission occurring in developing countries (Schulz, 2000).
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1.2.2.2. Molecular biology of KSHV
The genomic sequence of KSHV has been determined from a PEL cell line
and a KS biopsy specimen, and contains a 140.5kb unique region containing at
least 81 ORFs flanked by reiterated 0.8kb terminal repeat sequences (Russo et al.,
1996; Neipel et al., 1997). In common with the other rhadinovirus members, the
genome contains ORFs conserved between other members of the herpesvirus
family, gammaherpesvirus specific ORFs and KSHV specific ORFs (designated
K1-K15). The left unique region of the KSHV genome contains the highly
variable K1 ORF, which is used to subdivide KSHV strains (Zong et al., 1999).
K1 transforms fibroblasts in vitro (Lee et al., 1998b), and interferes with
intracellular signal transduction pathways (Lee et al., 1998a; Lagunoff et al.,
1999). The most striking feature of the KSHV genome is the number of genes
with significant homology to cellular genes, thought to have been captured from
host cells ("molecular piracy", Figure 1.4.3.2). It contains cellular homologues of
cell-cycle regulators (v-cyc and vGPCR), apoptosis inhibitors (vbcl-2 and vFLIP),
interferon signalling pathway regulators (vIRFl) and a wide variety of cytokines,
chemokines and chemokine receptors (vGPCR, vIL6, vMIP-I, II and III). The role
of these genes in the pathogenesis of KSHV is the subject of much investigation
(see 1.6), and is reflected in the hypotheses concerning the role of KSHV in the
genesis of KS. One theory states that KSHV directly causes KS by the malignant
transformation of epithelial cells, which is supported by evidence showing that
most of the tumour cells are clonal in origin (Rabkin et al., 1997; Judde et al.,
2000). However, others argue that KS is indirectly caused by the release of
numerous secreted viral and cellular growth factors during viral replication
(Mesri, 1999), and this is supported by evidence showing that transformation of
endothelial cells in vitro by KSHV is dependant on paracrine mechanisms (Flore
et al., 1998). This is also suggested by the fact that although KSHV latently
infects B lymphocytes (Cesarman et al., 1995), the KS lesion is a spindle cell
tumour whose cells express endothelial, smooth muscle, macrophage or dendritic
cell markers and thus may be due to cellular proliferation.
Studies of latent gene expression have been carried out on PEL cell lines,
which harbour episomal latent KSHV (Cesarman et al., 1995). Although a small
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proportion (under 1%) of these cells will undergo lytic replication, lytic
replication can be induced in the majority of cells by chemical agents such as
phorbol esters in a manner similar to EBV-infected cell lines. KSHV transcripts
have therefore been classed as either unaffected by chemical treatment (Class I or
latent transcripts), normally transcribed in PEL cells but induced to higher
transcription levels by chemical treatment (Class II or latent/lytic) or only
transcribed after chemical induction of lytic replication (Class III or lytic
transcripts; Sarid et al., 1998). These results have shown that LANA-1, v-cyc and
vFLIP are transcribed from the same promoter on a polycistronic transcript as
Class I (latent) transcripts (Talbot et al., 1999), and another newly discovered
gene (K10.5) is also expressed during latency in PEL cells (Rivas et al., 2001). A
variety of genes are classified as Class II, including two small polyadenylated
RNA species (TO.7 and Tl.l) and possibly K10 (Jenner et al., 2001). Rta (ORF
50) induces the switch from latent infection to lytic replication, and leads to the
orderly cascade of early and late genes (Class III) similar to that observed during
HSV-1 lytic replication (see 1.1.3.1). Most of the cellular homologues encoded by
the virus are expressed during lytic replication in both in vitro and in vivo biopsy
specimens, suggesting that expression of these viral growth factors contributes to
the pathogenesis ofKS (Sun et al., 1999; Jenner et al., 2001).
A large amount of knowledge has therefore been amassed in a short time
concerning the molecular biology of KSHV in vitro and in biopsy samples.
However, little is known about the pathogenesis of KSHV including primary
infection in humans, sites of latency in vivo and the contribution of the viral-
encoded cellular homologues to the pathogenesis of disease.
1.2.3. Herpesvirus saimiri
HVS is the prototypic rhadinovirus (72), and naturally infects squirrel
monkeys (Saimiri sciureus) where it is non-pathogenic. However, in other New
World primates, it causes rapidly progressing T-cell lymphomas (Fleckenstein &
Desrosiers, 1982). Therefore, unlike EBV and KSHV, it is associated with the T
lymphocyte population. A similar virus, herpesvirus ateles (HVA), naturally
infects spider monkeys {Ateles spp.) and causes T-cell lymphomas in other New
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World primates. HVS replicates productively in vitro and immortalises monkey
and human T lymphocytes (Biesinger et al., 1992). As such, it has been studied
extensively for the investigation of virus-mediated oncogenicity and also as a
vector for gene therapy, where the non-integrated viral episome can be used to
express foreign DNA in a variety of human cell types (Stevenson et al., 2000a;
Fickenscher & Fleckenstein, 2001).
The HVS genome contains a 112.9kb unique region containing at least 83
potential genes flanked by reiterated 1,4kb terminal repeat sequences (Albrecht et
al., 1992). Similarly to KSHV, it contains ORFs with homology to other
herpesviruses, and also a number of genes with cellular homologues including a
complement control protein homologue (ORF4), vFLIP, v-cyc, vGPCR and vbcl-
2. HVA has also been sequenced, and is closely related to HVS (Albrecht, 2000).
Neither HVS nor HVA contain any homologues of the EBV latency-associated
genes, and little is known about latent gene expression. Recent studies using a
human lung carcinoma cell line containing episomal HVS DNA which can
reactivate to give lytic virus upon chemical induction, showed expression of
ORF71, 72 and 73 during the latent state (Hall et al., 2000). These genes,
corresponding to the vFLIP, v-cyc and LANA-1 homologue in HVS respectively,
are also transcribed during latency in KSHV (see 1.2.2).
Of particular interest is the region at the left unique region of the HVS
genome (Figure 1.4.3.2), which contains genes essential for transformation and
pathogenicity (Koomey et al., 1984; Desrosiers et al., 1985; Murthy et al., 1989).
This region contains a unique gene, STP (saimiri transformation-associated
protein, ORFlb) and two genes with homology to cellular enzymes (ORF2 and 3),
as well as seven small RNA molecules, termed HSURs (herpesvirus saimiri TU¬
RNAs). Based on the heterogeneity at the left unique region of the genome, HVS
can be divided into three subgroups A, B and C (Medveczky et al., 1984;
Medveczky et al., 1989). Subgroup A contains a functional STP gene, whereas
subgroup B contains a non-transforming STP gene (Choi et al., 2000). However,
subgroup C viruses contain a functional STP gene and another unique gene TIP
(tyrosine kinase interacting protein, ORFla; Biesinger et al., 1990). STP is a
membrane-associated oncoprotein (Jung & Desrosiers, 1991), with subtype C
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STP possessing more potent transformation and oncogenic abilities than subtype
A STP (Jung et al., 1991). Both STP and TIP are not required for replication and
persistence in vivo, but are necessary for transformation and oncogenicity
(Duboise et al., 1998; Murthy et al., 1989). It is of note that HVA contains a gene
in this region of the genome that is homologous to both STP and TIP, termed TIO
(two-in-one) that may have similar functions (Albrecht et al., 1999). Thus the left
unique region of the genome plays an important role in HVS pathogenesis.
1.2.4. Alcelaphine herpesvirus 1 and Ovine herpesvirus 2
Malignant catarrhal fever (MCF) is a generally fatal sporadic
lymphoproliferative disease of domestic cattle, deer and other farm animal species
characterised by hyperplasia of lymphoid tissues, T lymphocyte infdtration,
vasculitis and necrosis (Reid et al., 1984). It occurs in two forms; either
wildebeest-associated MCF in Africa, caused by alcelaphine herpesvirus-1
(A1FIV-1) or sheep-associated MCF that occurs world-wide, caused by ovine
herpesvirus-2 (OvHV-2). Similarly to HVS, both viruses are non-pathogenic in
their natural hosts (wildebeest for A1HV-1 and domestic sheep for OvHV-2) but
cause disease when transmitted to other farm animal species or rabbits. In the
natural host, the virus is thought to be transmitted at a young age but the basis of
transmission from the host species to cause MCF is currently unknown.
A1HV-1 can be grown in tissue culture, and the genomic sequence has
been determined (Ensser et al., 1997). It contains a 130.6kb unique region
containing at least 70 ORFs flanked by reiterated l.lkb terminal repeat sequences.
In common with the other rhadinovirus members, it contains ORFs with
homologues in other herpesviruses and genes with cellular homologues such as
vGPCR and vbcl-2. The left unique region of the A1HV-1 genome also contains a
block of four unique genes (designated A1-A4, Figure 1.4.3.2), one of which is a
semaphorin homologue (ORFA3; Ensser & Fleckenstein, 1995). However, little is
known about the functional role of any of these genes in A1HV-1 pathogenesis. In
contrast to A1HV-1, relatively little is known about the genomic structure of
OvHV-2 as this virus can only be propagated in LCLs generated from animals
affected by MCF, in a similar manner to EBV. Limited sequence available from
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the OvHV-2 genome shows that OvHV-2 is a separate virus closely related to
A1HV-1 (Bridgen & Reid, 1991; Dunowska et al., 2001; J. Rosbottom, M.
Ackermann, H. Reid, R. Dalziel and J. Stewart; personal communication).
However, little is known about latent gene transcription or pathogenesis in either
A1HV-1 or OvHV-2.
1.2.5. Other gammaherpesviruses
A number of other gammaherpesviruses have been isolated and partially
characterised. Much research has concentrated on characterisation of the various
lymphocryptoviruses and rhadinoviruses that infect primates as models for EBV
and KSHV infection in man respectively (see 1.3). Equine herpesvirus 2 and 5
(EHV-2 and EHV-5) were also classified as gammaherpesviruses on the basis of
genomic sequence (Telford et al., 1993). The significance of EHV-2 as a
pathogen of horses is currently uncertain, although it has been implicated in
respiratory disease and immunosupression in foals (Mair, 1999). The complete
genomic sequence ofEHV-2 has been determined, and led to its classification as a
member of the Rhcidinovirus genera (Telford et al., 1995). It contains a 149.3kb
unique region containing at least 77 ORFs flanked by a 17.5kb direct repeat
sequence. In common with the other rhadinovirus members, it contains ORFs
with homologues in other herpesviruses and genes with cellular homologues such
as three vGPCRs, vFLIP and vIL-10. Ofparticular interest are the large regions of
non-coding DNA and the lack of a LANA-1 homologue (ORF73), which is
presumed to have a similar function to EBNA-1 in the rhadinoviruses and
therefore be essential for maintenance of latent infection (Ballestas et al., 1999).
The region at the left unique region of the genome also contains a functional CC
chemokine receptor homologue (El) with a possible role in viral immune evasion
(Camarda et al., 1999).
Partial sequence analysis and genomic organisation of bovine herpesvirus-
4 (BHV-4) has also shown it to be a gammaherpesvirus (Lomonte et al., 1996). It
has been isolated from both healthy and diseased cattle, but no association with
disease has been proven (Fenner, 1993). The region at the left unique region of
the BHV-4 genome contains two ORFs, one unique and one with homology to
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HVS ORF3 (N-formylglycinamide ribotide amidotransferase, FGARAT). A new
member, porcine gammaherpesvirus, has also recently been isolated as the cause
of PTLD in immunosupressed swine undergoing experimental transplantation
(Huang et al., 2001). This final member of the gammaherpesvirus subfamily
serves to emphasise the major relationships between this varied collection of
viruses: the tropism of gammaherpesviruses for lymphocytes and their association
with lymphoproliferative disease and oncogenesis.
1.3. Models of gammaherpesvirus pathogenesis
A number of problems have arisen with the study of gammaherpesvirus
pathogenesis. The most important viruses in the field of human medicine are EBV
and KSHV, but they have an extremely restricted host range in vivo. Studies of
natural EBV infection have been limited to the clinical presentation of infectious
mononucleosis, but primary infection with these human gammaherpesviruses is
frequently asymptomatic, with a substantial delay between infection and the
presentation of clinical disease. Initial studies attempted to infect various primate
species with EBV, but Old World primates were found to have cross-reacting
antibodies due to natural infections with closely related lymphocryptoviruses
(Frank et al., 1976). However, New World primates such as the common
marmoset (Callithrix jacchus) and the cottontop tamarin (Saguinus Oedipus
Oedipus) are susceptible to EBV infection, but as these animals are not natural
hosts for EBV, the disease observed does not mirror human EBV infection.
Infection of the common marmoset leads to an infectious mononucleosis-like
syndrome (Wedderburn et al., 1984), but without the lymphadenopathy and B cell
proliferation normally observed in man (Emini et al., 1986). Infection of the
commontop tamarin leads to the rapid development ofmalignant lymphomas and
has therefore been used as a model of EBV tumourogenesis (Shope et al., 1973),
and to study candidate EBV vaccination programmes against tumourogenesis
(Epstein et al., 1985). Studies of viral gene expression in these lymphomas in vivo
suggests that they do not show the characteristic latency gene programmes
observed in human EBV tumours (Young et al., 1989).
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Due to these problems, infection of primates with simian homologues of
gammaherpesviruses has been developed as models for EBV and KSHV disease.
Lymphocryptoviruses (LCV) such as rhesus monkey LCV and baboon LCV are
closely related to EBV genetically (Moghaddam et al., 1998; Rivailler et al.,
2002), and cause clinical disease similar to that seen during human primary EBV
infection (Moghaddam et al., 1997). The recent discovery of a New World LCV
with more distant homology to EBV may also provide insights into the host
adaptation of these viruses (Cho et al., 2001). Rhadinoviruses closely related to
KSHV have also been isolated from Old World primates (Searles et al., 1999;
Alexander et al., 2000). However, experimental infection of primates with these
viruses suggests that they may develop an arteriopathy in the context of
concurrent immunosupression, but not KS-like lesions (Mansfield et al., 1999).
However, a number of problems arise with the use of primate in vivo models of
gammaherpesvirus pathogenesis, including expense, biosecurity and strict
governmental regulation of their use. Our understanding of primate biology and
their immune response, including the development of transgenic animals, is also
at an early stage of development.
A number of non-primate models have therefore been developed for the
study of gammaherpesvirus pathogenesis. The infection of rabbits with primate
lymphocryptoviruses leads to the induction of malignant lymphomas (Hayashi &
Akagi, 2000) and also hemophagocytic syndrome, a condition seen after EBV
infection of humans with X-linked lymphoproliferative syndrome (see 1.2.1.1;
Hayashi et al., 2001). Another small animal model that has been developed is the
use of the C.B-17 scid/scid mice (severe combined immunodeficient, SCID),
which lack mature B and T lymphocytes due to a defect in lymphocyte
maturation. Reconstitution of these mice with human EBV-positive lymphocytes
leads to the development of B cell lymphomas that are latently infected with EBV
and show Latency III gene expression (Rowe et al., 1991). They thus resemble
PTLD tumour in humans, and have been developed as a model for the study and
treatment of PTLD in man (Johannessen & Crawford, 1999). However, due to the
species differences between the primate viruses and the laboratory animal hosts,
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these models are not natural infections and the murine host influences the
pathology observed.
A natural gammaherpesvirus infection in laboratory animals would
therefore greatly assist our understanding of gammaherpesvirus pathogenesis, by
enabling the manipulation of the host immune system by the use of transgenic
mice disabled for various components of the immune system, and evaluation of
individual viral genes in viral pathogenesis. It would also permit the investigation
of novel antiviral drugs and immunomodulatory therapies in vivo.
1.4. Murine gammaherpesvirus 68
MHV-68 is one of five viruses originally isolated from two species of
murid rodents in Slovakia (Blaskovic et al., 1980). Initial characterisation of the
ultrastructural changes in infected cell cultures revealed typical features of
herpesvirus infection (Ciampor et al., 1981), and growth characteristics of these
five isolates and their cytopathic effect in vitro led to their classification on
biological characteristics as members of the alphaherpesvirus subfamily (see
1.1.2; Svobodova et al., 1982a). However, initial studies on the pathogenesis of
MHV-68 showed that laboratory mice developed a severe pneumonia with
widespread haematogenous dissemination of the virus (Blaskovic et al., 1984;
Rajcani et al., 1985), features not normally associated with alphaherpesvirus
infection. Subsequent molecular characterisation and partial sequence analysis
revealed close homology with the gammaherpesvirus family, and in particular
HVS (Efstathiou et al., 1990a; Efstathiou et al., 1990b). This led to the
reclassification of MHV-68 as a member of the rhadinovirus genera of the
gammaherpesvirus subfamily, and this was confirmed by later sequence analysis
of the genome (Virgin et al., 1997; Nash et al., 2001).
Infection of laboratory mice with MHV-68 resembles EBV infection in
humans in that the primary infection leads to an infectious mononucleosis-like
syndrome, and latent infection is associated with lymphoproliferative disease (see
1.4.1). MHV-68 replicates productively in tissue culture, so that virus can be
grown to high titres and the viral genome can be manipulated using molecular
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techniques in vitro. MHV-68 has therefore been used as a laboratory model for
the study of gammaherpesvirus infection in a natural host, and has enabled the
evaluation of potential antiviral drugs (Barnes et al., 1999) and vaccination
strategies (Stewart et al., 1999).
1.4.1. Pathogenesis ofMHV-68
The natural route of MHV-68 infection is unknown, but is likely to
involve close contact and entry of the virus via the respiratory or gastrointestinal
tracts, as the virus can productively replicate in the lung and intestinal epithelium
(Sunil-Chandra et al., 1992a; Peacock & Bost, 2000). Recent evidence from a
related strain of murine herpesvirus, MHV-72 (see 1.5), suggests that neonatal
transmission may occur via the mammary gland (Raslova et al., 2001).
Experimental transmission has also been demonstrated via the intravenous and
intraperitoneal routes. Intranasal inoculation ofMHV-68 results in the productive
infection of alveolar epithelial cells and mononuclear cells, causing a severe
interstitial pneumonia that may be fatal depending on the age of the mice
(Blaskovic et al., 1984; Rajcani et al., 1985; Sunil-Chandra et al., 1992a). Viral
titres in the lung peak at day 5-7 post-infection, and infectious virus is cleared
from the lungs by approximately day 14 although lymphoid accumulations remain
in the lung up to 5 months post-infection (Figure 1.4.1). The vims then enters the
bloodstream and is detectable in other organs in the body, including lytic
replication in the adrenal glands and latent infection of B lymphocytes in the
spleen (Sunil-Chandra et al., 1992a; Sunil-Chandra et al., 1992b). The exact
method of dissemination in the body is unclear, with the current hypothesis
suggesting that B-lymphocytes traffic the vims to the spleen rather than viral
spread via viraemia (Stewart et al., 1998b; Week et al., 1999a).
MHV-68 establishes latency in splenic B lymphocytes (Sunil-Chandra et
al., 1992b; Usherwood et al., 1996c), and there is a characteristic expansion in the
number of latently infected cells two weeks post-infection to a peak of 1 per 104
splenocytes latently infected (Figure 1.4.1). This peak is associated with a marked
splenomegaly, as determined by a doubling in the spleen mass and the total





Figure 1.4.1 Schematic representation of the key events during MHV-68 infection
in vivo after intranasal infection. Initial lytic replication occurs in the lung (red line
showing viral titres in the lung) and is cleared by day 14. The virus then establishes
latency in B lymphocytes in the spleen (green line showing latent virus levels),
characterised by a dramatic splenomegaly (blue line showing total splenocyte
numbers) which peaks at two weeks post-infection. A prolonged infectious
mononucleosis-like phase then occurs at later stages post-infection (purple line
showing Vp4+ CD8+ T cell numbers in the circulation). Figure adapted from
Coppola et al., 1999.
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This splenomegaly is driven by CD4+ T cells (Ehtisham et al., 1993;
Usherwood et al., 1996a) and is dependant on the presence ofMHV-68 infected B
lymphocytes in the spleen (Usherwood et al., 1996c; Week et al., 1996). The
splenomegaly observed is similar to that seen during EBV-induced infectious
mononucleosis. The levels of latent virus in the spleen then decline to stable
lifelong numbers of approximately 1 in 106 splenocytes latently infected.
Infection of B cell-deficient mice (pMT mice which lack mature B
lymphocytes) with MHV-68 showed that latency was still established in these
mice (Usherwood et al., 1996c; Week et al., 1996), and this led to the discovery
of other cell types harbouring latent MHV-68. Linear and episomal DNA was
detectable in the lungs of mice at late timepoints post-infection, and in situ
hybridisation demonstrated the presence of latent vtRNA transcripts in lung
epithelial cells in the absence of lytic transcripts, suggesting the presence of latent
MHV-68 and confirming the lung as a site of viral persistence (Stewart et al.,
1998b). Infection of pMT mice with large doses of MHV-68 intraperitoneally
leads to the establishment of latency in peritoneal exudate cells, and macrophages
were demonstrated to contain latent MHV-68 in this cell population (Week et al.,
1999b). Another study sorted latently infected splenocytes by FACS into B cells,
macrophages and dendritic cells and demonstrated the presence of latent MHV-68
in all of these cell types (Flano et al., 2000). Thus latent virus has been
demonstrated in four cell types: B cells, macrophages, dendritic cells and lung
epithelial cells.
In common with the other members of the gammaherpesvirus subfamily,
long-term latent infection with MHV-68 is associated with lymphoproliferative
disease, with approximately 10% of mice developing lymphomas or other forms
of lymphoid hyperplasia (Sunil-Chandra et al., 1994). Immunosupression
increases this frequency to 60%, and cell lines have been generated from such
tumours that harbour latent MHV-68 (Usherwood et al., 1996b). A further disease
syndrome was observed in mice deficient in the gamma interferon receptor (IFN-y
R-/-), and thus unresponsive to gamma interferon. Infection of these mice with
MHV-68 results in splenic atrophy, characterised by a widespread destruction of
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the splenic architecture and fibrosis (Dutia et al., 1997). Further studies revealed
that these mice also develop severe large-vessel arteritis and multi-organ fibrosis,
with a consequent increase in mortality following high dose intraperitoneal
infection (Week et al., 1997; Ebrahimi et al., 2001). These findings have led to
novel insights into the role of viruses in the development of fibrotic disorders and
arteritis.
1.4.2. Immune response to MHV-68 infection
Acute productive viral replication in the lung leads to a large
inflammatory response consisting mainly of mononuclear phagocytes and
lymphocytes (Sunil-Chandra et al., 1992a). The clearance of infectious virus from
the lungs is mediated by CD8+ T cells, as demonstrated by results showing that
MHV-68 infected mice depleted for CD8+ T cells using monoclonal antibodies
cannot control productive viral replication (Ehtisham et al., 1993), although this is
dependant on other factors such as viral dose and mouse strain (Stevenson et al.,
1999c). Further evidence for the role of CD8+ T cells in the control of acute viral
replication is shown by intraperitoneal infection of mice lacking CD8+ T cells
(P2-microglobulin gene deficient; p2 -/-)> which cannot clear infectious virus from
the spleen (Week et al., 1996). A number of MHV-68 lytic cycle CD8+ T cell
epitopes have been identified, with the two dominant epitopes being p56/Db (from
ORF6) and p79/Kb (from ORF61), and T cells specific for the p56 epitope
dominate during the acute viral infection in the lung (Stevenson et al., 1998;
Stevenson et al., 1999a; Liu et al., 1999b). Vaccination programmes using the
p56 dominant epitope significantly reduced the acute viral titres in the lung,
demonstrating the role of the CD8+ T cell response in the clearance of virus from
the lung (Liu et al., 1999c; Stevenson et al., 1999b).
CD4 I T cells appear to play a minor role in the lung during initial
infection, but depletion of these cells dramatically reduces the splenomegaly and
peak of latently infected splenocytes seen 2-3 weeks after infection with MHV-68
(Ehtisham et al., 1993; Usherwood et al., 1996a), and similar results were
obtained by infection of mice with a non-functional CD4+ population due to
MHC Class II disruption (Cardin et al., 1996). The splenomegaly is also
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dependant on the presence of MHV-68 infected B lymphocytes in the spleen
(Usherwood et al., 1996c; Week et al., 1996), and it is currently thought that they
activate CD4+ T cells, leading to the production of elevated levels of cytokines
such as IL-6, IL-10 and IFN-y (Sarawar et al., 1996), which drive the proliferation
of infected B cells. Although infection of mice that lack IFN-y or IL-6 shows no
difference in splenomegaly and latently infected cell numbers as compared to
wild-type controls (Sarawar et al., 1997; Sarawar et al., 1998), lack of
responsiveness to IFN-y leads to dramatic splenic pathology (see 1.4.1; Dutia et
al., 1997) and infection of mice which lack IL-10 results in enhanced
splenomegaly and a reduction in the amount of latent virus (Peacock & Bost,
2001). Innate immune mechanisms also play a critical role in the immune
response to MHV-68, as mice deficient in the Type I interferon response rapidly
succumb to fatal MHV-68 infection (Dutia et al., 1999a).
The splenomegaly and peak of latently infected cells is controlled by
CD8+ T cells, as evidenced by the inability to control the viral infection in the
spleen at late timepoints after either CD8+ depletion or infection of mice lacking
functional CD8+ T cells (Cardin et al., 1996; Week et al., 1996; Kulkarni et al.,
1997). Depletion of CD8+ T cells in latently infected mice lacking B cells (pMT
mice) also leads to the recrudescence of infectious virus (Stewart et al., 1998b),
confirming a role for the CD8+ T cell subset in the control of long-term latent
infection. CD4+ T cells also play a vital role in the control of latent MHV-68
infection, as demonstrated by the infection of mice with disruptions in the MHC
Class II gene (Cardin et al., 1996). These mice control the initial infection, but
productive viral replication in the lung recurs 3 weeks post-infection leading to
death of these mice by 4 months post-infection. The CD8+ T cell epitope
dominating at this time post-infection switches to the p79 epitope, suggesting that
there is an increase in productive viral replication leading to increased
presentation of lytic cycle antigens (Liu et al., 1999b; Stevenson et al., 1999a). In
contrast, currently only one CD8+ T cell latent epitope has been discovered,
derived from the M2 gene (Husain et al., 1999). The M2 gene and thus the M2gi_
99 CTL epitope is only expressed transiently during the establishment of latency
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up to 21 days post-infection, and the immune response against this epitope has
been implicated in the control of the initial peak in latently infected splenocytes
(Usherwood et al., 2000; Usherwood et al., 2001). High levels of anti-MHV-68
antibody are also produced by approximately 3 weeks post-infection (Usherwood
et al., 1996c; Stevenson & Doherty, 1998), but the fact that B cell deficient mice,
which cannot produce antibodies, control MHV-68 infection suggests that
antibody plays a minor role in controlling MHV-68 infection (Usherwood et al.,
1996c; Week etal., 1996).
Approximately three weeks after infection, a dramatic increase in the
circulating activated CD8+ T cell population is observed, similar to that seen
during infectious mononucleosis in humans after primary EBV infection. This
increase persists for over a month (Figure 1.4.1), and the majority of these cells
express the V(34 T-cell receptor (Tripp et al., 1997). It was initially proposed that
the Vp4 T-cell receptor might bind to an MHV-68 encoded superantigen, an
antigen that binds to a site on the MHC Class II outside the peptide-binding
groove (thus presented by many MHC Class II alleles) resulting in the stimulation
and expansion of a high frequency of CD8+ T cells (Scherer et al., 1993).
However, subsequent studies have shown this Vp4+ CD8+ expansion to be MHC
independent and oligoclonal, arguing against the role of a superantigen (Coppola
et al., 1999; Hardy et al., 2000). The precise nature of the ligand and the
biological function of this Vp4+ CD8+ expansion remains to be determined, but
appears to be dependant on CD4+ T cell assistance (Flano et al., 1999).
The knowledge of the immune response to MHV-68 has been utilised to
determine optimal vaccination strategies against gammaherpesviruses.
Vaccination using a vaccinia virus expressing the major virion glycoprotein,
gpl50, dramatically reduced the splenomegaly and peak of latent virus in the
spleen at two weeks post-infection (Stewart et al., 1999). Vaccination using lytic
cycle epitopes (the immunodominant p56 and p79 epitopes, subdominant gB
epitope and CD4+ gpl50 epitope) also led to a reduction in lytic viral titres and
peak of latent splenic virus (Liu et al., 1999c; Stevenson et al., 1999b), and DNA
vaccination against M2 results in a reduction in the load of latently infected
34
CHAPTER ONE INTRODUCTION
splenocytes in the initial stages of the latent infection (Usherwood et al., 2001).
One interesting result from these studies was that the latent and lytic viral
amplification processes appear to be separate, in that high levels of acute viral
replication are not necessary for the efficient establishment and amplification of
latent virus (Stevenson et al., 1999b). However, none of these vaccination
strategies managed to prevent the establishment and maintenance of latency
suggesting that multiple approaches may be necessary, and that it may not be
possible to protect against the establishment of latent gammaherpesvirus
infection.
1.4.3. Molecular biology of MHV-68
The MHV-68 genome contains a 118.2kb unique region containing at least
73 potential genes flanked by reiterated 1.2kb terminal repeat sequences (Virgin
et al., 1997; Nash et al., 2001). Like the other members of the rhadinovirus
genera, the genome is largely colinear with other members of the
gammaherpesvirus family, containing gammaherpesvirus specific ORFs that are
most closely related to homologous genes in HVS and KSHV, as well as MHV-68
specific ORFs (designated Ml-14). Figure 1.4.3.1. shows a detailed schematic
representation of the MHV-68 genome. Conserved herpesvirus family genes
include most of the structural proteins (such as capsid proteins and virion
glycoproteins) and proteins involved in DNA replication (such as DNA
polymerase), and Figure 1.4.3.2 shows that the gammaherpesviruses have large
blocks of collinear genes (depicted as orange, green, pink and blue blocks),
interspersed with virus-specific ORFs. These virus-specific ORFs are thought to
encode genes associated with latency, transformation and pathogenicity, reflecting
species and cell type-specific constraints. Thus MHV-68, like the other
rhadinoviruses, does not contain any of the EBV latency-associated genes, such as
the EBNA or LMP genes.
MHV-68 contains a number of genes with homology to cellular genes.
Two ORFs have been shown to be important in the induction of cellular
proliferation. The v-cyclin gene (ORF72) has been shown to promote cell cycle





















































































































Figure 1.4.3.1 The MHV-68 genome. A single green line represents the unique
region of the MHV-68 viral genome, with the genomic co-ordinates marked at lOkb
intervals. The positions of the terminal repeats (TR) and internal repeats (IR) are
indicated by the green boxes. The open reading frames (ORFs) are drawn as arrows
pointing in the direction of transcription, and are labelled according to either
function or designation according to Virgin et al., 1997 and Nash et al., 2001. Blue
arrows indicate genes conserved amongst other members of the herpesvirus family,
purple arrows indicate genes involved in the control of virus transcription, dark
green arrows indicate MHV-68 glycoproteins, red arrows indicate genes involved in
nucleotide metabolism, yellow arrows indicate genes that are unique to the MHV-
68 genome and orange arrows indicate genes involved in viral pathogenesis and
cellular homologues. The eight vtRNAs are represented by blue arrows.
Abbreviations used: crp, complement regulatory protein; gB, glycoprotein B; K3,
homologue of the KSHV K3 gene; TK, thymidine kinase; gH, glycoprotein H; gM,
glycoprotein M; ung, uracil DNA glycosylase; gL, glycoprotein L; rta, R
transactivator; gpl50, glycoprotein 150; dut, dUTPase; mta, M transactivator; rr2,
small subunit ribonucleotide reductase; rrl, large subumt ribonucleotide reductase;
v-cyc, viral cyclin D homologue; vbcl-2, viral bcl-2 homologue; vGPCR, viral G-











































































































































































Figure 1.4.3.2 Comparison of the genomic organisation among the members of the
gammaherpesvirus family. The genomes of herpesvirus saimiri (HVS), murine
gammaherpesvirus 68 (MHV-68), Kaposi's sarcoma-associated herpesvirus
(KSHV), alcelaphine herpesvirus 1 (A1HV-1), equine herpesvirus 2 (EHV-2) and
Epstein-Barr virus (EBV) are depicted schematically (not to scale). The EBV
genome has been inverted relative to its conventional orientation. The four blocks
of genes conserved among the members of the gammaherpesvirus family are shown
(block I in orange, block II in green, block III in red and block IV in blue), with
open reading frame (ORF) designations referring to the HVS numbering system.
Interspersed between these conserved gene blocks are ORFs that are either virus
specific or have homology to cellular genes (blue triangles pointing in the direction
of transcription). These genes are involved in cell transformation, latency or
pathogenesis. Large non-coding regions in the A1HV-1 and EHV-2 genomes are
denoted by black diagonal lines. Abbreviations used: STP, saimiri transformation-
associated protein; TIP, tyrosine kinase interacting protein; DHFR, dihydrofolate
reductase; crp, complement regulatory protein; vIL, viral interleukin homologue;
vCD59, viral CD59 homologue; vbcl-2, viral bcl-2 homologue; TS, thymidylate
synthetase; vFLIP, viral FLICE inhibitory protein; v-cyc, viral cyclinD homologue;
vGPCR, viral G-protein coupled receptor homologue; vCKBP, viral chemokine
binding protein; K3 and K5, KSHV specific ORFs (also found in MHV-68)
involved in downregulation of surface MHC Class I; gp, glycoprotein; vMIP, viral
macrophage inflammatory protein; vIRF, viral interferon regulatory factor; LANA-
1, latency-associated nuclear antigen 1; vOx2, viral Ox2 cellular adhesion molecule
homologue; LAMP, latency-associated membrane protein; sema, semaphorin
homologue; vCKR, viral chemokine receptor homologue; LMP, latent membrane
protein; EBNA, EBV nuclear antigen. Adapted from Simas & Efstathiou, 1998.
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1999), and the vGPCR (ORF74) can transform rodent fibroblast cells in vitro
(Wakeling et al., 2001). The functional significance of these genes in MHV-68
pathogenesis is uncertain, as v-cyclin is expressed only during the lytic cycle (van
Dyk et al., 1999) and MHV-68 cannot transform lymphocytes in vitro (Dutia et
al., 1999b), but studies using recombinant viruses deleted for v-cyclin show that it
is required for efficient reactivation from latency (Hoge et al., 2000; van Dyk et
al., 2000). MHV-68 also contains a gene with homology to the bcl-2 family,
which inhibits apoptosis in vitro (Wang et al., 1999; Roy et al., 2000), and a
homologue of the complement regulatory protein family, which inhibits
complement activation (Kapadia et al., 1999). Thus these genes with cellular
homologues appear to play an important role in immune evasion during viral
pathogenesis (see 1.6).
Several genes are expressed during MHV-68 latency in vitro and in vivo,
including the vtRNAs, M2, M3, v-bcl2, vGPCR and LANA-1 homologue
(ORF73). In vitro studies have utilised the SI 1 cell line, which contains episomal
MHV-68 and is therefore analogous to the latently infected cell lines ofEBV and
KSHV (Usherwood et al., 1996b). Northern analysis of RNA extracted from SI 1
cells coupled with in situ hybridisation studies of latently infected mouse tissues
have demonstrated the expression of the M2 gene during latency, and the vtRNA-
like sequences and M3 during latent and lytic infection in vitro and in vivo
(Bowden et al., 1997; Husain et al., 1999; Simas et al., 1999). These results were
confirmed by further studies using RT-PCR, which showed expression of M2,
M3, M9, v-bcl2, vGPCR and LANA-1 homologue (ORF73) in latently infected
spleen and peritoneal exudate cells derived from B cell deficient mice (Virgin et
al., 1999) and M2, M3, vGPCR and v-bcl2 in the lungs and spleens of latently
infected BALB/c mice (Roy et al., 2000; Usherwood et al., 2000; Wakeling et al.,
2001). The v-bcl2 and vGPCR genes are expressed from a bicistronic transcript
(Wakeling et al., 2001). Recent analysis of MHV-68 gene expression using an
RNase protection assay suggested that K3, M8 and M9 may also be latent
transcripts (Rochford et al., 2001), but caution is required in the interpretation of
these results as this study used mouse spleens up to day 16 post-infection when
lytic replication is still occurring in the spleen (Usherwood et al., 2000) and M8
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and M9 are homologues of known herpesvirus lytic cycle genes (Mta and HVS
ORF65 capsid protein respectively; Nash et al., 2001). All these studies on MHV-
68 latent gene expression suggest that MHV-68 may have multiple latent gene
expression programmes similar to those observed in EBV latency, which vary
depending on the cell type (B lymphocyte, dendritic cell, macrophage or epithelial
cell) or organ (lung, mediastinal lymph node or spleen) latently infected, the
immune response to the particular latent antigens expressed and the degree of
permissiveness for lytic replication.
1.4.4. Left end of the unique region of the MHV-68 genome
The region at the left end of the MHV-68 genome is of interest as it
contains four genes unique to MHV-68 (Ml, M2, M3 and M4) as well as eight
vtRNAs. This position of the genome in other gammaherpesviruses contains a
block of virus-specific genes involved in cellular transformation (K1 of KSHV),
oncogenesis (LMP1 of EBV and STP/TIP of HVS) and immune evasion (A3 in
A1HV-1 and El/vCKR in EHV-2; Figure 1.4.3.2). This region of the MHV-68
genome is hypothesised to encode a viral origin of replication (Bowden et al.,
1997), and readily accommodates the insertion of foreign DNA via non¬
homologous recombination (Simas et al., 1998; D. Roy, I. Atkin, M. Wakeling,
unpublished observations). However, insertion of foreign DNA into this region
with no apparent disruption of known ORFs leads to alterations in viral phenotype
(Clambey et al., 2000; Adler et al., 2001). The current data on the function of the
genes in this region is summarised below.
• Ml. This is predicted to encode a 420 a.a. protein expressed during lytic
replication (Virgin et al., 1999), with significant homology to the poxvirus serpins
(serine protease inhibitors), which are thought to modulate apoptosis, and the
MHV-68 M3 protein (see 1.6; Bowden et al., 1997; Virgin et al., 1997). Two
studies have generated recombinant viruses deleted for the Ml gene with little
effect on viral replication in vitro and in vivo (Simas et al., 1998), with one study




• M2. Northern analysis on RNA isolated from SI 1 cells and in vivo studies
using RT-PCR and in situ hybridisation have demonstrated that M2 is a latency-
associated gene (Husain et al., 1999; Virgin et al., 1999), and is also expressed at
low levels during lytic replication in vitro (Virgin et al., 1999; Rochford et al.,
2001). It is transiently expressed during the establishment of latency, with no
expression detectable in the spleen or lung after one month post-infection
(Usherwood et al., 2000). It is expressed as a complex spliced transcript,
predicted to encode a 192 a.a. protein (Figure 5.2.1), and utilises an alternative
polyadenylation signal (AGUAAA, nucleotide positions 3398-3). A recent survey
of polyadenylated expressed sequence tags (ESTs) showed that this variant
polyadenylation signal occurs in approximately 3% of human genes (Beaudoing
et al., 2000), but is polyadenylated and cleaved with an efficiency of only 30%
compared to the normal AAUAAA signal (Sheets et al., 1990). The M2 protein
also contains an epitope recognised by the CD8+ T cell response (Husain et al.,
1999). Modulation of the immune response to M2 prior to MHV-68 infection,
either by the adoptive transfer of M2-specific CD8+ T cells or DNA vaccination
using M2 leads to a reduction in the initial load of latently infected splenocytes
but not the establishment and maintenance of latency (Usherwood et al., 2000;
Usherwood et al., 2001). It is therefore hypothesised that the recognition of the
M2 protein by the immune system is important in the control of the initial peak of
latently infected cells seen two weeks post-infection.
• M3. Northern analysis, RT-PCR and in situ hybridisation studies have all
shown that M3 is expressed during lytic and latent infection in vivo and in vitro
(Husain et al., 1999; Simas et al., 1999; Virgin et al., 1999; Rochford et al.,
2001), with the detection of M3 transcripts by RT-PCR up to 10 months post¬
infection in the lung and spleen (Usherwood et al., 2000). It is transcribed as a
single early-late lytic transcript, and encodes an abundant secreted protein of
44kDa (van Berkel et al., 1999). The M3 protein binds a broad spectrum of
chemokines with high-affinity (including CC, CXC, C and CX3C classes of
chemokine), and blocks the interactions of chemokines with their cellular
receptors thus preventing their function (Parry et al., 2000; van Berkel et al.,
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2000). Generation of an M3-deficient recombinant virus lacking chemokine-
binding activity (Parry et al., 2000) showed that although the lack of a functional
M3 had no effect on lytic viral replication in the lung and spread of virus to the
draining lymph nodes, there was a dramatic reduction in the peak of latently
infected splenocytes at 2 weeks post-infection (Bridgeman et al., 2001). This
reduction could be reversed by CD8+ T cell depletion, suggesting that M3 is
necessary to block recruitment of CD8+ T cells into the spleen.
• M4. Northern analysis and RT-PCR has shown that this ORF is transcribed
solely during lytic replication (Simas et al., 1999; Virgin et al., 1999; Wan, 2002).
It is predicted to encode a 459 a.a. protein, containing an N-terminal signal
sequence and a heparin sulphate binding domain, and is therefore postulated to
have cytokine-like properties (Wan, 2002).
• vtRNAs. MHV-68 encodes eight tRNA-like sequences interspersed with
the ORFs in this region of the genome (Figure 1.4.3.1 and 3.2C; Bowden et al.,
1997; Virgin et al., 1997). They are abundantly expressed during lytic replication
and latent infection (Bowden et al., 1997), and have therefore been used as a
molecular marker of latency when their transcription is detectable by in situ
hybridisation in the absence of detectable lytic gene transcription such as TK or
gB (Stewart et al., 1998b). Only three of the vtRNAs specify for amino acids, and
although they are processed into mature tRNA species, they are not
aminoacylated indicating that they are non-functional during normal translation
(Bowden et al., 1997). Four of the vtRNAs can be deleted with no effect on viral
replication or pathogenesis (Simas et al., 1998). As previously mentioned (see
1.2), other gammaherpesviruses encode small RNA species, including the EBERs
in EBV (see 1.1.3.2) and the HSURs of HVS (see 1.2.3), which may play
important roles in oncogenesis (Takada & Nanbo, 2001).
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1.5. Other murine herpesvirus isolates
MHV-68 was one of five murine herpesviruses originally isolated
(Blaskovic et al., 1980). Strains 60, 68 and 72 were isolated from the bank vole
(Clethrionomys glariolus) and strains 76 and 78 were isolated from the yellow-
necked wood mouse (Apodemus flavicollis). The isolates were passaged numerous
times in vivo and in vitro prior to isolation, and following ultrastructural analysis
of infected cells and growth characteristics of these five isolates in vitro, the
isolates were subsequently classified as herpesviruses (Ciampor et al., 1981;
Svobodova et al., 1982a). However, only the pathogenesis of MHV-68 was
studied in mice (Blaskovic et al., 1984) and characterised further, leading to our
current knowledge of MHV-68 as a model of gammaherpesvirus pathogenesis
(see 1.4).
Of the other murine herpesviruses originally isolated, only MHV-72 has
been characterised in detail. This strain has similar biological properties to MHV-
68 in that it infects lymphocytes and peritoneal cells in vitro and in vivo
(Mistrikova et al., 1994), immunosupression leads to the recrudescence of latent
virus (Mistrikova et al., 1996a) and latent infection is associated with
tumourogenesis (Mistrikova et al., 1996b). Recent studies using MHV-72
showing evidence of viral replication in mammary tissue and transmission to
neonatal animals via milk suggests that natural infection may occur by this route
(Raslova et al., 2001). Limited sequence analysis of MHV-72 has been
performed, showing that the gpl50 (GenBank Accession No. AF294428) and TK
genes are over 99% identical at the nucleotide level to MHV-68 (Raslova et al.,
2000), suggesting that they are nearly identical viruses.
Apart from MHV-68 and MHV-72, few studies have been performed on
the other murine herpesvirus isolates. Initial serological characterisation showed
that all the isolates appeared to be very closely related antigenically (Svobodova
et al., 1982b), and polypeptide profiles from lytically infected fibroblasts were
also very similar (Reichel et al., 1991). It is of interest that MHV-68 and MHV-78
appear to lack a 46kDa protein compared to the other isolates, although this may
be a cellular protein rather than a viral protein. A comparison of DNA from
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MHV-76, murine CMV and rat CMV infected cells using restriction endonuclease
analysis and cross-hybridisation appeared to show close homology between
MHV-76 and rat CMV, leading to the conclusion that MHV-76 was a strain of rat
CMV that had infected mice (Hamelin & Lussier, 1992). However none of these
studies have determined the sequence of any of these isolates, and thus their
relationship to MHV-68 remains unknown. One argument suggests that all the
isolates are extremely similar or identical to MHV-68 as they were all isolated in
the same geographical region, whereas another hypothesis suggests that the
strains may have diverged reflecting the two different species that they were
isolated from.
1.6. Evasion of the host response to viral infection
As gammaherpesviruses are the subject of this thesis, this review will
concentrate on the immune evasion mechanisms utilised by these viruses, but
examples of other viral mechanisms are also detailed where appropriate to
illustrate the broad diversity of viral immune evasion strategies.
1.6.1. Immune response to viral infection
The immune response to viral infection is an extremely complex process,
and is summarised in Figure 1.6.1. The first line of defence against viruses
involves a series of physical barriers such as the skin, mucous membranes and
stomach acid. However, once these defences are breached, the initial immune
response following infection is antigen non-specific (innate response). This
involves a number of effector mechanisms including type I interferons (IFN-a/p),
apoptosis of infected cells, activation of complement and destruction of cells by
natural killer (NK) cells, macrophages and neutrophils. Viral infection of cells
upregulates IRF3 expression, leading to the activation of IFN-p. This IFN-P
results in the upregulation of IRF3 and IRF7, leading to the production of IFN-
a/p (Taniguchi et al., 2001). IFN-a/p then bind to their cognate receptors on the
cell surface, activating the Jak/STAT intracellular signalling pathway which























Figure 1.6.1 Overview of the immune response to viral infections. For clarity, the
immune response has been divided into innate and adaptive responses. Green
arrows indicate some of the many complex interactions between the two types of
response that help in the co-ordination of the immune response.
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dependant protein kinase R (PKR) that stops protein translation, 2'-5'
oligoadenylate synthetase (OAS) that non-specifically degrades mRNA via
activation of RNase L, Mx proteins that interfere with virus replication and
induction of the caspase pathway leading to apoptosis of the infected cell
(Goodbourn et al., 2000). The vital role of type I interferons in the response to
viral infections is demonstrated by studies showing that MHV-68 infection is
rapidly fatal in mice with disabled type I interferon pathways (Dutia et al.,
1999a). Viral infection can also lead to the induction of apoptosis (programmed
cell death) via the tumour necrosis factor (TNF) cytokine family or Fas receptor
activation, the caspase pathway or a number of other pathways (Barry &
McFadden, 1998; Everett & McFadden, 1999). Apoptosis is regulated by the bcl-
2 family of proteins that includes both pro and anti-apoptotic family members,
and it is postulated that in some instances apoptosis may help viruses disseminate
more widely (Everett & McFadden, 1999).
Viral infection of cells also leads to the production of pro-inflammatory
cytokines such as IL-1, IL-8 and MlP-la that recruit and activate inflammatory
cells such as macrophages, phagocytes and NK cells. Phagocytosis is enhanced by
coating of the infected cell with antibody and complement, a process called
opsonisation. During viral infection, the complement pathway is activated by
antibody-antigen complexes (classical pathway) resulting in a regulated enzyme
cascade that leads to either lysis of the infected cell via the membrane attack
complex (MAC) or opsonisation of the infected cell and subsequent phagocytosis.
The complement cascade during viral infection is therefore dependant on
antibody, and thus the adaptive immune response. NK cells are cytotoxic cells
that are the major effector cells of the innate immune response against virally
infected cells, and are activated and recruited by type II interferon (IFN-y). They
recognise infected cells via Fc receptors (antibody mediated), and it is also
thought that downregulation of MHC Class I in infected cells leads to enhanced
NK cell lysis.
Viral proteins are degraded and processed into antigenic peptides by
antigen-presenting cells (APC) such as dendritic cells, which then migrate to the
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local lymph nodes to initiate the adaptive (specific) immune response. APCs
present antigens as a complex with MHC Class II on the cell surface, and this
complex is recognised by CD4+ T lymphocytes (helper T cells). This leads to
activation of the CD4+ T cells via IL-1 and IL-2, resulting in clonal expansion of
the antigen-specific T cell population. The CD4+ T cells secrete a number of
cytokines that act to enhance the innate immune response (via IFN-y), expand the
number of T lymphocytes (via IL-2) and regulate antibody production by B
lymphocytes (via IL-4 and IFN-y). The antiviral response is held to be a
predominantly Thl response, although there are substantial areas of overlap
between the two types ofCD4+ T cell response. Pro-inflammatory cytokines such
as IL-1, TNF-a and IFN-y also lead to the production of chemokines, which result
in migration of leukocytes to the site of viral infection (Luster, 1998).
Presentation of antigen in association with MHC Class I is recognised by CD8+ T
cells (cytotoxic T cells) and this leads to the lysis of the infected cells by secretion
of perforin or granzymes, or the induction of apoptosis via Fas receptor binding.
These CD8+ T cells also secrete IFN-y and IL-2, leading to enhancement of the
immune response to the virus.
Recognition of antigen by B lymphocytes via the B cell receptor (BCR)
results in the activation and clonal expansion of the antigen-specific B
lymphocyte population. These then differentiate and produce antibodies (humoral
immunity), which can neutralise and precipitate viruses directly, or enhance
various innate responses such as complement and phagocytosis. There are
substantial interactions between B cells and CD4+ T cells; activated B cells
express MHC Class II and can thus present antigen to CD4+ T cells, and IL-4, IL-
5 and IFN-y released by CD4+ T cells assists in the activation of B lymphocytes.
A subset of the B and T cell populations activated during the immune response
called memory cells persist for many years afterwards, and enable the immune
response to respond quickly to repeated infections. Thus there are a number of
complex interacting pathways involved in the immune response to viral
infections, and viruses have evolved a number of different mechanisms to bypass
these responses. Evidence of this is demonstrated by the vast number of genes
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encoded by DNA viruses such as poxviruses and herpesviruses that are involved
in immune evasion, but even the limited size of the RNA viral genomes can
contain multi-functional immunomodulatory genes. Some of these genes have
sequence homology to cellular genes and represent genes acquired by "molecular
piracy" whereas others have no cellular homologues, representing viral genes that
that have either co-evolved with the host or have cellular homologues yet to be
identified.
1.6.2. Inhibition of the innate immune response
The innate immune response acts rapidly and non-specifically, and viruses
must therefore overcome this response in order to replicate and produce infective
progeny virions. Apoptosis can occur as a response to a variety of virally-induced
stimuli (Everett & McFadden, 1999), and thus viruses have adopted a number of
approaches to counteract this. One approach is to produce homologues of the
cellular anti-apoptotic protein bcl-2, and this is demonstrated by the herpesvirus
family. MHV-68 encodes a functional bcl-2 homologue that protects cells from
Fas and TNFa mediated apoptosis (Wang et al., 1999; Roy et al., 2000). It is also
expressed during viral latency suggesting that this protein may protect latently
infected cells from apoptosis. Other herpesvirus bcl-2 homologues appear to be
expressed during lytic infection only, suggesting a role during initial infection
(Barry & McFadden, 1998). Another anti-apoptotic cellular homologue encoded
by KSHV, HVS and EHV-2 is the vFLIP (viral FLICE-dependant apoptosis
inhibitor) that interferes with apoptosis signalled through the CD95 death receptor
(Thome et al., 1997), and these molecules are also involved in tumourogenesis
(Djerbi et al., 1999). Other mechanisms by which viruses can inhibit apoptosis
include the expression of proteins such as poxvirus serpins that inhibit the caspase
pathway (Brooks et al., 1995; Dobbelstein & Shenk, 1996), and inactivation of
p53, which is also involved in the apoptotic pathway (Evan & Littlewood, 1998;
Friborg et al., 1999). Thus viruses can interfere at multiple stages of the apoptotic
pathway.
The anti-viral effects of interferons also present a major barrier to initial
viral replication in the cell. The sequestration of dsRNA is one mechanism by
49
CHAPTER ONE INTRODUCTION
which to avoid the production of IFN (Goodbourn et al., 2000). However, once
IFN is produced viruses can target the Jak/STAT signalling pathway to block the
actions of IFN as shown by the adenovirus ElA protein (Leonard & Sen, 1996)
and EBNA2 of EBV (Kanda et al., 1992). Viruses can target several steps of the
interferon pathway at once to ensure complete inhibition of the pathway;
adenoviruses and EBV produce small RNA molecules that bind to PKR, but fail
to activate it and thus act as competitive inhibitors (Sharp et al., 1993; Mahr &
Gooding, 1999). However, other studies suggest that the EBERs can deliberately
activate the OAS pathway, possibly to prevent the production of cellular antiviral
proteins (Sharp et al., 1999). Inhibition of the IFN-inducible antiviral pathways
(PKR and OAS/RNaseL) is achieved by a number of mechanisms such as binding
dsRNA (necessary for activation of PKR) or PKR itself (Haig et al., 1998; Sharp
et al., 1998), and the expression of cellular RNaseL inhibitors by viruses such as
HIV-1 (Martinand et al., 1999). The importance of this inhibition of the IFN
pathway in viral pathogenesis is demonstrated by HSV mutants deleted in
ICP34.5, an ORF that interferes with PKR function. This mutant virus is
attenuated in normal mice, but exhibits wild-type virulence in PKR null mice
demonstrating the importance of disruption of the IFN pathway in HSV
pathogenesis (Leib et al., 2000).
Disruption of the complement cascade is critical for the virus, both as a
means of escaping the antibody response and also phagocytosis via opsonisation.
Many herpesviruses and poxviruses encode complement control proteins (Kotwal,
2000), including ORF4 of MHV-68. This protein inactivates C3 convertase,
reducing C3 deposition in a similar manner to HVS ORF4 (Fodor et al., 1995;
Kapadia et al., 1999). HVS also targets another step in the complement cascade
by containing a CD59 homologue that inhibits the terminal C9 polymerisation
step (Rother et al., 1994). Other viruses encode IgG Fc receptors, such as gE/gl of
HSV-1 and the FcR of murine CMV, which bind IgG and thus prevent Fc-
dependant activation of complement (Johnson et al., 1988; Thale et al., 1994).
NK cells are another significant effector mechanism of the innate immune
response, and it is hypothesised that NK cells destroy cells that do not express
MHC Class I molecules (the "missing-self' hypothesis; Lanier, 1997). Thus
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viruses that downregulate MHC Class I to escape CD8+ T cell cytotoxicity (see
1.6.3) may be more susceptible to NK-mediated cytotoxicity. It is of interest in
this respect that the cytomegaloviruses encode MHC Class I homologues and
upregulate HLA-E to inhibit NK cell activity (Farrell et al., 1997; Reyburn et al.,
1997; Tomasec et al., 2000; Tortorella et al., 2000).
Co-ordination, recruitment and regulation of the innate and adaptive
immune responses is performed by cytokines and chemokines, so therefore
viruses have assembled a vast assortment of proteins to inhibit or modulate their
activity (Alcami & Koszinowski, 2000; Lalani et al., 2000; Murphy, 2001).
Poxviruses contain soluble cytokine receptors that bind IFNa/p, IFN-y, TNF and
IL-ip and therefore prevent binding to their cellular receptors (Alcami & Smith,
1995), and other poxvirus proteins stop the maturation and secretion of cytokines
by inhibiting the IL-ip-converting enzyme necessary to convert proIL-ip into the
active form (Messud-Petit et al., 1998). Due to the multiple cytokine pathways
involved, secretion of a soluble IL-18 binding protein also inhibits IL-18 induced
IFN-y production (Smith et al., 2000). However, viruses not only act to inhibit
cytokine pathways but also use them for their advantage. The LMP-1 protein of
EBV activates the TNF receptor/CD40 signalling pathway, leading to
immortalisation of B cells (Farrell, 1998) and the viral IL-6 homologue encoded
by the KSHV K2 gene is a B cell growth factor as well as stimulating
angiogenesis, and therefore contributing to KSHV pathology (Aoki et al., 1999).
Chemokines are also important effector molecules during the initial stages
of the anti-viral response, trafficking leukocytes to sites of viral infection and
activating them (Luster, 1998). KSHV encodes a group of chemokine homologues
(vMIP-I, vMIP-II and vMIP-III), some of which are agonists that act to redirect
the adaptive immune response and stimulate angiogenesis (vMIP-I; Stine et al.,
2000) and others that encode chemokine antagonists that act to decrease
inflammation (vMIP-II; Chen et al., 1998). Many poxviruses also contain
chemokine homologues (Murphy, 2001), and the affinity of HIV-1 gpl20 for
CCR5 and CXCR4 receptors enables the virus to bind and infect cells (Littman,





proteins (vCKBP), which act to bind chemokines and therefore inhibit binding to
their receptors (Lalani et al., 2000). There are divided into three structural classes,
and the broad-spectrum chemokine scavenger of MHV-68 (M3, see 1.4.4) is a
member of the vCKBP-III class. These vCKBP have no known cellular
homologues. The final mechanism by which viruses can subvert the chemokine
pathways is by encoding chemokine receptor homologues. Some of these
receptors like the El protein of EHV-2 are thought to enable infected cells to
respond to chemokines and therefore act in subversion of the immune response
(Camarda et al., 1999), but other receptors such as the GPCRs encoded by KSHV
and MHV-68 are constitutively active (agonist-independent), and therefore may
have a role in cellular transformation (Bais et al., 1998; Wakeling et al., 2001).
Thus viruses have adopted numerous mechanisms to not only evade the immune
response, but also to utilise it for their advantage.
1.6.3. Inhibition of the adaptive immune response
Viruses such as herpesviruses that establish life-long infections also need
to ensure their survival in the face of a vigorous adaptive immune response. The
adaptive response requires the recognition of antigen in order to function, and
therefore viruses such as HIV and influenza virus can modify their antigenic
properties via random mutations (antigenic drift/shift). This variation in antigenic
proteins can not only affect immune recognition but also alter proteolysis and
MHC association. In order for the CD8+ cytotoxic T cell response to recognise
viral antigens, the viral proteins must be degraded and then presented in
association with MHC Class I (see 1.6.1). The presence of the Gly-Ala repeat
sequence in EBNA-1 inhibits degradation by the proteasomes, and thus
processing of EBNA-1 antigens (Levitskaya et al., 1995). As EBNA-1 is thought
to play an essential role in the EBV latent life cycle and be permanently expressed
during latency (see 1.1.3.2 and 1.2.1), this feature is thought to prevent
recognition of infected cells during latency. However, functional cytotoxic T
lymphocytes specific for EBNA-1 are still found during EBV infection, and thus
there appears to be another mechanism to enable the immune response to process
EBNA-1 antigens. Recent research has also postulated that there may be a type of
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EBV latency without expression of EBNA-1. After processing, the antigenic
peptides are associated with MHC Class I and transported from the ER to the cell
surface as a complex with transporter-associated with antigen processing (TAP),
and HSV-1 ICP47 prevents peptide binding to the complex by interactions with
TAP (Hill et al., 1995). Another way in which viruses can stop surface expression
of the MHC Class I-antigen complex is to retain the complex in the ER. HCMV
encodes three gene products that interfere with this pathway; US3 that retains
MHC Class I in the ER (Jones et al., 1996), and US2 and US11 that relocate
MHC Class I into the cytosol for degradation by the proteasome via recruitment
of the normal cellular machinery that degrades abnormal proteins (Schust et al.,
1998). Proteins encoded by MHV-68 (K3) and KSHV (K3 and K5) serve to
downregulate surface expression ofMHC Class I via rapid endocytosis (Ishido et
al., 2000b; Stevenson et al., 2000b). Another virus that needs to establish long-
term persistence is HIV, and it encodes two proteins, Nef and Vpu, that
downregulate MHC Class I expression (Kerkau et al., 1997; Cohen et al., 1999).
To circumvent the problem of enhanced NK cell lysis due to reduced MHC Class
I expression (see 1.6.2), Nef specifically targets certain HLA locus products
leaving HLA-C and HLA-E locus products that inhibit NK cell activity, and
KSHV also downregulates surface ICAM-1 and B7-2 receptors, which are the
ligands for NK cell-mediated cytotoxicity receptors (Ishido et al., 2000a). Thus all
these different mechanisms to prevent antigen presentation ensure viral survival
from CD8+ T cell cytotoxicity (Brodsky et al., 1999; Haig, 2001).
Prevention ofMHC Class II antigen presentation interferes with CD4+ T
cell recognition, and thus the numerous effector mechanisms and co-ordination of
the antiviral response by these T lymphocytes. Expression of surface MHC Class
II is driven by IFN-y, and thus mechanisms that disrupt interferon pathways also
disrupt MHC Class II expression (see 1.6.2). The HCMV protein US2 targets
MHC Class II as well as Class I molecules for degradation (Tomazin et al., 1999),
whereas the human papillomavirus E5 protein targets the endocytic pathway,
which is necessary for transport of proteins and complexes to the cell surface
(Straight et al., 1993). The multifunctional Nef and Vpu proteins of HIV also
target the CD4+ T cell response but by an alternative mode. Nef interacts with
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CD4 at the cell surface, resulting in CD4 endocytosis and transport to the
lysosomes. Vpu induces the proteasomal degradation of CD4 in the cytosol via
the ubiquitin pathway (Piguet et al., 1999). These two proteins therefore
efficiently hijack the host cell machinery to downregulate surface CD4 molecules.
Humoral immunity (antibody) also contributes significantly to the antiviral
response. The viral mechanisms of avoiding the complement pathway have
already been discussed (see 1.6.2), but the viral Fc receptors also bind to
antibodies, thus preventing neutralisation of the virus particles and Fc-dependant
immune activation. Viral Fc receptors are particularly common in herpesviruses,
and it is postulated that these receptors are especially required as latency and
reactivation of herpesviruses requires replication in a previously exposed host
where high-affinity antiviral antibody is present as a result of prior infection
(Tortorella et al., 2000). Measles virus can also bind to CD32, resulting in
antagonism of signals from the B cell receptor and attenuation of antibody
production (Ravanel et al., 1997). A model for the establishment of latency by
EBV in B lymphocytes suggests that EBV uses the normal B cell differentiation
pathway to establish latency in resting memory B cells, using LMP2A to
substitute for the B cell receptor and LMP1 to substitute for CD40 to provide the
necessary growth and survival signals (Thorley-Lawson & Babcock, 1999). Thus
the immune response is used by EBV to provide a suitable host for life-long
infection.
The immune response is a highly complicated system to protect the host
from infection, but viruses have evolved to evade and also utilise the immune
system for their own purposes. Herpesviruses have to subvert the immune
response in order to establish life-long latent infection, and the gammaherpesvirus
subfamily in particular have evolved to establish latency in lymphocytes, so it is
probably not surprising that they have evolved so many complex strategies with a
high degree of functional redundancy to achieve this.
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The composition of general solutions (Appendix 1), the sequence of PCR
primers (Appendix 2), plasmid vectors (Appendix 3) and commercial suppliers
(Appendix 4) are detailed in the appendices at the end of Chapter 2.
2.1 Tissue culture
2.1.1. Cell lines
CELL LINE DESCRIPTION ECACC No. REFERENCE









HeLa Human cervical carcinoma
Epithelial, adherent
85060701 (Scherer et al.,
1953)
293 Human embryo kidney
Epithelial, adherent
85120602 (Graham et al.,
1977)





A20 Mouse B-cell lymphoma
line derived from BALB/c
mice. Suspension
(Kim et al., 1979)
Table 2.1.1 Cell lines used.
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All cells were obtained from in-house stocks (Table 2.1.1). They were
cultured in sterile plasticware (Nunc) and incubated at 37°C in a humidified
atmosphere containing 5% C02. Baby Hamster Kidney (BHK) cells were grown
in Glasgow's modified Eagle's medium (GMEM, Invitrogen Life Technologies)
supplemented with 10% v/v new born calf serum (NBCS, Invitrogen Life
Technologies), 10% v/v tryptose phosphate broth (TPB, Invitrogen Life
Technologies), 70pg/ml penicillin (Merck), 10pg/ml streptomycin (Sigma) and
2mM L-glutamine (Merck). COS-7, HeLa and 293 cells were grown in
Dulbecco's modified Eagle's medium (DMEM, Invitrogen Life Technologies)
supplemented with 10% v/v foetal calf serum (FCS, Sigma), 70pg/ml penicillin,
10pg/ml streptomycin and 2mM L-glutamine. Sll cells were grown in Roswell
Park Memorial Institute 1640 (RPMI 1640, Invitrogen Life Technologies)
supplemented with 10% v/v FCS, 70pg/ml penicillin, lOpg/ml streptomycin,
50pM P-mercaptoethanol (Sigma) and 2mM L-glutamine. A20 cells were grown
in RPMI 1640 supplemented with 5% v/v FCS, 70pg/ml penicillin, 10pg/ml
streptomycin, 50pM P-mercaptoethanol and 2mM L-glutamine.
2.1.2. Harvesting of adherent cells
Cells were harvested by trypsinisation. The medium was decanted from
the flask, and the cell monolayer washed with 0.02% w/v versene. The monolayer
was then incubated with a 0.05% w/v trypsin, 0.02% w/v versene solution for
approximately 3 mins, until the cells became detached from the surface of the
flask. The cells were resuspended in fresh medium, transferred to a sterile
universal and pelleted by centrifugation at 500 x g for 5 mins. The cell pellet was
resuspended in 10ml fresh medium, counted and 1-5 x 106 cells used to reseed a
new 175cm tissue culture flask (Nunc) containing fresh medium.
2.1.3. Counting cells
Cells were counted by adding 50pl of cell suspension to 50pl of 0.4%
Trypan Blue (Sigma), and then placing the mixture in a haemocytometer. The
number of unstained viable cells was counted per 1mm square.
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2.1.4. Transfection ofmammalian cells by electroporation
Cells were subcultured 24 hours before transfection, so that they had
achieved approximately 50% confluency on the day of transfection. The cells
were harvested, counted and resuspended at 2.5 x 106 cells/ml. An 800pl sample
of the cell suspension (2 x 106 cells) was added to a chilled 4mm electroporation
cuvette (EquiBio), 5 - 20pg ofDNA added and the suspension mixed thoroughly.
The cells were then electroporated using an Easyject electroporator (EquiBio).
COS-7 cells were transfected using the single pulse program (260V, 1050pF,
99mQ). BHK-21, HeLa, 293, A20 and Sll cells were transfected using the
double pulse program (600V, 25pF, 99mQ followed by 0.1s delay then 250V,
1050pF, 99mQ). Immediately after electroporation, the cell suspension was
removed from the cuvette and resuspended in 10ml fresh medium. The cell
suspension was then subcultured into 2 wells of a 6 well plate. Transiently
transfected cells were harvested 24 or 48 hours post-transfection. The efficiency
of transfection was estimated using a control plasmid expressing GFP (such as
pEGFP-Cl). The cells were examined either under ultraviolet light or by FACS
analysis to determine the percentage of cells expressing GFP.
2.2 Molecular biology analysis
All molecular cloning methods were based on methods described in
Sambrook et al., 1989. * indicates proprietary formulations contained within kits,
for which the manufacturer has not disclosed the chemical composition.
2.2.1. Polymerase Chain Reaction (PCR)
Polymerase chain reaction (PCR) reactions contained 20mM Tris [pH
8.4], 50mM KC1, 1.5mM MgCl2, 0.25mM each of dATP, dGTP, dCTP and dTTP
(Ultrapure dNTP set, Amersham Pharmacia), 0.2pmol of each primer, 100-500ng
DNA template and 1U Taq DNA Polymerase (Invitrogen Life Technologies) in a
final volume of lOOpl. PCR primers were obtained from MWG-Biotech.
Oligonucleotide sequences and pairs were as described in Appendix 2. Negative
control reactions were performed using diH20 instead of template DNA. All
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reactions were set up in a contamination-free environment using barrier tips to
minimise the risk of false positive reactions. PCR was carried out in thin-walled
0.5ml tubes (Hybaid) on an Omnigene thermal cycler (Hybaid). A modified "hot-
start" protocol was used to ensure high product specificity. Reactions were heated
to 95°C for 1 min, and then held at the annealing temperature while the Taq DNA
Polymerase was added. 25 - 40 cycles of PCR amplification were then performed,
consisting of 1 min annealing (at primer specific temperatures), extending at 72°C
for 1 min/kb of product and 30 s denaturing at 95°C. The reactions were then
finally incubated at 72°C for 5 mins.
DNA for cloning or sequencing was amplified using PfuTurbo™ DNA
Polymerase (Stratagene). PCR reactions contained PfuTurbo DNA Polymerase
reaction buffer (20mM Tris [pH8.8], 2mM MgS04, lOmM KC1, lOmM
(NH4)2S04, 0.1% TritonX-100, O.lmg/ml BSA), 0.25mM each of dATP, dGTP,
dCTP and dTTP (Ultrapure dNTP set, Amersham Pharmacia), 0.2pmol of each
primer, 100-500ng DNA template and 2.5 U of PfuTurbo DNA Polymerase in a
final volume of lOOpl. Reaction conditions were similar to those used for PCR
with Taq DNA polymerase.
2.2.2. Purification of PCR products
Amplified DNA was purified using CONCERT™ Rapid PCR Purification
System (Invitrogen Life Technologies). The PCR reaction was mixed thoroughly
with 400pl of Binding Solution (HI*). The mixture was then loaded into the spin
cartridge, and the DNA attached to the membrane by centrifugation at 12,000 x g
for 1 min. The cartridge was washed with 700pl of Wash Buffer (H2*), and then
dried by centrifugation twice at 12,000 x g for 1 min to ensure that all residual
wash buffer was removed. The DNA was recovered by the addition of 50pl TE at
65°C, followed by a 1 min incubation and centrifugation at 12,000 x g for 2 mins.
2.2.3. Agarose gel electrophoresis
DNA was analysed by electrophoresis on an agarose gel containing 0.8-
3% agarose (SeaKem®, Flowgen) and 0.5pg/ml ethidium bromide (Sigma) in
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TAE buffer. The DNA samples were made up to 10-15pl volume with TE, and
mixed with 2pl gel loading buffer (15% w/v Ficoll type 400, 0.25% w/v
bromophenol blue and 0.25% w/v xylene cyanol or 0.25% w/v Orange G in
diH20). Samples were loaded into the wells, and electrophoresis was carried out in
a horizontal tank (BIO-RAD) containing TAE buffer at 70V. DNA molecular
weight markers (lpg of lkb DNA ladder or lkb Plus DNA ladder, Invitrogen Life
Technologies) were used as molecular size standards to estimate the size ofDNA
bands. DNA bands were visualised under ultraviolet light using an ultraviolet
transilluminator (UVP). Images were photographed and stored onto a Personal
Computer disk.
2.2.4. Extraction ofDNA
DNA was purified by phenol : chloroform extraction. A mixture of phenol
(equilibrated to pH 7.8): chloroform: iso-amyl alcohol (25:24:1 v/v) was added to
an equal volume of DNA in a 1.5ml Eppendorf tube, and mixed by vortex for 2
mins. After centrifugation at 10,000 x g for 3 mins, the aqueous phase was
removed to a clean Eppendorf and the process was repeated until no protein
debris was observed at the interface between the aqueous and non-aqueous
phases. Remaining phenol was then removed by adding a mixture of chloroform :
iso-amyl alcohol (24:1 v/v) to an equal volume of the DNA, mixed by vortex for 2
mins and then centrifugation at 10,000 x g for 3 mins. The aqueous phase was
then removed to a clean Eppendorf, and the DNA concentrated by ethanol
precipitation.
2.2.5. Ethanol precipitation
DNA was precipitated by the addition of 0.3 volumes 7.5M ammonium
acetate or 0.1 volumes 3M sodium acetate [pH5.2], and then 3 volumes of 96%
ethanol (at -20°C). The mixture was mixed thoroughly, and incubated at -20°C for
at least 1 hour. The precipitated DNA was recovered by centrifugation at 12,000 x
g for 5 mins, washed with 70% ethanol, air-dried for 2-5 mins and resuspended in
an appropriate volume ofTE or diH20.
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2.2.6. Quantification ofDNA
DNA concentration was quantified using two methods. Approximate
concentrations were obtained by agarose gel electrophoresis of an appropriate
volume ofDNA, and then comparing the intensity of the DNA to a sample with a
known DNA concentration (lkb DNA ladder, Invitrogen Life Technologies).
Accurate DNA concentration was measured using a fluorometer (DyNA Quant
200, Hoefer, Amersham Pharmacia). DNA was diluted 1:1000 into 0.2M NaCl,
lOmM Tris [pH7.4], ImM EDTA containing 0.1pg/ml bisbenzimide (Hoechst
H33258, Amersham Pharmacia). Binding of the Hoechst dye to DNA results in a
shift in the emission spectrum of the dye that can be measured using a
photodetector. The DNA concentration was calculated by comparing this shift to
that obtained with a 1 OOng/ml DNA standard.
2.2.7. Restriction enzyme digestion
DNA restriction enzymes were obtained from either Invitrogen Life
Technologies or New England Biolabs. They were used according to
manufacturer's instructions with recommended buffers (supplied as 10 times
working concentration). DNA restriction digests were typically carried out for 2
hours at 37°C, in a suitable volume containing 10 units of enzyme per 1-1 Opg of
DNA.
2.2.8. Generation of deletions using Exonuclease III and Mung Bean
Nuclease
A series of deletions in the M2 gene of MHV-68 were generated using
Exonuclease III. Cosmid clone A8 (cA8) contains MHV-68 DNA (nucleotide
sequence 115,165-26,842 (see Appendix 3)). A 10pg sample of cA8 was digested
for 3 hours at 37°C with Sail (Invitrogen Life Technologies). Sail cuts cosmid A8
once at position 4336-4341 (MHV-68 co-ordinates), which is within the M2 ORF.
The digestion was extracted twice with phenol : chloroform : iso-amyl alcohol
and once with chloroform : iso-amyl alcohol (see 2.2.4). All extractions were
performed gently on a rotating wheel with wide bore tips to avoid shearing of the
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linearised DNA. The extracted DNA was precipitated with 96% ethanol, washed
once with 70% ethanol and resuspended in 20pl lOmM Tris [pH8.5]. Examination
of lpl of the digest by agarose gel electrophoresis showed that the cosmid was
completely linearised.
The DNA was resuspended in 50mM Tris [pH8], 5mM MgCE, lOpg/ml
yeast tRNA (Invitrogen Life Technologies) and lOmM P-mercaptoethanol in a
final volume of 150pl. The reaction mixture was equilibrated to 23°C for 5 mins,
and then 200U of Exonuclease III (Invitrogen Life Technologies) was added and
the mixture gently mixed by inverting. The reaction was kept at 23°C and 25pl
aliquots (containing approximately 1.5pg of cosmid A8 DNA) of the reaction
mixture were removed at 0 s (before the addition of the Exonuclease III), 20, 40,
60, 80 and 100 second intervals after the addition of the enzyme. The aliquots
were added to 175pl Mung Bean Nuclease buffer (lOmM sodium acetate [pH5],
O.lmM zinc acetate, ImM L-cysteine, 50mM NaCl, 5% v/v glycerol) and kept at -
80°C until all the aliquots were taken. The samples were heated to 68°C for 15
mins, and then placed on ice.
Each sample was then mixed gently by inversion with 7.5U ofMung Bean
Nuclease (Invitrogen Life Technologies) and incubated at 30°C for 30 mins. The
samples were then made up to 250pl total volume containing 0.4% w/v SDS,
50mM Tris [pH 9.5] and 0.8M LiCl, gently extracted once with phenol :
chloroform : iso-amyl alcohol, once with chloroform : iso-amyl alcohol and
precipitated with 96% ethanol. The pellet was washed in 70% ethanol, air-dried
and resuspended in diFEO. A ligation mixture containing the cosmid DNA was
incubated overnight at 4°C (see 2.2.10) and used to transform ElectroMAX
DH10B™ bacteria (Invitrogen Life Technologies) by electroporation.
2.2.9. De-phosphorylation of linearised plasmid DNA
To stop self re-ligation of plasmid vectors, the 5'-phosphate group on each
end of linearised plasmid DNA was removed using calf intestinal alkaline
phosphatase (Roche). Following restriction enzyme digestion, 20U of alkaline
phosphatase was added to the reaction mixture and incubated at 37°C for 20 mins.
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The reaction was stopped by extraction with phenol : chloroform, and the DNA
was recovered by ethanol precipitation.
2.2.10. Ligation ofDNA fragments
Ligation reactions were set up using approximately 50-1 OOng of linearised
plasmid DNA and 250-500ng of DNA fragments (1 : 5-10 ratio of plasmid :
fragments). The reaction mixture contained T4 DNA ligase buffer (50mM Tris
[pH7.6], lOmM MgCE, ImM ATP, ImM DTT, 5% w/v polyethylene glycol-
8000, Invitrogen Life Technologies) and 1U T4 DNA ligase (Invitrogen Life
Technologies) in a final volume of 20pl. All ligation reactions included negative
controls, containing diH20 instead of DNA fragments to check for self-ligation of
the plasmid. Ligation was performed overnight at 4°C.
2.2.11. Transformation of competent bacteria by heat pulse
Escherichia coli bacteria (Epicurian Coli® XLl-Blue competent cells,
Stratagene) were transformed according to the manufacturer's protocol.
Competent cells were thawed on ice, and a 50pl aliquot was placed into prechilled
15ml Falcon polypropylene tubes. P-mercaptoethanol was then added to a final
concentration of 25mM, and the tubes gently mixed on ice for 10 mins. lpl of the
ligation mixture or 50ng of DNA was then added, and the mixture incubated on
ice for 30 mins. The tubes were placed at 42°C for 45 s, and then chilled on ice
for a further 2 mins. SOC medium (900pl) was then added, and the tubes
incubated at 37°C for 1 hour with shaking. A 100pi sample of this mixture was
spread onto LB agar plates containing the appropriate antibiotic selection agent
(either 1 OOpg/ml ampicillin or 30pg/ml kanamycin, Sigma). The remaining
transformation mixture was pelleted by centrifugation at 4,000 x g for 2 mins, and
the bacterial pellet resuspended in 100pi medium and spread onto another LB
agar plate. Plates were incubated overnight at 37°C, and examined for the number
of colonies. Plates were stored wrapped in parafilm at 4°C for up to 2 weeks, and
bacterial stocks in 15% glycerol were stored at -80°C.
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2.2.12. Transformation of competent bacteria by electroporation
Escherichia coli bacteria (ElectroMAX DH10B™ Cells, Invitrogen Life
Technologies) were transformed according to the manufacturer's protocol. The
DNA was purified and concentrated using a Microcon® YM-30 (Millipore)
centrifugal filter device. The DNA was added to the filter device and dried by
centrifugation at 12,000 x g for 7 mins. The filter device was then washed twice
with 200pl diH20, followed by centrifugation at 12,000 x g for 7 mins. The DNA
was recovered by adding 50pl of diH20 to the device, and the sample reservoir
was then inverted into a clean Eppendorf and the DNA solution recovered by
centrifugation at 12,000 x g for 30 s.
A 4pl sample of the purified DNA was then added to a chilled 0.75ml
Eppendorf tube. ElectroMAX DH10B™ Cells were thawed on ice, and a 40pl
aliquot of the cells was added to the DNA in the tube. The mixture was
transferred to a chilled 2mm electroporation cuvette (EquiBio), and electroporated
using a single pulse (2500V, 25pF, 156mQ, 0.004 s). SOC medium (1ml) was
then immediately added, and the cell mixture incubated at 37°C for 1 hour with
shaking. The bacteria were then spread onto LB agar plates containing the
appropriate antibiotic selection agent (see 2.2.11) and incubated overnight at
37°C.
2.2.13. Isolation ofDNA from agarose gels
DNA bands were excised from agarose gels using a scalpel blade under
ultraviolet light. The agarose gel slice was inserted into clean sterile dialysis
tubing (Visking size 2-18/32", Medicell) and 300pl TAE added. All air bubbles
were removed and the tubing sealed at both ends. The dialysis tubing was placed
in a mini-gel tank and subjected to electrophoresis at 80V for 1 hour. The current
was briefly reversed for 30 s to remove DNA from the side of the tubing. The
TAE solution containing the DNA was transferred to a clean Eppendorf tube, and
the DNA extracted using phenol : chloroform and recovered by ethanol
precipitation.
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2.2.14. Small scale preparation of plasmid DNA (mini-prep)
Mini-preps were usually performed using the alkaline lysis method. A
single bacterial colony was grown overnight at 37°C with shaking in 10ml LB
medium containing either lOOpg/ml ampicillin or 30pg/ml kanamycin. A sterile
flamed loop was used to streak out a sample of the overnight culture onto LB agar
plates containing the appropriate selective antibiotic. The bacterial suspension
was pelleted by centrifugation at 4,000 x g for 5 mins, and the bacterial pellet
resuspended in 200pl of Solution I (50mM glucose, 25mM Tris [pH8], lOmM
EDTA, 100pg/ml RNase A (QIAGEN), lmg/ml lysozyme (Sigma)) and
incubated at RT for 15 mins. The solution was then gently mixed by inversion
with 400pl of Solution II (0.2N NaOH, 1% w/v SDS), and incubated on ice for 5
mins. Solution III (300pl of 5M potassium acetate, 12% v/v glacial acetic acid
[pH4.8]) was added, gently mixed by inversion and incubated on ice for 10 mins.
After centrifugation at 10,000 x g for 5 mins, the supernatant was removed to a
new Eppendorf tube. The nucleic acids were precipitated by the addition of 500pl
isopropanol and the solution was incubated on ice for 15 mins. After
centrifugation at 10,000 x g for 5 mins, the supernatant was removed and the
pellet air dried. The pellet was resuspended in 200pl TE, then lOOpl of 7.5M
ammonium acetate was added and the mixture incubated on ice for 15 mins.
Precipitated debris was pelleted by centrifugation at 10,000 x g, the supernatant
was transferred to a fresh tube and the DNA precipitated using 600pl of 96%
ethanol at -20°C for 1 hour. The DNA was pelleted by centrifugation at 10,000 x
g for 5 mins, washed with 70% ethanol, the pellet was air-dried and resuspended
in 20pl TE.
High quality plasmid DNA for sequencing and small scale cosmid DNA
preparations were prepared using a QIAprep® Spin Miniprep Kit (QIAGEN)
according to the manufacturer's instructions. A single bacterial colony was grown
overnight at 37°C with shaking in 10ml LB medium containing the appropriate
selective agent. The bacterial suspension was pelleted by centrifugation at 4,000 x
g for 5 mins, and the bacterial pellet resuspended in 250pl of Buffer PI*. Buffer
P2* (250pl) was added, the Eppendorf tube mixed by gentle inversion and
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incubated for 5 mins. Buffer N3* (350pl) was added, the solutions mixed gently
by inversion and the insoluble fraction pelleted by centrifugation for 10 mins at
10,000 x g. The supernatant was placed in a QIAprep spin column and the DNA
attached to the membrane by centrifugation at 10,000 x g for 1 min. The QIAprep
spin column was washed by centrifugation (10,000 xg, 1 min) firstly with 500pl
Buffer PB* and then 750pi 1 Buffer PE*, and then dried by centrifugation at 10,000
x g for 1 min to remove residual wash buffer. The DNA was eluted from the
column using 50pl Tris [pH8.5], Cosmids were eluted with 50pl Tris [pH8.5]
heated to 70°C.
2.2.15. Large scale preparation of plasmid DNA (maxi-prep)
Large scale plasmid purification was performed using anion exchange
columns (EndoFree Plasmid Maxi Kit, QIAGEN) according to manufacturer's
instructions. An overnight bacterial culture (250ml) was pelleted by centrifugation
at 6,000 x g for 15 mins at 4°C, and the bacterial pellet resuspended in 10ml of
Buffer PI (50mM Tris [pH8], lOmM EDTA, 100pg/ml RNase A). Buffer P2
(10ml of 200mM NaOH, 1% SDS) was then added, the solutions mixed by gentle
inversion and incubated at RT for 5 mins. Buffer P3 (10ml of 3M potassium
acetate [pH5.5]) was then added, mixed gently by inverting and after 10 mins
incubation, the mixture was filtered using a QIAfilter cartridge. Buffer ER*
(2.5ml) was added to the filtrate, mixed by inversion and incubated on ice for 30
mins to remove endotoxins. A QIAGEN-tip 500 anion exchange column was
equilibrated using 10ml ofBuffer QBT (750mM NaCl, 50mM MOPS [pH7], 15%
isopropanol, 0.15% TritonX-100), and the filtered lysate applied to the
equilibrated column. The column was then washed twice with 30ml Buffer QC
(1M NaCl, 50mM MOPS [pH7], 15% isopropanol), and the DNA eluted with
15ml Buffer QN (1.6M NaCl, 50mM MOPS [pH7J, 15% isopropanol). t he DNA
was precipitated with 0.7 volumes isopropanol, pelleted by centrifugation at
15,000 x g for 30 mins at 4°C, and the DNA pellet washed twice with 5ml of 70%
ethanol. The DNA pellet was air dried, and resuspended in 200pl TE.
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2.2.16. Large scale preparation of cosmid DNA (maxi-prep)
Large scale cosmid purification was performed using anion exchange
columns (QIAGEN Large-Construct Kit, QIAGEN) according to manufacturer's
instructions. Composition of buffers was identical to EndoFree Plasmid Maxi Kit
unless otherwise stated (see 2.2.15). An overnight bacterial culture (500ml) was
pelleted by centrifugation at 6,000 x g for 15 mins at 4°C, and the bacterial pellet
resuspended in 20ml ofBuffer PL Buffer P2 (20ml) was then added, the solutions
mixed by gentle inversion and incubated at RT for 5 mins. Buffer P3 (20ml) was
then added, mixed gently by inversion and incubated on ice for 10 mins. The cell
debris was pelleted by centrifugation at 20,000 x g for 30 mins at 4°C, and the
supernatant filtered to remove all particulate matter. The DNA was precipitated
by the addition of 0.6 volumes isopropanol, and pelleted by centrifugation at
15,000 x g for 30 mins at 4°C. The DNA pellet was washed with 5ml of 70%
ethanol, the pellet air dried and redissolved in 9.5ml Buffer EX (50mM Tris
[pH8.5], lOmM MgCf). ATP-dependant Exonuclease (200pl) and lOOmM ATP
(300pl) were added to the DNA solution, and incubated for 60 mins at 37°C. This
exonuclease digestion step removed contaminating genomic DNA and damaged
cosmid DNA, but did not digest supercoiled cosmid DNA. Conditions to allow
DNA binding to the column were adjusted by the addition of 10ml of Buffer QS
(1.5M NaCl, lOOmM MOPS [pH7], 15% isopropanol) to the DNA solution. A
QIAGEN-tip 500 anion exchange column was equilibrated using 10ml of Buffer
QBT, and the adjusted DNA solution applied to the equilibrated column. The
column was then washed twice with 30ml Buffer QC and the DNA eluted with
15ml Buffer QF (1.25M NaCl, 50mM Tris [pH8.5], 15% isopropanol) at 65°C.
The DNA was precipitated with 0.7 volumes isopropanol, pelleted by
centrifugation at 15,000 x g for 30 mins at 4°C, and the DNA pellet washed twice
with 5ml of 70% ethanol. The DNA pellet was air dried, and resuspended in
200pl TE.
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2.2.17. Preparation of purified viral DNA for sequencing
Ten 175cm2 tissue culture flasks of BHK-21 cells were infected with virus
in suspension at a Multiplicity of Infection (MOI) of 0.1 (see 2.5.1). When 100%
cytopathic effect was observed after 4 days, the cells were scraped off into the
medium and pelleted by centrifugation at 500 x g for 20 mins at 4°C. The
supernatant was transferred to a sterile centrifuge bottle, and the virus particles
were pelleted by centrifugation at 22,100 x g for 2 hours at 4°C, and the pellet
was resuspended in 3ml sterile PBS. The virus particles were layered on top of a
sorbitol gradient (20% D-sorbitol in PBS), and pelleted by centrifugation at
141,000 x g for 80 mins at 4°C. The viral pellet was resuspended in 500pl DNase
buffer (40mM Tris [pH8], lOmM MgSC>4, ImM CaCE), and 20U of DNase I
(Sigma) was added and incubated at 37°C for 20 mins. High Molecular Weight
DNA Extraction buffer (5ml of 0.2M Tris [pH8], 0.1M EDTA, 0.5% SDS) was
added to the DNA solution, and Proteinase K (Roche) added to 100pg/ml final
concentration. The mixture was incubated overnight at 53°C.
The DNA solution was then very gently extracted four times with phenol :
chloroform : iso-amyl alcohol. The extraction was carried out on a tilting platform
for 30 mins each time. The phases were separated by centrifugation at 500 x g for
5 mins, and all pipetting was carried out using wide-bore tips. The DNA solution
was then extracted twice with chloroform : iso-amyl alcohol, and the DNA
precipitated with 0.3 volumes 7.5M ammonium acetate and 3 volumes of 96%
ethanol. The precipitated DNA was spooled, and transferred into 20ml of 70%
ethanol. The DNA was pelleted by centrifugation at 8,000 x g for 30 mins at 4°C,
and the pellet washed twice with 70% ethanol. After briefly air drying the pellet,
the DNA was resuspended in 500pl TE.
2.2.18. Preparation of purified viral DNA for electroporation
Ten 175cm2 tissue culture flasks of BHK-21 cells were infected with virus
in suspension at a Multiplicity of Infection (MOI) of 0.1 (see 2.5.1). When 100%
cytopathic effect was observed after 4 days, the cells were scraped off into the
medium and pelleted by centrifugation at 500 x g for 20 mins at 4°C. The cell
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pellet was resuspended in 4ml sterile PBS, and the cells disrupted by
homogenisation for 30 strokes using a chilled Wheaton-Dounce homogeniser. The
suspension was clarified by centrifugation at 2000 x g for 20 mins at 4°C. The
supernatant was carefully removed and stored at 4°C. The cell pellet was
resuspended in 1ml sterile PBS, subjected to homogenisation for 30 strokes using
a chilled Wheaton-Dounce homogeniser and clarified by centrifugation at 2000 x
g for 20 mins at 4°C. The supernatant was removed and pooled with the previous
supernatant.
The virus supernatant was layered on top of a sorbitol gradient (20% D-
sorbitol in PBS), and pelleted by centrifugation at 141,000 x g for 80 mins at 4°C.
The viral pellet was resuspended in 500pl of 50mM Tris [pH8], and 5ml High
Molecular Weight DNA Extraction buffer (0.2M Tris [pH8], 0.1M EDTA, 0.5%
SDS) was added. Proteinase K (Roche) was added to final concentration of
100pg/ml, and the mixture was incubated overnight at 53°C. The viral DNA
solution was then extracted with phenol : chloroform and the viral DNA
precipitated as previously described (see 2.2.17).
2.2.19. Preparation of DNA from virally infected cells
One 175cm2 tissue culture flask of BHK-21 cells was infected with virus
in suspension at a Multiplicity of Infection (MOI) of 0.1 (see 2.5.1). When 100%
cytopathic effect was observed after 4 days, the cells were scraped off into the
medium and pelleted by centrifugation at 1000 x g for 20 mins at 4°C. The cell
pellet was washed once with PBS, and then resuspended in 10ml High Molecular
Weight DNA Extraction buffer (0.2M Tris [pH8], 0.1M EDTA, 0.5% SDS).
RNase A (QIAGEN) was added to 20pg/ml, and the solution incubated at 37°C
for 1 hour. Proteinase K (Roche) was then added to lOOpg/ml, and incubated at
56°C overnight. The DNA solution was then gently extracted with phenol :
chloroform three times and chloroform once using a rotator for 15 mins each time.
The high molecular weight DNA was precipitated with 0.3 volumes 7.5M
ammonium acetate and 3 volumes 96% ethanol as previously described (see
2.2.17).
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2.2.20. Southern blot analysis ofDNA
DNA samples (10pg per agarose gel lane) were digested with 50-150 units
of restriction enzyme for 6-16 hours (see 2.2.7). The digested DNA was
precipitated with 0.1 volume sodium acetate [pH5.2] and 3 volumes 96% ethanol
and resuspended in 15pl of TE for loading onto the gel. Alternatively, 15pi of
PCR products were loaded per well. The DNA samples were electrophoresed
through a 0.8-1.5% TAE agarose gel (see 2.2.3), visualised under ultraviolet light
using an ultraviolet transilluminator and photographed. The gel was washed in
0.4N NaOH for 20 mins. The blotting rig was assembled by covering the gel
platform of an electrophoresis tank in two layers of 3MM filter paper (Whatman)
pre-wetted in 0.4N NaOH, with the ends of the filter paper submerged in 0.4N
NaOH. The gel was placed on top of the filter paper, and covered in a piece of
Hybond N+ (Amersham Pharmacia) pre-wetted in 0.4N NaOH. The membrane
was exactly the same size as the gel, and rolled with a Pasteur pipette to ensure
that no air bubbles were present. The gel was surrounded by parafilm to stop
short-circuiting of the blotting apparatus. Two pieces of 3MM filter paper were
placed on top of the membrane, and a stack of dry paper towels was then placed
on the top to ensure capillary transfer of the DNA. A 500g weight was placed on
top of the paper towels, and the DNA transferred overnight.
The blotting apparatus was disassembled and the membrane removed,
having marked the lanes and bottom right corner of the membrane. The DNA was
stabilised on the membrane by UV cross-linking using the "auto crosslink" setting
(Stratalinker 1800, Stratagene) and the membrane washed with 2 x SSC for 5
mins. The DNA markers were excised using a scalpel blade, and the membrane
stored at -20°C.
2.2.21. Staining of DNA molecular weight markers
The membrane strip containing the DNA markers was incubated in 1M
acetic acid for 10 mins at RT, and then incubated in staining solution (0.4M acetic
acid, 0.4M sodium acetate, 0.2% methylene blue) for 10 mins at RT. The
membrane was then washed in di^O until the markers were visualised. The
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markers were then used to estimate the molecular weight of DNA bands detected
on the Southern blot. If the staining of DNA markers was poor, the molecular
weight of DNA bands was estimated from the photograph of the gel and ruler
taken prior to Southern transfer.
2.2.22. Radiolabelling of DNA probes
DNA probes for hybridisation were labelled using the Random Primed
DNA Labelling Kit (Roche) according to manufacturer's instructions. DNA probe
(25ng) in a volume of 9pl was heated to 100°C for 10 mins and then cooled
rapidly on ice. The DNA was then added to a solution containing 25pM dATP,
dGTP, dTTP, hexanucleotide mixture, 50pCi [a32-P]dCTP (Amersham
Pharmacia), 2U Klenow DNA polymerase in 20pl total volume. The mixture was
incubated at 37°C for 30 mins.
Unincorporated nucleotides were then removed using NICK Columns
(Amersham Pharmacia) according to manufacturer's instructions. These columns
contain Sephadex G-50, which removes nick-translated DNA from
unincorporated nucleotides. Labelled DNA was eluted in 400pl TE [pH7.5], and
denatured with 0.1 volumes 3N NaOH for 5 mins at RT. The mixture was then
neutralised with 0.05 volumes 1M Tris [pH7.2] and 0.1 volumes 3N HC1, and
added to the hybridisation solution.
2.2.23. Hybridisation of Southern blots with DNA probes
The blot was prehybridised in 10ml hybridisation solution (6 x SSC, 5 x
Denhardt's reagent, 0.5% SDS, 1 OOpg/ml denatured salmon sperm DNA (Sigma))
for 2 hours at 55-65°C in a Techne roller bottle in a hybridisation oven (Techne
Hybridiser HB-1). The solution was then poured off, and replaced with fresh
hybridisation solution containing the denatured radiolabelled DNA probe.
Hybridisation was performed overnight at 55-65°C. The blot was then washed
twice for 15 mins each in 5 x SSC, 0.5% SDS at RT; twice for 15 mins each in 1 x
SSC, 0.5% SDS at 37°C; three times for 15 mins each in 0.1 x SSC, 1% SDS and
then finally once briefly in 0.1 x SSC at RT. The blot was then wrapped in saran
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wrap and exposed to autoradiographic film (X-OMAT, Kodak) at -70°C. Films
were developed using an automatic X-ray film processor (Optimax).
2.2.24. Automated DNA sequencing
DNA sequencing was performed using the di-deoxy chain termination
sequencing method by Mr. Ian Bennet (Dept. of Veterinary Pathology, University
of Edinburgh). Reactions were performed using a SequiTherm EXCEL II DNA
Sequencing kit (cycle sequencing protocol) on a 4000L automated sequencing
machine (MWG-Biotech).
2.2.25. Sequence analysis of DNA
Analysis of sequenced DNA such as mapping of restriction sites and
comparison to other database sequences was made using the University of
Wisconsin Genetics Computer Group Sequence Analysis Software Package
(GCG10; Devereux et al., 1984). This service was provided by UK Human
Genome Mapping Project computer services, UK HGMP Resource Centre,
Hinxton, Cambridge, CB10 1SB (http://www.hgmp.mrc.ac.uk/).
2.3 Protein analysis
Protein techniques were predominantly based on methods described by
Harlow & Lane, 1988.
2.3.1. Protein analysis and prediction of protein structure
Comparison of the M2 nucleotide and amino acid sequence against all
database entries was regularly made using the BLAST database search program
(Altschul et al., 1997) available at www.ncbi.nlm.nih.gov/BLAST/. Comparison
of the M2 amino acid sequence against known blocks of homology with protein
domains was made using the program "Block Searcher" (Henikoff & Henikoff,
1994), available at www.blocks.fhcrc.org/. Sequence alignment of related
sequences was made using the Blosum scoring matrix with the "ClustalW"
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program (Thompson et al., 1994), and displayed using the "BOXSHADE"
program, both available at www.ch.embnet.org/index.html.
Prediction of M2 protein structure was made using programs at Expert
Protein Analysis System (ExPASy) Proteomics tools, available at
http://ca.expasy.org/tools/ Prediction of hydropathicity was made using
"ProtScale" (Kyte & Doolittle, 1982), prediction of common motifs was made
using "ScanProsite" (Hofmann et al., 1999), prediction of O-linked glycosylation
sites was made using "NetOGlyc 2.0" (Hansen et al., 1998) and prediction of
phosphorylation sites was made using "NetPhos 2.0" (Blom et al., 1999).
2.3.2. Sodium dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-
PAGE)
SDS-PAGE analysis was performed using an Atto AE-6400 Dual Mini
Slab kit (by the method of Laemmli, 1970). The apparatus was assembled as per
manufacturer's instructions, ensuring that the glass plates were clean and dry.
Depending on the resolution required, resolving gels contained 7.5%, 10% or 15%
w/v acrylamide (Ultra Pure Protogel [30% w/v acrylamide : 0.8% w/v bis-
acrylamide], National Diagnostics), 375mM Tris [pH8.8], 0.1% w/v SDS, 0.06%
w/v ammonium persulphate and 0.08% v/v TEMED (Sigma). The resolving gel
was poured and allowed to set before the stacking gel containing 5% w/v
acrylamide, 125mM Tris [pH6.8], 0.1% w/v SDS, 0.08% w/v ammonium
persulphate and 0.2% v/v TEMED was poured on top of the resolving gel, and a
plastic comb inserted to form the sample wells. Once set, the gels were assembled
in the tank and 500ml SDS-PAGE running buffer (25mM Tris, 250mM glycine,
0.1% w/v SDS) added to the reservoirs. Samples for analysis were all diluted 1:1
with 2 x SDS-PAGE sample buffer (lOOmM Tris [pH6.8], 4% w/v SDS, 4% P-
mercaptoethanol, 20% v/v glycerol, 0.1% w/v bromophenol blue) and heated to
95°C for 10 mins prior to loading on the gel. A lOpl sample of Broad Range
Prestained SDS-PAGE Standards (BIO-RAD) diluted 1:1 with 2 x SDS-PAGE
sample buffer was loaded in one lane to enable estimation of protein relative
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molecular masses. Electrophoresis was performed at 20mA per gel, until the dye
front had reached the end of the gel.
2.3.3. Coomassie staining of SDS-PAGE gels
SDS-PAGE gels were stained by immersion in Coomassie Blue stain
(0.25% Coomassie Blue (Sigma), 10% glacial acetic acid, 45% methanol) for 30
mins with gentle shaking. The gel was then destained using Coomassie destain
(20% methanol, 5% glacial acetic acid). The destain was replaced at intervals over
a period of 12-24 hours until all excess stain was removed. The gel was then dried
onto 3MM paper using a Model 583 Gel Dryer and HydroTech Vacuum Pump
(BIO-RAD).
2.3.4. Immunoprecipitation
A20 cells were transfected with 20pg of plasmid DNA (see 2.1.4). After
24 hours the cells were harvested, washed once in sterile PBS and then lysed by
the addition of 1ml RIPA buffer (50mM Tris [pH7.6], 150mM NaCl, 0.5% w/v
sodium deoxycholate, 1% v/v NP-40, 0.1% w/v SDS) for 30 mins at 4°C. The
lysate was pre-cleared by the addition of 35pl of 50% v/v protein A-sepharose
beads (Protein A Sepharose™ CL-4B, Amersham Pharmacia) in TBS containing
10% w/v BSA, and gently mixed for 30 mins at 4°C, followed by centrifugation
at 10,000 x g for 1 min to pellet the beads. The supernatant was then divided into
four Eppendorf tubes. Rat monoclonal 3F10 anti-HA antibody (lpg; Roche) was
added to an aliquot of cell lysate. As a negative control, lpg of rat IgG (Sigma)
was added to an aliquot of cell lysate. The samples were incubated for 2 - 3 hours
at 4°C with gentle rotation. Rabbit anti-rat Ig antibody (7pl; DAKO) was then
added to the samples, and incubated for 30 mins at 4°C with gentle rotation.
Protein A-sepharose beads (35pl of a 50% suspension of beads in TBS containing
10% w/v BSA) was then added to the samples, and incubated for 1 hour at 4°C
with gentle rotation.
The beads were pelleted by centrifugation at 10,000 x g for 1 min, and
then washed five times with 500pl RIPA buffer. The final pellet was transferred
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to a clean Eppendorf tube, and resuspended in 35pl of 2 x SDS-PAGE sample
buffer.
2.3.5. Inhibition of N-linked glycosylation using tunicamycin
A20 cells were transfected with 20pg of plasmid DNA (see 2.1.4).
Immediately following transfection, the cells were divided into two aliquots.
Tunicamycin (Sigma) was added to one aliquot to a final concentration of
1 Opg/ml, and the other aliquot was left untreated. The cells were harvested after
24 hours, washed once in PBS and resuspended in lOOpl of 2 x SDS-PAGE
sample buffer for analysis by SDS-PAGE and immunoblot (see 2.3.8).
As a positive control to ensure that the tunicamycin was inhibiting N-
linked glycosylation, BHK-21 cells were infected with MHV-68 at an MOI of 5
for 1 hour at 37°C. As a negative control, a duplicate experiment was performed
with no viral inoculum (mock infection). After infection, the viral inoculum was
removed and replaced with medium containing either 10p.g/ml tunicamycin or
untreated medium. The cells were harvested after 24 hours, washed once in PBS
and resuspended in lOOpl of 2 x SDS-PAGE sample buffer. The samples were
analysed by SDS-PAGE and immunoblot for glycoprotein B expression (see
2.3.8).
2.3.6. Labelling of cells with [9,10(n)-3H] myristic acid
A20 cells were transfected with 20pg of plasmid DNA (see 2.1.4). After
24 hours, the cells were harvested and resuspended in 1ml fresh medium
"3
containing lOOpCi [9,10(n)- H] myristic acid (Amersham Pharmacia). The cells
were radiolabeled for 4 hours at 37°C, then harvested and washed once with
sterile PBS. A sample (4 x 105 cells) was resuspended in 40pl of 2 x SDS-PAGE
sample buffer, and the rest of the cells were analysed by immunoprecipitation as
described previously (see 2.3.4).
The samples were analysed by electrophoresis on a 12.5% SDS-PAGE
gel. The gel was then fixed by immersing in protein fixer solution (10% v/v
glacial acetic acid, 30% v/v methanol) for 1 hour with gentle agitation. The gel
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was impregnated with EN3HANCE (Perkin Elmer Life Science) for 1 hour,
washed in water for 30 mins and dried onto 3M filter paper. The dried gel was
then exposed to autoradiographic film (X-OMAT, Kodak) at -70°C.
2.3.7. Western blotting (transfer of proteins to PVDF membrane)
After analysis of protein samples by SDS-PAGE gel as previously
described, the proteins were transferred to a PVDF membrane (Immobilon-P,
Millipore) by the tank transfer system using a Mini-Trans Blot Cell (BIO-RAD).
The transfer apparatus was assembled according to the manufacturer's
instructions, the tank filled with prechilled transfer buffer (25mM Tris, 250mM
glycine, 20% v/v methanol) and the transfer was performed at 250mA for 1 hour.
2.3.8. Immunoblotting
Membranes were incubated in BLOTTO (5% w/v skimmed dried milk,
0.1% v/v Tween-20 in TBS) containing 1% v/v normal rabbit/sheep/donkey
serum (depending on which species had been used to raise the secondary
antibody) for 1 hour at RT with gentle agitation to prevent non-specific binding to
the membrane. The membrane was then washed five times with an excess volume
of TBS containing 0.1% v/v Tween-20. Antibodies and their working dilutions
are detailed in Table 2.3.8. All antibodies were sourced from commercial
suppliers, with the exception of rabbit polyclonal anti-GST (Dr. J. Stewart,
unpublished data), rabbit polyclonal anti-MHV-68 (Sunil-Chandra et al., 1992a)
and rabbit polyclonal anti-gB (Stewart et al., 1994).
The membrane was incubated with the primary antibody diluted in
BLOTTO for 2 hours at RT with gentle agitation, and then washed five times with
an excess volume of TBS containing 0.1% v/v Tween-20. The membrane was
then incubated with the secondary antibody diluted in BLOTTO for 1 hour at RT
with gentle agitation, and then washed five times with an excess volume of TBS
containing 0.1% v/v Tween-20. If required, the membrane was then incubated
with the tertiary streptavidin conjugate diluted in BLOTTO for 1 hour at RT with
gentle agitation. The membrane was then washed seven times with an excess
volume of TBS containing 0.1% v/v Tween-20 and then once in TBS before the
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detection step. For the detection of phosphoproteins using phospho-specific
antibodies, the blocking and incubation steps were performed in TBS containing
0.1% v/v Tween-20 and 1-5% w/v BSA.
Two methods were used to detect enzyme activity. For the detection of
alkaline phosphatase (AP) activity, the membrane was incubated with BCIP/NBT
solution (Sigma FAST™ 5-bromo-4-chloro-3-indolyl phosphate / nitro blue
tetrazolium). Detection of horseradish peroxidase (FIRP or POD) activity was
performed using the ECL Western Blotting analysis system (Amersham
Pharmacia) according to manufacturer's instructions. An equal volume of
detection solution 1 was mixed with detection solution 2, and the membrane
incubated with the mixture for 1 min. Excess detection solution was drained from
the membrane. The membrane was then wrapped in Saran wrap and exposed to
autoradiographic film for 1-60 mins (Hyperfilm ECL, Amersham Pharmacia) at
RT.
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Table 2.3.8 Antibodies used in immunoblotting. Suppliers are given in green, and
working dilutions given in blue.
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2.4. Antibody production
2.4.1. Production of a GST fusion protein
The M2 ORF was amplified by PCR (see 2.2.1) using the primers GEX1
and GEX2 (see Appendix 2). The PCR product was purified and ligated into the
bacterial expression vector pGEX-2T (Amersham Pharmacia) in frame with the
Schistosoma japonicum glutathione-S-transferase gene (GST). A 225bp fragment
of M2 (corresponding to a 75 a.a internal region of M2) was also amplified by
PCR using the primers GEX3 and GEX4 and ligated into pGEX-2T. Ligation and
transformation of bacteria by heat pulse were carried out as previously described
(see 2.2.10 and 2.2.11).
Clones positive after mini-prep and restriction enzyme digestion for the
inserted DNA were tested for expression of the fusion protein. Individual bacterial
colonies were grown up overnight in 10ml LB containing 100pg/ml ampicillin,
and then diluted 1:10 into 10ml fresh LB and ampicillin. The culture was
incubated in a sterile universal at 37°C in an orbital shaker until O.D.595 > 0.6.
Protein expression was then induced by the addition of IPTG (Invitrogen Life
Technologies) to a final concentration of 0.5 - 1.5mM, and the culture incubated
for a further 3 hours. A negative control sample of the culture was not induced.
A 1.5ml sample of the bacterial culture was pelleted by centrifugation at
2,000 x g for 5 mins, and the pellet resuspended in 300pl PBS containing 1% v/v
Triton-X, 1% v/v Aprotinin and ImM PMSF. The bacteria were lysed by
sonication on ice, and the suspension clarified by centrifugation at 10,000 x g for
5 mins. A sample of the supernatant was removed and diluted 1:1 with 2 x SDS-
PAGE sample buffer. The pellet was resuspended in 150pl of 2 x SDS-PAGE
sample buffer. The soluble and insoluble fractions were then analysed by SDS-
PAGE.
2.4.2. Inclusion body preparation of bacterial fusion proteins
Partial purification of GST fusions protein was achieved using the
inclusion body protocol (Harlow & Lane, 1988). Bacterial clone number 2 of the
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pGEX-2T vector containing the 225bp fragment of M2 (designated pGEX-
2T/M274-148) was grown up overnight and diluted 1:10 into 10ml fresh medium.
The culture was induced by the addition of IPTG to a final concentration of
0.5mM and incubated for a further 3 hours. The bacterial culture was pelleted by
centrifugation at 4,000 x g for 5 mins, and the pellet resuspended in 1ml Inclusion
Body Prep Buffer (lOOmM NaCl, ImM EDTA, 50mM Tris [pH 8.0]). Lysozyme
(Sigma) was added to lmg/ml, and the suspension incubated at RT for 20 mins.
After centrifugation at 5,000 x g for 10 mins, the pellet was snap frozen at -80°C.
The pellet was thawed, resuspended in 1ml Inclusion Body Prep Buffer
containing 0.1% w/v sodium deoxycholate and incubated on ice for 10 mins with
occasional mixing. MgCf was added to a final concentration of 8mM, and
DNasel (Roche) added to a final concentration of 10pg/ml. The solution was
incubated at 4°C with occasional mixing for 1 hour, and then clarified by
centrifugation for 10 mins at 2,000 - 10,000 x g. A sample of the supernatant was
mixed 1:1 with 2 x SDS-PAGE sample buffer. The pellet was washed once with
lml Inclusion Body Prep Buffer containing 1% v/v NP-40, once with 1ml
Inclusion Body Prep Buffer and then resuspended in 200pl of 2 x SDS-PAGE
sample buffer. The fractions were then analysed by SDS-PAGE.
2.4.3. Preparation of purified GST-M274_i48 fusion protein
The inclusion body protocol produced soluble GST-M274_i48 fusion
protein, and therefore a modification of this protocol was used to purify the fusion
protein. pGEX-2T/M274_i48 was grown up overnight and diluted 1:10 in 500ml
fresh medium. The culture was induced by the addition of IPTG to a final
concentration of 0.5mM, and incubated for a further 3 hours. The bacterial culture
was pelleted by centrifugation at 7,000 x g for 5 mins, and the pellet resuspended
in 50ml Inclusion Body Prep Buffer. Lysozyme (Sigma) was added to lmg/ml,
and the suspension incubated at RT for 20 mins. After centrifugation at 5,000 x g
for 10 mins, the pellet was snap frozen at -80°C.
The pellet was thawed, resuspended in 50ml Inclusion Body Prep Buffer
containing 0.1% w/v sodium deoxycholate and incubated on ice for 10 mins with
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occasional mixing. MgCf was added to a final concentration of 8mM, and
DNasel added to a final concentration of 1 Ogig/inl. The solution was incubated at
4°C with occasional mixing for 1 hour, and then clarified by centrifugation at
6,000 x g for 10 mins. A 10ml suspension of 50% v/v glutathione-sepharose
beads (Glutathione Sepharose™ 4B, Amersham Pharmacia), 1% v/v Triton-X in
PBS was added to the supernatant, and incubated for 30 mins with gentle rotation.
The beads were pelleted by centrifugation at 2,000 x g for 5 mins, and the beads
washed twice in PBS containing 1% v/v Triton-X, and twice in PBS. The fusion
protein was then eluted from the beads by the addition of 5ml of 5mM glutathione
(Sigma). The suspension was mixed thoroughly, the beads pelleted by
centrifugation at 2,000 x g for 5 mins and the supernatant removed and stored.
The elution process was repeated three times. The eluted fraction was dialysed
against three changes of PBS over 24 hours at 4°C to remove excess glutathione,
and the fusion protein solution concentrated using a Centriplus YM-30 (Millipore)
centrifugal filter device into a final volume of 2ml. The fusion protein was
divided into aliquots and stored at -20°C, and aliquots were analysed by SDS-
PAGE.
2.4.4. Immunisation of sheep
Sheep were immunised by Professor J. Hopkins, Department ofVeterinary
Pathology, R(D)SVS, University of Edinburgh. Two sheep (Numbers 7/413 and
705D) were immunised with fusion protein. Each sheep received two intra¬
muscular injections containing 18pg of GST-M274.i48 fusion protein in PBS
mixed by vortex with adjuvant 1:1 (TiterMax® Gold, CytRx) in a total volume of
600pl per injection (36pg fusion protein per immunisation). Both sheep received
three booster injections at 4 week intervals. A blood sample was taken prior to
immunisation (pre-bleed), and four weeks after each immunisation.
2.4.5. Preparation and purification of serum
Blood samples were allowed to clot overnight at 4°C, and the samples
clarified by centrifugation at 2,000 x g for 5 mins. The serum was carefully
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removed and aliquots stored at -20°C. Aliquots of antibody (1ml of both pre-bleed
and third bleed) were purified using caprylic acid followed by ammonium
sulphate precipitation. The serum was acidified by the addition of 2 volumes of
60mM sodium acetate [pH4.0], followed by 0.07 volumes of caprylic acid
(Sigma) dropwise while the serum was constantly stirring. After 30 mins stirring
at RT, the serum was incubated at 4°C overnight. The precipitated protein
impurities were pelleted by centrifugation at 5,000 x g for 10 mins at 4°C, and the
supernatant removed to a fresh universal. One volume saturated ammonium
sulphate was added dropwise whilst the sample was constantly stirring. After 30
mins stirring at RT, the serum was incubated at 4°C overnight. The proteins were
pelleted by centrifugation at 3,000 x g for 30 mins, and the pellet washed twice
with 50% saturated ammonium sulphate. The pellet was resuspended in 0.4
volumes PBS, and dialysed against three changes of PBS over 24 hours at 4°C to
remove excess ammonium sulphate. The purified antibody was divided into
aliquots and stored at -20°C. A sample of each purified antibody was analysed by
SDS-PAGE and immunoblot.
2.4.6. Analysis of anti-M2 reactivity of serum
Purified antibody was assessed for reactivity against M2 by
immunoblotting and immunofluorescence. Details of secondary antibodies,
tertiary conjugates and dilutions used to assess the reactivity of the purified
antibodies are detailed in Table 2.4.6.
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Pre-bleed and third bleed
1:100- 1: 500





Table 2.4.6 Antibodies used in assessing the reactivity of anti-M2 antibody.
Suppliers are given in green, and working dilutions given in blue.
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2.5. Virological methods
2.5.1. Preparation of viral stocks
MHV-68 working stocks were produced from sub-master stocks of clone
g2.4 (Sunil-Chandra et al., 1992a). MHV-76 was kindly provided by Dr.
Mistrikova, Slovakia, and plaque purified on BHK-21 cells three times to obtain
pure master stocks. Viral stocks were generated by infection of BHK-21 cells.
BHK-21 cells (3 x 106 cells per 175cm2 tissue culture flask) were infected with
virus in suspension for 1 hour at 37°C on a shaker at a Multiplicity of Infection
(MOI) of 0.01. The infected cells were then seeded into 175cm2 tissue culture
flasks (Nunc) and incubated at 37°C for 5 - 7 days until 100% cytopathic effect
was observed.
The cells were scraped off into the medium using a cell scraper, and pelleted
by centrifugation at 2000 x g for 20 mins at 4°C. The cell pellet was resuspended
in 5 - 10ml sterile PBS, and the cells disrupted by homogenisation for 30 strokes
using a chilled tight-fitting Wheaton-Dounce homogeniser. After homogenisation,
the cell suspension was sonicated in a glass universal using a sonicating ice bath
for 15 mins. The suspension was clarified by centrifugation at 2000 x g for 20
mins at 4°C and the supernatant carefully removed and stored at 4°C. The cell
pellet was resuspended in 1ml sterile PBS, subjected to homogenisation for 30
strokes using a chilled Wheaton-Dounce homogeniser and clarified by
centrifugation at 2000 x g for 20 mins at 4°C. The supernatant was removed and
pooled with the previous supernatant. Aliquots were stored in sterile CryoTube™
vials (Nunc) at -80°C.
2.5.2. Titration of infectious virus
Titration of infectious virus was performed by plaque assay on BHK-21
cells as previously described (Sunil-Chandra et al., 1992a). Samples were serially
diluted 10-fold in medium in a sterile plastic bijou, and 106 BHK-21 cells per
60mm Petri dish added to each dilution. The cell suspension was incubated on a
shaker for 1 hour at 37°C, and then placed into 60mm Petri dishes. Medium was
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then added to give a final volume of 5ml per dish. All dilutions were performed in
duplicate, and negative control incubations containing uninfected BHK-21 cells
were also performed. The plates were incubated for 4 days at 37°C. The
monolayers were fixed with 4% neutral buffered formaldehyde (Surgipath) for at
least 30 mins, and then stained with 0.1% toluidine blue for 15 mins. The number
of plaques per dilution was then counted using a light microscope, and the number
of plaque-fonning units (PFU) was calculated per ml or per organ.
2.5.3. In vitro growth curves
In vitro growth curves were performed by infection of sub-confluent
BHK-21 cells at an MOI of 5 (single step growth curve) or 0.01 (multi-step
growth curve). BHK-21 cells (70 - 80% confluent) in a 24 well plate were
infected with virus, and allowed to absorb for 1 hour at 37°C. The cells were then
washed three times with fresh medium to remove unbound virus, then 1ml of
fresh medium was added to each well and the plates incubated at 37°C. Samples
were taken in duplicate at appropriate timepoints by scraping all the cells into the
medium, starting immediately after the post-absorption washes (0 hour
timepoint). The samples were transferred to a sterile CryoTube™ vial and freeze-
thawed three times to release virus. The samples were clarified by centrifugation
at 2,000 x g for 5 mins at 4°C to pellet the cell debris, and infectious virus was
measured by plaque assay (see 2.5.2). All titrations were performed on the same
day using the same BHK-21 cells to ensure accurate comparison between values.
All experiments were carried out in duplicate.
2.6. Animal experiments
2.6.1. Infection of mice
All animal experiments were performed under a Home Office personal
and project license issued under the Animals (Scientific Procedures) Act 1986.
Female 3-4 week old BALB/c mice were obtained from Bantin and Kingman,
and kept in-house for 2 weeks prior to use. Mice underwent light anaesthesia
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with halothane (Merial) using an anaesthetic chamber, and were inoculated with 2
x 105 PFU virus in 40pl sterile PBS intranasally. At various times post-infection,
mice were euthanased by cervical dislocation and tissues harvested for analysis.
Blood samples were collected via the tail vein immediately prior to euthanasia.
The spleen was removed and kept in complete RPMI medium on ice. Lungs,
heart, kidneys and adrenal glands were snap frozen at -80°C.
2.6.2. Determination of spleen weight
Spleen weights were determined using a Mettler AE 163 balance (to the
nearest mg).
2.6.3. Infective centre assay for the detection of latent virus
The spleen was placed in a 60mm Petri dish containing 3mls of complete
RPMI medium (RPMI 1640 supplemented with 10% v/v FCS, 70pg/ml penicillin,
lOpg/ml streptomycin, 50pM (3-mercaptoethanol, 2mM L-glutamine and 25mM
HEPES (Invitrogen Life Technologies)). The spleen was teased to a single cell
suspension using a scalpel blade, and the cells were transferred to a sterile pre-
rinsed universal. The cell suspension was pelleted by centrifugation at 600 x g for
5 mins at 4°C, and the supernatant discarded. The red blood cells were lysed by
osmosis by the addition of 1ml sterile distilled water to resuspend the cell pellet
for 15 s followed by the addition of 9mls sterile PBS to establish equilibrium. The
cellular debris was allowed to settle, and then the cell suspension was carefully
removed, the cells pelleted by centrifugation at 600 x g for 5 mins at 4°C and
resuspended in 5ml complete RPMI medium.
The splenocytes were counted (see 2.1.3), and the total number of
splenocytes per spleen was calculated. The splenocytes were then placed onto a
permissive BHK-21 monolayer. BF1K-21 cells (106 cells) and 5ml complete
RPMI medium were added to each 60mm Petri dish and then 107, 106 and 10"
splenocytes were added to each dish. All assays were done in duplicate. The
plates were incubated at 37°C for 5 days. The monolayers were fixed with 4%
neutral buffered formaldehyde (Surgipath) for at least 30 mins, and then stained
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with 0.1% toluidine blue for 15 mins. The number of plaques per 107 splenocytes
were then counted using a light microscope.
Excess splenocytes were stored at -80°C and used to determine the
quantity of preformed infectious virus in the spleen cells. The splenocytes were
freeze-thawed to disrupt the cells, and infectious virus was measured by plaque
assay (see 2.5.2). The number of latently infected splenocytes per 107 cells was
calculated by subtracting the number of preformed infectious virus plaques from
the number of plaques per 107 splenocytes as determined by infective centre
assay.
A modification of this protocol was used to detect latent virus in blood.
Blood (approximately 500pl) was collected prior to euthanasia, and stored on ice
in an EDTA collecting tube. The red blood cells were lysed by osmosis, and the
cell pellet resuspended in 500pl complete RPMI medium. The white blood cells
were counted by adding lOpl cell suspension to 90pl White Blood Cell Counting
Fluid (5% v/v glacial acetic acid, 2% v/v ethanol, 0.0002% w/v methylene blue)
and then placing the mixture in a haemocytometer. The number of cells was
counted per 1mm square.
The white blood cells were then placed onto BHK-21 cell monolayers to
give 106, 105 and 104 cells per 60mm Petri dish, and incubated for 5 days at 37°C
as previously described.
2.6.4. Titration of infectious virus in mouse tissues
Lung, adrenal, kidney and heart tissues were stored frozen at -80°C. The
samples were thawed, and homogenised in a tissue homogeniser containing 1ml
Glasgow's complete medium. Lung tissue was homogenised twice in a total
volume of 1.8ml Glasgow's complete medium. The suspension was freeze-
thawed to disrupt cell membranes, and clarified by centrifugation at 2,000 x g for
5 mins at 4°C. Titration of infectious virus was performed by plaque assay on
BHK-21 cells (see 2.5.2).
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2.6.5. Analysis of data
Data were analysed using Microsoft Excel 97 SR-2 and GraphPad Prism
version 3.02 for Windows. The data were statistically analysed using two-way
ANOVA with Bonferroni post-tests, and P values are indicated in the text.
2.6.6. MACS of latently infected splenocytes
Six week old female BALB/c mice were inoculated intranasally with 2 x
10" PFU MHV-76 and the spleens harvested after 14 days. The splenocytes were
isolated as described in infective centre assay for the detection of latent virus (see
2.6.3). Splenocytes (10 cells) were washed once in cold PBS containing 1% v/v
FCS, and resuspended in 1ml PBS containing 1% v/v FCS. The splenocyte
suspension was incubated with lOpl rat anti-mouse CD 19 antibody (Phanningen)
for 15 mins at 4°C. The splenocytes were washed by the addition of 15ml PBS
containing 1% v/v FCS and pelleted by centrifugation at 600 x g for 5 mins at
4°C. The cells were resuspended in 800pl PBS containing 1% v/v FCS, and then
200pl goat anti-rat IgG microbeads (Miltenyi Biotec) were added and incubated
for 15 mins at 4°C. The microbeads were washed by the addition of 15ml PBS
containing 1% v/v FCS, pelleted by centrifugation at 600 x g for 5 mins at 4°C
and resuspended in 500pl PBS containing 1% v/v FCS. The microbeads were
added to a MACS column (Miltenyi Biotec) loaded in the magnet. The column
was washed with PBS containing 1% v/v FCS, the flow through collected and the
cells recovered by centrifugation at 600 x g for 5 mins. This non-B cell fraction
was resuspended in RPMI 1640 complete medium.
The column was washed again with 15ml PBS containing 1% v/v FCS,
and then the column was removed from the magnet and the B cell fraction eluted
with 15ml PRS containing 1% v/v FCS. The B cell fraction was pelleted by
centrifugation at 600 x g for 5 mins and resuspended in RPMI 1640 complete
medium. The amount of latent virus in the B cell, non-B cell and total splenocyte
fractions was determined by infective centre assay as previously described (see
2.6.3). The purity of the B-cell and non-B-cell fractions was determined by FACS
analysis of a representative aliquot of separated cells (see 2.6.7).
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2.6.7. FACS analysis
A sample of 2 x 105 cells in 50pl FACS buffer (1% w/v BSA, 0.1% w/v
azide in PBS) was dispensed into each FACS tube. Antibodies used in FACS
analysis are detailed in Table 2.6.7. Primary antibody (25pl) was added to the
tube, and the tubes incubated at RT for 15 mins. The cells were washed by adding
750pl of FACS buffer to the tube and centrifuging at 600 x g for 5 mins. If
required, 25pi of secondary antibody was added to the cells and the tubes
incubated at RT for 15 mins in the dark. The cells were washed by adding 750pl
of FACS buffer to the tube and centrifuging at 600 x g for 5 mins. The cells were
resuspended in 200pl of 2% neutral buffered formaldehyde in PBS and then
analysed using a Becton-Dickinson FACScan. The lymphocyte population was
identified on the basis of size (forward scatter) and granularity (side scatter), and
the lymphocyte population was then analysed for FITC staining.
For the FACS analysis of EGFP expressing A20 cells, the cells were
harvested, washed once in PBS and resuspended at 4 x 106 cells per ml in PBS
with 1% v/v BSA. Cells were then analysed using a Becton-Dickinson FACScan.
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CD19 Primary - rat anti-mouse
CD 19. Monoclonal 1D3





Table 2.6.7 Antibodies used in FACS analysis.
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2.6.8. Histopathology
Mice were euthanased by CO2 asphyxiation and the lungs were perfused
in situ via the trachea using 10% neutral buffered formaldehyde. Portions of
spleen were also fixed in 10% neutral buffered formaldehyde and the tissues were
processed routinely into paraffin wax-embedded sections. These were stained
with haematoxylin and eosin, and examined by light microscopy.
2.6.9. Immunostaining of histopathological samples
Paraffin wax sections of 4pm thickness were fixed onto microscope slides
coated with BIOBOND (British Biocell International). The sections were
dewaxed using xylene for 15 mins, and then ethanol for 5 mins. The slides were
incubated in 0.3% v/v hydrogen peroxide in methanol for 30 mins, and then
hydrated through a series of ethanol solutions (100% - 30%). The slides were then
incubated in 1% v/v TritonX-100 for 90s, washed twice with water and then
digested for 20 mins at 37°C with lOpg/ml Proteinase K (Roche) in 20mM Tris
[pH7.0], 2mM CaCE. After incubation in PBS containing 25mM glycine, 5mM
EDTA for 5 mins and PBS for 3 mins, the slides were incubated overnight in PBS
with 2% v/v normal goat serum to prevent non-specific antibody binding.
The sections were incubated for 2 hours at RT with 500pl polyclonal
rabbit anti-MHV-68 antibody (Sunil-Chandra et al., 1992a) diluted 1:500 in PBS
with 2% v/v normal goat serum. The sections were washed three times with PBS,
and incubated with 500pl biotinylated goat anti-rabbit IgG (Sigma) diluted 1:500
in PBS with 2%o v/v normal goat serum for 2 hours at RT. After three washes with
PBS, the slides were incubated for 1 hour with 500pl streptavidin-POD conjugate
(Roche) diluted 1:1500 in PBS for 1 hour at RT. The sections were then exposed
to DAB substrate (3,3' Diaminobenzidine, SIGMA FAST™ DAB Tablet, Sigma).
The slides were washed in PBS and then water, and then lightly counterstained
with haematoxylin for 1 min. The slides were then dehydrated through a series of
ethanol solutions (30% - 100%) and mounted.
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2.6.10. Detection of viral DNA in mouse tissues
Mice were infected with 2 x 105 PFU virus, and euthanased five months
post-infection. The liver, lung, kidney, spleen and white blood cells were
removed, and stored at -80°C. Viral DNA was extracted using a DNeasy Tissue
Kit (QIAGEN) according to the manufacturer's instructions. Approximately
25mg of tissue was cut into small pieces, and 180pl Buffer ATL* added to the
tissue pieces. Proteinase K was added to a final concentration of 2mg/ml, and the
sample incubated at 55°C overnight with occasional mixing by vortex. Buffer
AL* (200pl) was added to the digested sample, mixed by vortex and incubated at
70°C for 10 mins. Ethanol (200pl) was added to the sample, mixed by vortex and
placed in a DNeasy mini column. After centrifugation at 6,000 x g for 1 min, the
column was washed with 500pi Buffer AW1* and then 500pl Buffer AW2*. The
column was dried by centrifugation at 12,000 x g for 3 mins, and the DNA eluted
with 200pl Buffer AE*. The extracted DNA was quantified using a fluorometer
(see 2.2.6).
PCR amplification (40 cycles) was performed on lpg of high molecular
weight DNA using primers specific for the gpl50 or M3 genes as previously
described (see 2.2.1). A 15pl sample of the PCR products was electrophoresed
through a 1.5% w/v TAE agarose gel, and analysed by Southern blot hybridisation
with probes specific for gpl50 and M3 to confirm the specificity of the PCR
products as previously described (see 2.2.20).
2.7. Fluorescent microscopy analysis
2.7.1. Fixation of cells
Cells were transfected with 20pg of plasmid DNA (see 2.1.4). The cells
were harvested 24 hours post-transfection, washed once with PBS and
resuspended at approximately 106 cells/ml in PBS. The cells were then either air-
dried or attached by centrifugation using a Cytospin 2 (ThermoShandon) onto a
glass slide. The cells were fixed by incubating the slides with 4% w/v
paraformaldehyde in PBS for 10 mins at RT. The slides were washed twice in
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PBS, and the cells were then permeabilised by incubating the slides in PBS
containing 0.2% v/v TritonX-100 for six to ten mins. The slides were washed four
times in PBS, air-dried and stored at -20°C. In some instances when cells were
transfected with EGFP fusion proteins, the cells were fixed first in 4% w/v
paraformaldehyde in PBS, washed twice in PBS and then cytospun or air-dried
onto glass slides.
2.7.2. Fluorescent microscopy
Samples for fluorescent microscopy were mounted in fluorescent
mounting medium (DAKO), and initially examined using a Nikon Diaphot 200
Ultraviolet Microscope. Confocal microscopy, image production and analysis
were performed using a Leica TCSNT confocal system at the Confocal
Microscope Facility, BioMedical Sciences, University of Edinburgh.
2.7.3. Staining of DNA in cells
Cell samples were fixed and permeabilised (see 2.7.1). To visualise DNA
using the BandPass filter 600/30, DNA was stained using propidium iodide. The
sample was incubated in PBS containing 10pg/ml RNaseA (QIAGEN) and
lpg/ml propidium iodide (Molecular Probes) for 30 mins at 37°C in the dark. The
slide was washed twice in PBS, and mounted. To visualise DNA using the
LongPass filter LP665, DNA was stained by incubating the sample in PBS
containing 10pg/ml RNaseA and 2pM TO-PRO-3 (Molecular Probes) for 30 mins
at 37°C in the dark. The slide was washed twice in PBS, and mounted in
fluorescent mounting medium (see 2.7.2).
2.7.4. Staining of the plasma membrane
Cells were transfected with 20pg of plasmid DNA (see 2.1.4). The cells
were harvested 24 hours post-transfection, washed once with PBS and the cells
resuspended at 4 x 106 cells/ml in incubation buffer (PBS with 3% w/v BSA, 1%
v/v normal rabbit serum and 0.1% w/v azide). A 50pl sample of the cell
suspension was placed into a tube. To stain with anti-CD19 antibody, rat anti-
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mouse CD19 antibody (Pharmingen) was added to the cell suspension at a
dilution of 1:150. To stain with anti-MHC Class II antibody, the cells were
pelleted by centrifugation at 500 x g for 5 mins, and resuspended in 50pl rat anti-
MHC Class II (Monoclonal SW 73.2; Hopkins et al., 1986) in medium with 1%
v/v normal rabbit serum and 0.1% w/v azide. The cells were incubated for 1 hour
at 4°C.
The cells were washed three times with 750pl cold wash buffer (PBS with
3% w/v BSA and 0.1% w/v azide). The cells were then incubated with 25pl of
rabbit polyclonal anti-rat IgG TRITC conjugate (Sigma) diluted 1:150 in
incubation buffer for 45 mins in the dark at 4°C. The cells were washed three
times with 750pl cold wash buffer and resuspended in lOOpl PBS. The cells were
cytospun onto glass slides, fixed and examined (see 2.7.2).
2.7.5. Staining of the Endoplasmic Reticulum
Cells were transfected with 20pg of plasmid DNA (see 2.1.4). The cells
were harvested 24 hours post-transfection, and resuspended in medium containing
50pg/ml Concanavalin A TRITC conjugate (Molecular Probes). The cells were
incubated for 5 mins at 4°C, and then washed twice with PBS. The cells were
fixed, cytospun onto glass slides and mounted in fluorescent mounting medium
(see 2.7.2).
2.7.6. Staining of Iysosomes
Cells were transfected with 20pg of plasmid DNA (see 2.1.4). The cells
were harvested 24 hours post-transfection, and resuspended in medium containing
50nM LysoTracker Red DND-99 (Molecular Probes). The cells were incubated at
37°C for 2 hours. An aliquot of cells was resuspended in fresh medium and
examined under ultraviolet light to check the cell staining. The cells were then
washed once in PBS, and fixed for 30 mins in 2% w/v paraformaldehyde in PBS.
The cells were washed three times in PBS, cytopsun onto glass slides and
mounted in fluorescent mounting medium (see 2.7.2).
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2.7.7. Staining of Golgi apparatus
BODIPY TR (Molecular Probes) was complexed to BSA as per the
manufacturer's instructions. Cells were transfected with 20pg of plasmid DNA
(see 2.1.4). The cells were harvested 24 hours post-transfection, washed once with
HBSS and incubated in HBSS containing 5pM BODIPY TR complex with BSA
for 30 mins at 4°C. The cells were then washed twice in ice-cold HBSS and
incubated with fresh HBSS for 30 mins at 37°C. The cells were washed once in
PBS, fixed, cytospun onto glass slides and mounted in fluorescent mounting
medium (see 2.7.2).
2.7.8. Indirect immunofluorescence
Cells were transfected with 20pg of plasmid DNA (see 2.1.4) and the cells
were harvested 24 hours after transfection, then fixed and permeabilised (see
2.7.1). To stain cells expressing His6 epitope-tagged proteins, the slides were
blocked by incubation with PBS containing 5% v/v normal rabbit serum for 30
mins at RT. The slides were then incubated with mouse monoclonal anti-His6
(Roche) diluted 1:10-1:50 in PBS containing 5% v/v normal rabbit serum for 2
hours at 37°C. As a negative control, duplicate slides were incubated with mouse
monoclonal anti-LMPl diluted 1:20 (DAKO). The slides were then washed four
times with PBS containing 0.05% v/v Tween-20, and incubated with biotinylated
anti-mouse IgG (Sigma) diluted 1:100-1:500 in PBS containing 5% v/v normal
rabbit serum for 45 mins at 37°C. The slides were again washed four times with
PBS containing 0.05% v/v Tween-20, and the slides were then incubated with
streptavidin-FITC conjugate (Sigma) diluted 1:300 in PBS containing 5% v/v
normal rabbit serum for 45 mins at 37°C. The slides were washed four times in
PBS containing 0.05% v/v Tween-20 and the slides mounted in fluorescent
mounting medium (see 2.7.2).
To stain cells expressing HA epitope-tagged proteins, the slides were
blocked by incubation with PBS containing 5% v/v normal goat serum for 30
mins at RT. The slides were then incubated with rat monoclonal anti-HA (Roche)
diluted 1:300 in PBS containing 5% v/v normal goat serum for 2 hours at 37°C.
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As a negative control, duplicate slides were incubated with rat IgG (Sigma)
diluted 1:3000. The slides were then washed four times with PBS containing
0.05% v/v Tween-20. The slides were then incubated with goat polyclonal anti-rat
Ig FITC conjugate (Pharmingen) diluted 1:250 in PBS containing 5% v/v normal
goat serum for 45 mins at 37°C. The slides were washed four times in PBS
containing 0.05% v/v Tween-20, the DNA was counterstained with propidium
iodide and the slides mounted in fluorescent mounting medium (see 2.7.2).
2.8. Recombinant virus production
2.8.1. Generation of recombinant viruses
Recombinant viruses were generated by co-transfection of BHK-21 cells
with purified viral DNA (see 2.2.18) and a fragment of the viral genome allowing
homologous recombination. To generate MHV-76 rescue viruses, cosmid A8
(cA8, see Appendix 3) was used to restore the left end of the genome.
To generate deletions and frame-shift mutations in the M2 ORF, a series
of deletions were made in cosmid A8 using Exonuclease III and Mung Bean
Nuclease (see 2.2.8). Cosmid clones were analysed by restriction enzyme analysis
and sequencing of the M2 ORF, and two clones were chosen containing a 4bp
deletion in M2 (CA8-M2A4336-4339) and a 256bp deletion in M2 (CA8-M2A4239-
4494). These two cosmid clones were used to generate recombinant viruses
identical to MHV-68 with deletions in the M2 ORF.
To generate MHV-76 viruses with the M2 ORF and the tRNA7+8 region
restored, a DNA sequence corresponding to the terminal 3kb of the left end of the
unique region of the MHV-76 genome was amplified by PCR and inserted into
pKS(-) to generate the plasmid pKS/76LHE (see 5.2). A 4kb fragment containing
the M2 cDNA and promoter region was amplified by PCR and inserted into
pKS/76LHE to give the plasmid pKS/76LHE/M2insert. A lkb fragment
containing tRNA7+8 was amplified by PCR and inserted into pKS/76LHE to give
the plasmid pKS/76LHE/tRNAinsert. The cassettes were excised from pKS(-)
prior to transfection.
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BHK-21 cells were transfected with 5jag virus DNA and 10|ag of the
homologous plasmid / cosmid DNA (see 2.1.4). Following transfection, the cells
were placed into 6-well plates and incubated at 37°C overnight. The cells were
washed with fresh medium at 24 hours post-transfection. Fresh medium was
added to the MHV-76 rescue virus transfections, and all other recombinant virus
transfections were overlaid with medium containing 1% w/v LGT agar
(Seaplaque® Agarose, Flowgen). The plates were incubated at 37°C, and
examined for the presence of viral plaques daily.
2.8.2. Purification of MHV-76 rescue viruses
After 6 days, the infected cell monolayer was harvested, the cells pelleted
by centrifugation at 2,000 x g for 20 mins and the cells resuspended in 1ml PBS
with 1% v/v FCS. Virus particles were released from the cells by freeze-thawing
at -70°C three times. The cellular debris was pelleted by centrifugation at 2,000 x
g for 5 mins, and 20pl of the mixture of viruses in the supernatant was mixed with
20pl PBS and used to infect two 6 week old BALB/c mice. After 14 days, the
spleens were harvested and analysed by infective centre assay (see 2.6.3). After
two days of the infective centre assay, the monolayer was overlayed with 1% w/v
LGT agararose in medium. The plates were incubated at 37°C, and examined for
the presence of viral plaques daily.
2.8.3. Purification of recombinant viruses
The positions of viral plaques were marked on the underside of the plate,
and a Pasteur pipette was used to remove an agarose plug containing virus-
infected cells. The agarose plug was transferred to a sterile CryoTube™ vial
containing 500pl of medium. Virus particles were released from the cells by
freeze-thawing at -70°C three times. The cellular debris was pelleted by
centrifugation at 2,000 x g for 5 mins, and the supernatant used in subsequent
purification steps.
Viruses were purified using limiting dilution assay. BHK-21 cells were
grown until approximately 60% confluent in a 96 well plate. The wells were then
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infected with serial dilations of virus (10"1 to 10"4), with the aim of infecting cells
at a concentration of 0.4 PFU/well to give rise to single plaques in 40% of the
wells. The assay was incubated at 37°C for 6 days, and wells containing single
plaques were harvested by scraping the cells into the medium. A lOOpl aliquot of
the sample was placed in a CryoTube™ vial, and freeze-thawed at -70°C three
times to release virus particles. The remainder of the sample was pelleted by
centrifugation at 500 x g for 5 mins. The cell pellet was washed with 500pl of
modified TE (20mM Tris [pH8.0], ImM EDTA) and then resuspended in 50p.l
modified TE. The sample was freeze-thawed once, PCR Grade Proteinase K
(Roche) was added to a final concentration of 400p.g/ml and the sample incubated
at 55°C overnight. The sample was heated to 95°C for 10 mins to inactivate the
Proteinase K, and lOpl of the sample was used as template for PCR analysis (see
2.2.1). Plaques positive by PCR for the desired insert (M2 or tRNA) were
subsequently used to infect the next limiting dilution assay. PCR for ORF74 was
used as a control to check for the presence of viral DNA.
A modification of this protocol was used to directly analyse viral plaque
picks for the MHV-76 rescue viruses and viral stocks. A lOOpl PCR reaction was
set up containing 20mM Tris (pH 7.4), 50mM KC1, 1.5mM MgCf, lOOpM dNTP
mixture, 0.2pmol primer mixture (M2 or ORF 74) and 10p,l of virus sample in
medium (containing approximately 10 PFU of virus). Proteinase K (Roche) was
then added to a final concentration of 200p,g/ml. The reaction was run at 55°C for
20 mins, and then 95°C for 10 mins. One unit of Taq DNA polymerase
(Invitrogen Life Technologies) was then added and 40 cycles of PCR performed
(see 2.2.1).
Plaques positive by PCR for the desired insert (M2 or tRNA) were
subsequently used to infect the next limiting dilution assay. Viruses were purified
until homogeneous by PCR screening. Master stocks were made by infecting
BHK-21 cells in a 25cm2 tissue culture flask at an MOI of 0.01, and incubating
for 4-6 days until 100% CPE was observed. The cells were scraped into the
medium, pelleted by centrifugation at 2,000 x g for 20 mins and resuspended in
lml medium. Virus particles were released from the cells by freeze-thawing at -
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70°C three times. The sample was clarified by centrifugation at 2,000 x g for 5
mins, and the supernatant divided into CryoTube™ vials and stored at -70°C.
2.8.4. Analysis of recombinant viruses
DNA was made from virally infected cells (see 2.2.19), and analysed by
Southern blotting (see 2.2.20) and PCR forMHV-68 specific ORFs (see 2.2.1).
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Appendix 1 General solutions
Unless otherwise stated, all chemicals were obtained from Sigma or Merck BDH
TE buffer : lOmM Tris-HCl [pH8.0], ImM EDTA
TAE buffer : 40mM Tris-acetate, ImM EDTA
Luria-Bertani (LB) medium : 1% w/v tryptone, 1% w/v NaCl, 0.5%
yeast extract, pH7.0
LB Agar : LB containing 1.5% Bacto-Agar (BD)
SOC medium : LB containing 20mM glucose, 20mM
MgCl2
20 x SSC : 3M NaCl, 300mM Na citrate, pH7.0
50 x Denhardt's solution : 1% w/v Ficoll 400, 1% w/v
polyvinylpyrrolidone, 1% BSA (FractionV)
Tris-buffered saline (TBS) : 50mM Tris-HCl, 150mM NaCl, pH 7.6
Phosphate-buffered saline (PBS) : 150mM NaCl, 2.5mM KC1,
lOmM Na2HP04, ImM KH2P04, pH 7.4
Hank's buffered salt solution (HBSS): 150mM NaCl, 25mM HEPES, 5mM KC1,
5mM glucose, ImM CaCl2, ImM KH2P04,
ImM MgCl2, ImM Na2HP04, ImM MgS04,
0.001% w/v phenol red, pH 7.0
100
Appendix 2 PCR primers
All primers were synthesised by MWG Biotech AG.
















EcoK\ 6 x His
5'-CGCGAATTCTTAATGATGATGATGATGATG
CTCCTCGCCCCACTCCAC-3'






































































































51 °C 4623 - 5806 1200bp
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tRNA7for 5'- GAG CGG CAG ACA CCA-3' 58°C 4967 - 5034 68bp
tRNA7rev 5'-TAG CTG GCC AGG ACT-3'
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Appendix 3 Plasmid Vectors
NaeI 131
Ssp I 442









, Pvu II 529
. SssH II 619













I Leu Val Pro Arg^Gly Ser I Pro Gly lie His Arg Asp
CTG GTT CCG CGTGGA TCCCCG GGA ATT C,AT CGT GAC TGA CTG ACG
BamH I gma I ^coR ' ^top cc,c'ons
pGEX-2T was obtained from Amersham Pharmacia.
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pcDNA3.1 was obtained from Invitrogen
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Note: The left LTR serves
pBABE puro retroviral vector (Morgenstern & Land, 1990). The plasmid map
was obtained from www.pharmacy.purdue.edu/~phrm302/molbiol
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Hindlll
pVR1255 was obtained under license from Vical Incorporated (Hartikka et al.,
1996). To obtain pVR1255luc", pVR1255 was cut with Notl and BamWX to excise
the luciferase gene. The termini were filled in and the blunt ends ligated to give
the multiple cloning site containing Pstl, Sail and EcoRM.
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TAC AAG TCC GGA CTC AGA TCT CGA GCT CAA GCTTCG AAT TCT GCA GTC GAC GGTACC GCG GGC CCG GGATCC ACC GGA TCTAGA TAA CTGATCA
BspEI Sg/ll JOiolV, Hint III fcoRI Ball Sail Kpnl 7 ApsT s BanMI Xbal- Bel I*
„ Acc I Asp718 L Bs/7l201 Afma IIcIIXII * Sac II 57na I
GCTAGCG CTA CCG GAC TCA GAT CTC GAG CTC AAG CTT CGA ATT CTG CAG TCG ACG GTA CCG CGG GCC CGG GAT CCA CCG GTC GCC ACC ATG GTG
Nhe I EcoAl III Sg/ll Xho I _ , Wjfrd III fcoR I Psfl Sa/I Xpn I \ Apa I Saa;H I Agel
/acl »ccl AspJWI \ Bspmi XmalEcu3611 ' Sac II ' 5777a!




The plasmids pSG5/M2-3'HA and pSG5/M2-5'HA were kindly provided by Dr.
Jeff Sample, St. Jude Children's Research Hospital, Memphis. The plasmids
contained the M2 gene with three consecutive 27bp DNA sequences
corresponding to the influenza haemagglutinin (HA) protein epitope
(YPYDVPDYA) inserted in frame either immediately upstream of the M2 ORF
(pSG5/M2-5'HA) or immediately upstream of the M2 STOP codon (pSG5/M2-
3'HA). As positive controls, pSG5/Jic-HA (Zhao et al., 1996) and pSG5/IRF7-HA
(Zhang & Pagano, 1997) were also kindly provided by Dr. Sample.
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O Stratagene
The parent cosmid vector SuperCos 1 was modified by the replacement of the Not\
fragment of the original cloning site with a cloning region containing the
configuration EcoR\ - Not\ - Ascl - Pacl - BamlU - Asd - Pad - Not\ - £coRI
(Cunningham & Davison, 1993).
Cosmid A8 was kindly provided by Dr. Andrew Davison, MRC Virology Unit,
Glasgow. This cosmid was a modified SuperCos 1 containing nucleotides 1 15165
to 26842 of MHV-68 DNA inserted into the Bam\A\ site (MHV-68 co-ordinates
shown in red). To aid interpretation, the four MHV-68 genes (Ml, M2, M3 and
M4) present at the left end of the unique region of the MIIV-68 viral genome are
shown in green.
1 1 1
Appendix 4 Commercial suppliers
Amersham Pharmacia Biotech UK Limited, Amersham Place, Little Chalfont
Buckinghamshire HP7 9NA
www.apbiotech.com
BD Biosciences, 21 Between Towns Road, Cowley, Oxford, 0X4 3LY
www.bd.com
BD Biosciences Clontech UK, Unit 2, Intec 2, Wade Rd., Basingtoke, Hampshire
RG24 8NE
www.clontech.com
BD PharMingen, 10975 Torreyana Road, San Diego, CA 92121
www. pharm inuen.com
BD Transduction Laboratories, 133 Venture Court, Lexington, KY 40511
www.translah.com
Bio-Rad Laboratories Ltd., Bio-Rad House, Maylands Avenue, Hemel
Hempstead, Hertfordshire HP2 7TD
www, h i o-rad .com
British Biocell International, Golden Gate, Ty Glas Avenue, Cardiff, CF14 5DX
www.british-biocell.co.uk
CytRx Corporation, 154 Technology Parkway Suite 200, Norcross, Georgia
30092
www.cytrx.com
DAKO Ltd., Denmark House, Angel Drove, Ely, Cambridgeshire CB7 4ET
www .dako.com
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3.1. Aims
The field studies in Slovakia that resulted in the isolation of MHV-68
recovered five strains of herpesvirus from two species of rodents (Blaskovic et al.,
1980). Strains 60, 68 and 72 were isolated from the bank vole (Clethrionomys
glariolus) and strains 76 and 78 were isolated from the yellow-necked wood
mouse (Apodemus flavicollis). However, only MHV-68 and MHV-72 have been
studied in detail (for recent reviews see Mistrikova et al., 2000; Nash et al.,
2001). It was hypothesised that the study ofMHV-76, which was isolated from a
different species of rodent, might reveal differences between the viral strains that
would yield further insights into gammaherpesvirus pathogenesis.
The aim of this project was to characterise MHV-76, and compare the
molecular structure and biological features of MHV-76 with MHV-68. By
comparing the two viruses, it would be possible to determine which differences in
the viral genome were responsible for any alterations in phenotype observed.
3.2. Molecular characterisation of the MHV-76 genome
MHV-76 virus stocks were kindly provided by Dr. Mistrikova, Comenius
University, Slovak Republic, and the virus stocks were plaque purified by limiting
dilution three times on BHK-21 cells to obtain a pure virus stock (see 2.8.3). All
virus stocks were grown by infection of BHK-21 cells at an MOI of 0.01 (see
2.5.1), and purified viral DNA was prepared for molecular analysis (see 2.2.17).
Detailed molecular characterisation of MHV-76 was performed by Dr.
Andrew Davison and Steven Milligan at the MRC Virology Institute, Glasgow.
Restriction fragment banding patterns with eight different restriction
endonucleases and sequencing of the MHV-76 viral genome from co-ordinates
115,587 to 26,842 revealed the following differences between the MHV-68 and
MHV-76 viral genomes (Macrae et al., 2001).
1. Copy number variation in the internal repeat sequences (approximately 10
copies fewer of the 40bp element, and 12 copies more of the lOObp
element).
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2. A deletion of 9,538bp at the left end of the unique region in MHV-76
compared to MHV-68. MHV-76 therefore lacks the unique MHV-68
genesMl, M2, M3 and M4 and all 8 vtRNA-like sequences.
3. A nucleotide substitution at position 12,280, which leads to a substitution
of a serine for a glycine residue in ORF 6.
To check that the 9,538bp deletion was a true deletion and not re-arranged
elsewhere within the viral genome, MHV-76 genomic DNA was analysed by PCR
as previously described (see 2.2.1). MHV-76 and MHV-68 viral DNA was
purified from infected BHK-21 cells, and 40 cycles of PCR were performed on
lpg viral DNA template. Primers were used to amplify MHV-68 specific ORFs
(see Chapter 2, Appendix 2) including Ml (Mlfor and Mlrev primers), M2
(M2GEX1 and M2GEX2 primers), M3 (M3+ and M3- primers), M4 (M4A and
M4B primers), gpl50 (gpl50A and gpl50B primers), Mil (M11+ and Mil-
primers), ORF73 (ORF73+ and ORF73-) and ORF74 (GCR-5' and GCR-3'
primers). Negative control reactions were performed for all primer sets using
water instead of template DNA. A 10pl sample of the products was analysed on a
1% TAE agarose gel.
All primer sets were able to amplify correctly sized sequences from MHV-
68 DNA (Figure 3.2A and 3.2B). In contrast, no sequences corresponding to Ml,
M2, M3 and M4 were amplified from MHV-76 DNA showing that these ORFs
are absent in MHV-76. However, correctly sized sequences corresponding to
gpl50, Mil, ORF73 and ORF74 were amplified (Figure 3.2A and 3.2B). These
results are consistent with the previous molecular characterisation, and show that
MHV-76 is a deletion mutant ofMHV-68 that lacks Ml, M2, M3, most of the 5'
portion of M4 and all eight vtRNA-like genes. This result is depicted
schematically in Figure 3.2C.
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Figure 3.2 PCR analysis of MHV-76 and MHV-68 viral genomes. 40 cycle PCR
was performed on lpg viral DNA, and the products were analysed on a 1% TAE
agarose gel. Molecular weights are shown relative to the marker on the left hand
side. (A) PCR using primers specific for the Ml, M2, M3, M4 and gpl50 genes.















Figure 3.2C Schematic diagram of the structures present at the left end of the
unique region of the genome in MHV-68 (A) and MHV-76 (B). The unique region
of the genome from the terminal repeats to 12kb is shown as a black line, with
green arrows indicating MHV-68 unique ORFs (Ml, M2, M3 and M4), blue
arrowheads indicating the eight viral tRNA-like sequences (vtRNAs) and the red
arrow indicating ORF 4 (complement regulatory protein). The green rectangle in
MHV-76 denotes the remaining M4 sequence, joined to the terminal repeats (TR).
Scale bar at the top of the diagram represents lkb divisions. Genomic co-ordinates
of relevant positions are given in black above the features, according to Virgin et
al., 1997.
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3.3. Biological characterisation ofMHV-76
3.3.1. Replication in vitro
The replication of MHV-76 in vitro was assessed by a one-step growth
curve. BHK-21 cells were infected with MHV-76 or MHV-68 at an MOI of 5, and
harvested at various timepoints post-infection as previously described (see 2.5.3).
MHV-76 replicated with the same kinetics and achieved similar titres to MHV-68
(Figure 3.3.1). Thus there was no significant difference between the replication of
MHV-68 and MHV-76 in vitro as measured by this assay.
3.3.2. Replication in the lung
The ability of MHV-76 to replicate productively in vivo was assessed.
Mice were infected with 2 x lCf PFU MHV-76 or MHV-68 (see 2.6.1) and the
virus titre in the lungs determined at various times post-infection by plaque assay
(see 2.6.4). Figure 3.3.2 shows the results of a single experiment, and is
representative of four separate experiments. When compared to MHV-68, MHV-
76 replication in the lungs peaked at day 4 post-infection (compared to day 6 in
MHV-68 infection) and was cleared more rapidly from the lungs. At day 6 post¬
infection, there was approximately a logio difference in viral titres between MHV-
76 and MHV-68 (PO.OOl), and by day 8, MHV-76 had nearly been cleared from
the lung. These results show than MHV-76 can replicate productively in vivo, but
is cleared more rapidly from the site of primary viral replication.
3.3.3. Lytic replication in other organs
Examination for other sites of lytic viral replication in vivo was also
undertaken. Mice were infected with 2 x lCf PFU MHV-76 or MHV-68 (see
2.6.1) and the virus titre in the adrenal glands, heart and kidneys determined at
various times post-infection by plaque assay (see 2.6.4). In the adrenal glands,
virus was detectable in MHV-68 infected mice in variable amounts up to 8 days
post-infection, achieving maximum titres of 100 PFU per adrenal (Figure 3.3.3).
In contrast, no virus was detectable in the adrenals ofmice infected with MHV-
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Figure 3.3.1 One step growth curve ofMHV-68 ( ) and MHV-76 ( ■ ) on
BHK-21 cells at an MOI of 5. Data points are shown for virus titre logl0 ± standard
error. The results shown are representative of two separate experiments, each
carried out in duplicate.
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Figure 3.3.2 Viral titres in the lungs of BALB/c mice infected intranasally with 2 x
105 PFIJ ofMHV-68 (—^—) or MHV-76 ( M ). Mean virus titre logI0 per lung
± standard error for four mice per group is shown for each time point. The results
are representative of four separate experiments. * indicates statistically significant
difference between MHV-76 and MHV-68 viral titres as determined by two-way
ANOVA with Bonferroni post-tests.
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Figure 3.3.3 Infectious virus in the adrenal glands of BALB/c mice infected
intranasally with 2 x 105 PFU ofMHV-68 ( or MHV-76 ( B ). Virus titre logU)
per adrenal glands per mouse is shown for four mice per group for each timepoint.
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76. No virus was detectable by plaque assay in the heart or kidneys of mice
infected with either MHV-76 or MHV-68 (data not shown).
3.3.4. Virus-induced splenomegaly
To determine the extent of splenomegaly during MHV-76 infection, the
spleen weight (see 2.6.2) and total number of splenocytes (see 2.6.3) was
determined in BALB/c mice infected intranasally with either MHV-76 or MHV-
68. As seen in Figure 3.3.4A and B, MHV-68 induced a characteristic increase in
spleen weight and total splenocyte numbers that peaked at two weeks post¬
infection. MHV-76 infection also caused a slight increase in spleen weight and
cell numbers, but there was a significant reduction in total spleen weight and total
number of splenocytes after infection with MHV-76 compared with MHV-68.
This difference in spleen cell numbers was most pronounced at day 14 post¬
infection (HO.001) and continued during the resolution phase (day 17 and 21:
HO.01). Figure 3.3.4 shows the results of a single experiment, and is
representative of four separate experiments.
3.3.5. Latent virus in blood leukocytes
The ability to detect latent virus in blood leukocytes was determined for
mice infected with MHV-76 and MHV-68 by infective centre assay (see 2.6.3).
Latent virus was detectable at 2 - 3 weeks post-infection, with less than 1 in 105
blood leukocytes latently infected with MHV-68 (Figure 3.3.5). Only one mouse
had detectable latent MHV-76 in blood leukocytes, but the low level of detectable
latent virus in all mice meant that these results were not significant.
3.3.6. Latent virus in the spleen
The establishment of latency in vivo was determined using an infective
centre assay (see 2.6.3) to detect latently infected splenocytes at various
timepoints post-infection in BALB/c mice infected intranasally with MHV-76 and
MHV-68. Latent MHV-68 was detected at day 6 post-infection and peaked at 2
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Figure 3.3.4A Spleen weights of BALB/c mice infected intranasally with 2 x 105
PFU ofMHV-68 (——) or MHV-76 ( U ). Mean spleen weight (mg) ± standard
error is shown for four mice per group for each timepoint. The results are
representative of four separate experiments. * indicates statistically significant
difference between MIIV-76 and MHV-68 spleen weights as determined by two-
way ANOVA with Bonferroni post-tests.
125
25
_ . _ _ j
0 10 20 30 40
Days post-infection
Figure 3.3.4B Total splenocyte numbers of BALB/c mice infected intranasally with
2 x 105 PFU of MHV-68 ( ♦ ) or MHV-76 ( Mean total number of
splenocytes ± standard error is shown for four mice per group for each timepoint.
The results are representative of four separate experiments. * indicates statistically
significant difference between MHV-76 and MHV-68 total splenocyte numbers as
determined by two-way ANOVA with Bonferroni post-tests.
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Figure 3.3.5 Latent virus in blood leukocytes of BALB/c mice infected intranasally
with 2 x 105 PFU of MHV-68 ) or MHV-76 ( ■ ) as determined by infective
centre assay. The number of infective centres per 106 blood leukocytes is shown per























Figure 3.3.6 Latent virus in the spleens of BALB/c mice infected intranasally with
2 x 105 PFU ofMHV-68 ( —^—) or MHV-76 ( M ) as determined by infective
centre assay. Infectious virus titres (less than 50 PFU per spleen) were subtracted
from the infective centre results. Mean infective centres per spleen ± standard error
for four mice per group is shown for each timepoint. The results are representative
of four separate experiments. * indicates statistically significant difference between
the number of infective centres in mice infected with MHV-76 and MHV-68 as
determined by two-way ANOVA with Bonferroni post-tests.
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spleen, peaking at day 10 post-infection. However, the amount of latent MHV-76
was dramatically reduced compared to MHV-68. (Day 10, 14 and 17: AO.001 ;
Day 21: AO.01). Figure 3.3.6 shows the results of a single experiment, and is
representative of four separate experiments. A small amount of infectious virus
(less than 50 PFU per spleen) was detectable in splenocytes up to 14 days post¬
infection (data not shown). Splenocytes latently infected with MHV-76 were still
detectable at 31 days post-infection, at levels of 5 in 107 splenocytes. This result
showed that MHV-76 can still establish latency in the spleen cell population in
vivo, but at much lower detectable levels compared to MHV-68. This could be
due to lower levels of latently infected splenocytes during MHV-76 infection, or
due to defective reactivation from latency in the infective centre assay.
3.4. Determination of the splenocyte population harbouring
latent MHV-76
One possible explanation for the marked reduction in latently infected
splenocytes following MHV-76 infection was that MHV-76 might have an altered
cellular tropism compared to MHV-68. To check which spleen cell populations
were infected with latent MHV-76, two mice were infected with MHV-76, the
spleens harvested at 14 days post-infection and the splenocytes separated into
CD 19+ cells (B lymphocytes) and CD 19- cells (non-B lymphocytes) using
MACS (see 2.6.6). The purity of the separated fractions was assessed by FACS
analysis (see 2.6.7). The B lymphocyte population was over 90% pure, and the
non-B cell fraction was contaminated with less than 3% CD 19+ cells in both mice
(Table 3.4).
The amount of latent virus in the B cell, non-B cell and total splenocyte
populations was determined by infective centre assay (see 2.6.3). The majority of
infective centres were present within the CD 19+ B lymphocyte sub-population,
with a small amount of latent virus detectable within the CD19- non-B
lymphocyte fraction in one mouse (Figure 3.4). Separating the splenocyte
populations by MACS did not have a significant effect on the ability of latent


















Figure 3.4 Determination of the splenocyte population harbouring latent MHV-76.
Two mice were infected with 2 x 105 PFU ofMHV-76, and the spleens harvested at
day 14 post-infection. The splenocytes were sorted by MACS using CD 19
antibody, and the amount of latent virus in the B cell (CD19+), non B cell (CD19-)
and total splenocyte populations determined by infective centre assay. Results are
shown as number of infective centres per 107 splenocytes for each fraction, for two
mice.
Mouse A Mouse B
Total
cells




B cells Non B
cells
CD19+ 68.5 95.1 2.9 58.1 92.0 1.12
CD4+ 19.7 3.2 56.3 25.4 6.1 64.7
CD8+ 7.2 0.5 24.0 7.6 0.5 28.63
Table 3.4 Purity of separated MHV-76 infected splenocytes sorted by MACS.
Aliquots of each sorted fraction (Total cells, B cells, Non B cells) were incubated
with fluorescent conjugated antibodies to cell surface markers CD4, CD8 and




□ Non B-cells (CD19-)
Mouse A Mouse B
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number of infective centres in the total splenocyte populations with the separated
cell fractions. The distribution of latent MHV-76 within the splenocyte population
therefore appears to be similar to that of MHV-68, predominantly infecting B
lymphocytes (Sunil-Chandra et al., 1992b).
3.5. Long-term persistence of MHV-76 in vivo
The results of the infective centre assays showed that MHV-76 was able to
establish latency in vivo. To determine whether MHV-76 is able to maintain long
term persistence or is cleared by the immune system, mice were infected with
MHV-76 and MHV-68. At 5 months post-infection, organs from these mice were
analysed for the presence of virus. Three of the four mice infected with MHV-76
were positive by infective centre assay for latent virus in the spleen at levels of
approximately 1-2 latently infected cells per 107 splenocytes. No infectious virus
was detected in the splenocyte populations.
To detect virus in other organs, DNA was extracted from the liver, lung,
kidney, spleen and white blood cells of four mice infected with MHV-76 at five
months post-infection (see 2.6.10). As a positive control, one mouse infected with
MHV-68 was harvested at 5 months post-infection. As a negative control, two
uninfected mice were also analysed by this method. Extracted DNA was
quantified (see 2.2.6), and PCR amplification was performed on lpg of the
extracted high molecular weight DNA using primers specific for the gpl50 gene
(Chapter 2, Appendix 2: gp 150-1 and gpl50-2). This was followed by Southern
39
blot hybridisation with a P-radiolabelled gpl50-specific probe to confirm the
identity of the PCR products (see 2.2.20). Positive controls (purified viral DNA
template) and negative controls (no DNA template) were included for each set of
PCR reactions. To determine the sensitivity of detection of viral DNA, tenfold
copy number dilutions of cloned template DNA in a background of lpg of high
molecular weight DNA were analysed by this method. It was determined that this
process was sensitive to between 1 and 10 copies of the viral genome in lpg of
high molecular weight DNA (data not shown).
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Figure 3.5 Detection of viral DNA in the tissues of mice at 5 months post¬
infection. Four BALB/c mice were infected with 2 x 105 PFU ofMHV-76 and the
lungs, liver, spleen, kidney and blood was harvested at 5 months post-infection.
Two uninfected mice were also harvested as negative controls, and one mouse
infected with MF1V-68 was harvested as a positive control. Viral DNA was
extracted and PCR amplification performed on lpg of high molecular weight DNA.
Positive control reactions containing MFIV-68 viral DNA (first lane) and negative
control reactions containing no DNA (second lane) were also performed. (A) PCR
amplification using primers specific for gpl50, followed by Southern hybridisation
with 32P-labelled gpl50 probe to confirm specificity. (B) PCR amplification using
primers specific for M3 (a gene absent from MHV-76), followed by Southern
hybridisation with 32P-labelled M3 probe to confirm specificity.
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As shown in Figure 3.5A, viral DNA was not detected in any negative
control reactions or uninfected mice. In the MHV-68 infected positive control
mouse, viral DNA was detected in the lung and spleen, but not in the liver, kidney
or white blood cells. In the MHV-76 infected mice, viral genomes were found in
the spleens of all four mice, but only in the lungs of one mouse.
To ensure that the persisting virus detected in mice infected with MHV-76
was not due to contamination with MHV-68, lpg of the extracted DNA was
analysed by PCR using primers specific for the M3 gene (Chapter 2, Appendix 2:
M3+ and M3-). The M3 gene is present in MHV-68 but absent from MHV-76.
This was followed by Southern blot hybridisation with a 32P-radiolabelled M3-
specific probe to confirm the identity of the PCR products (see 2.2.20). As shown
in Figure 3.5B, the M3 sequence was detected only in the positive control mouse
infected with MHV-68, and not in the negative control uninfected mice or any of
the mice infected with MHV-76. This results shows that the MHV-76 viral stocks
were free ofMHV-68, and the persisting virus in the mice was definitely MHV-
76. The ability to detect MHV-76 both by infective centre assay and by the
presence of the viral genome by PCR at late timepoints post-infection shows that
MHV-76 can persist long-term in vivo.
3.6. Histopathological changes during MHV-76 infection
In order to examine any differences in the inflammatory response to
MHV-76, mice were infected with either MHV-76 or MHV-68. The lungs and
spleens were harvested at various times post-infection and examined by
histopathology (see 2.6.8).
3.6.1. Histopathology of lung after viral infection
In the lung at day 4 following intranasal infection with MHV-76, there
was a marked inflammatory reaction consisting of perivascular infiltration of
lymphoid cells and oedema (Figure 3.6.1 A). However, no inflammatory changes
were observed at this time following MHV-68 infection (Figure 3.6.IB). By day 6
post-infection, the inflammatory changes seen during MHV-76 infection were
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Figure 3.6.1 Histopathological changes in the lungs of mice infected with MHV-76
or MHV-68. Representative sections of lung stained with haematoxylin and eosin
are shown for mice infected at the timepoints indicated. Scale bar represents 0.5mm
Abbreviations: P - perivascular infiltration; BV - blood vessel; AE - alveolar
exudate; I - interstitial infiltration; V- vasculitis.
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marked, consisting of perivascular and interstitial lymphoid infiltration, intra-
alveolar exudates and vasculitis (Figure 3.6.1C). Subpleural lymphoid
accumulations were also observed (data not shown). In contrast, inflammatory
changes were relatively minor in mice infected with MHV-68 at day 6 post¬
infection, consisting mostly of perivascular lymphoid aggregations and alveolar
exudate (Figure 3.6.ID). At days 8 and 10 post-infection in the lung, no
significant differences were observed in the inflammatory response between
MHV-76 and MHV-68, which consisted of vasculitis and interstitial lymphoid
accumulations (Figure 3.6.IE and 3.6.IF). These results demonstrate that the
inflammatory changes seen in the lung during MHV-76 infection occur earlier
and are more substantial compared to MHV-68.
3.6.2. Detection of viral antigens by immunostaining in the lungs
The enhanced inflammatory response to MHV-76 may have suppressed
the expression of viral antigens in the lung, or altered the cell tropism of the virus.
To examine for this possibility, lung sections were examined for the presence of
viral antigens by immunostaining at days 4 and 6 post-infection using polyclonal
anti-MHV-68 serum, and stained by the peroxidase method using DAB substrate
(see 2.6.9). Viral antigen was readily detected in the lungs ofMHV-76 and MHV-
68 infected mice, showing that MHV-76 expresses very similar antigens to MHV-
68 (Figure 3.6.2). Numerous positive cells were observed at day 4 and 6 post¬
infection in MHV-76 infected lungs, but there was no observable difference in
either the amount or distribution of antigen-positive cells between MHV-76 and
MHV-68 infected lungs (Figure 3.6.2 A and B). Most antigen positive cells were
alveolar epithelial cells (Figure 3.6.2 C and D), and strong staining was observed
in both the nucleus and cytoplasm. These results are consistent with previous
results of immunostaining on MHV-68 infected lungs (Sunil-Chandra et al.,
1992a).
3.6.3. Histopathology of spleen after viral infection
The dramatic differences between the splenomegaly and amount of latent
virus detectable following MHV-76 infection might lead to alterations in the
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Figure 3.6.2 Detection of viral antigens by immunostaining in the lungs of mice
infected with MHV-76 or MHV-68. Representative sections of lung were labelled
using polyclonal anti-MHV-68 antiserum, and stained by the peroxidase method using
DAB substrate. Sections were then counterstained with haematoxylin. Scale bar
represents 0.5mm. Abbreviation: AE - alveolar epithelial cell.
A. MHV-76 Day 10 post-infection B. MHV-68 Day 10 post-infection
GC
GC
Figure 3.6.3 Histopathological changes in the spleens of mice infected with MHV-76
or MHV-68. Representative sections of spleen stained with haematoxylin and eosin are
shown for mice infected at the timepoints indicated. Scale bar represents 0.5mm.
Abbreviations: GC - germinal centre; IMZ - marginal zone.
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typical inflammatory response seen in the spleen following MHV-68 infection
(Sunil-Chandra et ai, 1992a). To examine this, spleens of mice infected with
MHV-76 and MHV-68 were examined by histopathology (Figure 3.6.3). In the
spleen at day 10 and 14 post-infection with MHV-68 and MHV-76, there was
evidence of active inflammation as shown by follicular hyperplasia, with germinal
centre formation and an increase in the marginal zone of the white pulp (Figure
3.6.3A and 3.6.3B). There were no detectable histopathological differences
between MHV-68 and MHV-76.
3.7. Construction and molecular characterisation of rescue
viruses
To determine whether the differences in phenotype observed between
MHV-68 and MHV-76 were due to deletion of genes at the left end of the unique
region of the viral genome or due to unidentified mutations elsewhere in the
genome, rescue viruses (rescuants) were constructed by reintroducing the left end
of the unique region of the MHV-68 genome into MHV-76.
3.7.1. Construction and purification of rescue viruses
Rescuants were generated using cosmid A8 (Chapter 2, Appendix 3), by
the co-transfection of BHK-21 cells with MHV-76 genomic DNA and cosmid A8
(see 2.8.1). Rescuants in which the deletion had been restored were likely to be
less attenuated in vivo than MHV-76, and thus the resulting mixture of viruses
was passaged in BALB/c mice. The spleens were harvested at 14 days post¬
infection and the latent virus reactivated using an infective centre assay (see
2.8.3). Individual plaques were then picked and purified by limiting dilution assay
on BHK-21 cells (see 2.8.3). Virus plaques containing rescuants were identified
by the presence or absence of M2 DNA using a PCR amplification screening
method (see 2.8.3) with primers M2GEX1 and M2GEX2 (Chapter 2, Appendix
2). PCR amplification ofORF 74 DNA (Primers GCR-5' and GCR-3'; Chapter 2,
Appendix 2) was used to check that the viral DNA was suitable for PCR
amplification (data not shown). After 3 rounds of plaque purification and
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screening, the plaques were judged to represent pure viral clones as evidenced by
the fact that all subsequent viral plaque picks were positive for the M2 ORF by
the PCR screening method.
After plaque purification, 3 individual viral clones were chosen for further
characterisation. MHV-76(cA8+)3 and MHV-76(cA8+)4 were both positive for
M2 by PCR, and were therefore rescuants in which the deleted region had been
restored to MHV-76. MHV-76(cA8-)5 was negative for M2 by PCR but had been
selected in exactly the same way as the rescue viruses, and was therefore chosen
to control for any possible effects that the in vivo passage and subsequent
isolation procedures may have had on the viruses.
3.7.2. Southern analysis of rescue viruses
DNA was made from virally infected cells (see 2.2.19) and Southern
analysis was performed using diagnostic Hindlll and EcoRl digestions (see
2.2.20). These digests were then probed with a P-radiolabelled cosmid A8
probe. The cosmid A8 probe identifies the MHV-68 Hindlll fragments B, C, E, G,
I, J, N, S, T2, U2, Z2 (Figure 3.7.2.2). However, in MHV-76 the Hindlll E and U2
fragments are deleted, and the J fragment is reduced in size (fragment JA) but
becomes bound to the terminal repeats. Southern analysis showed that the rescue
viruses MHV-76(cA8+)3 and MHV-76(cA8+)4 yielded identical profiles to
MHV-68, containing the Hindlll E fragment (Figure 3.7.2.1 A). The Hindlll E
fragment was not present in MHV-76 or MHV-76(cA8-)5. The Hindlll fragments
S and Z2 were too small to be visualised on the blot, and fragments containing the
terminal repeats (U2+, T2+ and JA+) appeared as high molecular weight products.
A 32P-radiolabelled probe consisting of the full length M3 ORF DNA
(which crosses the Hindlll E and J fragment junction; Figure 3.7.2.2) was also
used to analyse the Hindlll digest. The results showed that the correct sized
Hindlll E and J fragments were present in MHV-68, MHV-76(cA8+)3 and MHV-
76(cA8+)4 but not in MHV-76 or MHV-76(cA8-)5 (Figure 3.7.2.IB). These
results show that the rescue viruses MHV-76(cA8+)3 and MHV-76(cA8+)4
contain all of the sequence deleted in MHV-76.
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Figure 3.7.2.1 Southern analysis of rescue viruses. DNA was isolated from BHK-
21 cells infected with MHV-76, MHV-68, MHV-76(cA8+)3, MHV-76(cA8+)4 and
MHV-76(cA8-)5, digested with Hindlll and analysed by Southern blot on a 0.8%
agarose gel. The blots were hybridised with 32P-labelled probes of (A) cosmid A8
or (B) M3 (nucleotides 6060-7277). The sizes of molecular weight markers in bp













































































































































































































CHAPTER THREE CHARACTERISATION OF MHV-76
3.7.3. PCR analysis of rescue viruses
To fully characterise the rescue viruses and check that all the deleted
ORFs had been restored (Figure 3.2C), rescue virus DNA was analysed by PCR.
Primers were used to amplify MHV-68 specific ORFs (see Chapter 2, Appendix
2) including Ml (Ml for and Ml rev primers), M2 (M2GEX1 and M2GEX2
primers), M3 (M3+ and M3- primers) and M4 (M4A and M4B primers). The
results showed that Ml, M2, M3 and M4 were all present in the rescue viruses
MHV-76(cA8+)3 and MHV-76(cA8+)4, but were not present in the control virus
MHV-76(cA8-)5 (Figure 3.7.3). As a control to check for template DNA integrity
and concentration, primers for ORF 74 (GCR-5' and GCR-3' primers) amplified
correctly sized DNA fragments from all three viral DNA samples. To check the
purity of viral stocks, PCR amplification following proteinase K digestion of viral
samples (see 2.8.3) gave the same results (data not shown). This result
demonstrated that the rescuants MHV-76(cA8+)3 and MHV-76(cA8+)4 contain
the unique MHV-68 genes Ml, M2, M3 and M4, whereas the control virus MHV-
76(cA8-)5 and MHV-76 do not contain these genes.
Dr. Andrew Davison, MRC Virology Institute, Glasgow, also undertook
sequence analysis of the region containing nucleotide 12280. This showed that
MHV-68, MHV-76(cA8+)3 and MHV-76(cA8+)4 contained a G residue at this
position, and that MHV-76 and MHV-76(cA8-)5 contained an A residue. This
showed that sequences adjacent to the deletion in MHV-76 had also been rescued
by cosmid A8.
3.7.4. Derivation of rescue viruses
The MHV-76 rescue viruses did not contain any marker genes (e.g. green
fluorescent protein or (3-galactosidase), and therefore contamination with wild-
type MHV-68 was a possibility. In other gammaherpesviruses such as EBV, the
copy number of the internal repeat sequences has been shown to vary between
viral strains (Bornkamm et al., 1980) and this has recently been shown to also
occur in MHV-68 (Adler et al., 2000). Therefore determination of the copy
number of the lOObp repeat in the viral genome would help to assess the origin of
the rescue viruses. Viral DNA was digested with Hindi (which digests the viral
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Figure 3.7.3 PCR analysis of viral DNA from MHV-76(cA8+)3, MHV-76(cA8+)4
MHV-76(cA8-)5. 40 cycle PCR analysis was performed using primers specific for
the unique MHV-68 genes Ml, M2, M3 and M4 and also ORF 74 (GPCR), and the
products analysed on a 1% agarose gel. The sizes of molecular weight markers in
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Figure 3.7.4.1 Derivation of rescue viruses. DNA was isolated from BHK-21 cells
infected with MHV-76, MHV-68, MHV-76(cA8+)3, MHV-76(cA8+)4 and MHV-
76(cA8-)5, digested with HincW and analysed by Southern blot on a 0.8% agarose
gel. The blots were hybridised with 32P-labelled BamM probe (containing the lOObp
repeat). The sizes of molecular weight markers in bp are shown on the left, and
Hincll E fragment or approximate copy number of the lOObp repeat sequence on
the right side of the autoradiograph.
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Figure 3.7.4.2 Interpretation of Southern analysis for the determination of the copy
number of the lOObp internal repeat sequence. The unique region of the MHV-68
genome from nucleotide co-ordinates 90kb to 105kb is shown as a yellow bar, with
the lOObp internal repeat sequence (IR) in red vertical bars (MHV-68 nucleotide
co-ordinates 98,981 - 101,170 shown in red above). Restriction enzyme sites for
HincU are shown in black, with the fragment sizes in kb and fragment designation
above. The location of the BamM probe used in Southern analysis is shown
underneath as a blue bar (nucleotide co-ordinates 97,586 - 101,653). The size of the
HincU fragment containing the lOObp internal repeat sequence is given in kb by the
formula 0.3 + O.lx, where x is the number of copies of the lOObp internal repeat
sequence. Genomic co-ordinates are given according to Virgin el al., 1997.
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genomic DNA at positions 98858 and 101358 either side of the lOObp repeat),
and then analysed by Southern blot using a radiolabelled BamM probe (Efstathiou
et al., 1990b), which is predicted to hybridise to the fragment containing the
lOObp repeat (Figure 3.7.4.2). This confirmed that the estimated copy number of
the MHV-68 lOObp internal repeat sequence was 22 (21 complete copies and a
90bp partial repeat; Figure 3.7.4.1; Virgin et al., 1997). However in MHV-76,
MHV-76(cA8+)4 and MHV-76(cA8-)5, the fragment containing the lOObp repeat
was approximately 4kb in size, corresponding to approximately 37 copies of the
lOObp repeat (Figure 3.7.4.1). MHV-76(cA8+)3 appeared to consist of two viral
populations with 37 and 30 copies of the lOObp repeat sequence. MHV-76, the
two rescue viruses and the control virus contained a larger number of copies of
the lOObp repeat compared to MHV-68, and these results prove that the rescue
viruses were all derived from MHV-76, and were not produced by contamination
with MHV-68. As MHV-76(cA8+)3 appeared to consist of two virus populations,
this virus was not studied further.
3.8. Biological characterisation of rescue viruses
3.8.1. Replication in vitro
To investigate the effect of the 9.5kb deletion in MHV-76 on viral
replication in vitro, the replication of MHV-68, MHV-76, MHV-76(cA8+)4 and
MHV-76(cA8-)5 was compared in a single round of replication in BHK-21 cells
(one-step growth curves at an MOI of 5; see 2.5.3). The one-step growth curves
showed that all viruses replicated at a similar rate in vitro (Figure 3.8.1),
demonstrating that the deleted sequence has no detectable effect on lytic
replication in BHK-21 cells.
3.8.2. Replication in the lung
BAFB/c mice were infected with 2 x 105 PFU of MHV-68, MHV-76,
MHV-76(cA8+)4 or MHV-76(cA8-)5 intranasally and the virus titre in the lungs
was assessed at various timepoints post-infection by plaque assay (see 2.6.4). The
144
CHAPTER THREE CHARACTERISATION OF MHV-76
Figure 3.8.1 One step growth curve of MHV-68 ( A ), MHV-76 ( * ),
MHV-76(cA8+)4 ( —a—) and MHV-76(cA8-)5 ( —a—) on BHK-21 cells at an
MOI of 5. Data points are shown for virus titre logl0 ± standard error.
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rescue virus MHV-76(cA8+)4 showed peak lung titres at day 7 comparable to
MHV-68 (Figure 3.8.2). However, MHV-76 and MHV-76(cA8-)5 were cleared
from the lungs more rapidly than MHV-68 and the rescue virus (Day 7 lung titre
MHV-68 vs. MHV-76; PO.OOl : MHV-76(cA8+)4 vs. MHV-76; PO.Ol). This
data therefore shows that deletion ofMl, M2, M3, M4 and the 8 vtRNAs leads to
a significant attenuation of infection in the lungs.
3.8.3. Virus-induced splenomegaly
To determine the effect of the 9.5kb deletion on splenomegaly during
infection, BALB/c mice were infected with 2 x 105 PFU of MHV-68, MHV-76,
MHV-76(cA8+)4 or MHV-76(cA8-)5 intranasally. The extent of splenomegaly
was determined by spleen weight (see 2.6.2) and counting the total number of
splenocytes (see 2.6.3; Figure 3.8.3A and B). There was a significant reduction in
spleen weight and total splenocyte numbers after infection with MHV-76 or
MHV-76(cA8-)5 compared to MHV-68 (Day 14 splenocyte numbers MHV-68 vs.
MHV-76; P<0.001). The rescue virus MHV-76(cA8+)4 showed splenomegaly
comparable to wild-type MHV-68, peaking at 14 days post-infection (Day 14
splenocyte numbers MHV-76(cA8+)4 vs. MHV-76; P<0.001). This data shows
that deletion of Ml, M2, M3, M4 and the 8 vtRNAs leads to a significant
reduction in the degree of splenomegaly observed during MHV-68 infection.
3.8.4. Latent virus in the spleen
BALB/c mice were infected with 2 x 105 PFU of MHV-68, MHV-76,
MHV-76(cA8+)4 or MHV-76(cA8-)5 intranasally and the amount of latent virus
in the spleen quantified by infective centre assay (see 2.6.3). The rescue virus
MHV-76(cA8+)4 showed levels of latent virus comparable to MHV-68, peaking
at day 14 post-infection (Figure 3.8.4). Latent MHV-76 and MHV-76(cA8-)5
were detectable in the spleen, but at significantly lower levels than MHV-68
(MHV-76(cA8+)4 vs. MHV-76; Day 14 PO.OOl: MHV-76 vs. MHV-68; Day 14
P<0.001). Latently infected splenocytes were still detectable in MHV-76 and
MHV-76(cA8-)5 infected mice at day 32 post-infection. This data shows that
deletion ofMl, M2, M3, M4 and the 8 vtRNAs leads to a significant reduction in
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Figure 3.8.2 Viral litres in the lungs of BALB/c mice infected intranasally with 2 x
10s PFU ofMHV-68 ( A ). MHV-76 ( A ), MHV-76(cA8+)4 ( —■—) and
MHV-76(cA8-)5 (-Hi--). Mean virus titre log10 per lung ± standard error for four
mice per group is shown for each time point. * indicates statistically significant
difference between lung viral titres in mice infected with MHV-76 compared with
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Figure 3.8.3A Spleen weights of BALB/c mice infected intranasally with 7 x 105
PFU ofMHV-68 ( A ), MHV-76 ( —A—), MHV-76(cA8+)4 ) and
MHV-76(cA8-)5 ). Mean spleen weight (mg) ± standard error is shown for
four mice per group for each timepoint. * indicates statistically significant difference
between spleen weights in mice infected with MHV-76 compared with MHV-68
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Figure 3.8.3B Total splcnocytc numbers of BALB/c mice infected intranasally with
2 x 105 PFU ofMHV-68 ( A ), MHV-76 ( A ), MHV-76(cA8+)4 (
and MHV-76(cA8-)5 ). Mean total number of splenocytes ± standard error
is shown for four mice per group for each timepoint. * indicates statistically
significant difference between total splenocyte numbers in mice infected with
MHV-76 compared with MlIV-68 and MHV-76(cA8+)4 as determined by two-


























Figure 3.8.4 Latent virus in the spleens of BALB/c mice infected intranasally with
2 x 105 PFU ofMHV-68 ( A ), MHV-76 ( A ). MHV-76(cA8+)4 ( —U—)
and MHV-76(cA8-)5 ( as determined by infective centre assay. Infectious
virus titres (less than 50 PFU per spleen) were subtracted from the infective centre
results. Mean infective centres per spleen ± standard error for four mice per group is
shown for each timepoint. * indicates statistically significant difference between the
number of infective centres in mice infected with MHV-76 compared with MHV-
68 and MUV-76(cA8+)4 as determined by two-way ANOVA with Bonferroni post-
tests.
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the amount of latent virus detectable in the spleen following viral infection, but is
not essential for the establishment of latency and persistence.
3.9. Discussion
The detailed molecular characterisation ofMHV-76 described here and by
Steven Milligan and Andrew Davison (Macrae et al., 2001) has shown that MHV-
76 is very similar to MHV-68, except for a 9538bp deletion at the left end of the
unique region of the genome. This deletion means that MHV-76 lacks the unique
MHV-68 genes Ml, M2, M3 and M4 as well as all eight of the vtRNA-like
molecules. This deletion had no effect on viral replication in vitro, but led to a
significant reduction in pathogenesis in vivo. The analysis of rescue viruses with
the deletion restored to MHV-76 confirmed that this deletion plays a key role in
viral pathogenesis.
These results have resolved some of the ambiguity concerning the
classification of MHV-76. MHV-76 was originally described as an independent
herpesvirus isolate derived from the yellow-necked wood mouse, Apodemus
flavicollis (Blaskovic et al., 1980), and was initially characterised as an
alphaherpesvirus due to its cytopathic effect in vitro (Ciampor et al., 1981;
Svobodova et al., 1982a). However, another study used restriction enzyme
analysis and dot-blotting to conclude that MHV-76 was a betaherpesvirus
(Hamelin & Lussier, 1992). The results presented here conclusively show that
MHV-76 is a gammaherpesvirus. However, these results show that MHV-76 is
probably not a novel herpesvirus isolate but a deletion mutant derived from
MHV-68. This deletion more than likely occurred during the in vivo and in vitro
passages subsequent to isolation (Blaskovic et al., 1980). The evidence that
MHV-76 is derived from MHV-68 (or an extremely closely related virus) is that
apart from the 9538bp deletion, there is only one base difference in the remaining
20kb ofMHV-76 DNA that was sequenced. ORF 74 is also 100% identical at the
nucleotide level between the two viruses (M.Wakeling, unpublished
observations). These results show the extremely close relationship between MHV-
68 and MHV-76, and also raises the possibility that the other original herpesvirus
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isolates may not be novel isolates but closely related to MHV-68. Indeed, the TK
gene of MHV-72 has been shown to be identical in DNA sequence to that of
MHV-68 (Raslova et al., 2000).
The spontaneous deletion of sequences in gammaherpesvirus genomes is
not uncommon. In EBV, deletions have been described in the Raji, P3HR-1 and
Daudi strains (Bornkamm et al., 1980; Cho et al., 1984; Hatfull et al., 1988). In
HVS, spontaneous deletions also occur at the left end of the genome (Koomey et
al., 1984), and deletions in this region alter the oncogenic potential of HVS but
not viral replication (Medveczky et al., 1984; Desrosiers et al., 1985; Medveczky
et al., 1989). This is due to deletion of the STP gene (ORFlb; see 1.2.3; Murthy et
al., 1989). It is notable that there are similarities between the left end of the
genome in HVS and MHV-68, in that the left end of the HVS genome contains
few ORFs and also encodes seven small viral RNAs (HSURs; Albrecht et al.,
1992). The left end of the MHV-68 genome also appears to have a high capability
for undergoing recombination events in vitro (Simas et al., 1998; D. Roy, I.
Atkin, M. Wakeling, unpublished observations). This may be due to the proximity
of the terminal repeats, the presence of the highly transcribed vtRNA genes or a
putative origin of replication (Bowden et al., 1997). It is probable that
recombination occurred during the in vivo and in vitro passage steps during viral
isolation to delete a portion of the genome from MHV-68.
PCR analysis demonstrated that MHV-76 lacks the unique MHV-68 genes
Ml, M2, M3 and M4 and all eight vtRNA-like sequences. To confirm that this
deletion leads to the dramatic differences observed in vivo, rescue viruses were
constructed to restore the deleted sequence by recombination with MHV-68
sequences. These rescuants showed the same phenotype as MHV-68, proving that
genes within the deleted sequence play a key role in viral pathogenesis. Although
the entire overlapping region where homologous recombination occurred has been
sequenced in MHV-76 (Macrae et al., 2001), it is possible that the single
nucleotide substitution at position 12,280 in ORF 6 may affect the observed
phenotype in MHV-76. However, this point mutation leads to a semi-conservative
substitution of a serine for a glycine residue, and this residue (position 356) is not
near the ORF 6 CD8+ T cell epitope p56 (residues 487-495) (Stevenson et al.,
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1999a). It is also likely that a harmful point mutation would revert under selection
in vivo, and this residue is not conserved in another independently isolated murine
herpesvirus, MHV-Brest (S. Milligan, C. Chastel, S. Efstathiou and A. Davison,
unpublished data).
These results show that the left unique region of the genome plays a
critical role in MHV-68 pathogenesis. It contains four unique genes (Ml, M2, M3
and M4) and eight vtRNA-like sequences whose importance in viral pathogenesis
is only recently becoming understood (see 1.4.4). In particular, the broad-
spectrum chemokine-binding protein M3 appears to play a critical role in the
establishment of splenic latency in vivo (Bridgeman et al., 2001). It is of note that
insertion of foreign DNA sequences into this region of MHV-68 without the
obvious disruption of known ORFs can have marked effects on viral pathogenesis
(Clambey et al., 2000; Adler et al., 2001) It has also been postulated that some
MHV-68 ORFs may extend through or within the terminal repeats (Virgin et al.,
1997), possibly existing as multiple spliced transcripts like the LMP2 transcripts
of EBV, and therefore deletions in this region may affect these undiscovered
transcripts.
Virus-specific genes at the left end of the unique region of the genome
have also attracted considerable attention in other gammaherpesviruses as well as
MHV-68 (see 1.2; Figure 1.4.3.2). In KSHV, this region contains the K1 gene,
which shows a high level of variability in different viral isolates (Zong et al.,
1999; Hayward, 1999) and is associated with cellular transformation (Lee et al.,
1998b). In HVS, this region contains seven small RNAs (HSURs) and the STP
gene (Albrecht et al., 1992), which is required for cellular immortalisation and
oncogenesis (Desrosiers et al., 1985; Murthy et al., 1989). In EBV, this region
encodes LMP-1, a classic oncogene that is essential for B cell immortalisation
(Kieff, 1996). This region of the genome has thus been implicated in viral
pathogenesis in a range of gammaherpesviruses.
These results show that the unique MHV-68 genes Ml, M2, M3 and M4
and all eight vtRNA-like sequences are non-essential for lytic virus replication in
vitro and in vivo, and for the establishment and maintenance of latency in vivo,
but have important roles in viral pathogenicity. The enhanced clearance ofMHV-
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76 from the lungs, combined with an increased inflammatory response, shows that
this region plays a key role in evasion of the host response to the virus during
productive infection. The Ml, M3, M4 and vtRNA genes have all been shown to
be transcribed during lytic infection (Virgin et al., 1999; Simas et al., 1999), and
M2 expression has also been detected in the lungs at 3 - 6 days post-infection
(Rochford et al., 2001). Therefore all the genes may be involved in immune
evasion in the lung. Although previous studies have examined viruses deleted for
the Ml ORF, neither studied viral replication in the lung following intranasal
inoculation (Simas et al., 1998; Clambey et al., 2000). However, studies of a virus
with a disruption in the M3 gene suggested that a lack of M3 may lead to
enhanced viral clearance from the lungs (Bridgeman et al., 2001), and thus the
chemokine-binding actions ofM3 may play an important role in the lung.
A possible explanation for the lower levels of productive viral replication
in the lung and the reduction in latent virus in the spleen is that MHV-76 has an
altered cell tropism compared to MHV-68. The results of the infective centre
assay using MACS sorted splenocytes shows that MHV-76 establishes a latent
infection primarily in B lymphocytes, like MHV-68 (Sunil-Chandra et al., 1992b).
The small amount of latent virus detectable in the CD 19 negative fraction could
either be due to the small amount of contamination by CD 19+ cells, or latent virus
in other cell types (Week et al., 1999b; Flano et al., 2000). Similarly, the
immunostaining suggests that MHV-76 does not have any alteration in cellular
tropism in the lung. Although not significant, the low levels of productive virus
detectable in the adrenal glands of mice infected with MHV-76, an organ where
productive MHV-68 is detectable post-infection (Sunil-Chandra et al., 1992a),
suggests that the levels ofMHV-76 during the viraemic phase are lower and this
may be a reflection on the enhanced viral clearance from the lungs.
The dramatic reduction in splenomegaly and the amount of latently
infected splenocytes seen during MHV-76 infection shows that this region of the
genome plays an important role in the splenic pathology and establishment of
latency. There are two possible explanations for the low levels of latent MHV-76
observed using the infective centre assay; either there is a low level of latent virus
present in splenocytes or latent MHV-76 is unable to fully reactivate from latency
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in vitro. The data from the one-step growth curves demonstrates that there is no
alteration in viral replication in vitro, favouring the first explanation. However,
techniques such as quantitative fluorescent (QF)-PCR to determine the viral DNA
load would be necessary to prove this (Usherwood et al., 2001).
M2, M3 and the vtRNAs are all transcribed during the establishment of
latency 1-3 weeks post-infection (Bowden et al., 1997; Husain et al., 1999; Simas
et al., 1999; Usherwood et al., 2000), but there may also be a role forMl and M4
in splenomegaly as low levels of productive viral replication occur in the spleen
during the establishment of latency. Chemokines play an important role due to
their ability to direct the migration of leukocytes into sites of inflammation
(Luster, 1998), and these results provide evidence that the chemokine-binding
actions ofM3 may function in the development of splenomegaly. Studies using a
virus with a disruption in the M3 ORF have shown that M3 is responsible for the
B cell activation and amplification of latently infected B cells observed during the
establishment of latency (Bridgeman et al., 2001). The reduction in latent virus
observed was reversed by CD8+ T cell depletion, and this suggests that M3 may
act to prevent chemokine-mediated recruitment of cells into the lymphoid tissue.
Another possible hypothesis for the reduction in splenomegaly and the amount of
latent virus observed during MHV-76 infection is that the transient expression of
the M2 CD8+ T cell epitope during the establishment of latency (Husain et al.,
1999; Usherwood et al., 2000) assists the virus by expanding the numbers of
latently infected cells (Usherwood et al., 2001). Although not significant, the low
levels of detectable latent virus in circulating blood leukocytes during MHV-76
infection reflects this lack of expansion in the number of latently infected cells in
the spleen, which then enter the bloodstream. One report has also implicated Ml
in the suppression of viral reactivation, but this effect was observed only at later
timepoints in peritoneal exudate cells after intraperitoneal infection (Clambey et
al., 2000). No suppressive effect was observed in these experiments.
Despite the dramatic effects on splenomegaly and the establishment of
latency, this deletion has no effect on the long-term maintenance of latency and
viral persistence. Virus was detectable up to 5 months post-infection by infective
centre assay (a biological measure of latency) and detection of viral DNA by PCR
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in the spleen and lungs of mice infected with MHV-76. Although these results do
not definitively show this persistent MHV-76 to be latent as defined by the
presence of episomal forms of the genome or the absence of lytic transcripts,
other studies have shown the absence of lytic transcripts (ORF 50) in the spleens
of B cell deficient mice 46 days post-infection (Virgin et al., 1999) and BALB/c
mice at 10 months post-infection (Usherwood et al., 2000). It is therefore
probable that the persisting MHV-76 is in a latent form. This result also shows
that MHV-76 can persist in multiple sites, similar to MHV-68 (Sunil-Chandra et
al., 1992b; Stewart et al., 1998b).
These results show that the left end of the MHV-68 genome containing the
unique genes Ml, M2, M3, M4 and the vtRNA genes plays a major role in viral
pathogenesis and the development of immunopathology, and it is probable that
these genes have a central role in the viral immune evasion strategy during
infection.
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4.1. Aims
Previous work on the M2 ORF of MHV-68 has shown that this gene is
latency associated (Husain et al., 1999; Virgin et al., 1999), and is expressed
transiently in the first three weeks post-infection (Usherwood et al., 2000). The
M2 protein also contains an epitope recognised by CD8+ T lymphocytes (Husain
et al., 1999), and the immunological response to M2 has therefore been
implicated in the control of viral pathogenesis (Usherwood et al., 2000;
Usherwood et al., 2001). However, little is known about the basic biochemical
properties of the M2 protein. The aim of this work was to characterise the M2
protein of MHV-68, including the generation of an antibody against the M2
protein, expression of M2 in mammalian cells and determination of the cellular
localisation of M2. This would help in the understanding of the function of M2,
and its role in viral infection.
4.2. Sequence analysis of the M2 protein
Previous work on the M2 ORF has shown that the M2 transcript is spliced
(Husain et al., 1999), and due to the splice acceptor site used, the M2 ORF
encoded by the cDNA is 7 amino acids shorter than the genomic M2 ORF (Virgin
et al., 1997). It should be highlighted that previous work has designated the CTL
epitope as the M291.99 CD8+ T cell epitope (Husain et al., 1999), but due to the
cDNA sequence the epitope is in fact present at residues 84 to 92. The M2 ORF is
therefore predicted to encode a 192 amino acid protein, with a predicted
molecular mass of 21.2kDa. It is also predicted to be proline-rich, containing
19.8% proline residues.
A database search was regularly performed using the program "BLAST"
against all database protein entries. Apart from predicted similarities to other
proline-rich proteins due to random alignment of proline residues, the only low
but significant sequence similarity was between the M2 protein and the Grb2-
associated binder-2 protein (Gab2) of the mouse, rat and human. As shown in
Figure 4.2.1A and C, the strongest homology is present at M2 amino acid residues
122 to 150, with another region present at M230-38- A search was also performed
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Figure 4.2.1A Sequence alignment of the M2 protein of MHV-68 and the Gab2 protein
of the rat, mouse and human. The sequences were aligned using the Blosum scoring
matrix with the "ClustalW" program, and displayed using the "BOXSHADE" program.
Residues that are identical in two or more sequences are highlighted in black, while









Figure 4.2.1 B Sequence alignment of the M2 protein ofMHV-68, semaphorin 3 A, B, C
and E domains of the mouse, A1HV-1 A3 and vaccinia virus A39R . Sequence homology
was detected using the "Block Searcher" program. The sequences were aligned using the
Blosum scoring matrix with the "ClustalW" program, and displayed using the
"BOXSHADE" program. Residues that are identical in four or more sequences are
highlighted in black, while synonymous residues are highlighted in grey.
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1 MAPTPPQGKI PNPWPGGCSQ NPVLWGDGTiD
1 -
31 GNYRF*SEPWI LGQVPCDQRF PHPSGNKNSS
61 STSGGRPQRP PLPRTRFPKT IRRGFNKLRS
91 TLKSPWKPRP SPVPSPEEVN PAGSPEENIY
121 EJTANSEPVYI QPISTRSLMM LDSGSTDSPE!
151 NLGPPTRPLP KLPNQHPMNP EIRLPIIPPS
181 KCHKGFVEWG EE
Figure 4.2.1C Location of the areas of sequence homology present in the M2 protein.
The amino acid sequence ofM2 is shown (according to Virgin et ai, 1997 and Husain et
al., 1999). The area of homology to the mouse semaphorin 3 domain is shown
highlighted by a blue dashed box, the main areas of homology to the Gab2 family of
proteins are shown highlighted by a red dashed box and the CD8+ T cell epitope (Husain
et al., 1999) is shown surrounded by a green dashed box.
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using the "Block Searcher" program against a database of highly conserved
protein domains (Henikoff & Henikoff, 1994), which is used to detect short
regions of homology with families of proteins that may be missed in searches of
sequence databases. This revealed a region of sequence homology at the N-
terminus of M2 to the semaphorin domain, with the closest homology to the
semaphorin 3 family. Figure 4.2.IB shows the alignment of M2 with the mouse
semaphorin 3 A, B, C and E family domains (the human semaphorin 3 A, B, C
and E domains are identical to the mouse sequence), and also the A1HV-1 A3
semaphorin homologue (Ensser & Fleckenstein, 1995) and the vaccinia virus
A39R semaphorin homologue (Comeau et al., 1998). This region of homology to
the semaphorin domain is present at position M26_ig (Figure 4.2.1C).
A hydropathicity plot of the M2 amino acid sequence was perfonned (see
2.3.1), to examine whether the M2 protein contained any transmembrane or
membrane-anchoring regions. These regions of a protein typically contain a 20
amino acid hydrophobic region (Kyte & Doolittle, 1982). As shown in Figure
4.2.2, the M2 protein is largely hydrophilic, with no predicted regions of
membrane affdiation.
A variety of programs were also used to predict potential post-translational
modifications in the M2 protein (see 2.3.1). The amino acid consensus sequence
for N-linked protein glycosylation [N-any amino acid (not proline)-S/T] was
observed at residue 58 (Figure 4.2.3 highlighted blue), and 8 O-linked protein
glycosylation sites (Figure 4.2.3 highlighted purple) are also potentially present in
M2. Co-translational amide linkage of myristic acid to N-terminal glycine
residues (myristylation) has been shown to be important for cellular localisation
of proteins to the plasma membrane and protein function (Cross et al., 1984;
Resh, 1994). There are three predicted myristylation sites in the N-terminus of the
M2 protein (Figure 4.2.3 highlighted green).
The phosphorylation of proteins has been shown to be important in the
regulation of protein function and signal transduction pathways (Edelman et al.,
1987; Zhou et al., 1997), including the function of a variety of viral proteins
(Sylla et al., 1998; Yokoyama et al., 2001). The program "NetPhos 2.0" was used
to predict phosphorylated amino acid residues. Figure 4.2.3 shows that there are
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Figure 4.2.2 Hydropathicity plot of the M2 protein (using the method of Kyte and
Doolittle, 1982). Hydrophobic regions of the protein have positive values, and
hydrophilic regions have negative values.
1 maptppqgki pnpwpggcsq npvlwgdgtd gnyrpsepwi lgqvpcdqrf
51 phpsgnk(4ss stsggrpqrp plprtrfpki irrgfnklrs ilkspwkprp
101 spvpspeevn pagspeeniy etansepvyi qpistrslmm ldsgstdspe
151 nlgpptrplp klpnqhpmnp eirlpiipps kchkgfvewg ee
Figure 4.2.3 Diagrammatic representation of the potential post-translational
modifications present in the M2 protein. The amino acid sequence (according to
Virgin et al., 1997 and Husain et al., 1999) is shown with predicted motifs as
follows: N-linked glycosylation site (highlighted blue); O-linked glycosylation sites
(highlighted purple); myristylation sites (highlighted green); phosphorylation sites
(red letter underlined).
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predicted to be eleven phosphorylated serine residues, two phosphorylated
threonine residues and two phosphorylated tyrosine residues (shown by an
underlined red letter).
4.3. Generation of anti-M2 antibody
4.3.1. Expression ofM2 as a GST fusion protein
In order to investigate the cellular localisation and function ofM2 in vitro,
it was decided to generate an anti-M2 antibody. The M2 protein was therefore
expressed in bacteria to generate sufficient antigen that could be used to raise an
immune response in vivo. It was decided to express M2 as a GST fusion protein
using the pGEX bacterial expression system, as this system provides a convenient
method to express proteins in E. coli and their subsequent purification. The M2
ORF was amplified using primer pair M2GEX1 and M2GEX2 (Chapter 2,
Appendix 2) with PfuTurbo™ DNA polymerase (a proof-reading DNA
polymerase), and cloned into the pGEX-2T vector (Chapter 2, Appendix 3) using
the BamHl and EcoRl restriction enzyme sites to give the vector pGEX-2T/M2.
The M2 gene was inserted in frame with the glutathione S-transferase gene of
Schistosoma japonicum, and would be expressed as a GST fusion protein. XL-1
Blue bacterial clones positive for the M2 insert in pGEX-2T by mini-prep were
tested for their ability to express the GST-M2 fusion protein. Expression of the
fusion protein was induced by the addition of 0.5mM IPTG during exponential
growth phase of the culture (see 2.4.1). Upon induction with IPTG, the repression
of the Ptac promoter by the lac repressor is stopped leading to expression of the
fusion protein via the Ptac promoter. The bacterial culture was harvested 3 hours
after induction, the bacterial pellet sonicated and the cell lysate analysed on a 10%
SDS-PAGE gel. As shown in figure 4.3.1.1 A, all five colonies positive for the M2
insert induced with IPTG produced a small band with an apparent molecular mass
of 50kDa. This band was not present in colony number 6 that did not contain any
insert and thus produced only GST (visualised as a band at approximately



























Figure 4.3.1.1 Expression of the M2 protein as a GST-fusion protein. Five separate
bacterial colonies (lanes 1-5) with the correct M2 insert and one bacterial colony
(lane 6) with no insert were tested for expression of the fusion protein after induction
with 0.5mM IPTG. Crude cell lysates were analysed on a 10% SDS-PAGE gel. (A)
Coomassie blue stained gel (B) Immunoblot probed with polyclonal anti-MHV-68,
followed by anti-rabbit Ig-AP and visualised using Sigma FAST BCIP/NBT
solution. For clarity, a black dot has been placed just above each of the GST-M2
fusion protein bands. Molecular weights are given in kilodaltons relative to the
marker in the left lane.
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native GST is 27.5kDa, and the predicted molecular mass ofM2 is 21.2kDa. Thus
the expected size of the GST-M2 fusion protein is 48.7kDa, which is the
approximate size of the GST-M2 fusion protein band on the gel. The level of
GST-M2 expression was poor in all five clones.
To confirm that this band represented the GST-M2 fusion protein, an
identical gel to Figure 4.3.1.1 A was analysed by immunoblot. The blot was
incubated with polyclonal anti-MHV-68 antibody (diluted 1:500), followed by
swine anti-rabbit Ig conjugated to AP (diluted 1:1000) and visualised using Sigma
FAST BCIP/NBT solution. As shown in Figure 4.3.1.1B, the polyclonal anti-
MHV-68 antibody recognised the 50kDa GST-M2 fusion protein in the five
colonies positive for the M2 insert, but not in colony 6 (negative for the M2
insert). Thus the 50kDa band was the GST-M2 fusion protein, and the M2 fusion
protein was recognised by polyclonal anti-MHV-68 antibody (raised using
antigens from lytically infected cells). However, this confirmed that the
expression level of GST-M2 was poor.
To test the solubility of the GST-M2 fusion protein, the five colonies were
again induced with 0.5mM IPTG and harvested after three hours. After harvesting
and sonication of the bacterial pellet, the samples were separated by
centrifugation to give the supernatant (soluble) and cell pellet (insoluble) fractions
and the samples analysed on a 10% SDS-PAGE gel. This showed that the GST-
M2 fusion protein was only present in the cell pellet fraction (data not shown) and
not the supernatant fraction and was therefore insoluble.
It was decided to try and maximise the expression levels of the GST-M2
fusion protein, so that an inclusion body preparation could be used to produce
enough antigen for the generation of antiserum. Bacterial clone 1 of pGEX-
2T/M2 was induced with 0.5, 1.0 or 1.5mM IPTG and harvested after 3 hours.
The bacterial pellet was then analysed on a 10% SDS-PAGE gel for GST-M2
fusion protein production. As can be observed in Figure 4.3.1.2A, there was no
difference in the intensity of the GST-M2 band between the three samples with
varying concentrations of IPTG. This showed that varying the concentration of
IPTG had no effect on the levels of expression of fusion protein.
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Figure 4.3.1.2 Poor expression of GST-M2 fusion protein in bacteria. (A) The
bacterial culture was induced with 0.5, 1.0 or 1.5mM IPTG, and left for 3 hours
before harvesting. (B) The bacterial culture was induced with 0.5mM IPTG after 30
minutes (OD595~0.3) or 3 hours (OD595~1.2), and then left for 3 hours before
harvesting. A control sample was not induced. Crude cell lysates were analysed on
a 10% SDS-PAGE gel, and the gel was stained with Coomassie blue. For clarity, a
black dot has been placed just above each of the GST-M2 fusion protein bands.
Molecular weights are given in kilodaltons relative to the marker in the left lane.
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Another factor that can lead to poor expression of GST fusion proteins is
toxicity of the fusion protein. To analyse if this was the case with GST-M2, one
bacterial culture was induced in early exponential growth phase after 30 minutes
(the OD595 of the bacterial culture was 0.3), and another bacterial culture was
induced in late exponential / stationary growth phase after 3 hours (OD595 was
1.2). The cultures were harvested after a further 3 hours, and the bacterial pellet
analysed on a 10% SDS-PAGE gel for GST-M2 fusion protein production. One
culture was not induced, and left to grow for 6 hours (the same length of time as
the culture induced after 3 hours of growth). As can be observed in Figure
4.3.1.2B, there was no difference in the intensity of the GST-M2 band between
the two samples induced with IPTG. However, there was a dramatic difference
between the total protein yields of the cultures as estimated by intensity on the
Coomassie blue stained gel. Figure 4.3.1,2B shows that the culture induced in the
early exponential growth phase (after 30 minutes) contains much less total protein
than the culture induced in late exponential / stationary growth phase (after 3
hours), and these cultures contain much less protein than the uninduced negative
control culture. This result showed that induction of GST-M2 fusion protein
expression by the addition of IPTG leads to a large reduction in bacterial protein
production, and this is suggestive that the GST-M2 fusion protein may be toxic in
bacteria. However, the lack of a suitable control expressing only GST means that
this reduction in total protein yield may also be due to the induction of foreign
protein expression in bacteria, with consequent disruption of normal bacterial
protein synthesis.
4.3.2. Expression of a 75 amino acid fragment ofM2 (M274_14ff) as a GST
fusion protein
The previous results showed that attempts to produce a GST fusion protein
in bacteria containing the full length M2 protein led to the poor expression of an
insoluble GST-M2 fusion protein that was toxic in bacteria. This could have been
due to a number of factors including the high proline content (Wilkinson &
Harrison, 1991) or structure of the M2 protein (Makrides, 1996). It was therefore
decided to express a smaller region of the M2 protein in an attempt to circumvent
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these problems. A 75 amino acid region from amino acid residues 74 to 148 of the
M2 protein (designated M274_i48) was chosen as it contained predominantly
hydrophilic regions (see Figure 4.2.2). This polypeptide also contained the M2qi_
99 CD8+ T cell epitope (Husain et al., 1999) and contained only 14.6% proline
residues.
The M274_i48 coding region was amplified using primer pair M2GEX3 and
M2GEX4 (Chapter 2, Appendix 2) with PfnTurbo™ DNA polymerase and cloned
into the pGEX-2T vector (Chapter 2, Appendix 3) using the BamHl and CcoRI
restriction enzyme sites to give the vector pGEX-2T/M274_i48. Six XL-1 Blue
bacterial clones positive for the M274_i48 insert in pGEX-2T by mini-prep were
tested for their ability to express the GST-M274_i48 fusion protein. Expression of
the fusion protein was induced by the addition of 0.5mM 1PTG during
exponential growth phase of the culture (see 2.4.1), and one culture of colony
number 1 was left uninduced as a negative control. The bacterial culture was
harvested 3 hours after induction, the bacterial pellet sonicated and separated into
supernatant (soluble) and cell pellet (insoluble) fractions by centrifugation, and
the samples analysed on a 10% SDS-PAGE gel. The proteins were transferred to a
membrane by Western Blot, and the blot was incubated with polyclonal anti-GST
antibody (diluted 1:500), followed by swine anti-rabbit Ig conjugated to AP
(diluted 1:1000) and visualised using Sigma FAST BCIP/NBT solution.
As can be seen in Figure 4.3.2.1 A, analysis of the insoluble cell pellet
fraction by immunoblot showed that colonies 2 and 6 expressed a GST-M274_i48
fusion protein as a band at approximately 40kDa, with colony 6 expressing an
additional slightly larger band. This band was not present in the uninduced
negative control lane. The predicted molecular mass of the M274_i48 protein is
8.4kDa, and therefore the predicted mass of the GST-M274_i48 fusion protein is
35.9kDa. Thus the observed band is slightly larger than expected. The fusion
protein was also degraded, as evidenced by the multiple smaller bands observed
in the immunoblot and the major band at approximately 27.5kDa, which is
comprised of either native GST or a fusion protein consisting of GST with a few
amino acid residues of the M274.148 polypeptide. The actions of proteases were
reduced by sonication in a solution containing the protease inhibitors Aprotinin
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Figure 4.3.2.1 Expression of a 75 a.a. fragment of M2 (M274_l48) as a GST fusion
protein. 6 separate baeterial colonies (lanes 1-6) with the correct insert were tested
for expression of the fusion protein after induction with ().5mM 1PTG. One culture
of colony 1 was not induced as a negative control (Nl). After harvesting and
sonieation. the samples were centrifuged and separated into cell pellet (A) and
supernatant (B) fractions. The samples were analysed on a 10% SDS-PAGE gel
followed by immunoblotting. The immunoblots were probed with rabbit anti-GST,
followed by anti-rabbit Ig-AP and visualised using Sigma FAST BCIP/NBT
solution. For clarity, a black dot has been placed just above each of the GST-M274_
l48 fusion protein bands. Molecular weights are given in kilodaltons relative to the
marker in the left lane.
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and PMSF, and maintaining all solutions after harvesting of the bacterial culture
at 4°C. Poor expression of the GST-M274.148 fusion protein was also observed.
Figure 4.3.2.IB shows that the soluble supernatant fraction contained only native
GST, and no soluble GST-M274.148 fusion protein was detected.
It was therefore decided to attempt an inclusion body preparation (see
2.4.2) in order to produce enough antigen for the generation of antiserum. Clone
number 2 of pGEX-2T/M274_i48 was induced with 0.5mM IPTG, and incubated
for a further 3 hours before harvesting. One culture was left uninduced as a
negative control. A sample of the induced culture was sonicated, and the cell
lysate used as a positive control to ensure expression of the GST-M274.148 fusion
protein. The bacterial culture was harvested, resuspended in inclusion body
preparation buffer and subjected to gentle lysis with lysozyme and DNase 1. The
samples were divided into equal aliquots and separated by centrifugation over a
range of centrifugal forces (from 2,000 to 10,000gj to determine the optimum
centrifugal force that separated the insoluble GST-M274.148 fusion protein from
the contaminating bacterial cell proteins. Samples of the supernatant (soluble) and
cell pellet (insoluble) fractions were analysed on a 12.5% SDS-PAGE gel. The
proteins were transferred to a membrane by Western Blot, and the blot examined
for the presence of GST by immunoblot analysis using the rabbit polyclonal anti-
GST antibody as previously descrihed.
Figure 4.3.2.2 shows that GST-M274-i48 fusion protein was expressed upon
induction with IPTG, and that no fusion protein was observed in the uninduced
culture. Surprisingly, the GST-M274_i48 fusion protein was observed in the soluble
fraction (Figure 4.3.2.2B) as well as the insoluble fraction (Figure 4.3.2.2A), and
appeared to be present in higher concentrations in the soluble fraction. There was
no observed difference in the amount of GST-M274_|48 fusion protein detected
upon varying the centrifugal force used to separate the soluble and insoluble
fractions. All the smaller breakdown products of the fusion protein were observed
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Figure 4.3.2.2 Inclusion body preparation of pGEX-2T/M274 l4g . Clone 2 was
induced with 0.5mM IPTG, and incubated for 3 hours before harvesting. One
culture was not induced as a negative control (NI). An aliquot was sonicated and
resuspended in SDS-PAGE sample buffer (+ve control). The culture was
harvested, subjected to gentle lysis with lysozyme and DNase I and centrifuged
(2,000 - 10,000g). The cell pellet (A) and supernatant (B) fractions were analysed
on a 12.5% SDS-PAGE gel followed by immunoblotting. The immunoblots were
probed with rabbit anti-GST, followed by anti-rabbit Ig-AP and visualised using
Sigma FAST BCIP/NBT solution. Molecular weights are given in kilodaltons
relative to the marker in the left lane.
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4.3.3. Purification of GST-M274.i48 fusion protein
The solubility of the GST-M274_i48 fusion protein after the inclusion body
preparation meant that the fusion protein could be purified using the affinity of
the GST fusion protein for glutathione immobilised on sepharose beads, and
therefore large quantities of purified fusion protein could be made (see 2.4.3).
Clone number 2 of pGEX-2T/M274_i48 was induced with 0.5mM IPTG, and
incubated for a further 3 hours before harvesting. One culture was left uninduced
as a negative control. A sample of the induced culture was sonicated, and the cell
lysate used as a positive control to ensure expression of the GST-M274_i48 fusion
protein. The bacterial culture was harvested, resuspended in inclusion body
preparation buffer and subjected to gentle lysis with lysozyme and DNase I. The
protein preparation was clarified by centrifugation to remove insoluble debris, and
the soluble GST-M274-i48 fusion protein in the supernatant incubated with
glutathione-sepharose beads. The beads were washed and the fusion protein
eluted from the beads using 5mM glutathione three times to ensure as much of the
GST-M274.i48 fusion protein was recovered as possible. Excess glutathione was
removed by dialysis, and the final GST-M274_i48 fusion protein preparation
concentrated into a final volume of 2ml using a centrifugal filter device. Samples
of the positive control, GS beads after elution and final fusion protein preparation
were analysed on 12.5% SDS-PAGE gels. The gels were either stained using
Coomassie blue to determine protein yields, or analysed by immunoblot using the
rabbit polyclonal anti-GST antibody as previously described.
Figure 4.3.3A shows that the GST-M274.i48 fusion protein was present in
the final preparation, at a low concentration but detectable on the Coomassie blue
stained gel. The GST-M274.]48 fusion protein had therefore been successfully
purified. The breakdown products (down to native GST) were also present in the
final protein preparation, as well as a large amount of native GST. A significant
amount of GST-M274.i48 fusion protein and native GST had remained bound to
the GS beads after three separate elutions, suggesting that the fusion protein had a
high affinity for the beads. Figure 4.3.3B confirmed that these bands present on
the Coomassie gel were GST fusion proteins, and verified that the GST-M274_i48
fusion protein was expressed upon induction of the bacterial culture with IPTG. A
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Figure 4.3.3 Purification ofGST-M274 148 fusion protein. Clone 2 was induced with
0.5mM IPTG, and incubated for 3 hours before harvesting. An aliquot was
sonicated and resuspended in SDS-PAGE sample buffer (+ve control). The fusion
protein was partially purified using an inclusion body preparation, and the soluble
GST fusion protein was bound to glutathione-sepharose beads. The purified GST-
M274 l48 fusion protein was eluted from the beads, dialysed to remove excess
glutathione and concentrated. Aliquots of the glutathione beads (after elution) and
final GST- M274148 fusion protein preparation were analysed on a 12.5% SDS-
PAGE gel. (A) Coomassie blue stained gel. (B) Immunoblot probed with rabbit
anti-GST, followed by anti-rabbit Ig-AP and visualised using Sigma FAST
BC1P/NBT solution. Molecular weights are given in kilodaltons relative to the
marker in the left lane.
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faint band was present at the level of the full-length GST-M274_i48 fusion protein
on the immunoblot, but was poorly reproducible on the photograph. The
immunoblot showed that a substantial amount of the fusion protein preparation
remained bound to the beads, and that a large amount of native GST was present
in the final GST-M274.i48 fusion protein preparation. However, purified GST-
M274_i48 fusion protein had been made and sufficient antigen was available to be
used to raise an immune response in vivo.
4.3.4. Purification and reactivity of sheep antisera
Two sheep (numbers 7/413 and 705D) were immunised by Professor J.
Hopkins, Department of Veterinary Pathology, Edinburgh. Each sheep received
two intramuscular injections, each containing 18pg of GST-M274_I48 fusion
protein with adjuvant. The sheep received three booster injections at four week
intervals, and a blood sample was taken prior to immunisation (pre-bleed) and
four weeks after each immunisation. The serum was separated from the blood
sample, and samples of the pre-bleed and third bleed were purified and used to
assess the anti-M2 reactivity of the sheep serum. The serum was first purified
using caprylic acid, a short-chain fatty acid that precipitates most serum proteins
under mildly acidic conditions, with the exception of IgG. The IgG molecules
were then precipitated and concentrated using ammonium sulphate (see 2.4.5),
producing moderately pure IgG antibodies. The pellet was resuspended in PBS,
dialysed to remove excess ammonium sulphate and a sample of the purified
antibody analysed on a 12.5% SDS-PAGE gel. The proteins were transferred to a
membrane by Western Blot, and then incubated with biotinylated donkey anti-
sheep Ig antibody (diluted 1:20,000), followed by streptavidin conjugated to AP
(diluted 1:2,000) and visualised using Sigma FAST BCIP/NBT solution. Figure
4.3.4.1 shows that all samples contained immunoglobulin heavy (55kDa) and
light (25kDa) chains, and therefore sheep antibodies were present after the
purification process. The antibodies were present in approximately equal
concentrations in all the samples.
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Figure 4.3.4.1 Purification of sheep anti-M2 antibodies. Aliquots of sheep serum
taken before immunisation (pre-bleed) and four weeks after the third immunisation
with GST- M274l4g (third bleed) were purified using caprylic acid followed by
ammonium sulphate precipitation. Aliquots of purified antibody were analysed on a
12.5% SDS-PAGE gel, followed by immunobloting. The blot was probed with
biotinylated anti-sheep Ig, followed by strcptavidin-AP and visualised using Sigma
FAST BCIP/NBT solution. Results are shown for both sheep (7/413 and 705D).
Molecular weights are given in kilodaltons relative to the marker in the left lane.
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To assess the anti-M2 reactivity of the purified sheep antibodies, four
identical 15% SDS-PAGE gels were prepared containing the following samples:
A. GST-M274-i48 fusion protein (used as the antigen to raise the immune response
in the sheep). Although a sample containing only GST should have been
included to confirm that there were no antibodies present in sheep that might
cross-react with GST, it was decided that the GST-M274.i48 fusion protein
preparation contain a large amount of native GST (see Figure 4.3.3) and thus
this sample was also used as this control.
B. Cell lysate from 293 cells transfected with the pVR1255/M2-His vector (this
mammalian expression vector was thought to express M2 [see 4.4.1 and
4.4.2]).
C. Cell lysate from 293 cells transfected with the control vector pVR1255.
D. SI 1 cell lysate (SI 1 cells are known to express the M2 protein; Husain et al.,
1999).
The proteins were transferred to a membrane by Western Blot, and
incubated with purified pre-bleed or third bleed sheep antibody (diluted 1:1,000-
10,000). This was followed by biotinylated donkey anti-sheep Ig antibody (diluted
1:20,000-40,000), and then streptavidin conjugated to AP (diluted 1:2,000) and
visualised using Sigma FAST BCIP/NBT solution. Figure 4.3.4.2 shows that the
third bleed antibody samples from both sheep (panels B and L)) recognised the
GST-M274-i48 fusion protein, whereas the pre-bleed samples did not (panels A and
C). This result shows that both sheep have raised antibodies against the GST-
M274.i48 fusion protein. When compared with the pre-bleed samples, the third
bleed antibodies displayed no specific reactivity with the cell lysate from 293
cells transfected with pVR1255/M2-FIis. This result agrees with data showing that
no M2 expression was detectable from this vector by immunoblot analysis using
anti-PIiso antibody to detect the polyhistidine epitope (see 4.4.2). Flowever, the
third bleed antibody of sheep 705D (panel D) reacted against a band at
approximately 30-35kDa in the SI 1 cell lysate. This band was not present in the
pre-bleed immunoblot (panel C). This suggested that sheep 705D had produced
antibodies against a protein in the SI 1 cells, and this protein could be the M2
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Figure 4.3.4.2 Reactivity of purified sheep anti-M2 antibodies. The ability of the
sheep antibodies to detect M2 protein was assessed by immunohlot. Samples of
GST- M274_148 protein (lane 2), cell lysates of 293 cells transfected w ith pVR1255
(lane 3) or pVR1255/M2-His (lane 4) and SI l cells (lane 5) were separated on a
15% SDS-PAGE gel, and transferred onto a membrane by Western blot. The blots
were probed with pre-bleed (A) and third bleed (B) from sheep 7/413, and pre-
bleed (C) and third bleed (D) from sheep 705D. The sheep antibodies were detected
using biotinylated anti-sheep Ig, followed by streptavidin-AP and visualised using
Sigma FAST BCIP/NBT solution. M2* indicates predicted position of M2 protein.
Molecular weights are given in kilodaltons relative to the marker in the left lane.
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protein. The observed band at 30-35kDa was slightly larger than the expected
molecular weight ofM2 (21.2kDa).
Antibodies from sheep 705D were therefore used in subsequent
experiments to determine the reactivity of the purified sheep anti-M2 antibodies.
High levels of background staining were observed in all the immunoblots probed
with the sheep antibodies due to non-specific binding of the sheep antibodies to
proteins on the Western blot. In order to try and overcome this high background
staining, a range of different dilutions of the primary sheep antibody (1:1,000-
1:10,000) and secondary biotinylated donkey anti-sheep Ig (1:20,000-1:80,000)
were used. It was also decided to use ECL, as the enhanced sensitivity of
detection by ECL meant that more dilute concentrations of antibody could be
used. Two identical 12.5% SDS-PAGE gels were prepared containing samples of
Sll cell lysate, cell lysate from A20 cells transfected with pSG5/M2-3'HA (this
mammalian expression vector was known to express M2 [see 4.4.2]) and cell
lysate from A20 cells (a negative control for the transfected cell lysate). The
proteins were transferred to a membrane by Western Blot, and the blots were
incubated with purified pre-bleed or third bleed sheep antibody (diluted 1:10,000).
This was followed by biotinylated donkey anti-sheep Ig antibody (diluted
1:80,000), and then streptavidin conjugated to POD (diluted 1:5,000) and
visualised using ECL. Figure 4.3.4.3 shows that high background staining was
present in the immunoblot, which obscured any possible reactivity of the third
bleed antibody of sheep 705D (panel B) against the predicted M2 protein band
present at 30kDa. When compared with the pre-bleed samples, the third bleed
antibodies displayed no specific reactivity with the cell lysate from A20 cells
transfected with pSG5/M2-3'HA. High background levels were again observed in
all immunoblots at a range of different antibody concentrations. This suggested
that the non-specific binding of the sheep antibodies to proteins on the Western
blot was leading to high background levels that prevented definitive recognition
ofM2 by immunoblot.
The reactivity of the sheep antibodies to the M2 protein was also assessed
by immunofluorescence. Sll cells were fixed onto glass slides, and stained by
indirect immunofluorescence (see 2.7.8). The slides were incubated with either
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Figure 4.3.4.3 Reactivity of purified sheep anti-M2 antibodies. The ability of the
sheep antibodies to detect M2 protein was assessed by immunoblot. Aliquots of cell
lysates of A20 cells (lane 1), A20 cells transfected with pSG5/M2-3'HA (lane 2)
and SI 1 cells (lane 3) were separated on a 12.5% SDS-PAGE gel, and transferred
onto a membrane by Western blot. The blots were probed with pre-bleed (A) and
third bleed (B) from sheep 705D. The sheep antibodies were detected using
biotinylated anti-sheep Ig, followed by streptavidin-POD and visualised using ECL.
M2* indicates predicted position of M2 protein. Molecular weights are given in
kilodaltons on the left side.
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pre-bleed or third bleed purified antibodies from sheep 705D diluted 1:100-1:500
in PBS containing 5% v/v normal donkey serum, followed by donkey anti-sheep
Ig-FITC conjugate (diluted 1:250). There were no differences in FITC localisation
between the pre-bleed and the third bleed samples in the S11 cells. High levels of
background FITC staining were observed, even at lower antibody dilutions.
4.4. Expression ofM2 in mammalian cells
4.4.1. Expression constructs and epitope tagging ofM2
Due to the lack of a reliable antibody to the M2 protein, it was decided to
investigate the cellular localisation and function of M2 by expressing the M2
protein with an epitope tag. This epitope tag could then be used to detect protein
expression by the use of commercially available antibodies. It was decided to use
six histidine residues (Hisg) fused to the carboxy terminus as there are
commercially available antibodies to this epitope, it has been used successfully to
characterise as wide variety of proteins (Kao et al., 1994; Lackner & Condit,
2000) and the His6 epitope can be used to concentrate and / or purify proteins via
affinity chromatography (Hochuli et al., 1988; Bornhorst & Falke, 2000). The M2
cDNA ORF was amplified using primer pair M2GEX1 and M2-HIS (Chapter 2,
Appendix 2) with Taq DNA polymerase and cloned into the pcDNA3.1(+) vector
(Chapter 2, Appendix 3) using the BamYil and EcoBl restriction enzyme sites to
give the vector pcDNA3.1/M2-His (Figure 4.4.1.1A). The pcDNA3.1 vector
contains the HCMV immediate-early promoter for efficient, high-level expression
of inserted genes (Foecking & Hofstetter, 1986; Xu et al., 2001). The sequence
corresponding to the six histidine residues was inserted immediately upstream of
the M2 STOP codon so that it would be translated in frame with the M2 protein.
Determination of the sequence of the DNA insert in pcDNA3.1(+) (see 2.2.24)
showed that it was 100% identical at the nucleotide level to the M2 cDNA ORF,
with the sequence corresponding to the six histidine residue epitope present at the
3' end (data not shown).
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Figure 4.4.1.1 Schematic drawing (not to scale) of constructs for the expression of
M2 in mammalian cells, showing relevant features. Abbreviations: IE PCMV ,
human cytomegalovirus immediate-early promoter/enhancer; His6, six consecutive
histidine residues; BGH pA, bovine growth hormone polyadenylation signal; E
SV40 early promoter; OriSV40, SV40 origin of replication; SV40 pA, SV40SV40'
polyadenylation signal; LTR, Moloney murine leukaemia virus long terminal
repeats; Int ACMV, Intron A of the CMV immediate early gene; RBG pA, rabbit P-
globin polyadenylation signal; EGFP, enhanced green fluorescent protein; HSV
TK pA, herpes simplex virus thymidine kinase polyadenylation signal; Int 1IRBG,
Intron II of rabbit P-globin gene; HA, influenza haemagglutinin epitope; pA,
polyadenylation signal. For full details of plasmid vectors, see Chapter 2 Appendix
3.
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The pcDNA3.1/M2-His or pcDNA3.1 (empty negative control vector)
plasmid DNA (20pg) was transfected into BHK-21, COS-7 or HeLa cells by
electroporation (see 2.1.4), and the cells harvested after 24 hours. The cell lysates
were analysed by immunoblot following separation by SDS-PAGE. The blot was
incubated with mouse monoclonal anti-His6 antibody (diluted 1:500), followed by
biotinylated rabbit anti-mouse Ig (diluted 1:40,000) and then streptavidin-AP
conjugate (diluted 1:1,000). The reactive proteins were visualised using Sigma
FAST BCIP/NBT solution. No specific protein bands corresponding to M2 were
seen in the pcDNA3.1/M2-His cell lysate for any of the cell types transfected
(data not shown).
Attempts were also made to generate cell lines stably transfected with the
pcDNA3.1/M2-His plasmid. COS-7 cells (which express the SV40 large T
antigen) were transfected with 20pg of pcDNA3.1 (empty negative control
vector) or pcDNA3.1/M2-His by electroporation (see 2.1.4), which both contain
the SV40 origin of replication. Stably transfected cells were selected 24 hours
after transfection with 400pg/ml G418 antibiotic (Invitrogen Life Technologies).
Resistant foci of cells were cloned, and kept under G418 selection for a minimum
of 3 weeks. Cell lysates were again tested for M2-His expression by immunoblot
analysis using the mouse monoclonal anti-His6 antibody as previously described.
No specific protein bands corresponding to M2 were seen in the pcDNA3.1/M2-
His cell lysate for any of the G418 resistant cell clones analysed (data not shown).
DNA from G418 resistant cell clones transfected with pcDNA3.1/M2-His was
isolated using a DNeasy Tissue Kit (see 2.6.10), quantified (see 2.2.6) and tested
for the presence of the M2 DNA insert by 40 cycles of PCR (see 2.2.1) using the
primer pair M2GEX1 and M2-HIS (Chapter 2, Appendix 2). No M2 insert DNA
was detectable in any of the cell clones analysed (data not shown), suggesting that
the M2-His insert had been lost from these cells.
It was postulated that the high level of expression ofM2 protein from the
HCMV immediate-early promoter might be leading to cytotoxicity, and therefore
poor levels of expression. It was therefore decided to use a retroviral expression
vector, pBabe puro (Chapter 2, Appendix 3). This vector expresses inserted DNA
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under the control of the Moloney murine leukaemia virus (MoMuLV) long
terminal repeats (Morgenstern & Land, 1990), which gives lower levels of
expression than the HCMV immediate early promoter (Martin-Gallardo et al.,
1988). The M2 cDNA ORF was amplified using primer pair M2GEX1 and M2-
HIS (Chapter 2, Appendix 2) and cloned into the pBabe puro vector using the
BamKl and fscoRI restriction enzyme sites to give the vector pBabe puro/M2-His
(Figure 4.4.1.1B). The pBabe puro/M2-His or pBabe puro (empty negative
control vector) plasmid DNA (20pg) was transfected into BHK-21 or HeLa cells
by electroporation (see 2.1.4), and the cells harvested after 24 hours. Cell lysates
were again tested for M2-His expression by immunoblot analysis using the mouse
monoclonal anti-His6 antibody as previously described. No specific protein bands
corresponding to M2 were seen in the pBabe puro/M2-His cell lysate for any of
the cell types transfected (data not shown).
Due to the failure to detect any expression of M2 by transient or stably
transfected cell lines with the expression vectors pcDNA3.1/M2-His or pBabe
puro/M2-His, it was hypothesised that the levels of M2 expression might be
below levels detectable by immunoblot. It was therefore decided to use a lacZ-
inducible T cell hybridoma line specific for the M291.99 CD8+ T cell epitope to
detect expression of the M2 protein. LacZ-inducible T cell hybridomas contain a
P-galactosidase gene (lacZ) under the transcriptional control of the nuclear factor
of activated T cells element of the IL-2 enhancer (Karttunen & Shastri, 1991).
The recognition of its cognate epitope by the T-cell receptor of the hybridoma
results not only in the production of IL-2, but also in the production of p-
galactosidase, which can be detected by staining with X-gal. This technique is
therefore extremely sensitive for the individual ligand-activated T-cell detection
of antigen (Karttunen et al., 1992; Usherwood et al., 1999). A LacZ-inducible T
cell hybridoma had been developed in the Department of Immunology, St. Jude
Children's Research Hospital, Memphis specific for the M29i.99 CD8+ T cell
epitope, and Dr. E. Usherwood performed analysis of the plasmid vectors for M2
expression.
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Cells were transfected with the expression vectors pcDNA3.1/M2-His or
pBabe puro/M2-His, and these cells were used as antigen-presenting cells for the
LacZ-inducible T cell hybridoma. The numbers of cells positive for blue X-gal
staining were then counted per well. Negative control cells (either not transfected
or transfected with the plasmid pBabe puro/GPCR) showed only 1 - 3 positive
cells per well. Positive control Sll cells showed 73 positive cells per well. Cells
transfected with the expression vector pcDNA3.1/M2-His showed over 200
positive cells per well, and cells transfected with pBabe puro/M2-His showed 29
positive cells per well. These results showed that cells transfected with the M2
expression vectors presented the M291.99 CD8+ T cell epitope to the lacZ-
inducible T cell hybridoma, and were therefore expressing M2 protein. This was
an extremely sensitive assay, and the results suggested that the expression ofM2
by these vectors in BHK-21, COS-7 and HeLa cells was occurring, but was below
levels detectable by immunoblot.
Previous work had shown detectable levels of gpl50 expression using the
mammalian expression vector pVR1255 (Dr. I. Atkin, unpublished observations).
This vector has been modified to increase gene expression levels, and uses the
HCMV immediate-early promoter to express the reporter luciferase gene
(Hartikka et al., 1996). The vector was obtained under license from Vical Inc.,
and had been modified to remove the luciferase gene giving the plasmid
pVR1255luc" (Chapter 2, Appendix 3). The M2 gene was excised from the
sequenced plasmid pcDNA3.1/M2-His using the restriction enzymes PmeI and
EcoR\, and the M2-His fragment isolated from a 1% agarose gel (see 2.2.13).
The vector pVR1255luc" was digested with the restriction endonuclease EcoRV,
and the M2-His insert was ligated into the digested vector. The ligation mixture
was used to transform XL-1 Blue bacteria (see 2.2.11), and colonies analysed by
the mini-prep method (see 2.2.14). Diagnostic restriction enzyme digestion with
EcoRV only, or EcoRW and Hindlll, or EcoRW and Sail was used to confirm the
presence of the M2-His insert in the correct orientation, giving the vector
pVR1255/M2-His (Figure 4.4.1.1C). pVR1255/M2-His or pVR1255 (negative
control vector expressing luciferase) plasmid DNA (20pg) was transfected into




































































Figure 4.4.1.2 Expression of His6 tagged M2 protein in mammalian cells. BHK-21
or 293 cells were transfected with 20pg of plasmid DNA and harvested 24 hours
after transfection. Cells were transfected using either the single pulse (S.P.) or
double pulse (D.P.) electroporation program with pVR1255 (negative control) or
pVR1255/M2-His6. The cell lysates were analysed on a 12.5% SDS-PAGE gel, and
transferred onto a membrane by Western blot. Lane 1 contained GST-His6 as a
positive control. The blots were probed with mouse monoclonal anti-His6, followed
by biotinylated rabbit anti-mouse Ig and then streptavidin-AP. The conjugates were
visualised using Sigma FAST BC1P/NBT solution. Molecular weights are given in
kilodaltons on the left side.
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24 hours. Cell lysates were again tested for M2-His expression by immunoblot
analysis using the mouse monoclonal anti-Hisg antibody as previously described.
As a positive control, lOOng of GST tagged with the His6 epitope (GST-His6;
kindly provided by Dr. I. Atkin) was analysed on the same immunoblot. Figure
4.4.1.2 shows that the GST-His6 protein was visualised at the expected molecular
mass of approximately 27.5kDa. However, there were no differences specific for
M2 observed between the control plasmid pVR1255 and pVR1255/M2-His in
either the BHK-21 or 293 cell lysates by immunoblot analysis. There was
therefore no detectable expression of M2 by the plasmid pVR1255/M2-His by
immunoblot analysis.
Attempts were also made to detect expression of M2 by
immunofluorescence. COS-7, BHK-21, HeLa or 293 cells were transfected with
20pg of plasmid DNA (see 2.1.4), harvested 24 hours later and fixed onto slides
(see 2.7.1). The plasmids used were pcDNA3.1 and pcDNA3.1/M2-His; pBabe
puro and pBabe puro/M2-His; pVR1255 and pVR1255/M2. The slides were
incubated with either mouse monoclonal anti-His6 (diluted 1:10-1:50) or mouse
monoclonal anti-LMPl (isotype specific negative control for non-specific
binding; diluted 1:20), followed by biotinylated rabbit anti-mouse IgG (diluted
1:100-1:500) and then streptavidin-FITC conjugate (diluted 1:300; see 2.7.8). No
specific FITC staining was detectable in cells expressing the His6-tagged M2
protein, and there was therefore no detectable expression ofM2 by these plasmids
by immunofluorescence analysis.
These results showed that no expression of M2 was detectable from the
expression vectors pcDNA3.1/M2-His, pBabe puro/M2-His and pVR1255/M2-
His by immunoblot or immunofluorescence. However, expression was detectable
from the expression vectors pcDNA3.1/M2-His and pBabe puro/M2-His using
very sensitive assays for the M29i_99 CD8+ T cell epitope. This result suggested
that the levels ofM2 expression were below levels detectable by antibody, and a
more sensitive assay was required. It was therefore decided to construct GFP
fusion proteins, which would enable localisation of M2 in mammalian cells at
very low levels (Chalfie et al., 1994). GFP fusion proteins have been made for a
wide range of proteins, including viral proteins such as HIV-1 integrase
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(Pluymers et al., 1999), EBNA-1 of EBV (Marechal et al., 1999) and LANA-1 of
KSHV (Piolot et al., 2001). GFP fusion proteins usually localise and function
identically to the native protein (Stauber & Pavlakis, 1998; Lorenzon et al., 2001),
and the GFP thus serves as an excellent means of identifying proteins in living
and fixed cells.
The M2 cDNA ORE was amplified using primer pair M2GEX1 and
M2GEX2 (Chapter 2, Appendix 2) with PfuTurbo™ DNA polymerase, and
cloned into the pEGFP-Cl vector (Chapter 2, Appendix 3) using the Bglll and
AcoRI restriction enzyme sites to give the vector pEGFP-Cl/M2 (Figure
4.4.1. ID). The pEGFP series of expression vectors expresses cloned DNA inserts
as EGFP fusion proteins using the HCMV immediately early promoter. EGFP is a
variant of GFP that has been optimised for brighter fluorescence and higher
expression in mammalian cells. The M2 gene was therefore inserted in frame with
the EGFP protein, and would be expressed as a fusion to the C terminus of the
EGFP protein. Diagnostic restriction enzyme digestion of mini-prep DNA
samples with Pstl only, or BspEl and EcoPl, or Ncol and Pstl was used to
confirm the presence of the M2 insert in the correct orientation.
The M2 cDNA ORF was amplified using primer pair M2GEX1 and
M2GFP-N (Chapter 2, Appendix 2) with PfuTurbo™ DNA polymerase, and
cloned into the pEGFP-Nl vector (Chapter 2, Appendix 3) using the Bglll and
EcoBl restriction enzyme sites to give the vector pEGFP-Nl/M2 (Figure
4.4.1.IE). The M2 gene was therefore inserted in frame with the EGFP protein,
and would be expressed as a fusion to the N terminus of the EGFP protein.
Diagnostic restriction enzyme digestion of mini-prep DNA samples with Pstl
only, or Nhel and EcoRl, or Ncol and Pstl was used to confirm the presence of the
M2 insert in the correct orientation.
Two M2 expression constructs were kindly provided by Dr. Jeff Sample,
St. Jude Children's Research Elospital, Memphis. They contained the eukaryotic
expression vector pSG5, which expresses inserted DNA from the SV40 early
promoter (Chapter 2, Appendix 3). The plasmid pSG5/M2-5'ElA contained the
M2 gene with three consecutive 27bp DNA sequences corresponding to the
187
CHAPTER FOUR CHARACTERISATION OF THE M2 PROTEIN
influenza haemagglutinin (HA) epitope (YPYDVPDYA) inserted immediately
upstream of the M2 ORF so that it would be translated in frame with the M2
protein (Figure 4.4.1.IF). The plasmid pSG5/M2-3'HA contained the M2 gene
with the three HA epitope sequences inserted immediately upstream of the M2
STOP codon (Figure 4.4.1.1G). Dr. Sample also provided two control plasmids
that had been shown to express HA epitope tagged proteins in mammalian cells.
The plasmid pSG5/jk-HA expresses the cellular DNA-binding protein Jk (Zhao et
al., 1996), and plasmid pSG5/IRF7-HA expresses the interferon regulatory factor-
7 (IRF7) (Zhang & Pagano, 1997).
4.4.2. Expression of M2
A20 and 293 cells were transfected with 20pg of the HA epitope-tagged
expression constructs pSG5/IRF7-HA, pSG5/Jic-HA, pSG5/M2-5'HA and
pSG5/M2-3'HA. Mock transfected cells were used as a negative control. The
cells were harvested 24 hours after transfection, and the cell lysates were analysed
on a 12.5% SDS-PAGE gel, and transferred onto a membrane by Western blot.
The blot was incubated with mouse monoclonal anti-HA antibody (diluted
1:2000), followed by biotinylated rabbit anti-rat Ig (diluted 1:10,000) and then
streptavidin-POD conjugate (diluted 1:5,000). The reactive proteins were
visualised using ECL. Figure 4.4.2.1 shows the results of the immunoblot analysis
of A20 cells for the expression of HA epitope-tagged proteins. The positive
control proteins IRF7-HA (a 70kDa protein) and Jk-HA (a 60kDa protein) were
visualised as bands at their appropriate relative molecular masses. Unique bands
were also observed in the A20 cell lysates containing HA epitope-tagged M2 at a
relative molecular mass of approximately 30kDa. This is larger than the expected
mass of 22.3kDa (consisting of the 21.2kDa predicted molecular mass ofM2 with
the 1.1 kDa HA epitope). There did not appear to be any substantial size
differences between the M2-5'HA or M2-3'HA proteins, which are epitope-
tagged with HA at the N-terminus and C-terminus respectively. This result
suggested that there was no post-translational cleavage of the M2 protein. The HA
epitope-tagged M2 proteins also appeared as a doublet, a characteristic that is also
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Figure 4.4.2.1 Expression of HA-epitope tagged M2 protein in A20 cells. Cells
were transfected with 20pg of plasmid DNA and harvested 24 hours after
transfection. Mock transfected A20 cells were used as a negative control, and two
positive controls (pSG5/IRF7-HA and pSG5/Jic-HA) were also included. The cell
lysates were analysed on a 12.5% SDS-PAGE gel, and transferred onto a membrane
by Western blot. The blots were probed with rat monoclonal anti-HA, followed by
biotinylated rabbit anti-rat Ig and then streptavidin-POD. The conjugates were
visualised using ECL. Molecular weights are given in kilodaltons on the left side.
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observed following SDS-PAGE analysis of many phosphorylated proteins. The
bands observed for all the HA epitope-tagged proteins were not observed in the
negative control lane, containing mock transfected A20 cells. These results show
that the M2 protein is a 30kDa protein that appears as a doublet by Western blot
analysis. In contrast, immunoblot analysis of 293 cells transfected with the HA
epitope-tagged expression constructs only resulted in the visualisation of the
positive control proteins IRF7-HA and Jk-HA as bands at their appropriate
relative molecular masses. No HA epitope-tagged M2 was visualised after
transfection of 293 cells.
In a complementary approach, A20 cells were transfected with 20pg of the
EGFP expression constructs pEGFP-Cl and pEGFP-Nl, and the EGFP-M2 fusion
protein expression constructs pEGFP-Cl/M2 and pEGFP-Nl/M2. Mock
transfected cells were used as a negative control. The cells were harvested 24
hours after transfection, and the cell lysates were analysed on a 10% SDS-PAGE
gel, and transferred onto a membrane by Western blot. The blot was incubated
with mouse monoclonal anti-GFP antibody (diluted 1:1000), followed by sheep
anti-mouse Ig conjugated to POD (diluted 1:2,000). The reactive proteins were
visualised using ECL. Figure 4.4.2.2 shows the results of immunoblot analysis for
the expression of EGFP in A20 cells. The positive control vector pEGFP-Nl
shows a large positive band at 27kDa, which is the expected size of native EGFP
protein. The positive control vector pEGFP-Cl expresses the EGFP protein with
the multiple cloning site (MCS) attached to the C terminus (see Chapter 2,
Appendix 3). This attaches an extra 26 amino acids to the C terminus, which adds
2.5kDa to the 27kDa mass of EGFP protein. The EGFP protein expressed by the
pEGFP-Cl vector was therefore visualised as a large positive band with an
apparent molecular mass of 30kDa (white asterisk in Figure 4.4.2.2), with a
breakdown product corresponding to native EGFP at 27kDa (white dot in Figure
4.4.2.2). Due to the exposure time needed to visualise the GFP-M2 fusion protein
via ECL, both positive control EGFP protein bands are significantly overexposed
and a small background band is also visualised with an apparent molecular mass
of 30kDa. A smaller band with an apparent molecular mass of 23kDa was also
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Figure 4.4.2.2 Expression of EGFP fusion proteins in A20 cells. Cells were
transfected with 20pg of plasmid DNA and harvested 24 hours after transfection.
Mock transfected A20 cells were used as a negative control. The cell lysates were
analysed on a 10% SDS-PAGE gel, and transferred onto a membrane by Western
blot. The blots were probed with mouse monoclonal anti-EGFP, followed by sheep
anti-mouse Ig linked to POD. The conjugates were visualised using ECL. For
clarity, a white asterisk has been placed on the EGFP + MCS protein band and a
white dot placed on the EGFP protein bands. Molecular weights are given in
kilodaltons on the left side. Abbreviations: MCS, multiple cloning site present at
the C terminus of pEGFP-Cl, which adds a 2.5kDa polypeptide to the EGFP
protein (see text).
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visualised in the positive control vector pEGFP-Nl, possibly corresponding to an
EGFP breakdown product.
The expression vector pEGFP-Cl/M2 produced a single band with an
apparent molecular weight of 60kDa. This is larger than the expected 48.2kDa
mass of the EGFP-M2 fusion protein (containing the 27kDa EGFP protein with
the 21,2kDa M2), but does agree with the observation that the HA epitope-tagged
M2 migrates at an apparent molecular mass of 30kDa, giving an expected
molecular weight of the EGFP-M2 fusion protein at 57kDa. The expression vector
pEGFP-Nl/M2 produced a faint single band with an apparent molecular weight of
60kDa. However, there was also a band at 27kDa in the pEGFP-Nl/M2 lane,
showing that there was also native EGFP present in this sample. This suggests
that the M2-EGFP fusion protein is unstable, and is broken down in this sample to
give native EGFP. This breakdown to give a band at 27kDa was only observed in
cells transfected with pEGFP-Nl/M2, and not pEGFP-Cl/M2. The bands
observed for all the EGFP proteins were not observed in the negative control lane,
containing mock transfected A20 cells. These results show that these expression
vectors produce a 60kDa EGFP-M2 fusion protein that migrates as a single band
on Western blot analysis. However, the M2-EGFP fusion protein produced by the
pEGFP-Nl/M2 vector appears to be unstable, and is broken down to native
EGFP.
A20 cells that were transfected with the EGFP expression constructs were
observed to fluoresce green under ultraviolet light (see 4.5.1). However, the
number of cells fluorescing following transfection with the pEGFP-Cl/M2 and
pEGFP-Nl/M2 vectors was substantially lower than the number of fluorescent
cells after transfection with the control vectors pEGFP-Cl and pEGFP-Nl. This
observation corresponded with the reduced intensity of the bands seen by
immunoblot for the EGFP-M2 fusion proteins as compared to the quantity of
EGFP expressed by the control plasmids (Figure 4.4.2.2). This suggested that
even though large numbers of cells had been efficiently transfected (as evidenced
by the high numbers of cells fluorescing after transfection with the control
plasmids), many fewer cells were expressing the EGFP-M2 fusion protein. To
quantify this observation, A20 cells were transfected with the EGFP expression
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constructs and analysed 24 hours after transfection by FACS analysis for EGFP
expression (see 2.6.7). As shown in Figure 4.4.2.3, large numbers of A20 cells
transfected with the control vectors pEGFP-Cl and pEGFP-Nl showed green
fluorescence (37.4% for pEGFP-Cl [Figure 4.4.2.3B], 36.3% for pEGFP-Nl
[Figure 4.4.2.3C]) as compared to the mock transfected negative control cells
(Figure 4.4.2.3A). This showed that A20 cells were efficiently transfected with
plasmid DNA by electroporation. However, cells transfected with the EGFP-M2
fusion protein expression vectors exhibited an approximate 10-fold decrease in
the number of fluorescing cells when compared to the control vectors (4.7% for
pEGFP-Cl/M2 [Figure 4.4.2.3D], 2.9% for pEGFP-Nl/M2 [Figure 4.4.2.3E]).
This result suggested that either the intensity of the EGFP fluorescence was being
decreased by the addition ofM2 in the EGFP-M2 fusion protein, or that the level
of EGFP-M2 fusion protein expression was below the limit of detection by FACS
analysis in the majority of cells transfected. The results of the immunoblot
analysis would suggest the latter explanation, as there is substantially less EGFP
protein present in these cells. This finding suggests that the toxicity of the M2
protein in mammalian cells leads to substantially lower levels of expression of
EGFP-M2 fusion protein.
4.5. Cellular localisation of M2
4.5.1. Expression of EGFP-M2 fusion protein
The expression of M2 fused to either the C-terminus of EGFP (by the
expression vector pEGFP-Cl/M2) or N-terminus of EGFP (by the expression
vector pEGFP-Nl/M2) enabled the visualisation and thus the cellular localisation
of the EGFP-M2 fusion protein. 293 cells (a human epithelial cell line, see Table
2.1) were initially used for localisation studies as they showed high transfection
efficiencies (50%) by electroporation. 293 cells were transfected with 20pg of
plasmid DNA (pEGFP-Cl, pEGFP-Nl, pEGFP-Cl/M2 and pEGFP-Nl/M2) and
harvested 24 hours after transfection. The cell nuclei were counterstained with
propidium iodide, which stains nucleic acids red (specific nuclear staining was
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Figure 4.4.2.3 Expression of EGFP fusion proteins in A20 cells. Cells were
transfected with 20tig of plasmid DNA, harvested 24 hours after transfection and
analysed by FACS. The M1 marker details the number of fluorescent cells (given as
a percentage of the total number of cells analysed) for each transfection compared
to the negative control. Panel A shows A20 cells mock transfected (negative
control); panel B shows A20 cells transfected with pEGFP-Cl; panel C shows A20
cells transfected with pEGFP-Nl; panel D shows A20 cells transfected with
pEGFP-Cl/M2; panel E shows A20 cells transfected with pEGFP-Nl/M2. The
results are representative of three separate experiments.
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achieved by treatment of the cells with RNase A at the same time as staining), and
the cells analysed by confocal microscopy. Figure 4.5.1.1 shows that 293 cells
were efficiently transfected, as evidenced by the numerous cells transfected with
pEGFP-Cl and pEGFP-Nl expressing EGFP (panels A and D). Cells transfected
with the control vectors and thus expressing EGFP alone show typical localisation
of EGFP throughout the nucleus and cytoplasm (panels A-C and D-F). This is
illustrated by the image analysis in Figure 4.5.1.2, where the confocal images
were examined using the Leica TCSNT confocal analysis software which
illustrates the intensity of red or green fluorescence along a line of analysis via a
graph. The graph in Figure 4.5.1.2A and B shows that EGFP is expressed
throughout the nucleus (red fluorescence present) and cytoplasm (no red
fluorescence). There was no difference in EGFP localisation between the two
control vectors pEGFP-Cl and pEGFP-Nl (despite the extra 26 amino acid
sequence present at the C-terminus of the pEGFP-Cl vector).
In contrast, 293 cells transfected with pEGFP-Cl/M2 expressing EGFP-
M2 showed localisation of EGFP in the central region and at the periphery of the
cell (Figure 4.5.1.1G-I and 4.5.1.2C and D). Only one area of the nucleus showed
co-localisation with EGFP-M2 as evidenced by the yellow fluorescence in the
overlay image (Panel I), with the other nuclear areas showing no EGFP-M2
present. However, the nucleus in the majority of cells transfected with pEGFP-
C1/M2 demonstrated nuclear fragmentation (Figure 4.5.1.1 H), a feature
characteristic of apoptosis (Bellamy et al., 1995). This was not observed in
neighbouring cells or cells transfected with the control plasmids, suggesting that
this was not a fixation artefact. 293 cells transfected with pEGFP-Nl/M2 also
showed localisation of M2-EGFP in the central region, with patches present at the
periphery of the cell (Figure 4.5.1.1J-L and 4.5.1.2E and F). There was also
diffuse M2-EGFP present in the cytoplasm of cells transfected with pEGFP-
N1/M2, and nuclear fragmentation was observed in some cells. There were
substantially fewer cells fluorescing after transfection with pEGFP-Cl/M2 and
pEGFP-Nl/M2 compared to cells transfected with the control EGFP expression
vectors (pEGFP-Cl and pEGFP-Nl), in agreement with Figure 4.4.2.3.
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Figure 4.5.1.1 Transfection of EGFP expression constructs in 293 cells. Cells were
transfected with 20pg of plasmid DNA and harvested 24 hours after transfection.
Panels A, D, G and J show EGFP localisation; panels B, E, H and K show DNA
stained with propidium iodide; panels C, F, I and L show overlay images. Panels A,
B and C show pEGFP-CI; panels D, E and F show pEGFP-Nl; panels G, H and \
show pEGFP-C 1/M2; panels J, K and L show pEGFP-Nl/M2. All images are single
confocal slices, with scale bar representing 10pm.
196




































Figure 4.5.1.2 Analysis of confocal images of EGFP expression constructs
transfected into 293 cells. The images in Figure 4.5.1.1 were analysed using Leica
TCSNT confocal analysis software. Panels on the left show line of analysis (in
white) superimposed on the overlay single slice image, and graph on the right
shows the intensity of fluorescence of the image along the white line, plotted
against XY position on the line. Panel A shows pEGFP-Cl; panel B shows image
analysis of pEGFP-Cl; panel C shows pEGFP-Cl/M2; panel D shows image
analysis of pEGFP-Cl/M2; panel E shows pEGFP-Nl/M2; panel F shows image
analysis of pEGFP-N 1/M2. Scale bar represents 10pm.
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The nuclear degeneration observed in 293 cells 24 hours after transfection
with the M2-EGFP expression vectors suggested that 293 cells might not be
suitable for the expression ofM2, either due to species or cell type specificities of
the M2 protein. It was therefore decided to use A20 cells (a murine B-lymphocyte
line, see Table 2.1) for all further expression studies as these cells could be
efficiently transfected by electroporation (see Figure 4.4.2.3) and were as close as
possible to the cell type known to express M2 (Sll cells; Usherwood et al.,
1996b; Husain et al., 1999). A20 cells were transfected with 20pg of plasmid
DNA (pEGFP-Cl, pEGFP-Nl, pEGFP-Cl/M2 and pEGFP-Nl/M2) and
harvested 24 hours after transfection. The cell nuclei were counterstained with
propidium iodide, and the cells analysed by confocal microscopy. In agreement
with the previous transfections in 293 cells, A20 cells transfected with pEGFP-Cl
and pEGFP-Nl showed typical localisation of EGFP throughout the nucleus and
cytoplasm (Figure 4.5.1.3A-C and D-F, Figure 4.5.1.4A and B). A20 cells
transfected with pEGFP-Cl/M2 showed localisation of EGFP-M2 at the periphery
of the cell, with patches of EGFP-M2 present throughout the cell (Figure
4.5.1.3G-I and 4.5.1.4C and D). The EGFP-M2 present in the central region of the
cell did not show yellow fluorescence in the overlay image (Panel 1) suggesting
that the DNA and EGFP-M2 were not closely associated. A similar pattern ofM2-
EGFP localisation was also observed in cells transfected with pEGFP-Nl/M2
(Figure 4.5.1.3J-L and 4.5.1.4E and F), with the only difference being that the
intracellular M2-EGFP appeared more diffuse, reflecting the native EGFP
produced by the pEGFP-Nl/M2 construct (Figure 4.4.2.2). The specific nuclear
EGFP-M2 localisation and nuclear degeneration observed in 293 cells transfected
with pEGFP-Cl/M2 and pEGFP-Nl/M2 (Figure 4.5.1.1) was not seen in A20
cells. Again, there were substantially fewer cells fluorescing after transfection
with pEGFP-Cl/M2 and pEGFP-Nl/M2 compared to cells transfected with the
control EGFP expression vectors (pEGFP-Cl and pEGFP-Nl), in agreement with
Figure 4.4.2.3.
S11 cells have been shown to express the M2 protein (Husain et al., 1999),
and it was postulated that expression of the EGFP-M2 fusion proteins in these
cells might result in the localisation of the EGFP-M2 with the native M2 protein.
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Figure 4.5.1.3 Transfection of EGFP expression constructs in A20 cells. Cells were
transfected with 20pg of plasmid DNA and harvested 24 hours after transfection.
Panels A, D, G and J show EGFP localisation; panels B, E, F1 and K show DNA
stained with propidium iodide; panels C, F, I and L show overlay images. Panels A,
B and C show pEGFP-CI; panels D, E and F show pEGFP-Nl; panels G, II and I
show pEGFP-CI/M2; panels J, K and L show pEGFP-Nl/M2. All images are single
confocal slices, with scale bar representing 10p.m.
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Figure 4.5.1.4 Analysis of confocal images of EGFP expression constructs
transfected into A20 cells. The images in Figure 4.5.1.3 were analysed using Leica
TCSNT confocal analysis software. Panels on the left show line uf analysis (in
white) superimposed on the overlay single slice image, and graph on the right
shows the intensity of fluorescence of the image along the white line, plotted
against XY position on the line. Panel A shows pEGFP-Cl; panel B shows image
analysis of pEGFP-Cl; panel C shows pEGFP-Cl/M2; panel D shows image
analysis of pEGFP-C 1/M2; panel E shows pEGFP-Nl/M2; panel F shows image
analysis of pEGFP-N 1 /M2. Scale bar represents 10pm.
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leading to a more accurate indication of the cellular localisation of M2. Sll cells
were transfected with 20pg of plasmid DNA (pEGFP-Cl, pEGFP-Nl, pEGFP-
C1/M2 and pEGFP-Nl/M2), harvested 24 hours after transfection and the cells
analysed by confocal microscopy. In agreement with previous results, the Sll
cells transfected with pEGFP-Cl and pEGFP-Nl showed typical localisation of
EGFP throughout the nucleus and cytoplasm (Figure 4.5.1.5A). Sll cells
transfected with pEGFP-Cl/M2 showed localisation of EGFP-M2 at the periphery
of the cell, as well as EGFP present centrally within the cell (Figure 4.5.1.5B).
However, Sll cells were very poorly transfected with plasmid DNA as evidenced
by the low numbers of cells fluorescing after transfection with pEGFP-Cl
(despite a range of electroporation parameters being used) and thus were not used
further in the expression studies.
All the cells had been harvested 24 hours after transfection, and there was
a concern that harvesting cells at this stage after electroporation did not give the
cells enough time to recover from the procedure. It was also hypothesised that the
localisation of the EGFP-M2 might alter at later timepoints after transfection, due
to the cellular transportation of EGFP-M2 from the diffuse staining seen in the
centre of the cell to the periphery. A20 cells were transfected with 20pg of
plasmid DNA (pEGFP-Cl and pEGFP-Cl/M2) and harvested 48 hours after
transfection. The cell nuclei were counterstained with propidium iodide, and the
cells analysed by confocal microscopy. Figure 4.5.1.6 shows that A20 cells
transfected with pEGFP-Cl/M2 showed strong localisation of EGFP-M2 at the
periphery of the cell, with diffuse EGFP-M2 also present throughout the cell
(panels A-E). This was very similar to previous results, and due to the rapid
growth of the A20 cells (even in reduced FCS supplementation) it was therefore
decided to continue harvesting at 24 hours after transfection. There did not appear
to be any substantial difference in EGFP-M2 localisation at later timepoints after
transfection compared to 24 hours after transfection.
It was decided to determine the exact localisation of the EGFP-M2 fusion
proteins observed at the periphery of the cell. A20 cells were transfected with
20pg of plasmid DNA (pEGFP-Cl, pEGFP-Nl, pEGFP-Cl/M2 and pEGFP-
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Figure 4.5.1.5 Transfection of EGFP expression constructs in SI 1 cells. Cells were
transfected with 20pg of plasmid DNA and harvested 24 hours after transfection.
Panels A shows pEGFP-Cl; panels B shows pEGFP-Cl/M2. Both images are single





Figure 4.5.1.6 Transfection of pEGFP-Cl/M2 expression construct in A20 cells.
Cells were transfected with 20pg of plasmid DNA and harvested 48 hours after
transfection. Panel A shows EGFP localisation; panel B shows DNA stained with
propidium iodide; panel C shows overlay image. The image in panel C was analysed
using Leica TCSNT confocal analysis software. Panel D shows line of analysis (in
white) superimposed on the overlay single slice image, and the graph in panel E
shows the intensity of fluorescence of the image along the white line, plotted against
XY position on the line. All images are single confocal slices. Scale bar represents
10pm.
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N1/M2) and harvested 24 hours after transfection. The cells were stained for the
B-lymphocyte surface marker CD 19 (Janeway et al., 1999) using rat anti-mouse
CD 19 antibody, followed by anti-rat IgG TRITC conjugate (see 2.7.4). All
solutions included 0.1% w/v azide and were kept at 4°C to prevent capping and
internalisation of the cell surface markers. Control cells incubated with rat IgG or
no primary antibody followed by anti-rat IgG TRITC conjugate showed no
TRITC staining (data not shown). The cells were then attached by centrifugation
onto glass slides, fixed and analysed by confocal microscopy. Cells transfected
with the control vector pEGFP-Cl showed typical localisation of EGFP
throughout the cell, with no specific cell surface EGFP localisation (Figure
4.5.1.7A-C, Figure 4.5.1.8A and B). However, cells transfected with pEGFP-
C1/M2 showed co-localisation of the cell surface marker CD 19 (red fluorescence)
with M2-EGFP (Figure 4.5.1.7D-I). This was demonstrated by the visualisation of
a yellow area of co-localisation in the overlay confocal images (Panels F and I),
and quantitated by analysis of the images using Leica TCSNT confocal analysis
software. Analysis of Figure 4.5.1.71 showed a sharp peak of co-localisation at the
periphery of the cell between the CD 19 (red line) and EGFP-M2 (green line), as
well as diffuse low-level EGFP-M2 throughout the cell (Figure 4.5.1.8C and D).
However, cells transfected with pEGFP-Nl/M2 did not show consistent co-
localisation between CD 19 and M2-EGFP (Figure 4.5.1.7J-L), and this was
demonstrated by analysis of the image (Figure 4.5.1.8E-F). This result with the
pEGFP-Nl/M2 plasmid may have been influenced by the amount of native EGFP
produced by this expression construct (Figure 4.4.2.2). These results
demonstrated co-localisation of the cell surface marker CD 19 and the EGFP-M2
fusion protein in A20 cells.
To confirm this finding, A20 cells were transfected with 20pg of plasmid
DNA (pEGFP-Cl, pEGFP-Nl, pEGFP-Cl/M2 and pEGFP-Nl/M2) and the cells
were stained for the cell surface marker MHC Class II, which is present on
activated B-lymphocytes (Janeway et al., 1999). The cells were harvested 24
hours after transfection, and stained using rat monoclonal SW73.2 anti-MHC
Class II antibody, followed by anti-rat IgG TRITC conjugate (see 2.7.4).
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Figure 4.5.1.7 Co-localisation of CD19 and EGFP expression constructs in A20
cells. Cells were transfected with 20pg of plasmid DNA, harvested 24 hours after
transfection and stained with rat anti-mouse CD 19 antibody, followed by anti-rat IgG
TRITC conjugate. Panels A, D, G and J show EGFP localisation; panels B, E, H and
K. show CD 19 localisation; panels C, F, 1 and L show overlay images. Panels A, B
and C show pEGFP-Cl; panels D-I show pEGFP-Cl/M2; panels J, K and L show
pEGFP-Nl/M2. All images are single confocal slices, with scale bar representing
1 Opm.
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Figure 4.5.1.8 Analysis of confocal images of EGFP expression constructs
transfected into A20 cells, and stained with anti-CD 19 antibody. The images in
Figure 4.5.1.7 were analysed using Leica TCSNT confocal analysis software.
Panels on the left show line of analysis (in white) superimposed on the overlay
single slice image, and graph on the right shows the intensity of fluorescence of
the image along the white line, plotted against XY position on the line. Panel A
shows pEGFP-Cl; panel B shows image analysis of pEGFP-Cl; panel C shows
pEGFP-Cl/M2; panel D shows image analysis of pEGFP-C 1/M2; panel E shows
pEGFP-N I/M2; panel F shows image analysis of pEGFP-Nl/M2. Scale bar
represents 10pm.
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Although initially raised against sheep MHC Class II, the rat monoclonal SW73.2
anti-MHC Class II antibody shows cross-reactivity against the BALB/c mouse
MHC Class II molecule (Hopkins et ai, 1986). All solutions included 0.1% w/v
azide and were kept at 4°C to prevent capping and internalisation of the cell
surface markers. Control cells incubated with rat IgG or no primary antibody
followed by anti-rat IgG TRITC conjugate showed no TRITC staining (data not
shown). In agreement with previous results, cells transfected with pEGFP-Nl
showed localisation of EGFP throughout the cell, with no specific localisation
with the cell surface (Figure 4.5.1.9A-C, Figure 4.5.1.10A and B). However, cells
transfected with pEGFP-Cl/M2 showed co-localisation of EGFP-M2 with MHC
Class II (Figure 4.5.1.9D-I), as demonstrated by the yellow area at the cell margin
in the overlay image (Panels F and I) and the overlapping peaks of red and green
fluorescence upon analysis of the image (Figure 4.5.1.10C and D). Similar results
were obtained in cells transfected with pEGFP-Nl/M2, demonstrating co-
localisation of M2-EGFP and MHC Class II cell surface marker (Figure 4.5.1.9J-
L, Figure 4.5.1.10E and F).
The results of the co-localisation of the EGFP-M2 fusion protein and cell
surface markers CD 19 and MHC Class II in A20 cells demonstrated that EGFP-
M2 was specifically localised to the plasma membrane, as well as diffuse
localisation throughout the cell. However, the resolution of the confocal
microscope is 180nm but the thickness of the plasma membrane is 6-10nm. It is
therefore not possible to demonstrate if the co-localisation of EGFP-M2 with cell
surface markers is due to the position of EGFP-M2 at the inner or outer surface of
the plasma membrane. These results have therefore shown localisation of the
EGFP-M2 fusion protein to the plasma membrane.
It was also decided to investigate the pathways by which EGFP-M2 might
be trafficked to the plasma membrane, and the localisation of the EGFP-M2
distributed diffusely in the central region of the cell. The endoplasmic reticulum
(ER) is the site of lipid biosynthesis in the cell, and the location of protein
production by ribosomes that bind to the ER. The process of N-linkcd
glycosylation of proteins also commences in the ER. Concanavalin A is a plant
lectin, which binds the oligosaccharide residues a-mannopyranosyl and a-
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Figure 4.5.1.9 Co-localisation of MHC ClassII and EGFP expression constructs in
A20 cells. Cells were transfected with 20pg of plasmid DNA, harvested 24 hours
after transfection and stained with rat anti-MHC ClassII antibody, followed by anti-
rat IgG TRITC conjugate. Panels A, D, G and J show EGFP localisation; panels B, E,
H and K show MHC ClassII localisation; panels C, F, I and L show overlay images.
Panels A, B and C show pEGFP-Nl; panels D-i show pEGFP-Cl/M2; panels J, K
and L show pEGFP-NI/M2. All images are single confocal slices, with scale bar
representing 10pm.
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Figure 4.5.1.10 Analysis of confocal images of EGFP expression constructs
transfected into A20 cells, and stained with anti-MHC Classll antibody. The
images in Figure 4.5.1.9 were analysed using Leica TCSNT confocal analysis
software. Panels on the left show line of analysis (in while) superimposed on the
overlay single slice image, and graph on the right shows the intensity of
fluorescence of the image along the white line, plotted against XY position on the
line. Panel A shows pEGFP-Nl; panel B shows image analysis of pEGFP-Nl;
panel C shows pEGFP-Cl/M2; panel D shows image analysis of pEGFP-Cl/M2;
panel E shows pEGFP-Nl/M2; panel F shows image analysis of pEGFP-N 1/M2.
Scale bar represents 10pm.
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glucopyranosyl present in the ER and has therefore been used previously to
specifically stain the ER in a wide range of cell types (Virtanen et ai, 1980;
Bergmann & Fusco, 1990; Cottin et al., 1999). A20 cells were transfected with
20pg of plasmid DNA (pEGFP-Cl, pEGFP-Nl, pEGFP-Cl/M2 and pEGFP-
N1/M2) and harvested 24 hours after transfection. The cells were incubated for 5
minutes with 50pg/ml concanavalin A TRITC conjugate, then washed and fixed
before analysis by confocal microscopy (see 2.7.5). Cells stained with
concanavalin A TRITC conjugate exhibited two types of cellular staining;
staining of the ER (shown in Figure 4.5.1.1 IB, E and H) or staining at the
periphery of the cell (Figure 4.5.1.1 IB and E). This staining at the edge of the cell
by concanavalin A was subsequently shown to be at the plasma membrane
(Figure 4.5.1.13 and 4.5.1.14). There was no difference in the pattern of staining
with concanavalin A exhibited between live cells or fixed cells (data not shown).
Cells transfected with the control plasmid pEGFP-Cl showed typical localisation
of EGFP throughout the cell, with no specific localisation with concanavalin A
either at the periphery or ER (Figure 4.5.1.11A-C, Figure 4.5.1.12A and B). Cells
transfected with pEGFP-Cl/M2 showed no co-localisation of EGFP-M2 with
concanavalin A at the ER, but did show co-localisation of EGFP-M2 with
concanavalin A at the plasma membrane (Figure 4.5.1.11D-F). This is
demonstrated by the analysis of the images using Leica TCSNT confocal analysis
software in Figure 4.5.1.12C and D; the red (concanavalin A) and green (EGFP-
M2) peaks on the graph show only slight co-localisation on the left edge of the
graph at the ER (XY position 2.5-7pm) but strong co-localisation on the right
edge of the graph at the plasma membrane (XY position 13-15pm). Cells
transfected with pEGFP-Nl/M2 showed a similar result, with no co-localisation
observed between M2-EGFP and concanavalin A staining of the ER in A20 cells
(Figure 4.5.1.11G-I, Figure 4.5.1.12E and F). Cells transfected with pEGFP-
C1/M2 and pEGFP-Nl/M2, stained with concanavalin A-TRITC and the DNA
stained with TO-PRO-3 showed no co-localisation between either DNA and
concanavalin A TRITC or DNA and EGFP-M2 (data not shown). This result
showed that there was no co-localisation of EGFP-M2 and concanavalin A when
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Figure 4.5.1.11 Co-localisation of the endoplasmic reticulum marker Concanavalin
A and EGFP expression constructs in A20 cells. Cells were transfected with 20pg of
plasmid DNA, harvested 24 hours after transfection and stained with 50pg/ml
Concanavalin A TRITC conjugate. Panels A, D and G show EGFP localisation;
panels B, E and H show Concanavalin A TRITC localisation; panels C, F and I show
overlay images. Panels A, B and C show pEGFP-Cl; panels D, E and F show
pEGFP-Cl/M2; panels G, F1 and 1 show pEGFP-Nl/M2. Cells stained with
Concanavalin A exhibited staining of the endoplasmic reticulum (ER) or plasma
membrane (PM). All images are single confocal slices, with scale bar representing
10pm.
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Figure 4.5.1.12 Analysis of confocal images of EGFP expression constructs
transfected into A20 cells, and stained with concanavalin A TRITC conjugate.
The images in Figure 4.5.1.11 were analysed using Leica TCSNT confocal
analysis software. Panels on the left show line of analysis (in white) superimposed
on the overlay single slice image, and graph on the right shows the intensity of
fluorescence of the image along the white line, plotted against XY position on the
line. Panel A shows pEGFP-Cl; panel B shows image analysis of pEGFP-Cl;
panel C shows pEGFP-Cl/M2; panel D shows image analysis of pEGFP-Cl/M2;
panel E shows pEGFP-Nl/M2; panel F shows image analysis of pEGFP-Nl/M2.
Scale bar represents I Opm.
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the concanavalin A stained the ER, but there was localisation of EGFP-M2 with
concanavalin A at the edge of the cell.
Two distinct patterns of staining were observed with concanavalin A
staining in A20 cells, with the expected staining of the ER and also staining at the
periphery of the cell (Figure 4.5.1.11B, E and FI). This staining at the periphery of
the cell co-localised with M2-EGFP, and was assumed to be staining of the cell
surface by concanavalin A. Concanavalin A has been shown to interact with
immunoglobulin glycopeptides (Kornfeld & Ferris, 1975) and stimulate murine
spleen lymphocytes (Ruscetti & Chervenick, 1975), properties that suggest that
concanavalin A can bind to the cell surface of lymphocytes. Fluorescent
concanavalin A conjugates have also been used to stain the cell surface in HeLa
and 293 cells (Tarasova et al., 1998; Kuwasako et al., 2000). To show that this
staining at the cell margin was staining of the plasma membrane, A20 cells were
stained with rat anti-MHC Class II, followed by anti-rat Ig FITC and also
concanavalin A TR1TC as previously described. Control cells incubated with rat
IgG or no primary antibody followed by anti-rat IgG FITC conjugate showed no
FITC staining (data not shown). Figure 4.5.1.13 shows that MHC Class II
molecules stained in green (Panels A and D) co-localise with the concanavalin A
stained in red (Panels B and E). This co-localisation can be visualised as yellow
staining on tbe overlay image (Panels C and F), and also a sharp peak of co-
localisation between the green (MHC Class II) and red (concanavalin A)
fluorescent images at the cell margin in the graphical analysis of the image
(Figure 4.5.1.14A and B). Note that the analysis also shows concanavalin A
staining of the ER, visualised as a peak of red fluorescence only (XY position 3-
6pm). This result shows that the two patterns of concanavalin A staining
visualised in A20 cells are the ER and the plasma membrane. Co-localisation was
demonstrated between EGFP-M2 and the plasma membrane stained by
concanavalin A, but not between EGFP-M2 and the ER stained by concanavalin
A. There is therefore no evidence of localisation of EGFP-M2 and the ER.
The Golgi apparatus is the site of O-linked glycosylation of proteins, and
modification of N-linked glycosylated proteins. It is also the major sorting centre
of the cell, distributing proteins to lysosomes, secretory granules or the plasma
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Figure 4.5.1.13 Co-localisation of Concanavalin A and MHC ClasslI in A20 cells.
A20 cells were stained with rat anti-MHC ClasslI, followed by anti-rat Ig F1TC. The
cells were then stained with 50pg/ml Concanavalin A TRITC conjugate. Panels A
and D show F1TC localisation; panels B and E show Concanavalin A TRITC
localisation; panels C and F show overlay images. All images are single confocal
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Figure 4.5.1.14 Analysis of confocal images of A20 cells stained with anti-MHC
ClassII antibody and Concanavalin A TRITC. The images in Figure 4.5.1.13 were
analysed using Leica TCSNT confocal analysis software. The panel on the left shows
line of analysis (in white) superimposed on the overlay single slice image, and graph
on the right shows the intensity of fluorescence of the image along the white line,
plotted against XY position on the line. Panel A shows image in Figure 4.5.1.13
(panel F); panel B shows analysis of the image. Scale bar represents 10pm.
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membrane. BODIPY TR ceramide is a fluorescent ceramide analogue, which has
been shown to be a structural marker for the Golgi complex (Pagano et al., 1991;
McCabe & Berthiaume, 1999). A20 cells were transfected with 20pg of plasmid
DNA (pEGFP-Cl, pEGFP-Nl, pEGFP-Cl/M2 and pEGFP-Nl/M2) and
harvested 24 hours after transfection. The cells were incubated for 30 minutes
with 50pM BODIPY TR ceramide complexed with BSA at 4°C, followed by
incubation in fresh medium for 30 minutes at 37°C (see 2.7.7). The cells were
washed and fixed before analysis by confocal microscopy. A20 cells showed
strong red fluorescent staining of the Golgi complex, with a small amount of
plasma membrane staining (Figure 4.5.1.15B, E and H). Cells transfected with
pEGFP-Cl showed typical expression of EGFP throughout the cytoplasm and
nucleus, with no specific co-localisation with the Golgi complex (Figure
4.5.1.15A-C, Figure 4.5.1.16A and B). Cells transfected with pEGFP-Cl/M2 and
pEGFP-Nl/M2 showed typical EGFP-M2 localisation at the plasma membrane
and diffusely throughout the cell. There was no evidence of any co-localisation of
EGFP-M2 and the Golgi complex stained with BODIPY TR shown by lack of
yellow fluorescence on the overlay images or simultaneous red and green peaks
on the graph of analysis (Figure 4.5.1.15D-I, Figure 4.5.1.16C-F). There is
therefore no evidence for localisation of EGFP-M2 to the Golgi complex.
Lysosomes contain hydrolytic enzymes in an acidic environment that
degrade intracellular material. They are membrane-bound, and receive enzymes
and membrane proteins from the Golgi via transport vesicles. LysoTracker Red
DND-99 is a red fluorescent acidotropic probe used to label and track acidic
organelles, such as lysosomes (Tarasova et al., 1998; Bucci et al., 2000). A20
cells were transfected with 20pg of plasmid DNA (pEGFP-Cl, pEGFP-Nl,
pEGFP-Cl/M2 and pEGFP-Nl/M2) and harvested 24 hours after transfection.
The cells were incubated tor 2 hours at 3/°C with 50nM LysoTracker Red DND-
99 (see 2.7.6). The cells were washed and fixed before analysis by confocal
microscopy. Examination of live cells prior to fixation revealed strong red
fluorescent staining of lysosomes, as evidenced by the visualisation of red
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Figure 4.5.1.15 Co-localisation of the Golgi marker BODIPY TR and EGFP
expression constructs in A20 cells. Cells were transfected with 20pg of plasmid
DNA, harvested 24 hours after transfection and stained with 5pM BODIPY TR
complexed with BSA. Panels A, D and G show EGFP localisation; panels B, E and
H show BODIPY TR localisation; panels C, F and I show overlay images. Panels A,
B and C show pEGFP-Cl; panels D, E and F show pEGFP-Cl/M2; panels G, H and
I show pEGFP-Nl/M2. All images are single confocal slices, with scale bar
representing 10p.m.
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Figure 4.5.1.16 Analysis of confocal images of EGFP expression constructs
transfected into A20 cells, and stained with BODIPY TR. The images in Figure
4.5.1.15 were analysed using Leica TCSNT confocal analysis software. Panels on
the left show line of analysis (in white) superimposed on the overlay single slice
image, and graph on the right shows the intensity of fluorescence of the image
along the white line, plotted against XY position on the line. Panel A shows
pEGFP-Cl; panel B shows image analysis of pEGFP-Cl; panel C shows pEGFP-
CI/M2; panel D shows image analysis of pEGFP-Cl/M2; panel E shows pEGFP-
NI/M2; panel F shows image analysis of pEGFP-Nl/M2. Scale bar represents
1 Opm.
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spherical organelles in the cell cytoplasm. However, fixation led to a substantial
decrease in the red fluorescence, even when the fixative was reduced to 2% w/v
paraformaldehyde in PBS. Cells transfected with the control vector pEGFP-Cl
showed typical expression of EGFP throughout the cytoplasm and nucleus, with
no specific co-localisation with lysosomes (Figure 4.5.1.17A-C, Figure 4.5.1.18A
and B). Cells transfected with pEGFP-Cl/M2 and pEGFP-Nl/M2 showed typical
EGFP-M2 localisation at the plasma membrane and diffusely throughout the cell.
There was no evidence of any co-localisation of EGFP-M2 and lysosomes stained
with LysoTracker Red DND-99 shown by lack of yellow fluorescence on the
overlay images or simultaneous red and green peaks on the graph of analysis
(Figure 4.5.1.17D-I, Figure 4.5.1.18C-F). There is therefore no evidence for
localisation of EGFP-M2 and lysosomes.
These experiments with the expression of M2 as a fusion protein with
either the C or N terminus of EGFP showed that the EGFP-M2 fusion protein was
expressed in 293, A20 and Sll cells, but that expression had a detrimental effect
on 293 cells. There were no substantial differences in the localisation of M2 as a
fusion protein with either the C or N terminus of EGFP, although expression of
M2 as an N terminal EGFP fusion protein led to the production of free EGFP that
localised diffusely throughout the cell. There did not appear to be any differences
in the localisation of EGFP-M2 over longer periods of time. The EGFP-M2
protein was localised to the plasma membrane and diffusely throughout the cell.
In 293 cells there was evidence of close association of EGFP-M2 with DNA as
observed by yellow fluorescence in the overlay image, but artefacts produced in
apoptotic 293 cells probably influenced this result. No specific association ofM2
with DNA was observed in A20 cells. It was not localised to the ER, Golgi
complex or lysosomes.
4.5.2. Expression ofHA-tagged M2
The studies with the EGFP-M2 fusion proteins suggested that the M2
protein was localised to the plasma membrane, but concerns were expressed due
to the large size of the EGFP tag (27kDa). This might affect the localisation and
function of the M2-EGFP protein in cells and therefore might not be a true
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Figure 4.5.1.17 Co-localisation of the lysosome marker LysoTracker Red DND-99
and EGFP expression constructs in A20 cells. Cells were transfected with 20pg of
plasmid DNA, harvested 24 hours after transfection and stained with 50nM
LysoTracker Red DND-99. Panels A, D and G show EGFP localisation; panels B, E
and H show LysoTracker Red DND-99 localisation; panels C, F and I show overlay
images. Panels A, B and C show pEGFP-Cl; panels D, E and F show pEGFP-Cl/M2;
panels G, F1 and I show pEGFP-Nl/M2. All images are single confocal slices, with
scale bar representing 10pm.
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Figure 4.5.1.18 Analysis of confocal images of EGFP expression constructs
transfected into A20 cells, and stained with LysoTracker Red DND-99. The
images in Figure 4.5.1.17 were analysed using Leica TCSNT confocal analysis
software. Panels on the left show line of analysis (in white) superimposed on the
overlay single slice image, and graph on the right shows the intensity of
fluorescence of the image along the white line, plotted against XY position on the
line. Panel A shows pEGFP-Cl; panel B shows image analysis of pEGFP-Cl;
panel C shows pEGFP-Cl/M2; panel D shows image analysis of pEGFP-Cl/M2;
panel E shows pEGFP-Nl/M2; panel F shows image analysis of pEGFP-Nl/M2.
Scale bar represents 10pm.
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representation of the localisation of M2. It was therefore decided to use the HA-
epitope tagged M2 to confirm the cellular localisation of M2 in mammalian cells.
A20 cells were transfected with 20pg of plasmid DNA (pSG5/IRF7-HA,
pSG5/M2-5'HA and pSG5/M2-3'HA) and harvested 24 hours after transfection.
Negative control cells were transfected with no plasmid DNA (mock transfected).
The cells were harvested 24 hours after transfection, fixed and permeabilised (see
2.7.1), and stained by indirect immunofluorescence using rat monoclonal anti-
HA, followed by anti-rat Ig FITC conjugate (see 2.7.8). DNA was stained using
propidium iodide, and the cells examined by confocal microscopy. A20 cells
transfected with no plasmid DNA showed no evidence of FITC staining (Figure
4.5.2.1A-C). Control cells incubated with rat IgG or no primary antibody
followed by anti-rat Ig FITC conjugate showed no FITC staining (data not
shown). Cells transfected with pSG5/IRF7-HA showed characteristic cytoplasmic
localisation of IRF7 (data not shown).
Cells transfected with pSG5/M2-5'HA express M2 with a triple HA-
epitope tag at the N terminus of M2. As shown in Figure 4.5.2.1D-F, cells
expressing M2-5'HA exhibited FITC staining predominantly at the periphery of
the cell. This was confirmed by analysis of the confocal image (Figure 4.5.2.2A
and B), which shows that peaks of FITC staining are present in the cell margins,
with low levels of FITC present in the central region of the cell. Cells transfected
with pSG5/M2-3'HA express M2 with a triple HA-epitope tag at the C terminus
of M2. Figure 4.5.2.1G-I shows that cells expressing M2-3'HA showed an
identical pattern of FITC staining to cells expressing M2-5'HA, and analysis of
the confocal images confirmed this result (Figure 4.5.2.2C and D). These results
show that in A20 cells expressing M2 with a triple HA-epitope tag, M2 is
localised to the cell periphery with patchy low levels ofM2 present in the central
region of the cell. There was no difference in the localisation of M2 with a HA-
epitope tag at the C or N terminus. Expression ofM2 did not appear to have any
deleterious effect on the cells, as evidenced by the normal nuclear morphology.
The results of the indirect immunofluorescence are identical to the localisation
studies using the EGFP-M2 fusion protein, and confirm the localisation of M2 at
the cell margin.
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Figure 4.5.2.1 Indirect immunofluorescence of HA epitope-tagged expression
constructs transfected into A20 cells. Cells were transfected with 20pg of plasmid
DNA, harvested 24 hours after transfection and fixed with 4% paraformaldehyde in
PBS. Cells were stained with rat anti-HA, followed by anti-rat Ig FITC conjugate.
Panels A, D and G show FITC localisation; panels B, E and H show DNA stained
with propidium iodide; panels C, F and I show overlay images. Panels A, B and C
show mock transfected cells; panels D, E and F show pSG5/M2-5'HA; panels G, H
and I show pSG5/M2-3'HA. All images are single confocal slices, with scale bar
representing 10pm.
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Figure 4.5.2.2 Analysis of confocal images of indirect immunofluorescence of
HA epitope-tagged expression constructs transfected into A20 cells. The images in
Figure 4.5.2.1 were analysed using Leica TCSNT confocal analysis software.
Panels on the left show line of analysis (in white) superimposed on the overlay
single slice image, and graph on the right shows the intensity of fluorescence of
the image along the white line, plotted against XY position on the line. Panel A
shows pSG5/M2-5'HA; panel B shows image analysis of pSG5/M2-5'HA; panel
C shows pSG5/M2-3'HA; panel D shows image analysis of pSG5/M2-3'HA.
Scale bar represents 10pm.
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4.6. Post-translational modification of the M2 protein
4.6.1. N-linked glycosylation status of the M2 protein
N-linked glycosylation is a post-translational modification of proteins by
the linkage of oligosaccharide residues to the amino acid asparagine. This
modification has a wide variety of biological functions, including protein folding
and the assistance of protein-protein interactions (Helenius & Aebi, 2001) and the
targeting and recognition of cells (Rudd et al., 2001). The M2 protein migrates at
a higher relative molecular mass of 30kDa on SDS-PAGE analysis than the
expected mass of 22.3kDa, and has one predicted N-linked glycosylation site at
residue 58 (Figure 4.2.2). It was therefore decided to examine the M2 protein to
see if this predicted N-linked glycosylation was occurring. A20 cells were
transfected with 20pg of plasmid DNA (pSG5/M2-3'HA and pSG5/M2-5'HA).
Negative control cells were transfected with no plasmid DNA (mock transfected).
The cells were then placed immediately into medium containing lOpg/ml
tunicamycin (tunicamycin positive) or untreated medium (tunicamycin negative;
see 2.3.5). Tunicamycin is an antibiotic that inhibits the N-linked glycosylation of
proteins by blocking the first step in the synthesis of the lipid-linked
oligosaccharide precursor dolichol pyrophosphate N-acetylglucosamine (Elbein,
1987). The cells were harvested after 24 hours, and the cell lysates analysed on a
12.5% SDS-PAGE gel followed by immunoblot. The blot was incubated with rat
anti-HA antibody, followed by biotinylated rabbit anti-rat Ig and then
streptavidin-POD conjugate. Reactive proteins were visualised by ECL. Figure
4.6.1A shows that the M2 protein tagged with the HA epitope was expressed in
A20 cells and visualised as a doublet with an apparent molecular weight of
30kDa, in agreement with previous results (see 4.4.2). This band was not
visualised in the mock transfected A20 cells. There was no difference in the
relative molecular mass of the M2 protein doublet band between A20 cells treated
with tunicamycin or left untreated.
To ensure that the tunicamycin was effectively blocking N-linked
glycosylation of proteins, the effect of tunicamycin on the glycosylation ofMHV-
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Figure 4.6.1 N-linked glycosylation status of the M2 protein. (A) A20 cells were
transfected with 20pg of plasmid DNA, and immediately placed into medium
containing 10 pg/ml tunicamycin (tunicamycin positive) or left untreated (tunicamycin
negative). The cells were harvested 24 hours after transfection. Mock transfected A20
cells were used as a negative control. The cell lysates were analysed on a 12.5% SDS-
PAGE gel, and transferred onto a membrane by Western blot. The blots were probed
with rat monoclonal anti-HA, followed by biotinylated rabbit anti-rat Ig and then
streptavidin-POD. The conjugates were visualised using ECL. (B) Positive control to
ensure tunicamyicn efficacy. BHK-21 cells were mock infected (negative control) or
infected with MEIV-68 at an MOI of 5 for 1 hour. After infection, the inoculum was
removed and replaced with medium containing 10 pg/ml tunicamycin (tunicamycin
positive) or left untreated (tunicamycin negative). The cells were harvested after 24
hours, and the cell lysates were analysed on a 7.5% SDS-PAGE gel and transferred
onto a membrane by Western blot. The blots were probed with rabbit polyclonal anti-
gB, followed by donkey anti-rabbit Ig linked to peroxidase. The conjugates were
visualised using ECL. Molecular weights are given in kilodaltons on the left side.
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68 gB was examined. gB is a predominantly N-linked glycoprotein, with a mature
relative molecular mass of 105kDa and a non-glycosylated core protein of
approximately 92kDa (Stewart et al., 1994). BHK-21 cells were infected with
MHV-68 at an MOI of 5 for 1 hour. As a negative control, a duplicate mock
infected experiment was performed with no viral inoculum. After infection, the
viral inoculum was removed and replaced with medium containing 10pg/ml
tunicamycin (tunicamycin positive) or untreated medium (tunicamycin negative).
The cells were harvested after 24 hours, and the cell lysates analysed on a 7.5%
SDS-PAGE gel followed by immunoblot. The blot was incubated with rabbit anti-
gB antibody, followed by donkey anti-rabbit Ig linked to peroxidase. Reactive
proteins were visualised by ECL. Figure 4.6.IB shows that MHV-68 infected
cells produce gB with a relative molecular mass of approximately llOkDa.
Treatment ofMHV-68 infected cells with tunicamycin produced a novel band at
approximately 95kDa, and completely abolished the gB band at llOkDa. Neither
of these bands was present in the mock infected negative control samples. These
results for gB are consistent with previous published work on gB (Stewart et al.,
1994), and indicate that tunicamycin is effective in blocking the N-glycosylation
of viral proteins.
These results indicate that the M2 protein is not modified by N-linked
glycosylation. The predicted site at position 58 is therefore not utilised, and the
heavier than expected relative molecular mass is therefore not due to N-linked
glycosylation of the M2 protein.
4.6.2. Phosphorylation status of the M2 protein
The M2 protein is predicted to contain 11 phosphorylated serine residues,
2 phosphorylated threonine residues and 2 phosphorylated tyrosine residues
(Figure 4.2.2). These phosphorylated residues may be important tor the function
of M2, for example if the M2 protein has functional homology to the Gab2
proteins. The doublet observed for the HA epitope-tagged M2 protein on
immunoblot analysis is characteristic of phosphorylated proteins. It was therefore
decided to examine the phosphorylation status ofM2.
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A20 cells were transfected with 20pg of the HA epitope-tagged expression
constructs pSG5/IRF7-HA, pSG5/jK-HA, pSG5/M2-5'HA and pSG5/M2-3'HA.
Mock transfected cells were used as a negative control. The cells were harvested
24 hours after transfection, and the cell lysates were analysed on a 12.5% SDS-
PAGE gel, and transferred onto a membrane by Western blot. The blot was
incubated with mouse monoclonal anti-phosphotyrosine, anti-phosphothreonine
or anti-phosphoserine antibody, followed by biotinylated rabbit anti-mouse Ig and
then streptavidin-POD conjugate. The reactive proteins were visualised using
ECL. The results of the immunoblot using anti-phosphotyrosine antibody are
shown in Figure 4.6.2.1. No unique bands were observed at the expected relative
molecular mass ofM2 (approximately 30kDa) in the cells transfected with the HA
epitope-tagged M2 expression vectors. No other unique bands were observed in
the cells transfected with the HA epitope-tagged M2 expression vectors that might
indicate the phosphorylation or activation of cellular proteins. However, high
levels of background staining were observed in the immunoblot due to either non¬
specific binding or binding of antibody to a range of cellular phosphoproteins
present in the crude cell lysates. This background was not reduced by altering the
antibody concentrations, or by modifying the concentration and / or composition
of the blocking agents (data not shown). Similar results were observed in
immunoblots probed with anti-phosphothreonine and anti-phosphoserine (data not
shown).
In order to try and reduce the levels of non-specific background staining
and increase the amount and purity of the M2 protein present in the immunoblot
analysis, the HA epitope-tagged proteins were immunoprecipitated. A20 cells
were transfected with 20pg of the HA epitope-tagged expression constructs
pSG5/IRF7-HA, pSG5/M2-5'HA and pSG5/M2-3'HA. Mock transfected cells
were used as a negative control. The cells were harvested 24 hours after
transfection, the cells lysed using RIPA buffer and the HA epitope-tagged
proteins precipitated using either rat monoclonal anti-HA or rat IgG as a negative
control (see 2.3.4). The proteins were precipitated using rabbit anti-rat Ig followed
by protein A-sepharose beads, and after extensive washing of the beads with
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Figure 4.6.2.1 Immunoblot for the detection of phosphotyrosine residues. Cells
were transfected with 20pg of plasmid DNA and harvested 24 hours after
transfection. Mock transfected A20 cells were used as a negative control. The cell
lysates were analysed on a 12.5% SDS-PAGE gel, and transferred onto a membrane
by Western blot. The blots were probed with mouse monoclonal anti-
phosphotyrosine, followed by biotinylated rabbit anti-mouse Ig and then
streptavidin-POD. The conjugates were visualised using ECL. Molecular weights
are given in kilodaltons on the left side.
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RIPA buffer, the beads were resuspended in SDS-PAGE sample buffer. To check
that HA epitope-tagged proteins were effectively immunoprecipitated, samples
were analysed by immunoblot for the presence of HA epitope-tagged proteins. As
shown in Figure 4.6.2.2, there was a high degree of background staining due to
the cross-reactivity of the antibodies used in the immunoprecipitation (rat anti-HA
followed by rabbit anti-rat Ig) and the antibodies used in the immunoblot analysis
(rat anti-HA followed by biotinylated rabbit anti-rat Ig and then streptavidin-
POD). The negative control samples also contained a high amount of background
due to the rat IgG used as the negative control primary antibody in the
immunoprecipitation. Immunoprecipitated HA epitope-tagged M2 (30kDa) was
not visualised as it was obscured by the background levels caused by the
immunoglobulin light chains at the same relative molecular mass (25-30kDa).
However, a unique band was visualised for IRF-HA at the expected mass of
70kDa in the positive sample, which was not observed in the other samples. This
result showed that the HA epitope-tagged IRF7 protein had been successfully
immunoprecipitated, although this did not demonstrate that the M2-HA protein
had been immunoprecipitated.
Samples of the immunoprecipitated proteins were analysed on a 12.5%
SDS-PAGE gel, and transferred onto a membrane by Western blot. The blot was
incubated with mouse monoclonal anti-phosphotyrosine, anti-phosphothreonine
or anti-phosphoserine antibody, followed by biotinylated rabbit anti-mouse Ig and
then streptavidin-POD conjugate. Further examination of the immunoblots for the
presence of phosphotyrosine residues was performed using recombinant anti-
phosphotyrosine directly conjugated to HRP. This recombinant conjugate
contains only the high affinity binding site for phosphotyrosine residues, and the
direct conjugation with HRP ensures low cross-reactivity with the antibodies used
in the immunoprecipitation steps. The reactive proteins were visualised using
ECL. Figure 4.6.2.3 shows that no unique bands were observed at the expected
relative molecular mass of M2 (approximately 30kDa) in the samples that
contained HA epitope-tagged M2 in immunoblots probed with recombinant anti-
phosphotyrosine (Panel A) or anti-phosphothreonine (Panel B). An immunoblot
probed with anti-phosphoserine gave similar results (data not shown). High non-
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Figure 4.6.2.2 Immunoprecipitation of HA-epitope tagged proteins in A20 cells.
Cells were transfected with 20pg of plasmid DNA and harvested 24 hours after
transfection. Cells were lysed using RIPA buffer and pre-cleared. The HA-epitope
tagged proteins were precipitated using rat anti-HA antibody (+) or rat IgG as
negative control (-), followed by rabbit anti-rat Ig and then protein A-sepharose
beads. The beads were extensively washed using RIPA buffer and then analysed on
a 12.5% SDS-PAGE gel, and transferred onto a membrane by Western blot. The
blots were probed with rat monoclonal anti-HA, followed by biotinylated rabbit
anti-rat Ig and then streptavidin-POD. The conjugates were visualised using ECL.
Molecular weights are given in kilodaltons on the left side.
229


















































































Figure 4.6.2.3 Purification of HA-epitope tagged proteins in A20 cells by
immunoprecipitation, followed by immunoblot for the detection of phosphoprotein
residues. Cells were transfected with 20pg of plasmid DNA and harvested 24 hours
after transfection. Cells were lysed using RIPA buffer and pre-cleared. The HA-
epitope tagged proteins were precipitated using rat anti-HA antibody (+) or rat IgG
as negative control (-), followed by rabbit anti-rat Ig and then protein A-sepharose
beads. The beads were extensively washed using RIPA buffer and then analysed on
a 12.5% SDS-PAGE gel, and transferred onto a membrane by Western blot.
(A) Immunoblot probed with recombinant anti-phosphotyrosine linked to
peroxidase, visualised by ECL. (B) Immunoblot probed with mouse monoclonal
anti-phosphothreonine, followed by biotinylated rabbit anti-mouse Ig and then
streptavidin-POD. The conjugates were visualised using ECL. Molecular weights
are given in kilodaltons on the left side.
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specific background staining was also observed, with binding of the antibodies
used in the immunoblot analysis to the light chains of the antibodies used in the
immunoprecipitation masking the detection ofpossible phosphorylated residues in
M2 (Figure 4.6.2.3A).
These results show that there is no evidence for the presence of
phosphorylated residues in M2, using immunoblot analysis on cell lysates or
immunoprecipitated proteins. However, problems encountered with high levels of
non-specific background staining in the immunoblots and the lack of a suitable
positive control to ensure good specificity and sensitivity of the technique mean
that it has not been definitively proven that M2 does not contain phosphorylated
residues.
4.6.3. Myristylation status of the M2 protein
The M2 protein contains three glycine residues that are predicted to be
myristylated (Figure 4.2.2). The M2 protein migrates at a higher relative
molecular mass of 30kDa on SDS-PAGE gel analysis than the expected mass of
22.3kDa, and myristylation may be one possible reason for this discrepancy.
Myristylation of proteins has also been observed to play a role in the membrane
association of proteins (Cross et al., 1984; McCabe & Berthiaume, 1999). It was
therefore decided to determine if this predicted myristylation of M2 was
occurring. A20 cells were transfected with 20pg of the HA epitope-tagged
expression constructs pSG5/IRF7-HA, pSG5/M2-5'HA and pSG5/M2-3'HA.
Mock transfected cells were used as a negative control. After 24 hours, the cells
were harvested and labelled for 4 hours at 37°C with 100pCi/ml [9,10(n)-3H]
myristic acid (see 2.3.6). The crude cell lysates or HA epitope-tagged
immunoprecipitated proteins were then analysed by SDS-PAGE. The gel was
impregnated with EN HANCE, dried and exposed to autoradiographic film for
one month. No band specific for the M2 protein was observed (data not shown).
However, there was no positive control to ensure correct labelling of the cells
with [9,10(n)-3H] myristic acid. These results show that there is no evidence for
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myristylation of the M2 protein, but it has not been definitively proven that M2 is
not myristylated.
4.7. Discussion
These results demonstrate the initial characterisation of the M2 protein of
MHV-68, and illustrate a variety of possible functions. Methods including
sequence analysis, expression in prokaryotic and eukaryotic cell types enabled the
determination of the cellular localisation of M2 and the extent of any possible
post-translational modifications.
Searches of the M2 amino acid sequence against protein databases has
revealed low but significant homology to other proteins, which may help in the
understanding of the function of M2. A search using the "BLAST" program
revealed homology with the Gab2 protein. Gab2 belongs to a group of scaffolding
proteins including the Drosophila Daughter of Sevenless (DOS) protein and
insulin receptor substrate-1 (IRS-1). They contain an N-terminal pleckstrin
homology domain (thought to be involved in the recruitment of proteins to plasma
membranes and cytoplasmic signalling), a central proline-rich domain and
multiple tyrosine residues that serve as targets for phosphorylation and docking
sites for src homology 2 (SH2) domain-containing signalling molecules (Gu et al.,
1998; Nishida et al., 1999). Gab2 is expressed in a wide range of tissues including
haematopoietic cells, and functions as a scaffolding protein for the assembly of
signalling proteins, leading to the transduction of intracellular signalling pathways
involving cytokines (Gu et al., 1998; Nishida et al., 1999; Gadina et al., 2000),
the B-cell receptor (Gu et al., 1998; Gold et al., 2000) and macrophage activation
and differentiation (Liu et al., 2001). Gab2 has also been shown to be involved in
the negative regulation of signal pathways (Zhao et al., 1999), including T cell
receptor signalling (Yamasaki et al., 2001). The M2 protein is much smaller than
Gab2 and the other proteins in the scaffolding protein family (which are over 600
amino acids in size), and contains no pleckstrin homology domain. However,
these results show that the M2 protein is membrane-associated like Gab2.
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It is also of interest that the homology between M2 and the Gab2 proteins
is centred around two domains containing tyrosine residues (Figure 4.2.1 A,
4.2.1C), which are predicted to be phosphorylated in Gab2 (human Gab2 residues
452 and 563), and the region of homology at human Gab2 residue 452 contains a
binding motif for PI3 kinase. One of these conserved tyrosine residues is also
predicted to be phosphorylated in M2, at residue 129 (Figure 4.2.3). Thus
although M2 is much smaller than Gab2, it may contain some of the motifs
necessary for interfering with signal transduction pathways. Previous studies
using the adoptive transfer of M291.99 epitope-specific CD8+ T cells (Usherwood
et al., 2000) and DNA vaccination using M2 (Usherwood et al., 2001) showed a
reduction in the initial load of latently infected cells, and hypothesised that M2
may play a role in expanding the number of latently infected B cells during the
establishment of latency. Disruption of the signalling pathways via Gab2 mimicry
may be a mechanism for achieving this, and therefore allowing the establishment
of latent virus in as many B-lymphocytes as possible to ensure virus survival in
the host. Alternatively, disruption of Gab2 pathways may interfere with cytokine
signalling and be a mechanism of immune evasion by MHV-68.
A search for conserved protein domains using the program "Block
Searcher" revealed homology between M26-i8 and a domain in the semaphorin
family. Semaphorins are secreted, membrane glycosylphosphatidylinositol (GPI)-
anchored or transmembrane molecules which contain a 500 amino acid protein
element called the sema domain (Spriggs, 1999; Tamagnone & Comoglio, 2000).
The region ofhomology to M2 is located in the middle of the sema domain. Some
semaphorins also contain an immunoglobulin-like domain, signal sequences and
transmembrane domains. They were initially discovered due to their involvement
in the development of the nervous system and guidance of growth cone axons
(Kolodkin et al., 1993). Semaphorins bind to specific receptors (plexins or
neuropilins) and are involved in signal transduction pathways, possibly via
tyrosine phosphorylation of the receptors (Tamagnone & Comoglio, 2000). The
role of semaphorins in the immune response has only recently been uncovered
(Spriggs, 1999). CD100 is a cell surface semaphorin that was first discovered as
an activation molecule on T lymphocytes (Delaire et al., 1998). It has been shown
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to play a role in T-cell activation via CD45 (Delaire et al., 1998), and the soluble
isoform of CD100 has been shown to inhibit the migration of monocytes and B
lymphocytes (Delaire et al., 2001).
Further evidence for the involvement of semaphorins in the immune
response comes from the discovery of two viral encoded semaphorins. The
vaccinia virus A39R protein is the smallest known semaphorin at 441 amino
acids, containing only a truncated sema domain (Kolodkin et al., 1993).
Interestingly, not all strains of vaccinia produce functional A39R, as a deletion
and frameshift mutation in the Western Reserve strain leads to the production of a
truncated, non-secreted protein (Gardner et al., 2001). The secreted A39R
glycoprotein binds to the plexin virus-encoded semaphorin protein receptor
(VESPR) (Comeau et al., 1998), and exerts pro-inflammatory effects via the
activation of monocytes (Comeau et al., 1998) and recruitment of inflammatory
cells in vivo (Gardner et al., 2001). The gammaherpesvirus A1HV-1 also contains
a unique ORF A3 with significant homology to the semaphorin family (Ensser &
Fleckenstein, 1995; Ensser et al., 1997). The M26-is region shows strong
homology to the mouse semaphorin 3 domains, with less homology to the viral
semaphorins of vaccinia virus and A1HV-1. Like semaphorins, the M2 protein is
also associated with the plasma membrane. However, the M2 protein is much
smaller than all known semaphorin family members (being less than 50% of the
size of the smallest known member, A39R) and does not contain a recognisable
sema domain, transmembrane or secreted signal sequence or immunoglobulin-like
domains. It may however be possible that this conserved sequence is enough to
interfere with signalling pathways and modify the immune response to the virus.
The expression of the entire M2 cDNA ORF in bacteria as a GST fusion
protein using the pGEX system was achieved, but the low levels of expression of
insoluble GST-M2 fusion protein meant that it was not possible to purify the
fusion protein. This fusion protein was recognised by polyclonal anti-MHV-68
antibody, which was surprising as M2 is a latency-associated gene (Husain et al.,
1999; Virgin et al., 1999), and the polyclonal antibody was raised against lytic
cycle antigens (Sunil-Chandra et al., 1992a). The polyclonal anti-MHV-68
antibody did not recognise the GST present in the control lane, signifying that the
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antibody was not cross-reacting with the GST element of the fusion protein. This
recognition of the M2 fusion protein suggests that there is anti-M2 reactivity in
the polyclonal anti-MHV-68 antiserum, and concurs with recent data showing low
level transcription of M2 during lytic replication in vitro (Rochford et al., 2001;
Bridgeman et al., 2001). There are a number of possible reasons for the formation
of insoluble proteins in E. coli, including the formation of inclusion bodies in the
cytoplasm due to the high proline content of M2 (Wilkinson & Harrison, 1991).
Possible factors in the poor expression of the GST-M2 fusion protein include the
presence of infrequently used codons for arginine and proline in M2, protein
degradation and toxicity (Makrides, 1996). M2 contains 38 proline residues, 86%
of which are characterised as low-usage in E. coli (CCC, CCU, CCA); and 13
arginine residues, 7 ofwhich are the rare codons AGA and AGG which have been
shown to be a limiting factor in the expression of proteins in bacteria (Makrides,
1996). There was also evidence for the toxicity of the M2 protein in bacteria, as
evidenced by the dramatic reduction in total bacterial protein yields following
induction of GST-M2 protein expression. Although it is possible that this toxicity
in bacteria might be due to the addition of the IPTG to induce fusion protein
expression, varying the concentration of IPTG (0.5-1.5mM) did not have any
significant effect on bacterial total protein yield (Figure 4.3.1.2). It is also possible
that the induction of foreign protein expression in bacteria may have led to the
disruption of normal bacterial protein synthesis, thus leading to the reduction in
total bacterial protein yields observed.
These problems were partially overcome by the expression of a 75 amino
acid fragment ofM2 as a fusion protein with GST. Although this fragment ofM2
contained the M29i_99 CD8+ T cell epitope, it was not certain that this fragment
would fold in an identical manner to the native M2 protein and thus present the
same immunological epitopes. The GST-M274.i48 fusion protein was also poorly
expressed in bacteria, but the fact that it became soluble after the inclusion body
preparation meant that it was possible to purify the fusion protein using
glutathione-sepharose beads. The reason for this increase in solubility of the GST-
M274_i48 fusion protein after the inclusion body preparation (where the bacteria
undergo gentle lysis using lysozyme and DNase I treatment) as compared to the
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lack of solubility after sonication is unclear, but may be due to interaction of the
GST-M274_i48 fusion protein with other bacterial proteins and / or DNA which are
removed during the inclusion body preparation. The GST-M274_i48 fusion protein
also underwent substantial degradation, as evidenced by the multiple forms of the
fusion protein visualised by immunoblot analysis ranging from the entire GST-
M274_i48 fusion protein (40kDa) to GST alone (27.5kDa). Although attempts were
made to reduce the activity of bacterial proteases by the use of inhibitors such as
PMSF and Aprotinin and keeping all solutions at 4°C, it may be that the
proteolytic pathways present in E. coli may have overwhelmed these barriers. The
use of protease-deficient strains such as BL21 may have helped overcome this.
Alternatively this degradation may have been due to an inherent property of the
fusion protein, as instability or misfolding of the truncated M2 protein would lead
to targeting of the protein for breakdown by bacteria (Makrides, 1996).
The GST-M274_i48 fusion protein was purified and used as an antigen to
raise antisera in sheep. The GST could have been removed from the GST-M274_i48
fusion protein using the thrombin cleavage site, and the sheep immunised with
only the M2 fragments. This might have reduced the non-specific background
observed in the immunoblot analysis, but may have also reduced the antigenicity
of the protein. Sheep were chosen to raise the antiserum due to their accessibility
within the department, the availability of secondary antibodies and the ability to
obtain large quantities of antiserum. The presence of the multiple forms of the
fusion protein in the preparation due to the protein degradation may have either
assisted in the generation of anti-M2 antisera by the presentation of multiple
antigenic forms of the M2 polypeptide, or increased the amount of GST protein
present in the preparation thus leading to a greater immune response against the
GST moiety of the fusion protein. The majority of protein present in the GST-
M274_i48 fusion protein preparation was GST, or GST containing only a few
amino acid residues of the M2 protein (Figure 4.3.3). The antisera was purified
using caprylic acid and ammonium sulphate to give a relatively pure IgG antibody
preparation. Flowever, the IgG antibodies present would have had specificity for a
wide range of antigens, as these purification steps did not select for antibodies
specific for the GST-M274„i48 fusion protein. The antibodies were tested against
236
CHAPTER FOUR CHARACTERISATION OF THE M2 PROTEIN
Western blots containing the GST-M274.i48 fusion protein, Sll cells which are
known to express the M2 protein (Husain et al., 1999) and cells transfected with
pVR1255/M2-His. Antibodies from both sheep recognised the fragments of the
GST-M274.i48 fusion protein, which confirmed that an antibody response had been
raised against the antigen. However, this could have been against either the M2
polypeptide or against the GST. No specific reactivity for M2 was observed using
the antibodies raised for either of the sheep against proteins in the cell lysates
from 293 cells transfected with pVR1255/M2-His. This agrees with other data
showing a lack of detectable M2 expression using this vector (Figure 4.4.1.2), and
the apparent toxicity ofM2 expressed in 293 cells (Figure 4.5.1.1).
Antibodies raised by sheep 705D appeared to specifically react with a
band of approximately 30-35kDa present in the SI 1 cell lysates. As this band was
not present in the immunoblot probed with the pre-bleed antibody, this suggested
that this sheep produced antibodies reactive to the M2 protein. This band was only
observed in the Sll cell lysates and not in any of the different cell types
transfected with M2 expression vectors. A probable explanation for this is that the
majority of SI 1 cells express M2, whereas only a low number of transfected cells
will express M2, and therefore the Sll cell lysate will contain a higher
concentration ofM2 protein. However, this reactivity of the sheep antibodies to a
band close to the predicted size of M2 in S11 cells was obscured by the high
background levels present on the immunoblot, due to non-specific binding of
sheep antibodies to other proteins present on the blot. These high levels of
background were also observed using indirect immunofluorescence analysis.
Attempts to reduce this non-specific binding by using lower antibody dilutions or
more sensitive detection techniques such as ECL were unsuccessful, and it was
decided not to use immunoprecipitation as it was considered that the non-specific
binding of the sheep antibodies would have precipitated other proteins as well as
the M2 protein. This background could have been lowered by immunoaffinity
purification of the antibodies, which would have yielded pure, M2 specific
antibodies. This technique requires a source of pure antigen, which could have
been obtained from the GST-M274_i4g fusion protein by cleavage of the fusion
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protein using the thrombin cleavage site, but needs specialist reagents and is
expensive.
Due to the lack of a reliable anti-M2 antibody, it was decided to express
M2 in mammalian cells using an epitope tag to enable detection of the M2
protein. Initially, an epitope tag containing six histidine residues was used, as this
has been used to detect and purify recombinant proteins (Hochuli et al., 1988;
Bornhorst & Falke, 2000). A number of different expression vectors were used,
which express inserted genes from either the powerful HCMV immediate-early
promoter (pcDNA3.1 and pVR1255) or the Moloney murine leukaemia virus
LTR (pBabe puro). A comparison of these promoter elements and the SV40 early
promoter (contained within the plasmid pSG5) in expressing bovine growth
hormone in murine cells found that the HCMV immediate-early promoter and
SV40 early promoter were approximately two-fold more efficient that the
Moloney murine leukaemia virus LTR in the expression of the inserted gene
(Martin-Gallardo et al., 1988). A similar study comparing the SV40 early
promoter, HCMV immediate-early promoter and Rous sarcoma virus LTR found
the HCMV immediate-early promoter to be most efficient at expressing luciferase
in a range of human cell types (Xu et al., 2001). Similarly, the intron A ofHCMV
(contained within the plasmid pVR1255) has been shown to increase the
expression of heterologous genes in vitro and in vivo (Hartikka et al., 1996; Xu et
al., 2001). However, no expression ofM2 was detectable by either immunoblot or
indirect immunofluorescence using expression vectors containing these elements
(pcDNA3.1, pBabe puro or pVR1255) transiently transfected into a range of
different cell types. However, expression ofM2 by pcDNA3.1/M2-His and pBabe
puro/M2-His was detectable using a LacZ-inducible T cell hybridoma specific for
the M29i_99 CD8+ T cell epitope. This is an extremely sensitive assay for the
detection of M2, and suggested that M2 was being expressed by these vectors at
levels that were below detection by immunoblot or indirect immunofluorescence.
Further evidence for the expression ofM2 by pcDNA3.1/M2-His is provided by
data showing that DNA vaccination using pcDNA3.1/M2 induces a CD8+ T-cell
response to the M291.99 CD8+ T cell epitope (Usherwood et al., 2001). It is
therefore probable that the inability to detect M2 expression by pcDNA3.1,
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pVR1255 and pBabe puro was due to the detection methods used, and more
sensitive techniques such as ECL and multiple epitope tags were necessary.
Another major problem encountered in the expression ofM2 was toxicity
of the M2 protein. The protein appeared to be toxic in bacteria as evidenced by
the poor growth of the bacterial culture after induction of GST-M2 protein
expression (Figure 4.3.1.2) and poor expression of the full-length M2 protein as a
GST fusion protein. Detection of M2 expression in mammalian cells was only
achieved using extremely sensitive techniques such as ECL and a LacZ-inducible
T cell hybridoma specific for the M291.99 CD8+ T cell epitope. Further
circumstantial evidence is provided by attempts to generate COS-7 cell lines
stably transfected with M2 which resulted in the deletion of the M2 insert from
the pcDNA3.1/M2-His vector (see 4.4.1), and attempts to generate a recombinant
MHV-76 virus with the M2 ORF inserted ("knock-in" virus) when it was not
possible to purify the virus due to spontaneous deletion of the M2 insert (see
Chapter 5). The expression of M2 is extremely tightly regulated during the
establishment of latency in the viral life cycle (Usherwood et al., 2000), and this
tight regulation is probably necessary to avoid problems associated with the
toxicity ofM2.
Expression of the M2 protein was detectable in A20 cells by transient
transfection using the expression vector pSG5, and a triple HA epitope tag. This
expression vector uses the SV40 early promoter and intron II of the rabbit P-
globin gene to efficiently express inserted DNA sequences, neither of which
would be expected to have a significant advantage in the efficiency of expression
of heterologous DNA over the HCMV immediate-early promoter or intron A used
in pcDNA3.1/M2-His or pVR1255/M2-His (Hartikka et al., 1996; Xu et al.,
2001). Therefore, the reason for detection of M2 expression by this vector is
probably due to the presence of three copies of the epitope (therefore amplifying
the signal for detection) and the ECL technique used in detection. ECL is over ten
times more sensitive than other methods used in the detection of proteins by
immunoblot, with claims that the technique can detect as little as lpg of protein
antigen per sample (Amersham Pharmacia product literature), compared to lng
protein antigen per sample using BCIP/NBT solution (Harlow & Lane, 1988).
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Another factor was the cell type used, with A20 cells (a murine B-
lymphocyte cell line) and 293 cells (a human epithelial cell line) used in the
transient transfection assays. In contrast to the detection ofM2 expression in A20
cells, no expression ofM2 was detectable by transient transfection of pSG5/M2-
3'HA and pSG5/M2-5'HA in 293 cells, despite the detection of expression of the
positive control proteins IRF7-HA and Jk-HA by the pSG5 vector. This correlates
with the data showing that expression of EGFP-M2 fusion proteins in 293 cells
leads to apoptosis of these cells (Figure 4.5.1.1). Although GFP and EGFP have
been shown to be toxic and induce apoptosis in cells, these events occur at later
timepoints (48 hours after transfection; Liu et al., 1999a) or in stably expressing
cell lines (Hanazono et al., 1997) and would not be expected to occur in
transiently transfected cells. Concurrent transfection of 293 cells with the control
vectors pEGFP-Cl and pEGFP-Nl resulted in no evidence of apoptosis,
suggesting that the M2 protein is the cause of the cell death. This lack of
expression in 293 cells could therefore be due to either species or cell type
specific factors. Species-specific factors are a possibility due to the restricted host
range of the gammaherpesvirus family, although MHV-68 is an exception to this
rule as it can infect a wide range of cell types from different species in vitro
(Svobodova et al., 1982a). However, cell type-specific factors might also be
involved, which could explain the lack of expression detected from the His6
epitope-tagged expression constructs, as all of the cells used in those studies were
fibroblast or epithelial cell types. It is of note that another gammaherpesvirus,
KSHV, also contains a latency-associated gene LANA2, that is only expressed in
B lymphocytes, and is hypothesised to be involved in cell proliferation and / or
immune evasion (Rivas et al., 2001).
SDS-PAGE and immunoblot analysis of HA epitope-tagged M2 protein
expressed in A20 cells showed that it migrated with a relative molecular mass of
approximately 30kDa, which is substantially larger than the predicted mass of
22.3kDa. There were no differences in size with the HA epitope attached at either
the N or C terminus ofM2, suggesting that there is no post-translational cleavage
of M2 occurring. A similar result was observed in A20 cells expressing EGFP-
M2, with the fusion protein migrating with a relative molecular mass of
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approximately 60kDa (consisting of the 27kDa EGFP with the 30kDa M2
protein). The migration of M2 at a larger than expected relative molecular mass
may be due to a number of factors, including post-translational modification and
high proline content of M2. Proline-rich proteins tend to migrate at a higher
relative molecular mass than expected upon SDS-PAGE analysis (for example
EBNA-1 of EBV; Frappier & O'Donnell, 1991; Kieff, 1996). Indirect evidence
for the post-translational modification ofM2 comes from the expression ofM2 in
prokaryotic and eukaryotic systems. M2 expressed as a GST fusion protein in
prokaryotic cells migrated at a relative molecular mass of 50kDa (Figure 4.3.1.1),
whereas M2 expressed as an EGFP fusion protein in eukaryotic cells migrated at a
relative molecular mass of 60kDa (Figure 4.4.2.2). Both fusion protein partners
are approximately the same mass (GST is 27.5kDa; EGFP is 27kDa), and the
lOkDa difference in relative molecular masses could be due to the lack of post-
translational modification of proteins in prokaryotic cells. There are a number of
co-translational and post-translational modifications predicted to occur to the M2
protein, including N and O-linked glycosylation, myristylation and
phosphorylation (Figure 4.2.3). Figure 4.6.1 showed that the M2 protein was not
N-glycosylated, but it is possible that myristylation or O-linked glycosylation may
occur.
The possible myristylation of M2 is of interest due to the membrane
association ofmyristylated proteins (Cross et al., 1984). Although the addition of
myristic acid to a protein will increase its hydrophobicity and therefore increase
its potential for membrane association, this is not thought to be sufficient to allow
stable anchoring of the protein in a membrane (Resh, 1994; Bhatnagar & Gordon,
1997). Rather, this membrane affinity is thought to be due to electrostatic
interactions or molecular "switches" that target myristylated proteins to the
membrane compartments (Bhatnagar & Gordon, 1997), and localisation of
myristylated proteins to the plasma membrane requires a second signal such as
palmitylation (reversible post-translational linkage of palmitic acid to a cysteine
residue) or a polybasic domain (Welker et al., 1998; McCabe & Berthiaume,
1999). Thus although M2 is associated with the plasma membrane, there would
need to be further signals other than myristylation to localise M2 to the plasma
241
CHAPTER FOUR CHARACTERISATION OF THE M2 PROTEIN
membrane. Although there was no evidence for the attachment of H-labelled
myristic acid to M2, the lack of a suitable positive control to ensure adequate
labelling prevents the definitive answer to the myristylation status ofM2.
The presence of potential phosphorylated residues on the M2 protein is
also significant, due to the role of phosphorylated proteins in the regulation of
protein function and signalling pathways (Zhou et al., 1997; Sylla et al., 1998).
The double band visible on the immunoblot analysis ofHA epitope-tagged M2 is
characteristic of phosphorylated proteins, but it was not possible to demonstrate
the phosphorylation of M2 using antibodies specific for phosphoproteins. This
was due to problems encountered with high backgrounds due to non-specific
binding of these antibodies and binding to multiple phosphorylated proteins in
crude cell lysates, which were not solved by the use of antibodies pre-absorbed to
remove affinity for mouse proteins or recombinant antibodies. Attempts to purify
and concentrate the M2 antigen by immunoprecipitation prior to immunoblot
analysis were hindered by the fact that the M2 migrates at a similar relative
molecular mass to the antibody light chain molecule, and non-specific binding to
the light chain therefore masked the M2 protein. Another technique such as the
32
labelling of cells expressing M2 with [ P] orthophosphate might be required,
although this will not show which residues (tyrosine, threonine or serine) are
phosphorylated, and may not be as sensitive due to the low levels of M2
expression.
Studies using EGFP-M2 fusion proteins showed that M2 is present in
diffuse patches throughout the cell, with a proportion of the protein localised to
the plasma membrane. GFP and EGFP fusion proteins require no additional co-
factors or substrates (Chalfie et al., 1994), can be visualised in living cells and
have therefore been used to characterise a wide range of cellular (Forenzon et al.,
2001) and viral proteins (Welker et al., 1998; Marechal et al., 1999). Although
GFP is a large protein of 27kDa, most GFP fusion proteins retain the biological
activity and cellular localisation of the native protein. However, studies have
shown that attachment of EGFP to the N terminus of a GPCR prevents the
transport of the receptor to the cell membrane with consequent loss of function, in
contrast to C terminal EGFP fusion proteins that retain the native protein function
242
CHAPTER FOUR CHARACTERISATION OF THE M2 PROTEIN
(Tarasova et al., 1997). It should also be noted that the placement of any foreign
amino acid sequence could have a deleterious effect on protein function, as
evidenced by the reduction in enzyme activity due to the presence of a His6
residue (Araujo et al., 2000). To control for these possibilities, it was decided to
express M2 with EGFP fused to either the C terminus or the N terminus of M2
and also compare the results obtained with the EGFP-M2 fusion proteins with
indirect immunofluorescence on cells expressing E1A epitope-tagged M2 protein.
These four different expression constructs (EGFP or a triple HA epitope fused to
either the C terminus or the N terminus ofM2) gave nearly identical results. The
only slight difference observed was the more diffuse intracellular localisation of
the M2-EGFP protein (expressed by pEGFP-Nl/M2). This was probably due to
the breakdown of the fusion protein observed in the immunoblot analysis (Figure
4.4.2.2), which led to the formation of native EGFP that would localise
throughout the cell. The EGFP-M2 present in the central region of the cell did not
closely associate with DNA in A20 cells as evidenced by the lack of yellow co-
localisation, although transfections in SI 1 cells known to express M2 (Husain et
al., 1999) also showed central localisation of EGFP-M2. The significance of this
result remains uncertain.
No difference in the localisation of EGFP-M2 was observed at later
timepoints after transfection (Figure 4.5.1.6), which suggested that the
intracellular EGFP-M2 fraction was not in the process of being transported to the
plasma membrane and was therefore not an artefact due to the time of harvesting
the cells. Three different cell surface markers were used to stain the plasma
membrane (CD 19, MHC Class II and Concanavalin A), all of which showed co-
localisation with EGFP-M2 and thus demonstrate that M2 localises with the
plasma membrane. However it is not possible to demonstrate whether or not M2
is located at the inner or outer aspect of the plasma membrane using confocal
microscopy, and techniques such as immunogold electron microscopy would be
required to identify the exact location of M2 on the plasma membrane. The
hydropathicity plot reveals that M2 does not contain any membrane-associated
domains and is largely hydrophilic, suggesting that M2 is probably associated at
the inner plasma membrane, possibly associated with other proteins.
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Circumstantial evidence for this hypothesis comes from the homology with the
Gab2 family of proteins, and the presence of a semaphorin domain and predicted
phosphorylated residues on M2 all of which point to the involvement of M2 in
disruption of cellular signal transduction pathways. Cell signalling proteins also
tend to be located on the inner plasma membrane.
These results therefore show the initial characterisation of the M2 protein
of MHV-68. It has low level but significant homology to the Gab2 family of
proteins and a domain in the semaphorin family. It migrates as a doublet with an
apparent molecular mass of 30kDa on SDS-PAGE analysis. Studies using EGFP
fused to either the N or C terminus ofM2 show that M2 localises to the plasma
membrane, but not to the Golgi apparatus, ER or lysosomes. These results were
confirmed by indirect immunofluorescence studies using a different system, with
a triple HA epitope fused to either the N or C terminus of M2. M2 is not post-
translationally modified by N-linked glycosylation, but attempts to show the
phosphorylation and myristylation of residues in M2 were not conclusive. These
studies provide the basis for further research on the possible function of M2
during viral infection.
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5.1. Aims
The characterisation of MHV-76 (Chapter 3) has shown that the unique
MHV-68 genes Ml, M2, M3, M4 and the vtRNA genes play a major role in viral
pathogenesis and the development of virus-mediated immunopathology. Previous
studies have examined the contribution of the Ml and M3 ORFs in this region to
viral pathogenesis using deletion analysis (Simas et al., 1998; Clambey et al.,
2000; Bridgeman et al., 2001), but little is known of the function of the M2 ORF.
It is known to be a target for the CD8+ CTL response (Husain et al., 1999), and
expressed transiently during the establishment of latency (Usherwood et al.,
2000). Studies involving the modification of the immune response to the M2
protein by either the adoptive transfer of an M2-specific CD8+ T cell line or DNA
vaccination with M2 prior to infection with MHV-68 led to a reduction in the
number of latently infected cells during the establishment of latency (Usherwood
et al., 2000; Usherwood et al., 2001), but no reduction in the long-term latent
virus load. However, no studies have been undertaken using viruses solely
defective in the M2 ORF to examine the function of M2 during MHV-68
pathogenesis.
The aim was therefore to utilise two different approaches to generate
recombinant viruses for the study ofM2 function, by either inserting the M2 ORF
into MHV-76 ("knock-in" virus) or disrupting the M2 ORF in MHV-68 ("knock¬
out" virus). Production of these viruses would enable their characterisation in
vitro and in vivo, and therefore help to determine the role ofM2 in viral infection
5.2. Construction of recombinant viruses by insertion of genes
into MHV-76 ("knock-in" virus)
A number of factors were taken into consideration when designing
recombinant constructs for the insertion of genes into MHV-76. As transcription
and translation of the M2 gene is under tight control during the establishment of
latency (Usherwood et al., 2000), it was decided to insert genes into MHV-76
under the control of their natural viral promoters. The transcriptional map ofM2
has been revealed by cDNA sequencing (Husain et al., 1999), and it was therefore
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decided to include over lkb of DNA upstream of the transcriptional start site in
the M2 insertion construct (M2 insert; Figure 5.2.1). This upstream region was
chosen to include all possible transcriptional regulatory regions as
characterisation of other herpesvirus transcriptional control elements such as the
HCMV major IE gene modulator, enhancer and promoter elements (Meier &
Stinski, 1996), the KSHV LANA-1 promoter (Jeong et al., 2001) and the ORF50
promoter of MHV-68 (Liu et al., 2000) has shown that these are present up to
approximately lkb upstream of the transcriptional start site. This sequence
includes M2 promoter and regulatory elements that have been previously
characterised (M. Husain, J. Sample; unpublished data). This sequence at the 5'
end of the M2 insert includes over 90% of the M3 ORF, but does not include the
N-terminal 81 amino acids ofM3 or any of the M3 promoter elements and would
not therefore lead to the production of any M3 protein. Similarly, a 364bp
sequence downstream of the M2 polyadenylation signal was included in the M2
insert to include any downstream regulatory elements for M2 expression. This
sequence at the 3' end of the M2 insert includes some of the Ml ORF, but would
not lead to the production of any full-length functional Ml protein.
The region of the MHV-68 genome to be included in the M2 insert also
contains three of the vtRNA sequences (6,7 and 8). There was a possibility that
any phenotype observed with the insertion of the M2 insert into MHV-76 might
be due to the actions of these vtRNA sequences. It was therefore decided to make
a control virus that contained vtRNA 7 and 8, which would enable the
differentiation of any effects due to the vtRNAs from those due to M2. Promoter
and regulatory elements for mammalian tRNAs are largely contained within the
transcribed region (Paule & White, 2000). Mapping of the promoter elements
necessary for the transcription of the EBERs of EBV (which are also transcribed
by RNA polymerase III) showed that sequences up to 77bp upstream of the
EBERs were required for efficient transcription (Howe & Shu, 1989), and it has
been proposed that the vtRNAs of MHV-68 contain similar regulatory elements,
with termination signals present approximately 140bp downstream of the vtRNA
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approximately 300bp of the sequence flanking vtRNA7 and 8 in the tRNA7+8
insertion construct (tRNA7+8 insert; Figure 5.2.1).
To obtain recombinant MHV-76 viruses with either M2 or tRNA7+8
inserted, it was decided to use a strategy of homologous recombination using a
single crossover event to insert the relevant cassette into the junction of the left
end of the unique region of the MHV-76 genome and the terminal repeats. This
strategy was first developed for HVS, where it was found that insertion of DNA
sequences at the junction of the terminal repeats and unique region occurred more
efficiently in the correct locus if a single flanking sequence of unique genomic
DNA is used with no terminal repeat units (Grassmann & Fleckenstein, 1989).
This strategy has been used to successfully generate recombinant MHV-68
viruses (Simas et al., 1998; Adler et al., 2000). Recombinant viruses would then
be selected for the presence of the desired insert. Standard techniques for the
selection of recombinant herpesviruses include the insertion of marker genes,
such as lacZ (Simas et al., 1998; Bridgeman et al., 2001) or GFP (Vieira et al.,
1998; Adler et al., 2000), or genes encoding antibiotic resistance for the positive
selection of recombinant viruses (Herrold et al., 1996; Vieira et al., 1998).
However, there was concern that the insertion of foreign DNA into the left end of
the virus and possible alterations in viral transcription due to the introduction of
the HCMV IE promoter (used to express marker genes such as lacZ and GFP)
might affect the expression of neighbouring genes. These effects have been
observed with the introduction of foreign DNA into the left end of the MHV-68
genome (Clambey et al., 2000; Adler et al., 2001). It was therefore decided to
reintroduce only MHV-68 viral sequences (with no marker genes), and utilise a
PCR-based screening method to select recombinant viruses.
5.2.1. Design of recombination cassette for the insertion of M2 into MHV-
76.
A region corresponding to the terminal 3kb of MHV-76 (nucleotide
positions 9538-12563) was amplified using primer pair 76LHE1 and 76LHE2
(Chapter 2, Appendix 2) with PfuTurbo™ DNA polymerase, and inserted into the
pKS(-) vector (pBluescriptll KS(-); Chapter 2, Appendix 3) using the BamHl and
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EcoRl restriction enzyme sites to give the vector pKS/76LHE. Sequence analysis
of approximately 500bp of both termini of the 76LHE fragment in pKS(-) (see
2.2.24) confirmed that it was present in the correct orientation. The M2 insert
(Figure 5.2.1; nucleotide positions 3011-7031) was amplified using primer pair
M2-insertl and M2-insert2 (Chapter 2, Appendix 2) with PfuTurbo™ DNA
polymerase, and inserted into the pKS/76LHE vector using the BamW\ and Notl
restriction enzyme sites to give the vector pKS/76LHE/M2insert (Figure 5.2.2A).
Sequence analysis of approximately 500bp of the Notl termini of the M2insert in
pKS/76LHE (see 2.2.24) confirmed that it was present in the correct orientation.
A large scale preparation of pKS/76LHE/M2insert was made (see 2.2.15), and the
7kb recombination construct was excised from the pKS(-) plasnrid by digestion
with the restriction enzymes Notl and fscoRI prior to transfection to avoid any
recombination events leading to the incorporation of the pKS(-) plasmid into the
virus.
5.2.2, Design of recombination cassette for the insertion of vtRNA 7 and 8
into MHV-76.
The tRNA7+8 insert (Figure 5.2.1; nucleotide positions 4623-5806) was
amplified using primer pair tRNA7+8-insertl and tRNA7+8-insert2 (Chapter 2,
Appendix 2) with PfuTurbo™ DNA polymerase, and inserted into the
pKS/76LHE vector using the BamYll and Notl restriction enzyme sites to give the
vector pKS/76LHE/tRNA7+8insert (Figure 5.2.2B). Sequence analysis of
approximately 500bp of the Notl termini of the tRNA7+8insert in pKS/76LF!E
(see 2.2.24) confirmed that it was present in the correct orientation. The sequence
analysis also revealed the presence of a T residue at position 4945 (2bp upstream
of vtRNA7) in the vtRNA7+8 insert compared with the published MHV-68
genome sequence (Virgin et al., 1997), a difference that has been observed in
MHV-68 strain g2.4 (Bowden et al., 1997; Nash et al., 2001). A large scale
preparation of pKS/76LHE/tRNA7+8insert was made (see 2.2.15), and the 4.2kb
recombination construct was excised from the pKS(-) plasmid by digestion with





tRNA7+8 insert 76 LHE
Not\ BamHI EcoRI
pKS / 76LHE / tRNA7+8insert
Figure 5.2.2 Schematic diagram (not to scale) of the recombination cassettes for the
insertion ofM2 (A) and vtRNA7 and 8 (B) into MHV-76. The 3kb region at the left
end ofMHV-76 was amplified by PCR and inserted into the vector pKS(-), to give
the plasmid pKS/76LHE. The M2 insert region (4kb) was amplified by PCR and
inserted into pKS/76LHE to give the plasmid pKS/76LHE/M2insert (A). The
vtRNA7 and 8 region (1.1 kb) was amplified by PCR and inserted into pKS/76LHE
to give the plasmid pKS/76LHE/tRNA7+8insert (B). Unique restriction enzyme
sites encoded by the primers to facilitate directional cloning are shown in red.
MHV-68 genomic co-ordinates of the termini of the PCR fragments are shown
according to Virgin et al., 1997.
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recombination events leading to the incorporation of the pKS(-) plasmid into the
virus.
5.3. Construction of recombinant viruses with deletions in the
M2 gene ("knock-out" virus)
Previous results showed that cosmid A8 (cA8) could be utilised to
reintroduce the deleted 9.5kb sequence into MHV-76, and that this rescue virus
[designated MHV-76(cA8+)4] was identical to MHV-68 in both genomic
characterisation and in vitro and in vivo properties (Chapter 3). These results
demonstrated that one method for the construction of recombinant viruses with
deletions in the M2 gene was to generate mutations in the M2 ORF in cA8, and
then use the mutated cosmid as the recombination cassette. Due to the extensive
flanking sequences present in cA8, this represented a means of ensuring efficient
homologous recombination to generate recombinant viruses, which would be
almost genetically identical to MHV-68 except for mutations in the M2 ORF. A
further advantage was that the lack of any M2 sequence in MHV-76 meant that
contamination with wild-type virus (i.e. containing the M2 ORF) would not be a
factor during purification of the recombinant virus, as would be the case during
recombination with MHV-68.
As previously discussed (see 5.2), it was decided that the introduction of
foreign DNA into the left end of the unique region of the virus (such as marker
genes) might have deleterious effects on the expression of surrounding viral
genes. It was therefore decided to introduce a series of deletions and frame-shift
mutations into the M2 ORF to ensure disruption of the M2 protein, without the
addition of marker genes. These small deletions would have minimal effect on
surrounding genes. A PCR-based screening method would then be utilised to
select for M2 positive recombinant viruses.
5.3.1. Deletion of internal sequences in the M2 ORF of cosmid A8.
Cosmid A8 (MHV-68 nucleotide positions 115,165 to 26,842 in modified
SuperCosI vector; see Chapter 2, Appendix 3) contains a unique Sail site at
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nucleotide position 4335 (within the M2 ORF). Sail digests DNA to leave 4bp 5'-
protruding termini, and this was utilised to generate deletions in the M2 ORF.
Cosmid A8 DNA was linearised with Sail, and this was confirmed by agarose gel
electrophoresis (data not shown). Deletions were produced by digesting the
recessed 3'-termini with Exonuclease III (a 3' to 5' exonuclease), which resulted
in the bi-directional deletion of sequences starting from the Sail site at the rate of
approximately 250bp of the M2 ORF per minute at 23°C (see 2.2.8). Aliquots
were therefore removed at 20, 40, 60, 80 and 100-second intervals after the
addition of Exonuclease III. The termini of the digested DNA were blunted using
Mung Bean Nuclease, and ligated. In addition, one aliquot was removed before
the addition of Exonuclease III and only digested with Mung Bean Nuclease to
remove the 5'extensions at the Sail site to leave blunt ends, which were then re-
ligated. Digestions solely with Mung Bean Nuclease led to the deletion of 4bp in
the Sail site.
A sample of the ligated cosmid DNA from each of the reactions (labelled
0, 20, 40, 60, 80 and 100 seconds) was used to transform ElectroMAX DH10B
bacteria by electroporation (see 2.2.12), and cosmid DNA from ampicillin
resistant colonies was prepared by the mini-prep method (see 2.2.14). Four
colonies that produced cosmid DNA of the expected size that was not linearised
by digestion with Sail (due to deletion of the Sail site) were chosen for further
analysis. Colonies 4 and 5 were solely digested with Mung Bean Nuclease (0
second aliquots), colony 21 was digested with Exonuclease III for 60 seconds and
colony 32 was digested with Exonuclease III for 100 seconds.
5.3.2. Analysis of cosmid A8 mutants with deletions in the M2 ORF.
The M2 ORF was amplified using primer pair M2GEX1 and M2GEX2
(Chapter 2, Appendix 2) with PfuTurbo™ DNA polymerase using 1 pi of mini-
prep DNA from colonies 4, 5, 21 and 32 as template, and the products were
analysed on a 0.8% TAE agarose gel. Figure 5.3.2.1 shows that the M2 ORF
amplified from colonies 4 and 5 was the same size as the positive control (600bp).
Digestion of the positive control M2 PCR fragment (amplified from MHV-68
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Figure 5.3.2.1. Analysis of cosmid A8 colonies with deletions of internal sequences
in the M2 ORF. The M2 ORF was amplified by PCR using lpl ofmini-prep DNA
from individual colonies 4, 5, 21 and 32 as template, and the products were
analysed on a 0.8% TAE agarose gel. Positive control (MHV-68 genomic DNA
template) and negative control (diH20 template) reactions were also performed. To
investigate the presence or absence of the Sail restriction enzyme site in the
amplified M2 ORF, a 5pl sample of each PCR reaction was also digested using the
restriction endonuclease Sail, and analysed on the same gel. Molecular weights are
shown relative to the marker on the left side.
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genomic DNA) with Sail results in the production of 2 fragments (271bp and
335bp). However, the M2 fragments amplified from colonies 4, 5, 21 and 32 were
resistant to cleavage by Sail. The M2 fragment amplified from colony 21 was
approximately 450bp, and the fragment amplified from colony 32 was
approximately 350bp, indicating that they contained substantial deletions in the
M2 ORF.
The M2 fragments amplified by PCR were inserted into the pKS(-) vector
(Chapter 2, Appendix 3) using the BamHl and EcoRl restriction enzyme sites, and
the sequence was determined (see 2.2.24). Figure 5.3.2.2 shows the results of the
sequence analysis of the deletions present in the M2 ORF of the cA8 mutants.
Colonies 4 and 5 contained 4bp deletions in the Sail site (deletion of nucleotides
4336-4339), and this also leads to a frame shift mutation. As such, the M2 ORF in
these cosmids could potentially generate a 90 a.a. protein consisting of the N-
terminal 89 residues of M2 fused to an arginine residue in an alternative reading
frame before a stop codon arises. Significantly, this deletion also removes the last
3 residues of the M29i.99 CD8+ T cell epitope. Colony 21 contains a 166bp
deletion (nucleotides 4242-4407) that also leads to a frame shift mutation. This
cosmid could therefore potentially generate a protein consisting of the N-terminal
66 residues of M2, with the deletion of the entire M29i_99 CD8+ T cell epitope.
Colony 32 contains a 256bp deletion in the M2 ORF (deletion of nucleotides
4239-4494). This M2 ORF could potentially generate a protein consisting of the
N-terminal 37 amino acids ofM2, with a frame shift present due to the deletion.
This M2 ORF also does not contain any of the M29].99 CD8+ T cell epitope
sequence.
It was therefore decided to utilise two cosmids to generate recombinant
viruses; colony 4 (designated cA8-M2A4336-4339) containing the 4bp deletion and
colony 32 (designated cA8-M2A4239-4494) containing the 256bp deletion. It was
decided to use cA8-M2A4239-4494 in case the remaining N-terminal 89 residues of
M2 present in cA8-M2A4336-4339 were able to encode a functional protein. The
substantial deletion present in cA8-M2A4239-4494 was thought to be highly unlikely
to encode any functional protein.
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Figure 5.3.2.2 Analysis of cosmid A8 mutants with deletions in the M2 ORF. The M2
ORF was amplified by PCR from colonies 4,5,21 and 32. The PCR fragments were
ligated into the plasmid pKS(-) and sequenced. The nucleotide sequence of the M2 ORF
is shown, with nucleotide positions shown from 1 to 576 (MHV-68 genomic co-ordinates
4606 to 4031). The amino acid sequence of M2 is shown underneath the nucleotide
sequence, with the M29l.99 CD8+ T cell epitope shown in red underlined type. The extent
of deletions in colonies 4 and 5 are shown highlighted in green (M2A4336_4339), the
deletion in colony 21 is shown highlighted in green and blue (M2A4242-4407) and the
deletion in colony 32 is shown highlighted in green, blue and orange (M2A4239-4494).
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A large scale preparation of purified cosmid DNA was made of cA8-
M2A4336_4339 and cA8-M2A4239-4494 (see 2.2.16). To ensure that there were no
deletions or rearrangements within the cosmids, lpg of cosmid DNA was
digested with BamHl, EcoRI or Hindlll, analysed on a 0.8% TAE agarose gel and
compared with restriction digests of the parent cA8. Figure 5.3.2.3 shows that
restriction enzyme digests of CA8-M2A4336-4339 and cA8-M2A4239-4494 with three
different enzymes were identical to the parent cA8. These digests also agree with
published restriction enzyme maps of the MHV-68 genome (Efstathiou et al.,
1990b), with the presence of the 7.9kb SuperCosI vector. The one difference
noted was the slight reduction in size of the Hindlll E fragment in cA8-M2A4239_
4494 due to the 256bp deletion within the M2 ORF. This result showed that the
cosmids created were identical to parent cA8, except for deletions within the M2
ORF.
5.4. Production and purification of recombinant viruses
BHK-21 cells were transfected (see 2.1.4) with 5pg of MHV-76 viral
DNA (see 2.2.18) and 10pg of plasmid (pKS/76LHE/M2insert and
pKS/76LHE/tRNA7+8 insert, with the recombination cassette excised from pKS
(-) prior to transfection) or cosmid (CA8-M2A4336-4339 and cA8-M2A4239.4494,
undigested). The cells were overlaid with medium containing 1% w/v LGT
agarose 24 hours after transfection (see 2.8.1) and viral plaques were harvested
after 5-7 days (see 2.8.3).
As there were no marker genes present in any of the recombinant viruses, it
was decided to use a PCR-based screening method to select for recombinant
viruses. Viral plaques in the BHK-21 monolayer (from either 6 well plates or
limiting dilution assay) were harvested, and divided into two lOOpl aliquots. One
aliquot was stored at -70°C and retained as the viral stock. The other aliquot was
washed once with modified TE, and then resuspended in 50pl modified TE (see
2.8.3). After one freeze-thaw cycle, the sample was digested overnight with PGR
Grade Proteinase K at 55°C. The sample was heated to 95°C for 10 min to
inactivate the Proteinase K, and lOpl of the sample was used as template for PCR
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Uncut BamHI EcoRI H/ndlll
Figure 5.3.2.3 Restriction enzyme digestion of cA8 mutants with deletions in the
M2 ORF. Large scale preparation of cosmid DNA (cA8, cA8/M2A4336_4339
cA8/M2A4239_4494) was performed using a QIAGEN Large-Construct Kit. A 1 pg
sample was digested with the restriction enzymes SawHI, EcoRI and Hind\\\ and
analysed on 0.8% TAE agarose gel. A sample of uncut cosmid DNA (0.5pg) was
also analysed on the same gel. Molecular weights are shown relative to the marker
on the left side.
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analysis. 40 cycles of PCR were performed using primers specific for the M2
ORF (M2GEX1 and M2GEX2; Chapter 2, Appendix 2) to select for recombinant
viruses containing 76LHE/M2insert, CA8-M2A4336-4339 and CA8-M2A4239-4494. To
select for recombinant viruses containing 76LHE/tRNA7+8insert, PCR analysis
was performed using primers specific for the tRNA7+8insert (tRNA7+8insertl
and tRNA7+8insert2; Chapter 2, Appendix 2). As a control to check for the
presence and suitability of viral DNA for PCR analysis, PCR analysis was also
performed on all samples using primers specific for ORF74 (GCR-5' and GCR-
3'; Chapter 2, Appendix 2). PCR products were then analysed on a 1% TAE
agarose gel.
The sensitivity of this PCR-based screening method was assessed using the
M2GEX1 and M2GEX2 primers to amplify the M2 ORF in samples of MHV-68
virus stock serially diluted tenfold in modified TE. Figure 5.4.1 shows that this
technique was sensitive to the level of 1 PFU per sample. When the samples were
only digested with Proteinase K for 20 minutes at 55°C (instead of overnight), the
sensitivity of this method was 10 PFU (data not shown). These results showed
that this technique was sensitive enough for the screening of recombinant virus
samples.
Single plaques positive for the desired insert (the M2 ORF for recombinant
viruses containing 76LHE/M2insert, CA8-M2A4336.4339 and CA8-M2A4239-4494, or
the tRNA7+8insert for recombinant viruses containing 76LHE/tRNA7+8insert)
were purified using a limiting dilution assay on BHK-21 cells (see 2.8.3). Single
plaques per well of a 96 well plate were harvested after 6 days and analysed by
PCR. If they contained the desired insert, the stock virus samples were used to
infect the next limiting dilution assay. Recombinant viruses were purified until all
virus samples analysed were positive for the desired insert for at least two rounds
of purification. For viruses made by recombination with CA8-M2A4336-4339 and
CA8-M2A4239-4494, purification was judged to be complete after 5 rounds of
purification. Additionally, PCR analysis of CA8-M2A4239-4494 revealed the
presence of the smaller M2 ORF (350bp), which showed that there was definitely
no contamination with MHV-68 virus. A single purified viral plaque was used to
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Figure 5.4.1 Sensitivity of a PCR-based screening method for the purification of
recombinant viruses. MHV-68 virus stock of known titre was serially diluted
tenfold in modified TE (pH8.0), freeze-thawed once and samples containing 106 to
10"3 PFU were digested overnight with PCR grade Proteinase K at 55°C. The
samples were heated to 95 °C for 10 minutes to inactivate the Proteinase K, and 40
cycles of PCR amplification were performed using primers specific for the M2
ORF. The products were analysed on a 1% TAE agarose gel. Molecular weights are
shown relative to the marker on the left side.
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infect a TC 175cm flask of BHK-21 cells, to prepare DNA for Southern analysis
and PCR (see 2.2.19).
Problems were encountered with the purification of recombinant viruses
made with 76LHE/M2insert and 76LHE/tRNA7+8insert. Selection of
recombinant viruses positive for the 76LHE/M2insert by PCR analysis was
initially successful, but was unable to purify recombinant viruses to the high
degree of purity required, as the presence of single viral plaques negative for the
M2 ORF was detectable during every round of purification. This occurred despite
three separate attempts to purify MHV-76/M2insert viruses (each attempt
consisting of 4-5 rounds of plaque purification). It was postulated that the
recombinant MHV-76/M2insert viruses detectable in the initial rounds of plaque
purification either had a selection disadvantage due to poor replication in tissue
culture (possibly requiring the assistance of a "helper virus" to replicate in vitro)
or spontaneously deleted the M2 insert during replication to revert back to MHV-
76. It was decided to use a plaque from a stock of almost pure MHV-76/M2insert
virus to infect a TC 175cm flask of BHK-21 cells, to prepare DNA for Southern
analysis and PCR (see 2.2.19).
Selection of recombinant viruses positive for the 76LHE/tRNA7+8insert by
PCR analysis was problematic due to the PCR screening method used. Initially,
primer pair tRNA7+8insertl and tRNA7+8insert2 (Chapter 2, Appendix 2) was
used but failed to reliably amplify DNA in samples known to be positive, despite
adjustments to the PCR conditions. This was thought to be due to the large PCR
product size (1.2kb) to be amplified in a high background of cellular DNA, with
imperfect PCR conditions due to the presence of cellular ions. It was therefore
decided to use primer pair tRNA7for and tRNA7rev (Chapter 2, Appendix 2) to
amplify the tRNA7 gene. This amplified a very small product (68bp; B.Ebrahimi,
unpublished data), Avhich required the use of a 3% TAE agarose gel to
differentiate the PCR products from the primer complexes. This primer pair also
amplified other multiple larger bands non-specifically, which led to uncertainty in
the interpretation of the PCR analysis. Recombinant MHV-76/tRNA7+8insert
viruses were purified using primer pair tRNA7for and tRNA7rev to select for
viruses containing tRNA7, and a single purified viral plaque was used to infect a
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TC 175cm2 flask of BHK-21 cells, to prepare DNA for Southern analysis and
PCR (see 2.2.19).
5.5. Molecular characterisation of recombinant viruses
5.5.1. Southern analysis of recombinant viruses.
DNA was made from BHK-21 cells infected with MHV-76, MHV-68,
MHV-76(cA8+)M2A4336-4339, MHV-76(cA8+)M2A4239-4494, MHV-76/M2insert
and MHV-76/tRNA7+8insert (see 2.2.19) and Southern analysis was performed
using diagnostic Hindlll, Hindi and Bell digestions (see 2.2.20). The Hindlll
digests were then probed with a 32P-radiolabelled cA8 probe. The cA8 probe
identifies the MHV-68 Hindlll fragments B, C, E, G, I, J, N, S, T2, U2 and Z2 (see
Figure 3.7.2.2). Southern analysis showed that the recombinant viruses MHV-
76(cA8+)M2A4336-4339 and MHV-76(cA8+)M2A4239-4494 yielded identical profiles
to MHV-68, containing the Hindlll fragments B, C, E, G, I, J and N (Figure
5.5.1.1A). The Hindlll E fragment of recombinant virus MHV-76(cA8+)M2A4239-
4494 appeared slightly smaller than in MHV-68 due to the 256bp deletion. The
Hindlll fragments S and Z2 were too small to be visualised on the blot, and
fragments containing the terminal repeats (U2+ and T2+) appear as high molecular
weight products with laddering. In MHV-76, the Hindlll E and U2 fragments are
deleted, and the truncated Hindlll J fragment (JA) becomes bound to the terminal
repeats and is visualised as a high molecular weight product (JA+). The MHV-
76/tRNA7+8insert virus contains a larger Hindlll J fragment (2.7kb), which is
bound to the terminal repeats and thus has an identical profile to MHV-76 (the
Southern analysis of this virus is slightly obscured by smearing of the DNA). The
MHV-76/M2insert virus contains a normal Hindlll G fragment, a truncated
Hindlll J fragment (2.3kb) and 3.3kb Hindlll E fragment bound to the terminal
repeats (and thus observed as a high molecular weight product). The truncated
2.3kb Hindlll J fragment was not observed on the blot, despite prolonged
exposure (data not shown).
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Figure 5.5.1.1A Southern analysis of recombinant viruses. DNA was isolated from
BHK-21 cells infected with MHV-76, MHV-68, MHV-76(cA8+)M2A4336.4339,
MHV-76(cA8+)M2A4239.4494, MHV-76/tRNA7+8insert and MHV-76/M2insert. The
DNA was digested with HindlW and analysed by Southern blot on a 0.8% TAE
agarose gel. The blot was hybridised with a 32P-labelled probe of cosmid A8. The
sizes of molecular weight markers in bp are shown on the left, and HindlW
fragments on the right side of the autoradiograph.
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To visualise the Hindlll E and J fragments more easily, the HindUl digest
was probed with a 32P-radiolabelled M3 probe (nucleotides 6060-7277; see Figure
3.7.2.2). The results showed that the correct sized Hindlll E and J fragments were
present in MHV-68 and the recombinant viruses MHV-76(cA8+)M2A4336-4339 and
MHV-76(cA8+)M2A4239-4494 (Figure 5.5.1.1B). The Hindlll E fragment of
recombinant virus MHV-76(cA8+)M2A4239-4494 appeared slightly smaller than in
MHV-68 due to the 256bp deletion. As expected, the M3 probe did not hybridise
with MHV-76 and MHV-76/tRNA7+8insert viral DNA. The M3 probe was
expected to hybridise with the truncated Hindlll J fragment (2.3kb) and 3.3kb
Hindlll E fragment bound to the terminal repeats present in MHV-76/M2insert.
However, despite prolonged exposure, no evidence of this was seen.
To determine that the recombinant viruses had been satisfactorily purified
so that no MHV-76 contamination was present, recombinant viral DNA was
digested with Hincll and BelI, and Southern analysis was performed using a 32P-
radiolabelled probe of 76LHE (nucleotides 9538-12563). Figure 5.5.1.2 shows
that the 76LHE probe hybridised with the expected 1.4kb and 3.1kb Hindi
fragments and the 7.2kb Bell fragment in MHV-68 viral DNA. Figure 5.5.1.5
details the restriction map of the left end ofMHV-68 for the enzymes Hindi and
Bell. In MHV-76, the 3.1kb Hindi fragment is present but the 1.4kb Hindi and
7.2kb Bell fragments become truncated and bound to the terminal repeats, and
thus appear as a ladder of closely spaced high molecular weight bands.
Recombinant virus MHV-76(cA8+)M2A4336.4339 yielded an identical profile to
MHV-68, indicating that this virus was pure and free from MHV-76
contamination. However, recombinant virus MHV-76(cA8+)M2A4239-4494
exhibited a very similar profile to MHV-68, but also contained a ladder of closely
spaced higher molecular weight bands indicating that this recombinant virus was
contaminated with a small amount of MHV-76. MHV-76/tRNA7+8insert and
MHV-76/M2insert displayed identical profiles to MHV-76, and did not show the
expected novel fragments (3.6kb Hindi and 4.7kb Bell fragments in MHV-
76/M2insert; 2.4kb Hindi and 3.5kb Bell fragments in MHV-76/tRNA7+8insert;
264
CHAPTER FIVE THE ROLE OF M2 IN MHV-68 PATHOGENESIS
Figure 5.5.1.IB Southern analysis of recombinant viruses. DNA was isolated from
BHK-21 cells infected with MHV-76, MHV-68, MHV-76(cA8+)M2A4336_4339,
MHV-76(cA8+)M2A4239_4494, MHV-76/tRNA7+8insert and MHV-76/M2insert. The
DNA was digested with Hin&lU and analysed by Southern blot on a 0.8% TAE
agarose gel. The blot was hybridised with a 32P-labelled probe of M3 (nucleotides
6060-7277). The sizes ofmolecular weight markers in bp are shown on the left, and
Hind\\\ fragments on the right side of the autoradiograph.
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Figure 5.5.1.2 Southern analysis of recombinant viruses. DNA was isolated from
BHK-21 cells infected with MHV-76, MHV-68, MHV-76(cA8+)M2A4336.4339,
MHV-76(cA8+)M2A4239.4494, MHV-76/tRNA7+8insert and MHV-76/M2insert. The
DNA was digested with Hindi (A) and BcR (B) and analysed by Southern blot on a
0.8% TAE agarose gel. The blot was hybridised with a 32P-labelled probe of
76LHE (nucleotides 9538-12563). The sizes of molecular weight markers in bp are
shown on the left of the autoradiograph.
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Figure 5.5.1.6). The recombinant viruses MHV-76/tRNA7+8insert and MHV-
76/M2insert were thus predominantly composed ofMHV-76 alone.
In order to characterise the recombinant viruses more completely, the
Hincll and BcK digests were probed with a 32P-radiolabelled M2 probe
(nucleotides 4000-4606). This probe identifies three MHV-68 fragments in the
Hindi digest (2.2kb, 354bp, 58bp) and two fragments in the Bell digest (1.2kb,
and a 4.5kb fragment bound to the terminal repeats; Figure 5.5.1.5). Figure 5.5.1.3
shows that fragments of the expected size were visualised in MHV-68, with the
exception of the 58bp Hindi fragment that was too small to be visualised on the
blot. This probe did not hybridise with any DNA in MHV-76 or MHV-
76/tRNA7+8, consistent with the M2 ORF being absent in these viruses. In
recombinant virus MHV-76(cA8+)M2A4336-4339, the deletion also leads to the loss
of the Hindi site at position 4337 and thus the 58bp and 354bp fragments become
incorporated into a novel fragment of 408bp (Figure 5.5.1.5). In recombinant
virus MHV-76(cA8+)M2A4239-4494, the substantial deletion in this virus leads to
loss of the Hindi sites at positions 4337 and 4279, and the Bell site at 4464
(Figure 5.5.1.5). Thus the Hindi 58bp, 354bp and 2.2kb fragments become
incorporated into one novel 2.3kb fragment, and the Bell 1.2kb fragment is lost
and becomes incorporated into the fragment bound to the terminal repeats. The
expected profiles were observed for both recombinant viruses MHV-
76(cA8+)M2A4336-4339 and MHV-76(cA8+)M2A4239-4494 (Figure 5.5.1.3). The M2
probe was also expected to hybridise with three Hindi fragments (58bp, 350bp
and a 1.3kb fragment bound to the terminal repeats) and two Bell fragments
(1.2kb and 1.5kb bound to the terminal repeats) in the recombinant virus MHV-
76/M2insert (Figure 5.5.1.6). However, despite prolonged exposure, no evidence
of this was seen (Figure 5.5.1.3).
The Hindi and Bell digests were also probed with a 32P-radiolabelled
tRNA7+8 probe (nucleotides 4623-5806). This probe identifies two MHV-68
fragments in the Hindi digest (2.5kb and 354bp) and two fragments in the Bell
digest (1.2kb and 7.2kb; Figure 5.5.1.5). Figure 5.5.1.4 shows that fragments of
the expected size were visualised in MHV-68, with weak hybridisation to the
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Figure 5.5.1.3 Southern analysis of recombinant viruses. DNA was isolated from
BHK-21 cells infected with MHV-76, MHV-68, MHV-76(cA8+)M2A4336.4339,
MHV-76(cA8+)M2A4239_4494, MHV-76/tRNA7+8insert and MHV-76/M2insert. The
DNA was digested with HincW (A) and BelI (B) and analysed by Southern blot on a
0.8% TAE agarose gel. The blot was hybridised with a 32P-labelled probe of M2
(nucleotides 4000-4606). The sizes ofmolecular weight markers in bp are shown on
the left of the autoradiograph.
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Figure 5.5.1.4 Southern analysis of recombinant viruses. DNA was isolated from
BHK-21 cells infected with MHV-76, MHV-68, MHV-76(cA8+)M2A4336_4339,
MHV-76(cA8+)M2A4239.4494, MHV-76/tRNA7+8insert and MHV-76/M2insert. The
DNA was digested with Hincll (A) and Bell (B) and analysed by Southern blot on a
0.8% TAE agarose gel. The blot was hybridised with a 32P-labelled probe of
tRNA7+8 insert (nucleotides 4623-5806). The sizes ofmolecular weight markers in
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354bp Hincll fragment due to the small region (68bp) of cross-hybridisation. As
expected, the tRNA7+8 probe did not hybridise with any DNA in MHV-76. In
recombinant virus MHV-76(cA8+)M2A4336-4339, the loss of the Hindi site at
position 4337 led to the incorporation of the 354bp fragment into a novel
fragment which was visualised at 408bp on the Hindi digest (Figure 5.5.1.4). In
recombinant virus MHV-76(cA8+)M2A4239-4494, the substantial deletion in this
virus leads to loss of the Hindi sites at positions 4337 and 4279, and the Bell site
at 4464 (Figure 5.5.1.5). Thus the Hindi 58bp, 354bp and 2.2kb fragments
become incorporated into one novel 2.3kb fragment (appearing at the same region
as the 2.5kb fragment). The Bell 1.2kb fragment is lost and becomes incorporated
into the fragment bound to the terminal repeats. The expected profiles were
observed for both recombinant viruses MHV-76(cA8+)M2A4336-4339 and MHV-
76(cA8+)M2A4239-4494 (Figure 5.5.1.4), with minor bands present in the Bell
digest due to partial digestion. The tRNA7+8 probe was also expected to
hybridise with two Hindi fragments (354bp and 3.6kb) and two Bell fragments
(1.2kb and 4.7kb) in the MHV-76/M2insert virus, and two Hindi fragments
(2.4kb and 68bp bound to the terminal repeats) and two Bell fragments (3.5kb and
l.Okb bound to the terminal repeats) in the MHV-76/tRNA7+8insert virus (Figure
5.5.1.6). However, despite prolonged exposure, no evidence of this was seen
(Figure 5.5.1.4).
The results of Southern analysis of the four recombinant viruses revealed
that virus MHV-76(cA8+)M2A4336_4339 (containing a 4bp deletion in the M2 ORF)
was a pure viral population containing the expected genomic composition.
Recombinant virus MHV-76(cA8+)M2A4239-4494 (containing a 256bp deletion in
the M2 ORF) also contained the expected genomic organisation, but was
contaminated with a small amount ofMHV-76 and was therefore not a pure viral
population. Recombinant viruses MHV-76/M2insert and MHV-
76/tRNA7+8insert appeared to be identical MHV-76, and contained no inserted
sequences.
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5.5.2. PCR analysis of recombinant viruses.
To fully characterise the recombinant viruses, recombinant virus DNA
was analysed by PCR (see 2.2.1). Primers were used to amplify MHV-68 specific
ORFs (see Chapter 2, Appendix 2) including Ml (Ml for and Ml rev primers), M2
(M2GEX1 and M2GEX2 primers), M3 (M3+ and M3- primers), M4 (M4A and
M4B primers) and tRNA7 (tRNA7for and tRNA7rev primers). As a control to
check for template DNA integrity and concentration, primers for ORF74 (GCR-5'
and GCR-3' primers) were used to amplify the GPCR sequence present in all
virus samples. Figure 5.5.2.1A shows that Ml, M2, M3 and M4 were all present
in the recombinant viruses MHV-76(cA8+)M2A4336_4339 and MHV-
76(cA8+)M2A4239-4494, as well as the GPCR coding sequence. The M2 ORF is
reduced in size in virus MHV-76(cA8+)M2A4239-4494, consistent with previous
results (see Figure 5.3.2.1). Figure 5.5.2.IB shows that the GPCR region was
amplified in recombinant viruses MHV-76/M2insert and MHV-
76/tRNA7+8insert, indicating that viral DNA was present. The M2 ORF was also
present in MHV-76/M2insert, but not present in MHV-76/tRNA7+8insert, and the
Ml, M3 and M4 genes were all absent in these viruses. The region amplified by
the M3+ and M3- primers (nucleotides 6566-6946; Chapter 2, Appendix 2) is
present within the M2insert sequence (nucleotides 3011-7032; see Figure 5.2.1)
but was not amplified, showing that this region was not present in the MHV-
76/M2insert virus.
Analysis of recombinant viruses by PCR for the vtRNA7 gene showed
that this was present in MHV-68 as well as recombinant viruses MHV-
76(cA8+)M2A4336-4339, MHV-76(cA8+)M2A4239-4494 and MHV-76/M2insert
(Figure 5.5.2.2). The vtRNA7 gene was not present in MHV-76/tRNA7+8. In
addition, the M2 ORF in recombinant viruses MHV-76(cA8+)M2A4336_4339 and
MHV-76(cA8+)M2A4239-4494 was amplified using primer pair M2GEX1 and
M2GEX2 (Chapter 2, Appendix 2) with PfuTurbo™ DNA polymerase, inserted
into the pKS(-) vector (Chapter 2, Appendix 3) using the BamRl and EcoKl
restriction enzyme sites, and the sequence was determined (see 2.2.24). Sequence
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Figure 5.5.2.1 PCR analysis of viral DNA from recombinant viruses (A) MHV-
76(cA8+)M2A4336_4339 and MHV-76(cA8+)M2A4239.4494 and (B) MHV-76/M2insert
and MHV-76/tRNA7+8insert. 40 cycles of PCR analysis was performed using
primers specific for the unique MHV-68 genes Ml, M2, M3 and M4 and also ORF
74 (GPCR). Template consisted of either 500ng of DNA isolated from infected
BHK-21 cells or dil I20 (negative control reactions). The products were analysed on a
1% TAE agarose gel. The sizes of molecular weight markers in bp are shown on the
left.
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Figure 5.5.2.2 PCR analysis of viral DNA from MIIV-76, MHV-68 and the
recombinant viruses MHV-76(cA8+)M2A4336_4339, MHV-76(cA8+)M2A4239_4494,
MHV-76/M2insert and MHV-76/tRNA7+8insert. 40 cycles of PCR analysis were
performed using primers specific for vtRNA7. Template consisted of either 500ng
of DNA isolated from infected BHK-21 cells or diH20 (negative control reaction).
The products were analysed on a 3% TAE agarose gel. The sizes of molecular
weight markers in bp are shown on the left.
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analysis showed that both viruses contained deletions in the M2 ORF identical to
those observed in the parent cosmids (see Figure 5.3.2.2).
The results from Southern and PCR analysis of recombinant viral DNA
revealed that viruses MHV-76(cA8+)M2A4336-4339 and MHV-76(cA8+)M2A4239-
4494 were very similar to MHV-68, except for a 4bp and a 256bp deletion in the
M2 ORF respectively. However, only virus MHV-76(cA8+)M2A4336-4339 had been
successfully purified and was free from contamination with MHV-76.
Recombinant virus MHV-76/M2insert contained the M2 ORF and the vtRNA7
gene, but only partial recombination had occurred as evidenced by the deletion of
the region containing part of the M3 ORF. There was also contamination with
MHV-76, such that none of the inserted sequences was detectable by Southern
analysis. Recombinant virus MHV-76/tRNA7+8insert did not contain any of the
desired insert, and was identical to MHV-76.
It was therefore decided to utilise recombinant virus MHV-
76(cA8+)M2A4336-4339 (containing a 4bp deletion in M2) to assess the role of M2
in MHV-68 infection in vitro and in vivo. Comparison of this virus to MHV-76
(the parent virus) and MHV-76(cA8+)4 (the rescue virus generated in the same
manner as the recombinant virus, and genetically and phenotypically identical to
MHV-68; see Chapter 3) would enable assessment of the function ofM2 in viral
pathogenesis.
5.6. Preliminary results of the biological characterisation of
recombinant viruses
5.6.1. Replication in vitro.
To investigate the effect of disruption of the M2 ORF on viral replication
in vitro, the replication of MHV-76, MHV-76(cA8+)4 and MHV-
76(cA8+)M2A4336-4339 was compared in BHK-21 cells. A single round of
multiplication (one-step growth curve at a MOI of 5) showed that all viruses
replicated at a similar rate in vitro (Figure 5.6.1.1). Studies using multiple rounds
of growth (MOI of 0.01) also revealed that all viruses replicated with similar
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Figure 5.6.1.1 One step growth curve of MHV-76 ( A ), MHV76(cA8+)4
( —m—) and MHV-76(cA8+)M2A4336.4339 ( —«— ) on BHK-21 cells at an MOI
of 5. Data points are shown for virus titre logl0 ± standard error.
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kinetics and achieved comparable titres during replication in tissue culture (Figure
5.6.1.2). These results demonstrated that disruption of the M2 ORF has no effect
on lytic replication in BHK-21 cells.
5.6.2. Replication in the lung.
BALB/c mice were infected with 2 x 105 PFU of MHV-76, MHV-
76(cA8+)4 or MHV-76(cA8+)M2A4336.4339 intranasally, and the virus titre in the
lungs was assessed at various timepoints post-infection by plaque assay (see
2.6.4). MHV-76(cA8+)M2A4336-4339 displayed peak viral titres in the lung at day 5
post-infection that were significantly higher than either MHV-76 or MHV-
76(cA8+)4 (Figure 5.6.2)(Day 5 lung titre: MHV-76(cA8+)M2A4336-4339 vs.
MHV-76(cA8+)4 or MHV-76; P<0.001). MHV-76 was cleared more rapidly from
the lungs than MHV-76(cA8+)4 and MHV-76(cA8+)M2A4336-4339 at day 7 post¬
infection, in agreement with previous studies (see 3.8.2). This data therefore
shows that disruption of the M2 ORF leads to significantly higher peak viral titres
in the lung after intranasal infection, but has no effect on viral clearance from the
lung when compared to a virus with an intact M2 ORF.
5.6.3. Virus-induced splenomegaly.
To determine the effect of disruption of the M2 ORF on splenomegaly
during infection, BALB/c mice were infected with 2 x 105 PFU of MHV-76,
MHV-76(cA8+)4 or MHV-76(cA8+)M2A4336-4339 intranasally. The extent of
splenomegaly was determined using two independent measures, spleen weight
(see 2.6.2) and determination of the total number of splenocytes (see 2.6.3). There
was an increase in spleen weight (Figure 5.6.3.1) and total splenocyte numbers
(Figure 5.6.3.2) after infection of mice with MHV-76(cA8+)M2A4336-4339
comparable with that observed following infection with MHV-76(cA8+)4, which
peaked at day 14 post-infection. In agreement with previous studies (see 3.8.3),
both MHV-76(cA8+)4 and MHV-76(cA8+)M2A4336.4339 demonstrated a much
larger degree of splenomegaly compared to MHV-76. The spleen weights and
total splenocyte numbers of mice infected with MHV-76(cA8+)M2A4336-4339
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Figure 5.6.1.2 Multi step growth curve ofMHV-76 ( A ), MI IV76(cA8+)4
) and MHV-76(cA8+)M2A4336_4339 ( —■— ) on BHK.-21 cells at an MQI
of 0.01. Data points are shown for virus litre logl() ± standard error.
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Figure 5.6.2 Viral titres in the lungs of BALB/c mice infected intranasally with 2 x
105 PFU of MHV-76 ( ▲ ), MHV76(cA8+)4 ( —■— ) and MHV-
76(cA8+)M2A4336_4339 ( —■— ). Mean virus titre logl0 per lung ± standard error
for four mice per group is shown for each time point. * indicates statistically
significant difference between peak viral titres at day 5 post-infection in mice
infected with MHV-76(cA8+)M2A4336 4339 and mice infected with either MHV-76




















Figure 5.6.3.1 Spleen weights of BALB/c mice infected intranasally with 2 x 105
PFU of MHV-76 ( ^— ). MHV76(cA8+)4 ( —) and MHV-
76(cA8+)M2A4336.4339 ( —■— ). Mean spleen weight (mg) ± standard error is
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Figure 5.6.3.2 Total splenocyte numbers of BALB/c mice infected intranasally
with 2 x 105 PFU of MHV-76 ( ± ), MHV76(cA8+)4 ( and MHV-
76(cA8+)M2A4336.4339 ( —■— ). Mean total number of splenocytes ± standard
error is shown for four mice per group for each time point.
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remained higher than those of mice infected with MHV-76(cA8+)4 at 31 days
post-infection, although these results were not statistically significant. This data
therefore shows that disruption of the M2 ORF does not lead to any impairment in
the viral induction of splenomegaly when compared to a virus with an intact M2
ORF, although there may be possible evidence that the resolution of
splenomegaly is more protracted.
5.6.4. Latent virus in the spleen.
BALB/c mice were infected with 2 x 105 PFU of MHV-76, MHV-
76(cA8+)4 or MHV-76(cA8+)M2A4336-4339 intranasally, and the amount of latent
virus in the spleen was quantitated at various timepoints post-infection by
infective centre assay (see 2.6.3). Figure 5.6.4 shows that mice infected with
MHV-76(cA8+)4 showed high levels of latent virus in the spleen, peaking at day
14 post-infection. Mice infected with MHV-76 showed much lower levels of
latent virus in the spleen, but this latent virus was still detectable up to 31 days
post-infection. These results are in agreement with previous studies (see 3.8.4).
However, mice infected with MHV-76(cA8+)M2A4336-4339 showed low levels of
latent virus in the spleen at day 10, and these levels then gradually rose during the
time course of this experiment until the highest levels were observed at day 31
post-infection. There was no peak of latent virus detectable in the spleen during
the height of splenomegaly observed at day 14 post-infection in mice infected
with MHV-76(cA8+)M2A4336-4339- The difference in the amount of latent virus
detectable in the spleens of mice infected with MHV-76(cA8+)4 or MHV-
76(cA8+)M2A4336-4339 was statistically significant (MHV-76(cA8+)M2A4336_4339
vs. MHV-76(cA8+)4;Day 14, PO.OOl; Day 31, P<0.05).
There was a possibility that the latent virus detectable in the spleens of
mice infected with MHV-76(cA8+)M2A4336-4339 might be due to genetic
recombination in these viruses leading to the production of virus more competent
at establishing latency. This might occur by mutation at a second site in the M2
ORF, or by the insertion of a single nucleotide in the 4bp deletion to abolish the


































Figure 5.6.4. Latent virus in the spleens of BALB/c mice infected intranasally with
2 x 105 PFU of MHV-76 ( ± ), MHV76(cA8+)4 ( —) and MHV-
76(cA8+)M2A4336_4339 ( —■— ) as determined by infective centre assay. Infectious
virus titres (less than 10 PFU per 107 splenocytes) were subtracted from the
infective centre results. Mean infective centres per 107 splenocytes ± standard error
is shown for four mice per group for each time point. * indicates statistically
significant difference between the number of infective centres in mice infected with
MHV76(cA8+)4 and MHV-76(cA8+)M2A4336.4339 as determined by two-way
ANOVA with Bonferroni post-tests.
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for this possibility, three separate viral plaques from three different mice that
arose due to reactivation of latent MHV-76(cA8+)M2A4336-4339 in the infective
centre assay at day 14 post-infection were harvested. The DNA was extracted (see
2.8.3), and the M2 ORF amplified using primer pair M2GEX1 and M2GEX2
(Chapter 2, Appendix 2) with PfuTurbo™ DNA polymerase. The fragment was
inserted into the pKS(-) vector (Chapter 2, Appendix 3) using the BamRl and
EcoRl restriction enzyme sites, and the sequence was determined (see 2.2.24).
Sequence analysis showed that all three independent reactivated viral plaques
contained the 4bp deletion in the M2 ORF identical to that observed in the parent
cosmid (see Figure 5.3.2.2). There was therefore no evidence for the formation of
pseudorevertant viruses.
These results therefore show that disruption of the M2 ORF leads to a
significant decrease in the amount of latent virus detectable during the
establishment of latency in the spleen when compared to a virus with an intact M2
ORF. This may be due to either a decrease in the amount of latently infected
splenocytes or a failure of the virus to reactivate from latency. However, at day 31
post-infection higher levels of latent virus were detectable in the virus with a
disruption in the M2 ORF.
5.7. Discussion
These results describe a novel method for the generation of recombinant
viruses for the study of individual gene function in MHV-68, using mutagenesis
in cosmids to facilitate the creation of recombinant viruses. This method was used
to create a virus with a 4bp internal deletion in the M2 ORF, and preliminary
analysis of this virus showed that disruption of the M2 ORF had no effect on viral
replication in vitro. However, this recombinant virus achieved higher peak viral
titres in the lung but was significantly compromised in its ability to establish or
reactivate from latency in the spleen early in the course of infection. This virus
also appeared to be defective in the maintenance of latency at a later timepoint
post-infection. Disruption of the M2 ORF had no effect on the genesis of
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splenomegaly. These results show that M2 plays a significant role in MHV-68
pathogenesis.
The decision to construct recombinant viruses with no marker genes to
enable the selection of recombinant viruses was made because previous studies
have shown that the insertion of foreign DNA into the left end of the genome can
have deleterious effects on viral phenotype (Clambey et al., 2000; Adler et al.,
2001). This position-dependent effect does not occur in recombinant viruses that
contain deletions rather than insertions of foreign DNA, and it may be that
insertion of foreign DNA disrupts the expression of neighbouring genes.
However, selectable markers provide an excellent method of enriching
recombinant virus, and reducing the amount ofwild-type virus that was a problem
in the production of pure recombinant viruses in this study. Instead, a PCR-based
screening method was employed, which meant that no selectable marker genes
were required. This was a very sensitive technique, but had the disadvantage that
it could not distinguish pure recombinant virus from wild-type MHV-76. A
technique to detect the presence of MHV-76 is possible by using a PCR primer
pair to amplify a region bridging the terminal repeats and the left end ofMHV-76.
However, this requires one primer to anneal in the region of the terminal repeats,
which leads to non-specific annealing due to the repetitive nature and high GC
content of the terminal repeats (Virgin et al., 1997). This leads to amplification of
a number of bands, and makes interpretation of these results problematical
(B.Dutia, unpublished data). The experience of attempts to purify MHV-
76/tRNA7+8insert demonstrates that a reliable and robust PCR product is
required to enable proper selection of recombinant viruses.
The inability to purify recombinant virus MHV-76/M2insert despite three
independent attempts was apparently due to loss of the recombinant insert during
replication in vitro. Initially, most viral plaques were positive for the M2 ORF by
PCR but attempts to purify single plaques always led to the appearance of plaques
negative for the recombinant insert. One explanation for this is that the
recombinant virus MHV-76/M2insert was severely attenuated during replication
in vitro, and required the presence of wild-type MHV-76 to replicate ("helper"
virus). However, this is unlikely as no differences were observed between viruses
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containing an intact M2 ORF and a disrupted M2 ORF during viral replication in
BHK-21 cells (see 5.6.1). Purification by the selection of single plaques in a 96
well plate, which have arisen from a single plaque-forming unit, should lead to
purification or at least enrichment of the recombinant virus. However, it may be
that co-infection of cells with MHV-76 and MHV-76/M2insert was required to
propagate the recombinant virus. However, studies using MHV-76, MHV-
76(cA8+)4 and MHV-76(cA8+)M2A4336-4339 have all shown that M2 is non¬
essential for viral replication in vitro, arguing against the need for a helper virus.
Previous work has shown that expression of M2 leads to toxicity in
mammalian cells (Chapter 4), and this is supported by evidence showing that the
expression ofM2 is tightly regulated in vivo (Usherwood et al., 2000). M2 is also
transcribed at low levels in vitro (Bridgeman et al., 2001; Rochford et al., 2001),
which are below the levels of sensitivity for detection by Northern blot analysis
(Husain et al., 1999; Virgin et al., 1999). For this reason, it was decided to
produce a recombinant virus that expressed M2 from the natural viral promoter
rather than use an artificial promoter (such as the HCMV IE promoter) that may
have over-expressed the M2 protein. Attempts to purify recombinant virus MHV-
76/M2insert support the evidence for toxicity of the M2 protein, and suggest that
the insertion of the M2 ORF into MHV-76 leads to a selective disadvantage for
this virus, favouring deletion of this insert during replication. Attempts to purify
this recombinant virus resulted in the deletion of a portion of the recombination
cassette, as evidenced by the inability to amplify a section of the M3 ORF in the
cassette but the M2 ORF and the vtRNA7 locus were still detectable. MHV-68
has already been shown to spontaneously delete regions at the left end of the virus
during tissue culture passage (Chapter 3; Clambey et al., 2000) and this may be
assisted by the presence of deleterious sequences. The design of the recombinant
cassette for the generation of the M2insert virus may also have not included long-
range control elements further that lkb upstream of the transcriptional start site,
and it is also possible that the expression of M2 is tightly regulated or even
repressed by other genes in this genomic locus (for example Ml or M3), and that
it may not be feasible to insert the M2 ORF in isolation.
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The inability to purify recombinant virus MHV-76/tRNA7+8insert was
probably due to problems with the PCR-based screening method employed to
select for recombinant virus. The initial primer pair used generated a product that
was too large to be reliably amplified, and the second primer pair amplified a very
small region that was prone to false positive results. This demonstrates that a
reliable and robust PCR product is required to enable proper selection of
recombinant viruses, especially as the PCR reaction must work in the background
of cellular DNA and ions present in the sample (see 2.8.3). Two techniques could
be employed to circumvent these problems; either the design and use of a more
reliable primer pair to amplify a region of DNA in the insert sequence, or to
produce high quality viral DNA for use as template in the PCR reaction, free from
a background of cellular debris. Production of high quality DNA in sufficient
quantity would require more time, and would lead to a reduction in the number of
samples that it would be possible to screen for the presence of recombinant virus.
The manufacture of recombinant viruses by the construction of deletions
in cA8 gave a number of advantages over the traditional method of making
recombinant viruses by homologous recombination using plasmid constructs. The
use of cosmids enables mutations to be introduced by recombination in bacteria,
and by allowing homologous recombination with MHV-76, it facilitates the
isolation of recombinant viruses in the absence of background virus containing
the M2 ORF, making selection by a PCR-based screening method easier. The
large areas of overlap between the cosmid and MHV-76 allow for efficient
homologous recombination, and importantly viruses constructed in this manner
have shown to have an identical phenotype to MHV-68 in vitro and in vivo
(Chapter 3). As such, this technique should simplify the production of viruses
with deletions in the unique ORFs at the left end ofMHV-68.
It was decided to introduce small mutations in the M2 ORF in order to
minimise the potential disruption to the surrounding genes. Effects on
neighbouring genes are thought to be unlikely as the transcriptional control
elements for the Ml and M3 ORFs are located upstream of their respective
transcriptional start sites, away from the M2 ORF (see Figure 5.2.1), but this
requires confirmation by analysis of these transcripts in the recombinant viruses
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(for example, by RT-PCR or Northern analysis). There is also evidence of other
transcripts at the left end of the MHV-68 genome (B.Dutia, unpublished data),
which may be multiply-spliced transcripts crossing the terminal repeats in MHV-
68 similar to the LMP2 transcripts in EBV. Therefore minimal mutations in this
region are desirable to prevent effects on these transcripts. Disruption of the M2
ORF by the construction of a 4bp deletion at nucleotide positions 4336-4339 leads
to the production of a 90 a.a. protein consisting of the N-terminal 89 residues of
M2 fused to an arginine residue. This will lead to the deletion of the last three
residues of the M29i_99 CD8+ T cell epitope (Figure 5.3.2.2). This should be
enough to prevent recognition of the truncated M2 protein by the CTL immune
response, as the phenylalanine residue at position 2 and the leucine residue at
position 9 of the CD8+ T cell epitope are considered to be the H-2Kd allele
critical anchor residues for binding (Rammensee et al., 1995). However, it is still
possible that the remaining 89 residues of M2 present in M2A4336-4339 retain some
of the functions of M2. It is of note in this regard that a mutant of HSV-1
containing a 4bp deletion in UL14 generated using a similar method to that
described in this chapter was predicted to generate a protein consisting of the N-
terminal 96 a.a. of UL14. However, no UL14 protein was detectable by
immunoprecipitation (Cunningham et al., 2000). Studies using either independent
recombinant viruses with larger deletions in the M2 ORF (such as MHV-
76(cA8+)M2A4239-4494) or analysis of viral proteins using anti-M2 antibodies
would be required to demonstrate that no functional M2 protein was produced.
The inability to purify recombinant virus MHV-76(cA8+)M2A4239-4494 was
unexpected. This virus had been plaque purified five times on BHK-21 cells, and
there had been no evidence of M2 ORF negative viral plaques during the last
three rounds of purification. It is possible that the substantial deletion in the M2
ORF leads to a selective disadvantage in vitro, or it may be that spontaneous
deletion of the region at the left end of the genome occurred during the process of
producing viral stocks and viral DNA (similar to that which occurred to produce
MHV-76). This serves to emphasise that although MHV-68 and MHV-76 grow
well in tissue culture in a wide range of cell types, these viruses do not seem as
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tractable as HSV-1 in the generation of viral mutants. Time constraints have
meant that it was not possible to completely purify recombinant virus MHV-
76(cA8+)M2A4239-4494, but initial attempts have been made by in vivo passage of
the impure virus.
Preliminary results on the characterisation of the recombinant virus MHV-
76(cA8+)M2A4336-4339 have shown that this virus replicates identically in vitro to
the parent virus MHV-76 and a virus containing an intact M2 ORF, MHV-
76(cA8+)4. However, during lytic replication in the lungs of BALB/c mice,
MHV-76(cA8+)M2A4336-4339 exhibited peak lung viral titres that were
approximately 10-fold higher than either MHV-76 or MHV-76(cA8+)4 (Figure
5.6.2). Although expression of M2 has been demonstrated at low levels in the
lung during acute infection (Usherwood et al., 2000; Rochford et al., 2001), a role
for M2 during lytic replication in the lung was thought unlikely due to the fact
that M2 has been classified as a latency-associated gene (Husain et al., 1999;
Virgin et al., 1999). This increase in peak lung viral titres is unlikely to be due to
lytic viral replication alone, as the in vitro growth curves show that MHV-
76(cA8+)M2A4336-4339 has no replication advantage over MHV-76 or MHV-
76(cA8+)4. However, it would seem confusing why MHV-68 should possess the
M2 gene, which appears to limit viral titres in the site of primary replication in the
lung and therefore possibly reduce the seeding of virus to other organs and sites of
latency, unless it confers a significant advantage to the establishment of latency.
Disruption of the M2 ORF had no effect on the viral induction of
splenomegaly observed after infection with MHV-76(cA8+)M2A4336.4339. The
induction of splenomegaly is dependent on the presence of B lymphocytes
(Usherwood et al., 1996c; Week et al., 1996), CD4+ T lymphocytes (Ehtisham et
al., 1993; Usherwood et al., 1996a) and viral gene products present in the left end
of the genome (Bridgeman et al., 2001; see Chapter 3). It was hypothesised that
the M2 gene may be involved in the genesis of splenomegaly, as M2 is transiently
expressed in the spleen during the initiation of splenomegaly (Usherwood et al.,
2000). However, these results argue that the M2 ORF has no role in the
generation of splenomegaly, with the important caveat that the N-terminal 98 a.a.
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in M2 may still be functional in MHV-76(cA8+)M2A4336-4339. Studies using
viruses such as MHV-76(cA8+)M2A4239-4494 with more substantial deletions in
M2 would resolve this issue, and it is of note that subsequent steps to purify this
recombinant virus by in vivo passage resulted in splenomegaly in BALB/c mice
(data not shown).
In contrast to the generation of splenomegaly, disruption of the M2 ORF
had a significant effect on the amount of latent MHV-76(cA8+)M2A4336.4339
detectable in the spleen, and this demonstrates a critical role for the M2 protein in
the establishment or reactivation from latency. There was no peak of latently
infected splenocytes at day 14 post-infection in mice infected with MHV-
76(cA8+)M2A4336-4339, and this result is the first to dissociate splenomegaly and
the peak of latently infected splenocytes. The latent infection of B lymphocytes
leads to the activation and recruitment ofCD4+ T lymphocytes, leading to a rapid
increase in activated B and T lymphocyte populations (Usherwood et al., 1996a;
Stevenson & Doherty, 1999). This expansion is hypothesised to enable the virus
to establish latency in as many splenocytes as possible, maximising the number of
virus positive cells that escape CD8+ T lymphocyte-mediated control and thus
establish life-long persistence and latency (Stewart et al., 1998a; Nash et al.,
2001). These results suggest that the genesis of splenomegaly and the peak of
latently infected splenocytes are not as intricately linked as previously thought. It
is also thought that different MHV-68 viral genes are expressed in different stages
of latency, analogous to the different EBV latency programs (Rochford et al.,
2001; Usherwood et al., 2001). Infection of B cells by EBV in vitro leads to the
expression of all the latent genes presumed to facilitate the trans formation of B
cells (termed Latency III; Rickinson & Kieff, 1996). Similarly, M2 may be
expressed during a full latent gene expression program designed to expand the
number of latently infected cells, and therefore disruption of M2 would prevent
this peak in latently infected cells. The other possibility is that MHV-
76(cA8+)M2A4336-4339 is efficiently establishing a latent infection in splenocytes,
but that this virus has a greatly reduced efficiency of reactivation from latency in
the infective centre assay. This hypothesis could be tested by using techniques
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such as QF-PCR to quantitate the number of viral genome positive splenocytes
compared to the number of splenocytes reactivating virus in the infective centre
assay. However, the recombinant virus MHV-76(cA8+)M2A4336-4339 has no
deficiencies in lytic cycle replication as evidenced by the in vitro growth curves,
and the amount of virus reactivated in the infective centre assay increases over the
timecourse of the experiment, suggesting that there is no defect in reactivation.
The kinetics of the amount of latent virus detectable in the spleens of mice
infected with MHV-76(cA8+)M2A4336-4339 are also dramatically different from
that of MHV-76(cA8+)4. There is a gradual increase in the amount of latently
infected splenocytes detectable, such that the numbers are still increasing up to
the end of this experiment (31 days post-infection). Sequence analysis of three
independent reactivated viral plaques showed that this increase in the amount of
reactivated virus was not due to the generation of pseudorevertant viruses. Due to
time constraints, it was not possible to ascertain if the number of latently infected
splenocytes would peak and then decline, or if the immune response was unable
to control the latent infection and thus the numbers would continue to rise. The
control and decline in the number of latently infected splenocytes is mediated by
CD8+ T cells (Week et al., 1996; Stewart et al., 1998a), and it is thought that the
CTL response to the M29i.99 CD8+ T cell epitope results in the control of the
initial peak in latently infected cells during the first three weeks after infection
(Usherwood et al., 2000; Usherwood et al., 2001). One possibility is that the lack
of a functional M29i.99 CD8+ T cell epitope leads to a failure of recognition of
latently infected cells by the CD8+ T cell response, and thus a lack of control over
the latent infection. This would suggest that the only method of immunological
control over MHV-68 during the establishment of latency is via recognition of the
M2 protein, and analysis ofMHV-76 shows that this is not the case. During long-
term MHV-68 latency, the expression of M2 is silenced (either by the CTL
response or viral down-regulation) leading to a more restricted form of latency
(Usherwood et al., 2000). Along with the results showing that MHV-76 can
maintain long-term latency (Chapter 3), this suggests that disruption in M2 will
not prevent the virus MHV-76(cA8+)M2A4336-4339 maintaining long-term latency.
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In conjunction with the results from the characterisation of MHV-76
(Chapter 3), the phenotype of a recombinant virus with a disruption in the M2
gene gives further insights into the role of this region in MHV-68 infection, and
particularly the establishment and maintenance of latency. MHV-76 also lacks the
M291-99 CD8+ T cell epitope and the entire M2 ORF, but the immune response
still manages to quickly control the latent MHV-76 infection in the spleen, which
suggests that other genes at the left end of the genome are involved with M2 in
the subversion of the immune response. The most likely candidate is the M3 ORF,
due to its demonstration as a soluble chemokine-binding protein (van Berkel et
al., 1999; Parry et al., 2000; van Berkel et al., 2000) and the fact that deletion of
M3 severely reduces the ability of the virus to induce splenomegaly and establish
latency (Bridgeman et al., 2001). However, as shown by the studies with MHV-
76, none of these genes are essential for the establishment and maintenance of
latency suggesting that there is a degree of redundancy in the function of various
viral proteins.
Future work is required to confirm these results on the preliminary
characterisation of a recombinant virus disrupted in the M2 ORF. In particular,
purification of recombinant virus MHV-76(cA8+)M2A4239-4494 will address the
possibility that the remaining 98 N-terminal a.a. of M2 retain their function in
recombinant virus MHV-76(cA8+)M2A4336-4339. The construction and analysis of
revertant viruses will be necessary to show that there are no other deletions in the
recombinant viruses, although the Southern blot and PCR analysis suggest that
this is unlikely. It is also necessary to repeat these experiments over a longer
timecourse to ascertain the kinetics of latent virus in the spleen following
infection with MHV-76(cA8+)M2A4336-4339.
These results detail a novel method of producing recombinant viruses to
study the function of genes at the left end of the MHV-68 genome. Analysis of a
recombinant virus with a disruption in the M2 ORF reveals that this gene plays a
crucial role in the establishment of a normal latent load in the spleen, and the
control of latency after MHV-68 infection. Further studies using these viruses






The results presented in this thesis demonstrate that virus-specific gene
products present at the left end of the unique region perform key roles in the
pathogenesis of gammaherpesvirus infections, both in the evasion and
exploitation of the immune system. The Ml, M2, M3, M4 and eight vtRNA genes
in this locus of the MHV-68 genome play a central role in viral pathogenesis, as
deletion of these genes leads to a more rapid clearance of virus from the lungs
accompanied by an enhanced inflammatory response, and a dramatic decrease in
splenomegaly and the amount of latent virus during the establishment of latency
in the spleen. However, they are not essential for viral replication or the
maintenance of life-long latency. Herpesviruses only express an extremely
restricted set of viral genes during latency that are thought to be crucial for viral
persistence (see 1.1.3.2), and thus the classification of M2 and M3 as latency-
associated genes that are non-essential for latency presents the query of their role
during MHV-68 latency. In particular, M3 is expressed at late timepoints post¬
infection in vivo (Usherwood et al., 2000) so whilst expression of M3 is not
necessary for the virus to maintain latency, it is postulated to confer a significant
advantage to the virus at this time as it is transcribed as part of an extremely
restricted MHV-68 gene expression program (one of only 5 viral genes expressed
at late latent timepoints; see 1.4.3). The tightly regulated expression ofM2 during
the establishment of latency is also of interest, as the downregulation of M2
transcription appears to coincide with the induction of the CTL response against
the M2 protein (Usherwood et al., 2000). The marked reduction in the amount of
latent virus present during the establishment of latency shown by viruses which
do not expresses M2 (Chapters 3 and 5) and M3 (Chapter 3; Bridgeman et al.,
2001) suggests that M2 and M3 play a key role in assisting MHV-68 establish an
initial high latent viral load.
The spontaneous deletion of large sequences from the genome of
herpesviruses is a widely recognised but poorly understood phenomenon. The
deletion that resulted in the generation of MHV-76 most likely occurred during
the in vivo and in vitro passage steps during viral isolation. Apart from the 9.5kb
deletion, the remaining 20kb of sequence obtained from the MHV-76 genome
showed a single nucleotide difference from the MHV-68 sequence. MHV-76 was
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described as having been originally isolated from Apodemus species, which are
very divergent in evolutionary terms from the Clethrionomys species from which
MHV-68 was first isolated. Such a remarkably high degree of homology would
therefore be extremely unlikely to occur if MHV-76 was a naturally occurring
isolate, as the virus would be subject to variation due to mutations occurring
during replication over thousands of years. The most likely explanation is that
MHV-76 is not a true novel strain of murine herpesvirus but a deletion mutant of
MHV-68 that has occurred after isolation in vivo. It remains to be seen if the other
virus strains isolated at the same time are also closely related to MHV-68, but
previous work and sequence analysis of MHV-72 suggests that it is very similar
to MHV-68 (see 1.5). Conclusive results on the relationship of all the herpesvirus
isolates will require partial sequence analysis of the viral genomes and a
systematic evaluation of these viruses.
The precise mechanism whereby these deletions occur during replication
is unknown, but one hypothesis is that during replication in vitro the virus is not
under selective pressure from the immune system, and thus loss of these genes is
not deleterious to the virus and may in fact be advantageous if these genes are
toxic or impede lytic replication. However, these genes may be necessary for the
virus to reactivate from latency and this may be one explanation for the apparent
reduction in latent virus detectable by infective centre assay following MHV-76
infection. Future work to measure the amount of viral DNA present in the
splenocytes will be necessary to determine this.
The precise function of the M2 gene of MHV-68 has still to be resolved,
but the preliminary characterisation described in Chapter 4 gives some indication
as to its possible role. The localised sequence homology to the Gab2 and
semaphorin families is of interest due to their role in intracellular signal
transduction. Many gammaherpesviruses target intracellular signalling pathways,
such as the LMP-1 protein ofEBV (Farrell, 1998), and it may be that the localised
homology of M2 is sufficient to achieve this. The identification of a cellular
counterpart for the M2 protein awaits future data from the mouse and human
genome sequencing projects, but it may be that M2 has no cellular homologue and
has evolved and adapted to its natural host. Other results also suggest that M2
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may have a role in signal transduction such as the localisation of the M2 protein
to the plasma membrane in the cell, the predicted phosphorylation and
myristylation ofM2 and circumstantial evidence for the phosphorylation ofM2 as
shown by the visualisation ofM2 as a doublet band on Western analysis. It may
be necessary to use other techniques to purify and analyse M2 for potential
phosphorylation and myristylation, especially in view of the poor expression and
toxicity problems encountered. Further circumstantial evidence for the role ofM2
in signal transduction and in particular B lymphocyte activation pathways, is
provided by data showing that the M2 promoter is B-lymphocyte specific (S.M.
Husain, J.T. Sample, unpublished data), and that viruses containing a disruption in
the M2 ORF are defective in the establishment of splenic latency (Chapter 5).
These results suggest that M2 is expressed only in B cells during infection in vivo,
and that the M2 protein may result in the activation of B cells thus enhancing the
establishment of latency, particularly in the spleen. Future work to examine the
effects of M2 on B lymphocytes, especially naive cells, may help to resolve this
issue.
The exact localisation of the M2 protein at the plasma membrane remains
unknown, but due to the lack of a signal sequence suggestive of secretion and
hydrophobic domains that would be necessary for the M2 protein to interact with
the membrane, it is probable that the M2 protein is localised to the inner aspect of
the plasma membrane. The expression of M2 in mammalian cells means that the
use of techniques such as immunogold electron microscopy could be used to
determine the exact localisation of M2 in the cell. This probable localisation on
the inner aspect of the plasma membrane would enable M2 to interact with other
proteins involved in signal transduction, or other scaffolding proteins such as
Gab2. The role of the patchy nuclear and cytoplasmic expression ofM2 observed
in both the HA-epitope tagged M2 and the EGFP-M2 fusion proteins is unclear,
as these patches did not co-localise with markers used to stain DNA, the
endoplasmic reticulum, the Golgi apparatus or lysosomes. One explanation could
be that these areas are artefacts caused by the high level of M2 expression
promoted by the expression vectors, especially as M2 expression appears to be
tightly regulated at low levels during viral infection. An alternative explanation is
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that the M2 protein is in the process of being transported to the plasma membrane,
but expression in cells harvested at later timepoints after transfection shows a
similar pattern of expression (Figure 4.5.1.6) suggesting that this may not be the
case. Studies with a reliable purified anti-M2 antibody would enable visualisation
of M2 in S11 cells, and clarify whether or not the patchy cytoplasmic/nuclear
expression occurred during endogenous M2 expression.
The manufacture of recombinant viruses using MHV-76 and a cosmid
containing the left end of the unique portion of the viral genome enabled the rapid
and reliable production of mutant viruses, with the advantage of allowing
selection by a PCR-based screening method without wild-type virus background.
However, ensuring complete purification of mutant virus from MHV-76 was a
problem due to the lack of detection ofMHV-76 and thus it may be advantageous
to perform Southern analysis earlier during the purification process. Problems
were encountered with the production of recombinant viruses with the M2 insert
sequence due to the apparent toxicity of M2, and it therefore may be that
expression ofM2 is tightly regulated by other viral elements present in this region
of the genome. The large flanking sequences present in the cosmid ensured
efficient homologous recombination at the correct locus, and will enable the
production of recombinant viruses with deletions at the left end of the unique
portion of the genome to determine which genes are responsible for the altered
phenotype ofMHV-76.
The disruption of the M2 ORF using a 4bp deletion ensured that there was
minimal disruption to surrounding genes, which had been postulated to occur
previously during the insertion of foreign DNA into this region of the genome
(Clambey et al., 2000; Adler et al., 2001). However, this disruption could have
resulted in the formation of a protein containing the N-terminal 89 residues ofM2
that retained some function. Although this was thought to be unlikely, studies
using a mutant virus with a more substantial deletion in M2 (such as MHV-
76(cA8+)M2A4239-4494) would help to resolve this issue. This disruption in the M2
ORF led to higher peak viral titres in the lung and a dramatic reduction in the
amount and kinetics of latent virus in the spleen during the establishment and
maintenance of latency. The suppressive effect of M2 during lytic replication in
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the lung was unexpected, but may be explained by the observation that M2 is
toxic during expression in vitro (Chapter 4) and thus deleterious to the vims
during productive replication. Another explanation may be that the low levels of
M2 expression in the lung (Rochford et al., 2001) are sufficient to induce a CTL
response that results in the suppression of lytic replication. Preliminary
hypotheses that M2 was involved in the genesis of splenomegaly due to its
possible involvement in signal transduction pathways leading to B cell
proliferation also appear to be invalidated by these results showing that a
disruption in the M2 ORF has no effect on splenomegaly. However further work
is necessary to examine the expansion of particular splenocyte populations during
infection with MHV-76(cA8+)M2A4336-4339, as it may be that B cell proliferation
is impaired and this is concealed by the expansion in the T lymphocyte
population.
However, the most significant finding is that following infection with a
mutant vims with a dismption in the M2 ORF, the amount of latent vims
increases gradually after infection with the highest levels observed at the last
timepoint in the experiment (Figure 5.6.4). One possibility is that there is no
immune recognition of the M29i_99 CD8+ T cell epitope by BALB/c mice (H-2d),
and thus the CTL response cannot control the latent virus infection. However, the
M29i_99 CD8+ T cell epitope is not recognised in C57BL/6 mice (H-2b) that can
control latent MHV-68 infection, and this epitope is also absent in MHV-76,
which has a much reduced latent virus load so it would appear that this is not the
explanation. The other possibility is that there are compensatory mechanisms
involved in establishment of latency by MHV-68 and thus when the vims is
unable to establish latency efficiently during the period of splenomegaly, another
process is utilised by the virus at a time when M2 expression is switched off
during MHV-68 infection.
The results demonstrating that two vimses, MHV-76 and MHV-
76(cA8+)M2A4336-4339, do not generate the peak of latently infected splenocytes
normally observed at two weeks post-infection confirms previous findings that the
amplification processes utilised by MHV-68 during lytic replication and latent
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infection in vivo are separate. Thus a high titre of productive viral replication in
the lung is not necessary for seeding of virus to the spleen and the establishment
of normal levels of latent virus (Stevenson et ai, 1999b). These studies also
suggest two other consequences during MHV-68 infection. Firstly, that
splenomegaly and the peak of latently infected splenocytes observed during the
establishment of latency can be dissociated, and also that the lymphoproliferative
phase and expansion of latently infected cells is not necessary for the
establishment and maintenance of latency. Previous results with EBV suggested
that the Latency III gene expression programme is used during initial viral
infection to result in cellular proliferation and thus amplify the number of B
lymphocytes that can be latently infected, thus ensuring the establishment of
latency. However, results presented here suggest that this is not necessary and that
gammaherpesviruses can still establish and maintain latency at approximately
normal levels without the generation of splenomegaly (in the case of MHV-76) or
the initial peak of latently infected cells (in the case of MHV-76 and MHV-
76(cA8+)M2A4336„4339). It therefore remains to be determined exactly why
infection with MHV-68 results in an initial peak in the number of latently infected
cells if this is unnecessary, and may even be detrimental to the virus as it results
in an enhanced CD8+ T cell response via the M2 CTL epitope.
The amount of virus necessary to result in the establishment of lifelong
latency during natural primary infection with herpesviruses is currently unknown,
but thought to be low as the majority of the human population are infected with at
least one herpesviruses (such as HSV, VZV, CMV and EBV) showing that natural
infection is very efficient. However, most experimental techniques utilise
relatively high doses of virus during primary infection, including experimental
infection with MHV-68 using 2 x 105 PFU intranasally as described in this thesis.
One explanation of the results observed following infection with MHV-76 and
MHV-76(cA8+)M2A4336-4339 is that the high doses of infectious virus used
resulted in high levels of replicating virus in the lung, and these levels overcame
any defects that these viruses have during the establishment of latency. However,
if low doses of infectious viruses were used, MHV-76 and MHV-
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76(cA8+)M2A4336-4339 may have difficulty in establishing latency in vivo, with
latent infection being reduced, delayed or prolonged. Thus infection with low
doses of infectious viruses may reveal further defects in viral pathogenesis with
MHV-76 and MHV-76(cA8+)M2A4336-4339-
These results reveal the importance of the genetic elements present in the
left end of the unique region of the genome to MHV-68 pathogenicity, and also
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Infection of mice by murine gammaherpesvirus 68 (MHV-68) is an excellent small-animal model of gam¬
maherpesvirus pathogenesis in a natural host. We have carried out comparative studies of another herpesvi¬
rus, murine herpesvirus 76 (MHV-76), which was isolated at the same time as MHV-68 but from a different
murid host, the yellow-necked mouse (Apodemus flavicollis). Molecular analyses revealed that the MHV-76
genome is essentially identical to that of MHV-68, except for deletion of 9,538 bp at the left end of the unique
region. MHV-76 is therefore a deletion mutant that lacks four genes unique to MHV-68 {Ml, M2, M3, and M4)
as well as the eight viral tRNA-like genes. Replication of MHV-76 in cell culture was identical to that of
MHV-68. However, following infection of mice, MHV-76 was cleared more rapidly from the lungs. In line with
this, there was an increased inflammatory response in lungs with MHV-76. Splenomegaly was also significantly
reduced following MHV-76 infection, and much less latent MHV-76 was detected in the spleen. Nevertheless,
MHV-76 maintained long-term latency in the lungs and spleen. We utilized a cosmid containing the left end
of the MHV-68 genome to reinsert the deleted sequence into MHV-76 by recombination in infected cells, and
we isolated a rescuant virus designated MHV-76(cA8+)4 which was ostensibly genetically identical to MHV-68.
The growth properties of the rescuant in infected mice were identical to those of MHV-68. These results
demonstrate that genetic elements at the left end of the unique region of the MHV-68 genome play vital roles
in host evasion and are critical to the development of splenic pathology.
Infection of laboratory mice by murine gammaherpesvirus
68 (MHV-68) (formally designated murid herpesvirus 4) is an
excellent model system for the study of gammaherpesvirus
pathogenesis and for the development of therapeutic strategies
against these viruses (31). Following intranasal inoculation of
mice with MHV-68, productive infection initially occurs in the
lung (34). The acute, productive infection is cleared from the
lung by day 10 postinfection (p.i.) by CD8+ T cells (12), but the
virus then persists in a latent form in epithelial cells at this site
(32). MHV-68 spreads to the spleen during the subsequent
viremia, where it becomes latent in B lymphocytes, macro¬
phages, and dendritic cells (13, 35, 39, 44). Establishment of
latency in the spleen is associated with a marked splenomegaly
and a mononucleosis that resembles that caused by primary
infection of humans by Epstein-Barr virus (36). Splenomegaly
is driven by CD4+ T cells (12, 37) and is dependent on the
presence of MHV-68-infected B cells in the spleen (39, 43).
The resolution of splenomegaly is achieved by CD8+ T cells
(12, 43), which are also important in the long-term control of
persistent infection (5, 32, 43).
The MHV-68 genome consists of a unique region of 118,237
bp flanked on each side by multiple copies of a 1,213-bp ter¬
minal repeat (11, 42). The left end of the unique region has
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attracted considerable interest owing to the presence of four
protein-coding genes {Ml, M2, M3, and M4) and eight viral
tRNA-like (vtRNA) genes, all of which lack counterparts in
other gammaherpesviruses (4, 42). Of these, only the function
ofM3 has been elucidated. This gene encodes a secreted che-
mokine binding protein that is expressed during acute infection
and persistence in mice (25, 38, 40, 41). Ml has been shown to
be nonessential for lytic replication in vitro and in vivo for the
maintenance and establishment of latency (6, 28). M2 is ex¬
pressed during latency in vitro and in vivo (14, 41) and contains
a CD8+ T-cell epitope, which is a target for the host immune
response (14, 38). The vtRNA genes are abundantly expressed
during lytic and latent infection (4), but their functional sig¬
nificance is not known.
Field studies in Slovakia aimed at identifying a small-animal
vector for flaviviruses resulted in the isolation of five herpes¬
viruses from two species of murid rodents (3). MHV-60, -68,
and -72 were isolated from the bank vole {Clethrionomys
glareolus), and MHV-76 and -78 were isolated from the yellow-
necked wood mouse {Apodemus flavicollis). Further molecular
studies ofMHV-68 and sequencing of the genome showed that
it belongs to the genus Rhadinovirus (often referred to as
gamma-2 herpesviruses), which includes Kaposi's sarcoma-as¬
sociated herpesvirus and herpesvirus saimiri (HVS) (10, 24, 42).
Of the other herpesvirus strains isolated alongside MHV-68
(3), only MHV-72 has been studied. This virus, which was
isolated from the same host as MHV-68, appears to have
similar biological properties in that it infects B lymphocytes
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(22, 26) and long-term infection is associated with tumorigen-
esis (21). In contrast, MHV-76 was isolated from a different
murid species (3). Therefore, we hypothesized that it may have
different biological characteristics and thus yield additional
insights into gammaherpesvirus pathogenesis. In this paper, we
describe the characterization of MHV-76. We demonstrate
that the MHV-76 genome is essentially identical to that of
MHV-68 except that it lacks Ml, M2, M3, M4, and all of the
vtRNA genes. We show that MHV-76 shares many biological
features with MHV-68, including identical growth in vitro,
productive infection in the lung, and the establishment and
maintenance of latency in B lymphocytes. However, it is much
less pathogenic in vivo than MHV-68, and reduced pathoge¬
nicity is associated with an increased inflammatory response. A
rescuant virus was constructed by insertion of the left end of
the MHV-68 genome into that of MHV-76. The MHV-76-
derived rescuant regained the in vivo properties of MHV-68.
We conclude that this region of the MHV-68 genome plays an
important role in pathogenesis.
MATERIALS AND METHODS
Cell line and virus. Viruses were grown and titrated using BHK-21 cells as
described previously (34). MHV-68 was originally isolated during field studies
from the bank vole, C. glareolus (3), and was subsequently plaque purified on
BHK-21 cells to obtain clone g2.4 as described by Efstathiou et al. (11). MHV-76
was isolated from the yellow-necked mouse, A. flavicollis, during the same field
study and was plaque purified thrice on BHK-21 cells to obtain a pure stock
Purification of viral DNA. MHV-76 or MHV-68 DNA was prepared from
purified virions as described previously (11). The DNAs migrated as a single
band of high molecular weight by agarose gel electrophoresis and resulted in the
production of infectious virus when transfected into BHK-21 cells (not shown).
For some experiments, high-molecular-weight DNA was also prepared from
infected cells.
Analyses of MHV-76 DNA. Restriction endonuclease digestion and Southern
blot hybridization were carried out using standard procedures. Cosmid clones of
MHV-68 and MHV-76 DNAs were prepared as described previously (7) using
infected-cell DNA and were identified by standard colony hybridization proto¬
cols. Pertinent cosmids were an MHV-68 cosmid (cA8) containing nucleotides
115165 to 26842 and an MHV-76 cosmid (cMl) containing the region equivalent
to nucleotides 115587 to 26842. Both cosmids originated from circular or con-
catemeric forms and thus contain both ends of the genome. Nucleotide coordi¬
nates are given according to the genome sequence published by Virgin et al. (42).
The DNA sequence of cosmid Ml was determined by standard procedures of
sonication, end repair, and cloning into bacteriophage M13mpl9. Inserts were
sequenced using an ABI Prism 377 DNA sequencer, and the data were assem¬
bled into the finished sequence using the Sequence Assembly Program (30).
Determination of viral DNA in tissue samples. Viral DNA was extracted from
blood and tissues using QIAmp DNA minikits (Qiagen) according to the man¬
ufacturer's instructions. DNA quantification was performed using a DNA fluo-
rimeter (DyNA Quant 200; Pharmacia). PCR amplification was performed on 1
ixg of high-molecular-weight DNA using primers specific for the gpl50 or M3
gene as described below. PCR products (15 p.1) were electrophoresed through
1.5% agarose gels and analyzed by Southern blot hybridization to confirm the
specificity of the products. DNA was blotted onto Hybond N+ membranes
(Amersham) and hybridized to 32P-labeled probes specific for gpl50 or M3.
PCR analysis of viral genomes. PCR amplification was performed using 1 pg
of viral DNA as the template for 40 cycles under conditions described previously
(38). In addition, negative control reactions for all primer sets were performed
using water instead of template DNA (not shown). Primer sequences were as
follows: forMl, 5'-GTT ACC TAG GAC ATA CAG TGG-3' and 5'-CAG AAC
CTT ACC AGT CAT GTG-3' (product size, 279 bp); for M2, 5'-GCG GGA
TCC ATG GCC CCA ACA CCC CCA C-3' and 5'-GCG GAA TTC GTT ATG
TTC TGC GTT AGC ACC-3' (product size, 654 bp); for M3,5'-TGG CAC TCA
AAC TTG GTT GTG G-3' and 5'-TAA CAG GCA GAT TGC CAT TCC C-3'
(product size, 381 bp); for M4, 5'-GCG CGG ATC CGA CAC CTG GAG AAG
ATG ATG ATA TTC C-3' and 5'-CGC GGA ATT CGG TTC TAG AAA GTC
ATA AAT CTC AAT ACC-3' (product size, 1,452 bp); forgpl50, 5'-GCG CAA
GCT TCG CCG CCA CCA TGT GTG GCG TTA AAT-3' and 5'-CGC GCT
CGA GTT ATT CAT GTA AAC ACA CAC AG-3' (product size, 1,533 bp); and
for ORF 74, 5'-GCC ACG ATG CTT GTC CTG CG-3' and 5'-TTA GGA GCT
TAG TCT ACA AAC TG-3' (product size, 1,010 bp).
A modification was used to analyze viral plaques or viral stocks. The virus
sample (10 pi; approximately 10 PFU) was added to PCR mix without Taq DNA
polymerase. Proteinase K (Roche) was then added to 0.2 pg/pl. After incubation
at 65°C for 15 min and then at 95°C for 10 min, 1 U of Taq DNA polymerase
(Gibco/BRL) was added and 40 cycles of amplification were performed.
Construction of rescuant viruses. MHV-76 genomic DNA and cosmid A8
were cotransfected into BHK-21 cells by electroporation. After 6 days, the
monolayer was harvested and the supernatant was used to infect BALB/c mice.
After 14 days, the spleens were harvested and analyzed by infective-center assay.
Individual plaques containing rescued virus were identified by PCR amplification
of the M2 and ORF 74 open reading frames (ORFs). Viruses were plaque
purified by limiting-dilution assay on BHK-21 cells until they were homogeneous
by PCR screening.
Southern analysis. High-molecular-weight DNA was isolated from infected
BHK-21 cells and cut with restriction enzymes according to the instructions of
the manufacturer (Gibco/BRL). Southern analysis was then performed by estab¬
lished procedures (27), and probes were labeled with 32P using a random-primed
DNA labeling kit (Roche).
In vitro infections. Single-step growth curves were obtained by infecting sub-
confluent BHK-21 cells at a multiplicity of infection (MOI) of 5. After adsorption
for 1 h, the wells were washed with medium to remove unbound virus and fresh
medium was added. At various times p.i., the wells were harvested and infectious
virus was quantified by plaque assay as described below. All experiments were
carried out in duplicate.
Infection of mice and analysis of tissues. BALB/c mice were purchased from
Bantin and Kingman and infected when 4 to 6 weeks old. Mice were anesthetized
with halothane and inoculated intranasally with 2 X 105 PFU of virus in 40 pi of
sterile phosphate-buffered saline. At various times p.i., mice were euthanatized
by cervical dislocation and tissues were harvested for analysis. Plaque assays were
performed using BHK-21 cells to detect infectious virus as described previously
(34). The limit of detection of the plaque assay was 10 PFU per organ. An
infective-center assay was used to detect latent virus as described previously (34).
The data were analyzed statistically using the two-sample t test. P values are
indicated in Results.
Histopathology. After euthanasia by C02 asphyxiation, the lungs were per¬
fused in situ via the trachea using 10% neutral buffered Formol saline. Portions
of spleen were also fixed in 10% buffered Formol saline, and the tissues were
processed routinely into paraffin wax-embedded sections. These were stained
with hematoxylin and eosin and examined by light microscopy.
Nucleotide sequence accession number. The sequence of the MHV-76 insert
in cosmid Ml was deposited with the GenBank data library under accession
number AF324455.
RESULTS
The MHV-76 genome is essentially identical to that ofMHV-
68, except for a 9,538-bp deletion at the left end of the unique
region. To assess the genetic differences between MHV-68 and
MHV-76, we compared the restriction fragment banding pat¬
terns of the two strains. Figure 1A shows the products of
MHV-68 and MHV-76 DNAs digested with eight restriction
endonucleases cleaving at a total of 185 unique sites. Each
enzyme produced several fragments of identical mobility from
both DNAs, indicating that the genomes are closely related.
However, differences in the restriction profiles were apparent.
Using maps predicted from the MHV-68 genome sequence,
three regions of difference were identified. These are summa¬
rized in Fig. IB.
Two regions correspond to noncoding tandem repeats con¬
taining variable copy numbers of 40- or 100-bp elements, at
approximately kbp 27 and 100 in the genome, respectively. The
former region was 0.4 kbp smaller in MHV-76 (approximately
10 copies fewer of the 40 bp element), and the latter region was
1.2 kbp larger (approximately 12 copies more of the 100-bp
element). As examples, relevant bands are indicated for the
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FIG. 1. Structure of the MHV-76 genome. (A) Restriction endonuclease profiles of MHV-68 and MHV-76 virion DNAs. Samples were
analyzed on a 0.8% agarose gel. Fragments E and J are indicated in the WmdIII profile of MHV-68. These are absent from the Hindlll profile
of MHV-76. Fragments containing the 40-bp repeat (upper pair) and the 100-bp repeat (lower pair) are connected by lines in the Sacl profiles of
MHV-68 and MHV-76. Molecular size markers and their sizes in kilobase pairs are indicated to the left. (B) Restriction endonuclease maps of
the unique region of the MHV-68 genome, highlighting the three regions that differ in MHV-76. Variable copy numbers of the terminal repeat
(not shown) flank the unique region, resulting in heterogeneous populations of fragments from the genome termini differing by increments of 1.2
kbp. None of the restriction endonucleases for which maps are shown cleave the terminal repeat. Three regions in which MHV-76 and MHV-68
differ are denoted by thicker horizontal lines. Two correspond to variations in the copy number of reiterations in the 40-bp repeat (at kbp 27) and
100-bp repeat (at kbp 100). The third represents a deletion at the left end. Minimal and maximal extents of the deletion as deduced from panel
A are indicated by thicker and thinner lines, respectively. The location of the insert in MHV-68 cosmid A8 is indicated at the bottom, with terminal
repeat sequences dashed, and the corresponding fragment nomenclature is included in the Hindlll map.
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FIG. 2. (A) Autoradiograph of a Southern blot of a 0.8% agarose
gel showing the results of hybridizing radiolabeled Hindill E (isolated
from a plasmid [11]) to the //mdlll products of MHV-68 and MFIV-76
DNAs and three MHV-68 cosmids (cA8, cA4, and cA13) and one
MHV-76 cosmid (cMl) containing the left end of the genome. The
Hindlll E fragment (6,155 bp) is indicated. (B) PCR analysis of the
MHV-68 and MHV-76 genomes. PCR amplification was performed on
viral DNA templates using primers specific for Ml, M2, M3, M4, and
gpl50 as indicated. Reaction products were analyzed on a 1% agarose
SacI profile in Fig. 1A. Copy number variation in repeats has
long been known to occur in herpesvirus genomes (for exam¬
ple, see reference 8).
The third region corresponds to the left end of the unique
region. The profiles were consistent with the absence from the
MHV-76 genome of a sequence which extends in the MHV-68
genome from a position between nucleotides 1 and 111 to a
position between nucleotides 7962 and 10526. As examples,
relevant bands (E and J) are indicated for the HindlU profile
in Fig. 1A. The absence of sequences in HindlU E from
MHV-76 and cosmid Ml (derived from MHV-76 DNA) was
confirmed by Southern blot hybridization (Fig. 2A). The only
other difference detected between the two genomes was the
presence of an additional Sphl site in the MHV-76 Sphl frag¬
ment at nucleotides 32139 to 44301. This could in principle be
the result of a single nucleotide difference.
To characterize the sequence absent from MHV-76 accu¬
rately, the sequence of cosmid Ml was determined. In com¬
parison with MHV-68, a 9,538-bp region corresponding to the
last nucleotide of the terminal repeat and the first 9,537 bp of
the unique region in MHV-68 was absent from the cosmid. The
absence of this sequence is fully consistent with the genomic
restriction profiles described above. Two minor differences
were also observed between the 21,168-bp sequence of the
cosmid insert and the relevant part of the MHV-68 sequence.
One is trivial, mapping in a GC tract in the terminal repeat
known to be variable in length (24). The other consists of a G
residue at nucleotide 12280 in the coding region for MHV-68
ORF 6, which is present as an A residue in MHV-76, resulting
in substitution of a serine for a glycine residue. This difference
was confirmed by PCR and sequencing of the appropriate
regions of the MHV-68 and MHV-76 DNAs (not shown).
We conclude that MHV-76 and MHV-68 are essentially
identical, except for the absence from MHV-76 of 9,538 bp at
the left end of the unique region. MHV-76 therefore repre¬
sents a deletion mutant of MHV-68 or another highly related
virus rather than a distinct viral species.
MHV-76 lacks MHV-68 genes Ml, M2, M3, and M4 and
vtRNAs. To check that none of the sequences from the 9,538-bp
deletion are present elsewhere in the genome, MHV-76 DNA
was analyzed by PCR. MHV-76 and MHV-68 genomic DNAs
were tested using primers specific for the Ml, M2, M3, M4, and
gpl50 genes. The results are shown in Fig. 2B. All of the
sequences assayed were amplified from MHV-68 DNA, but
only the gpl50 sequence was amplified from MHV-76 DNA.
These results are consistent with the findings described
above. MHV-76 is thus a deletion mutant of MHV-68 that
lacks Ml, M2, M3, most of the 5' portion of M4, and all eight
vtRNA genes. This is depicted schematically in Fig. 2C.
MHV-76 growth in vitro is similar to that of MHV-68.
Figure 3A shows single-step growth curves determined for
MHV-76 and MHV-68 in BHK-21 cells infected at an MOI of
gel. Molecular size markers and their sizes in kilobase pairs are indi¬
cated to the left. (C) Schematic diagram (not to scale) showing the
structures of the left ends of the MHV-68 and MHV-76 genomes. The
open arrows indicate protein-coding regions, and the small arrowheads
indicate the vtRNA genes. The open rectangle in MHV-76 indicates
residual M4 sequence. TRs, terminal repeats.



































FIG. 3. Biological characterization of MHV-76. (A) Single-step growth curves of MHV-68 (■) and MHV-76 (O) on BHK-21 cells at an MOI
of 5. Data are shown as mean log1() virus titer ± standard error and are representative of two separate experiments, each carried out in duplicate.
(B) Viral replication in the lungs of BALB/c mice infected intranasally with 2 X 105 PFU of MHV-68 (■) or MHV-76 (O). The mean log10 virus
titer ± standard error for four mice per group is shown for each time point. (C) Numbers of spleen cells during intranasal infection of BALB/c
mice with 2 X 105 PFU of MHV-68 (■) or MHV-76 (O). The mean total number of splenocytes ± standard error for four mice per group is shown
for each time point. (D) Latent virus in the spleens of BALB/c mice infected with 2 x 105 PFU of MHV-68 (■) or MHV-76 (O) as determined
by infective-center assay. Infectious virus titers (less than 50 PFU per spleen) were subtracted from the infective-center results. The mean number
of infective centers per spleen ± standard error for four mice per group is shown for each time point.
5. As reported previously (33), MHV-68 replicated efficiently,
attaining maximal titers at around 60 h p.i. MHV-76 replicated
with the same kinetics and attained titers similar to those of
MHV-68. Thus, there was no significant difference between
MHV-68 and MHV-76 in their ability to replicate in vitro.
MHV-76 is cleared more rapidly than MHV-68 from the
lung. The ability of MHV-76 to replicate productively in vivo
was assessed. Mice were infected with MHV-76 or MHV-68,
and the virus titer in the lungs was assessed at various times p.i.
by plaque assay. Figure 3B shows that the titers of infectious
MHV-68 peaked at day 6 p.i. and remained detectable through
day 12 p.i. In contrast, MHV-76 titers peaked at day 4 p.i. and
were undetectable at day 10 p.i. There was also a significant
quantitative difference between the maximal titers achieved by
each virus (MHV-68, 1.9 X 105 PFU/lung; MHV-76, 2.4 X 104
PFU/lung [P = 0.001]). These results indicate that MHV-76
replicates productively in vivo but is cleared more rapidly than
MHV-68 from the site of primary viral replication.
MHV-76-induced splenomegaly is less marked than that
induced by MHV-68. To determine the extent of splenomegaly
after MHV-76 infection, the total number of splenocytes in
mice infected with MHV-76 or MHV-68 was determined. As
seen in Fig. 3C, MHV-68 induced a characteristic increase in
splenocyte number that peaked at 14 days p.i. MHV-76 infec¬
tion also caused an increase in cellularity in the spleen, but the
peak was significantly lower than that detected after MHV-68
infection (P = 0.01). In addition, maximal cell numbers were
achieved slightly earlier, at between 10 and 14 days p.i.
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MHV-76 establishes latency in the spleen but at much lower
levels than MHV-68. To investigate the ability of MHV-76 to
establish latency in vivo, mice were infected and latent virus in
the spleen was measured using an infective-center assay. The
results are shown in Fig. 3D. MHV-68 infective centers were
detected at around day 7 p.i. and peaked at day 14 p.i. In
contrast, latent MHV-76 in the spleen peaked at day 10 p.i.,
and the amount of latent virus was very much less (day 10, P —
0.003; day 21, P < 0.001). MHV-76 infective centers were still
detectable at 31 days p.i., at levels of approximately 5 per 107
splenocytes. This indicates that MHV-76 can establish latency
in the spleen cell population but at much-reduced levels com¬
pared to MHV-68.
To check that MHV-76 did not have an altered cellular
tropism in the spleen, we harvested spleens at 14 days p.i. and
fractionated cells into CD19+ cells (B lymphocytes) and
CD19" cells (non-B cells) using magnetic cell sorting as de¬
scribed previously (9). The purity of the separated fractions
was tested by fluorescence-activated cell sorter analysis and
found to be >95%. The two cell fractions as well as the total
cell population were analyzed for the presence of latent virus
using the infective-center assay. Greater than 90% of the in¬
fective centers present in the splenocytes were present within
the CD19+-B-cell subpopulation (not shown). A small amount
(<5%) of latent virus was also detected in the CD19" frac¬
tions. Thus, the distribution of the MHV-76 within different
cell types in the spleen during splenomegaly appears to be
similar to that of MHV-68 (35), in that the majority of infective
centers were associated with B lymphocytes.
MHV-76 maintains long-term persistence in the spleen and
lung. The results of the infective-center assays described above
demonstrated that MHV-76 was able to establish latency dur¬
ing the first 30 days of infection, albeit at a lower level than
MHV-68. To ascertain whether MHV-76 is subsequently
cleared or is able to persist, mice were infected with MHV-76
and MHV-68. After 5 months, organs from these mice were
analyzed for the presence of virus. Three of the four mice were
positive for MHV-76 infective centers in the spleen, at levels of
approximately 1 to 2 latently infected cells per 107 splenocytes.
No infectious virus was detected in this organ by plaque assay.
To analyze the presence of persisting virus in other organs,
DNA was extracted from the livers, lungs, kidneys, spleens, and
white blood cells of four MHV-76-infected mice at 5 months
p.i. Organs from one mouse infected with MHV-68 were also
harvested at 5 months p.i as a positive control, and those from
two uninfected mice were harvested as negative controls. Ex¬
tracted DNA was analyzed for the presence of the viral ge¬
nome by PCR amplification using primers specific for MHV-68
gplSO, followed by Southern blot hybridization with a gpl50-
specific probe to confirm the identity of the products. For each
set of PCRs, samples containing purified viral DNA or no
DNA were included as positive and negative controls, respec¬
tively. Using known amounts of cloned template, it was deter¬
mined that this process was sensitive to 1 to 10 copies of the
viral genome in 1 p.g of high-molecular-weight DNA (not
shown).
As shown in Fig. 4A, viral DNA was not detected in either
of the uninfected mice. In agreement with our previous find¬
ings (32), viral genomes were detected in the spleens and lungs
of the MHV-68-infected mouse but not in the blood or other
organs. Viral DNA was found in spleens of all four mice
infected with MHV-76 but in the lungs of only one of these
mice. To address the possibility that MHV-76-infected mice
may have been contaminated with MHV-68, we tested the
same DNA samples by PCR using primers specific for the
MHV-68 M3 gene, which is absent from MHV-76. Figure 4B
shows that the M3 sequence was detected only in the MHV-
68-infected mouse and not in any of the MHV-76-infected or
uninfected mice. The inability to detect the M3 sequence con¬
firmed that the MHV-76 viral stocks were free of MHV-68 and
that the persisting virus in MHV-76-infccted mice was defi¬
nitely MHV-76.
These results show that MHV-76 is able to persist as effi¬
ciently as MHV-68 in the spleen but that it was not as efficient
at persisting in lungs.
The inflammatory response is greater in the lung during
MHV-76 infection than during MHV-68 infection. The results
described above show that there were clear differences be¬
tween MHV-76 and MHV-68 in their ability to replicate pro¬
ductively in the lung and cause splenomegaly. This was prob¬
ably due to differences in the host response to the virus, as
there was no intrinsic difference in the ability of the viruses to
replicate in vitro. As a preliminary response to this hypothesis,
we undertook a histopathological study of organs after infec¬
tion, examining the lungs and spleens of infected mice at var¬
ious times p.i. Representative results are shown in Fig. 5.
At 4 days p.i. with MHV-76, there was a marked inflamma¬
tory response in the lungs, consisting of perivascular lymphoid
infiltrates and edema. Subpleural lymphoid accumulations
were also seen at this time p.i. (not shown). In contrast, no
inflammatory response was observed at day 4 p.i. in the lungs
of MHV-68-infected mice. By day 6 p.i., the inflammatory
changes seen during MHV-76 infection were more severe and
extensive than those on day 4, consisting of perivascular and
interstitial lymphoid infiltration, thickened alveolar walls, and
vasculitis. In contrast, the inflammatory changes were less pro¬
nounced in MHV-68 infection at day 6 p.i., consisting mostly of
perivascular and interstitial lymphoid aggregations. At later
times (days 8 and 10 p.i.), the inflammatory responses follow¬
ing MHV-76 and MHV-68 infections were similar (not shown).
These results demonstrate that the inflammatory changes
seen in the infected lung occur earlier and are more substantial
with MHV-76 than with MHV-68.
In the spleens of both MHV-68- and MHV-76-infected mice
at day 10 p.i., there was evidence of follicular hyperplasia as
revealed by germinal center formation and an increase in the
marginal zone of the white pulp. However, the differences
between the two groups, if any, were marginal and hard to
quantify by histopathology alone (not shown).
Construction of rescuant viruses. To determine definitively
whether the differences observed between MHV-76 and -68
were due to deletion of genes at the left end of the genome or
to unidentified mutations elsewhere in the genome, we con¬
structed rescuants by cotransfecting MHV-76 genomic DNA
with MHV-68 cosmid A8 into BHK-21 cells. Since rescuants in
which the deletion was restored were likely to be less attenu¬
ated in vivo, the progeny were passaged in mice. Spleens were
harvested, and virus was reactivated using an infective-center
assay. Plaques were screened for the presence or absence of
the M2 gene by PCR and assessed as representing pure viral
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FIG. 4. Detection of MHV-76 DNA in the tissues of mice at 5 months p.i. Four BALB/c mice were infected with 2 X 1()5 PFU of MHV-76,
and the lungs, livers, spleens, kidneys, and blood were harvested at 5 months p.i. Two uninfected mice were also harvested as negative controls,
and one mouse infected 5 months previously with MHV-68 was harvested as a positive control. Viral DNA was extracted, and PGR amplification
was performed on 1 p.g of high-molecular-weight DNA. Samples containing MHV-68 viral DNA as a template (first lanes) or lacking DNA (second
lanes) were used as positive and negative controls, respectively. (A) PGR amplification using primers specific for gp!50. PCR products were
analyzed by Southern blot hybridization with a 32P-labeled gpl50 probe to confirm specificity. (B) PCR amplification using primers specific for M3
(a gene absent from MHV-76). PCR products were analyzed by Southern blot hybridization with a :P-labeled M3 probe to confirm specificity.
clones on the basis of the presence or absence of M2 from all
subsequent plaques.
Three progeny clones were selected for further character¬
ization. MHV-76(cA8+)3 and MHV-76(cA8+)4 were both
positive for M2 and thus represented rescuants in which the
deleted region had been restored. MHV-76(cA8-)5 was nega¬
tive for M2 and thus represented unrestored MHV-76, which
had been subjected to in vivo passage in precisely the same way
as the rescuants. To check the genome structures, Hindlll and
EcoRI digests were analyzed by Southern blot hybridization
using MHV-68 cosmid A8 as a probe. The results are shown in
Fig. 6A. Cosmid A8 contains sequences from MHV-68Hindlll
B,C, E, G, 1, J, N, S, T2, U2, and Z2 (Fig. IB). Hindlll E, J, and
U2 are absent from MHV-76, and the remaining part of
Hindlll J is present in a novel fragment containing the termi¬
nal repeats. This fragment (JA) and T2 should thus appear as
a faint ladder of bands increasing to substantial sizes in in¬
crements of 1.2 kbp. As expected, rescuant viruses MHV-
76(cA8+)3 and MHV-76(cA8+)4 yielded profiles identical to
that of MHV-68, and /7/7;dIIl E was absent from MHV-76 and
MHV-76(cA8-)5. HindlU S and Z2 were too small to be
present on the blot. Hybridization to fragments containing the
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MHV-76: d4 lung
FIG. 5. Histopathological changes in the lungs of mice infected with MHV-76 or MHV-68. Representative sections of lung and spleen stained
with hematoxylin and eosin are shown for mice infected for the times indicated. Salient pathological features are highlighted as follows: P.
perivascular infiltration; 13V, blood vessel; I. interstitial infiltration; V. vasculitis.
terminal repeats (U2+, T2+, and appeared as high-nto-
lecular-weight products, and the laddering normally associated
with such fragments was too weak to be detected. The same
blot was reprobed with a fragment containing full-length M3
which crosses the boundary between Hindlll E and J. Figure
bB shows that both fragments are present in MHV-68 and the
two rescuants but absent from MHV-76 or MHV-76(cA8-)5.
These data indicate that the sequence absent from MHV-76
was restored in MHV-76(cA8+)3 and MHV-76(cA8+)4.
Sequence analysis of the region containing nucleotide 12280,
which is a G residue in MHV-68 but an A residue in MHV-76,
showed that the rescuants contain a G residue and MHV-
76(cA8-)5 contains an A residue. This is consistent with rescue
not only of the deleted sequences in MHV-76 by cosmid A8
but also of adjacent sequences.
We also analyzed viral DNA by PCR using primers specific
for Ml, M2, M3, and M4. The results are shown in Fig. 6C.
ORF 74 primers amplified fragments of the anticipated size
from all three viral DNA samples. Primers specific for Ml, M2,
M3, and M4 generated appropriately sized products from the
rescuants but not from MHV-76(cA8-)5. PCR of the viral
stocks produced the same results (not shown). This confirms
that Ml, M2, M3, and M4 were restored in the rescuants hut
not in MHV-76(cA8-)5.
Evidence that the rescuants were derived from MHV-76.
Variation in the copy number of reiterated sequences has been
shown to occur in MHV-68 (1). Therefore, we utilized the copy
number of the 100-bp repeat to assess the origin of the rescu¬
ants. Viral DNA was digested with HincU and analyzed by
Southern blot hybridization using a radiolabeled RamM probe,
which is predicted to hybridize to a fragment containing the
100-bp repeat and to an adjacent fragment of 5,032 bp. The
results are shown in Fig. 6D. The MHV-68 fiaginuit contain¬
ing the 100-bp repeat was approximately 2.4 kbp in size,
whereas that derived from MHV-76 was 4 kbp. A fragment of
approximately 4 kbp was identified in both rescuants and
MHV-76(cA8-)5, except that MHV-76(cA8+)3 also produced
a fragment of 3.4 kbp. These results show that the copy number
in MHV-68 DNA is approximately 22, as described previously
(42). However, MHV-76 and three derived viruses contained a
larger number (approximately 37 copies), and a subpopulation
of MHV-76(cA8+ )3 also contained an intermediate number
(approximately 30). These results are consistent with deriva¬
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FIG. 6. Molecular characterization of rescuant viruses. (A) Autoradiograph of a Southern blot of a 0.8% agarose gel showing the results of
hybridizing radiolabeled MHV-68 cosmid A8 to the Nindlll products of DNAs isolated from BHK-21 cells infected with MHV-76, MHV-68,
MHV-76(cA8+ )3, MHV-76(cA8 + )4, and MHV-76(cA8-)5. The sizes of molecular size markers (in kilobase pairs) are shown on the left, and
Hindill fragments are shown on the right (see Fig. IB for a map). (B) Autoradiograph of a Southern blot of a 0.8% agarose gel showing the results
of hybridizing radiolabeled M3 probe (nucleotides 6060 to 7277 in the MHV-68 genome) to the HindUl products of DNA isolated from BHK-21
cells infected with MHV-76, MHV-68, MHV-76(cA8+)3, MHV-76(cA8 + )4, or MHV-76(cA8-)5. The sizes of molecular size markers (in kilobase
pairs) are shown on the left, and HindUl fragments are shown on the right (see Fig. IB for a map). (C) PCR analysis of viral DNA from
MHV-76(cA8+)3, MHV-76(cA8+)4, or MHV-76(cA8-)5 using primers specific for the MHV-68 Ml, M2, M3, and M4 genes and ORF 74.
Reaction products were analyzed on a 1% agarose gel. Molecular size markers and their sizes are shown to the left, with sizes in kilobase pairs.
(D) Autoradiograph of a Southern blot of a 0.8% agarose gel showing the results of hybridizing a radiolabeled BamYW M probe (which contains
the 100-bp repeat) to the Hincll products of DNA isolated from BHK-21 cells infected with MHV-76, MHV-68, MHV-76(cA8 + )3, MHV-
76(cA8 + )4, or MHV-76(cA8-)5. The sizes of molecular size markers (in kilobase pairs) are shown on the left. Fragments containing the 100-bp
repeat, with approximate sizes, are indicated on the right, along with the adjacent 5,032-bp fragment present in each genome.
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FIG. 7. Biological characterization of MHV-68, MHV-76, and the rescuant viruses. Data points (mean value ± standard error) are shown in
each graph for MHV-68 (■), MHV-76 (O), MHV-76(cA8+)4 (A), and MHV-76(cA8-)5 (A). (A) Single-step growth curves comparing growth of
viruses on BHK-21 cells at an MOI of 5. The data are representative of two separate experiments, and each experiment was done in duplicate.
(B) Viral replication in the lungs of BALB/c mice infected intranasally with 2 X 105 PFU of virus. Data for four mice per group are shown at each
time point. (C) Numbers of spleen cells during intranasal infection of BALB/c mice with 2 x 105 PFU of virus. Data for four mice per group are
shown at each time point. (D) Latent virus in the spleens of BALB/c mice infected with 2 X 105 PFU of virus as determined by infective-center
assay. Infectious virus titers (less than 50 PFU per spleen in every case) have been subtracted from the infective-center results. Data for four mice
per group are shown at each time point.
contaminating MHV-68. Since MHV-76(cA8+)3 contained
variable numbers of this repeat domain, we did not include this
rescuant in any further biological analyses.
The viruses are indistinguishable in vitro. To investigate the
effect of the deletion on viral replication in vitro, single-step
growth curves of MHV-68, MHV-76, MHV-76(cA8+)4, and
MHV-76(cA8-)5 were compared (Fig. 7A). All four viruses
replicated with the same kinetics and attained similar maximal
titers at around 60 h p.i. There was no indication that the
deleted sequence had any effect on lytic replication in BHK-21
cells.
A lack of Ml, M2, M3, M4, and the vtRNA genes leads to
attenuation in the lung. Mice were infected with MHV-68,
MHV-76, MHV-76(cA8+)4, or MHV-76(cA8-)5, and the vi¬
rus titer in the lungs was assessed at various times p.i. by plaque
assay. As shown in Fig. 7B, MHV-68 and MHV-76(cA8+)4
achieved peak titers at around 7 days p.i. and were cleared by
14 days p.i. MHV-76 and MHV-76(cA8-)5 achieved similar
maximum titers, but the decrease in titer from this peak oc¬
curred earlier and was more rapid [MHV-68 versus MHV-76
at day 7 p.i., P = 0.037; MHV-76(cA8 + )4 versus MHV-76 at
day 7 p.i., P = 0.010], These data show that the deletion leads
to a significant attenuation of infection in the lungs.
Deletion ofMl, M2, M3, M4, and the vtRNA genes severely
attenuates virus pathogenicity in the spleen. Mice were in¬
fected with MHV-68, MHV-76, MHV-76(cA8+)4, or MHV-
76(cA8-)5, and the extent of ensuing splenomegaly was deter¬
mined by counting the total number of splenocytes and the
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increase in latently infected cells as monitored by infective-
center assay. The results are shown in Fig. 7C and D. After
infection with MHV-68 or MHV-76(cA8+)4, there was a
sharp increase in splenocyte number, peaking at around 14
days p.i. However, after infection with MHV-76 or MHV-
76(cA8-)5, there was only a modest rise in splenocyte number,
peaking earlier at around day 10 p.i. [MHV-68 versus MHV-
76, P = 0.003; MHV-76(cA8+)4 versus MHV-76, P = 0.005],
In mice infected with MHV-68 and MHV-76(cA8+)4, in¬
fective centers rose sharply from day 7 p.i. to a peak at day
14 p.i. Infective centers from mice infected with MHV-76 and
MHV-76(cA8-)5 were detectable in the spleen, but the peak
occurred earlier (day 10 p.i.) and was significantly less [MHV-
68 versus MHV-76, P = 0.002; MHV-76(cA8+)4 versus MHV-
76, P = 0.008]. However, latently infected cells were detected
in mice infected with MHV-76(cA8-)5 or MHV-76 even at the
latest time point tested (32 days p.i.). These data show that the
deleted sequence contributes significantly to splenomegaly and
the acute rise in latently infected cells in the spleen but is not
essential for the establishment of latency and persistence.
DISCUSSION
This work describes a primary analysis of a novel murine
gammaherpesvirus, MHV-76. The genome of this virus was
found to be essentially identical to that of MHV-68, with the
single major difference being the absence of 9,538 bp at the left
end of the unique region of the genome. MHV-76 replicated
similarly in cell culture and had similar biological properties as
MHV-68, but it appeared to be significantly less pathogenic in
vivo in the context of a much more rapid and intense inflam¬
matory response in the lungs. Recombinant viruses that had
the deletion in MHV-76 rescued had biological properties sim¬
ilar to those of MHV-68.
MHV-68 was reported as having been isolated from the
bank vole, C. glareolus (3), whereas MHV-76 was described as
an independent isolate derived in the same study from the
yellow-necked wood mouse, A. flavicollis. Our data strongly
suggest that MHV-76 is a deletion mutant derived from MHV-68
or an extremely similar virus during passage. It is formally
possible that this could have occurred in nature, since Clethri-
onomys and Apodemus species share similar habitats. This
question is an important one and is currently being addressed
by the investigation of free-living rodent samples from the
United Kingdom.
MHV-76 lacks 9,538 bp containing theMl, M2, M3, M4, and
vtRNA genes. We have shown that MHV-76 and MHV-68
differ dramatically in their pathogenic potential in mice. This
could be due to the deletion or to unidentified mutations
elsewhere in the genome. Consequently, we utilized rescuants
in which the deleted region in MHV-76 had been restored by
recombination with MHV-68 sequences. Replacement of the
deleted sequence changed the phenotype of MHV-76 to one
that was not significantly different from that of MHV-68. This
shows definitively that the left end of the MHV-68 genome is
nonessential for viral productive replication but plays a key
role in pathogenesis. It is overwhelmingly likely that the key
determinants are located in the deleted sequence. However,
our results have not formally ruled out the possibility that the
single nucleotide substitution at nucleotide 12280, resulting in
replacement of a glycine by a serine residue in the ORF 6
protein, may play a role. We consider this unlikely, since a
deleterious point mutation (unlike a deletion) can readily re¬
vert and is unlikely to survive under selection in mice. We are
also encouraged to view this residue as noncritical, since it is
not conserved in an independently isolated murine herpesvirus
in which the ORF 6 protein is 91.3% identical to that of
MHV-68 (it is an asparagine [S. Milligan, C. Chastel, S. Efsta-
thiou, and A. J. Davison, unpublished data]).
The left end of the MHV-68 genome appears to have a
propensity for undergoing recombination events in vitro (28).
This could be due to the proximity of multiple terminal repeats
or to the presence of highly transcribed vtRNA genes or a
putative origin of replication (4). Naturally occurring deletions
have been described for other gammaherpesvirus genomes.
The strains of Epstein-Barr virus in the Raji, Daudi, and
P3HR-1 cell lines all carry deletions of various sizes (15). For
HVS, spontaneous deletions at the left end of the genome have
been described (16). Indeed, the heterogeneity of the left end
of the HVS genome has been held responsible for the onco¬
genic potential of the virus (19, 20). It is also of note that the
left end of the HVS genome encodes seven small viral RNAs
(2).
Unique genes at the left end of the genome have attracted
considerable attention in other gammaherpesviruses as well as
in MHV-68. In Kaposi's sarcoma-associated herpesvirus, this
region contains the K1 gene, which shows unusual levels of
divergence in different virus isolates (45) and has been associ¬
ated with cellular transformation (17). In HVS, this region
contains the STP gene, which is required for cellular immor¬
talization and oncogenesis (16, 23), as well as the HVS small
viral RNAs (2). In Epstein-Barr virus, this region encodes
LMP-1, a classic oncoprotein that is essential for B-cell im¬
mortalization (15). For MHV-68, however, less is known about
the function of the genes in this region and their contribution
to viral pathogenesis. Indeed, only the function of M3 has been
identified, as a soluble chemokine binding protein (25, 40)
potentially subverting the inflammatory response. Deletion of
Ml had no phenotypic effect on viral replication in vitro or in
vivo (6, 28), although one study implicated this region of the
genome in the regulation of latency (6). Also, deletion of
vtRNA genes 1 to 4 had no effect on viral pathogenesis (28).
Our studies confirm and extend these findings in demonstrat¬
ing that genesMl, M2, M3, and M4 and all eight vtRNA genes
are nonessential for lytic virus replication in vitro and in vivo
and for the establishment and maintenance of latency in vivo.
Functions encoded at the left end of the MHV-68 genome
are nevertheless involved in virus pathogenicity. The more
rapid clearance from the lungs characteristic of MHV-76, com¬
bined with an enhanced inflammatory response, indicates a key
role for this region in the avoidance of restrictions placed on
viral productive replication, for example, via interferons or the
immune response. The Ml, M3, M4, and vtRNA genes are
transcribed during lytic infection (29, 41) and thus potentially
play roles in infection of the lung. Previous studies have ana¬
lyzed MHV-68 mutants lacking Ml (6, 28) but did not assess
viral replication in the lung after intranasal infection.
The dramatically smaller extent of splenomegaly and lower
number of infective centers observed during MHV-76 infec¬
tion constitute the first evidence that genes at the left end of
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the MHV-68 genome are specifically involved in splenomegaly
and generation of latently infected B cells. It is not clear,
however, precisely which of the known genes is responsible. A/2
and the vtRNA genes are candidates, since they are tran¬
scribed during latent infection of splenocytes (14, 29). M2 is
also expressed predominantly in B cells during splenomegaly
(38). Ml, M3, and M4 have not been shown definitively to be
associated with latency (14, 41) but may still have a role in
splenomegaly, since low levels of productive viral replication
occur in the spleen during the establishment of latency. Che-
mokines play an important role in directing the migration of
leukocytes to sites of inflammation (18). Thus, the chemokine-
binding actions of M3 may play an important role in spleno¬
megaly. One report has implicated Ml in -the suppression of
viral reactivation (6). However, the effect was observed only at
later time points in peritoneal exudate cells after intraperito¬
neal infection. In addition, that study employed recombinant
viruses containing the human cytomegalovirus immediate-
early promoter, which may in itself affect MHV-68 replication.
A suppressive effect of Ml was not observed in our experi¬
ments.
Both MHV-76 and MHV-68 persisted in the spleens of
infected mice for at least 5 months p.i. Thus, the genetic ele¬
ments necessary for this process are clearly not present in the
left unique portion of the genome. However, the persistence of
MHV-76 in the lungs was much less consistent, occurring in
only one of four mice. Long-term persistence of virus in the
lung is a consistent feature of MHV-68 infection (32). Thus,
although the numbers are low, our data suggest that sequences
missing in MHV-76 are important for long-term persistence in
the lung. The more rapid and intense inflammatory response
seen in the lung during MHV-76 infection may indicate that
the virus is more effectively cleared from this site by the host
response. In addition, there may be subtle variations in ge¬
nome copy number in the spleen that are influenced by the
locus absent in MHV-76. These questions await the results of
quantitative experiments on DNA load over an extended time
course.
In summary, we have demonstrated that a region of the
genome containing A/7, A/2, A/3, M4, and the vtRNA genes
plays a key role in infection in mice by MHV-68, probably
though evasion of the host innate defense mechanisms and
immune response. Ongoing studies in this laboratory are ex¬
pected to reveal the contributions of individual genes.
MHV-76 is anticipated to be a useful virus from which to
construct appropriate mutants.
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